La	O
dystrophie	O
musculaire	O
des	O
ceintures	O
autosomique	O
dominante	O
associée	O
à	O
des	O
troubles	O
de	O
la	O
conduction	O
cardiaque	O
(	O
LGMD1B	O
)	O
.	O

Description	O
de	O
8	O
nouvelles	O
familles	O
avec	O
mutations	O
du	O
gène	O
LMNA	O
.	O

INTRODUCTION	O
:	O
Limb	B-Disease
girdle	I-Disease
muscular	I-Disease
dystrophy	I-Disease
type	I-Disease
1b	I-Disease
(	O
LGMD1B	O
)	O
,	O
due	B-Reg
to	I-Reg
LMNA	B-Gene
gene	O
mutations	B-Var
,	O
is	O
a	O
relatively	O
rare	O
form	O
of	O
LGMD	O
characterized	O
by	O
proximal	O
muscle	O
involvement	O
associated	O
with	O
heart	O
involvement	O
comprising	O
atrio	O
-	O
ventricular	O
conduction	O
blocks	O
and	O
dilated	O
cardiomyopathy	O
.	O

Its	O
clinical	O
and	O
genetic	O
diagnosis	O
is	O
crucial	O
for	O
cardiac	O
management	O
and	O
genetic	O
counselling	O
.	O

Seven	O
LMNA	O
mutations	O
have	O
been	O
previously	O
reported	O
to	O
be	O
responsible	O
for	O
LGMD1B.	O
PATIENTS	O
AND	O
METHODS	O
:	O
We	O
describe	O
the	O
neurological	O
and	O
cardiologic	O
features	O
of	O
14	O
patients	O
belonging	O
to	O
8	O
families	O
in	O
whom	O
we	O
identified	O
6	O
different	O
LMNA	O
mutations	O
,	O
4	O
of	O
them	O
having	O
never	O
been	O
reported	O
.	O

Results	O
.	O

Eleven	O
patients	O
had	O
an	O
LGMD1B	O
phenotype	O
with	O
scapulohumeral	O
and	O
pelvic	O
-	O
femoral	O
involvement	O
.	O

Thirteen	O
patients	O
had	O
cardiac	O
disease	O
associating	O
conduction	O
defects	O
(	O
12	O
patients	O
)	O
or	O
arrhythmias	O
(	O
9	O
patients	O
)	O
.	O

Seven	O
patients	O
needed	O
cardiac	O
device	O
(	O
pacemaker	O
or	O
implantable	O
cardiac	O
defibrillator	O
)	O
and	O
two	O
had	O
heart	O
transplantation	O
.	O

CONCLUSION	O
:	O
This	O
study	O
allowed	O
us	O
to	O
specify	O
the	O
clinical	O
characteristics	O
of	O
this	O
entity	O
and	O
to	O
outline	O
the	O
first	O
phenotype	O
/	O
genotype	O
relations	O
resulting	O
from	O
these	O
observations	O
.	O

Genetics	O
of	O
laminopathies	O
.	O

Laminopathies	O
are	O
now	O
recognized	O
as	O
a	O
group	O
of	O
disorders	O
due	O
to	O
mutations	O
of	O
the	O
LMNA	O
gene	O
,	O
which	O
encodes	O
A	O
-	O
type	O
lamins	O
.	O

Primarily	O
,	O
mutations	B-Var
in	O
LMNA	B-Gene
have	O
been	O
associated	B-Reg
to	I-Reg
the	O
autosomal	O
forms	O
of	O
Emery	B-Disease
-	I-Disease
Dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
,	O
a	O
rare	O
slowly	O
progressive	O
humero	O
-	O
peroneal	O
muscular	O
dystrophy	O
accompanied	O
by	O
early	O
contractures	O
and	O
dilated	O
cardiomyopathy	O
with	O
conduction	O
defects	O
.	O

LMNA	O
mutations	O
have	O
been	O
reported	O
to	O
be	O
responsible	O
for	O
up	O
to	O
10	O
distinct	O
phenotypes	O
that	O
affect	O
specifically	O
either	O
the	O
skeletal	O
and/or	O
cardiac	O
muscle	O
,	O
the	O
adipose	O
tissue	O
,	O
the	O
peripheral	O
nervous	O
tissue	O
,	O
the	O
bone	O
tissue	O
or	O
more	O
recently	O
premature	O
ageing	O
.	O

So	O
far	O
more	O
than	O
180	O
different	O
LMNA	O
mutations	O
have	O
been	O
identified	O
in	O
903	O
individuals	O
.	O

The	O
first	O
studies	O
of	O
phenotype	O
/	O
genotype	O
relationships	O
revealed	O
no	O
dear	O
relation	O
between	O
the	O
phenotype	O
and	O
the	O
type	O
and/or	O
the	O
localization	O
of	O
the	O
mutation	O
,	O
except	O
perhaps	O
for	O
the	O
globular	O
tail	O
domain	O
of	O
lamins	O
A	O
/	O
C.	O
Studies	O
of	O
the	O
consequences	O
of	O
LMNA	O
mutations	O
in	O
the	O
skin	O
cultured	O
fibroblasts	O
from	O
the	O
patients	O
reveal	O
abnormal	O
nuclei	O
in	O
variable	O
proportions	O
,	O
with	O
dysmorphic	O
nuclei	O
exhibiting	O
abnormal	O
patterns	O
of	O
expression	O
of	O
B	O
-	O
type	O
lamins	O
and	O
emerin	O
.	O

Finally	O
,	O
the	O
development	O
of	O
KO	O
and	O
KI	O
LMNA	O
mice	O
,	O
will	O
certainly	O
give	O
further	O
insight	O
into	O
the	O
pathophysiological	O
mechanisms	O
associated	O
with	O
LMNA	O
mutations	O
.	O

For	O
example	O
,	O
Lmna(H222P	O
/	O
H222P	O
)	O
mice	O
harbour	O
phenotypes	O
reminiscent	O
of	O
Emery	O
-	O
Dreifuss	O
muscular	O
dystrophy	O
.	O

Mutations	B-Var
in	O
the	O
mouse	O
Lmna	B-Gene
gene	O
causing	B-Reg
progeria	B-Disease
,	O
muscular	B-Disease
dystrophy	I-Disease
and	O
cardiomyopathy	B-Disease
.	O

At	O
least	O
ten	O
different	O
diseases	O
have	O
been	O
linked	O
to	O
mutations	O
in	O
proteins	O
associated	O
with	O
the	O
nuclear	O
envelope	O
(	O
NE	O
)	O
.	O

Eight	O
of	O
these	O
diseases	O
are	O
associated	O
with	O
mutations	O
in	O
the	O
lamin	O
A	O
gene	O
(	O
LMNA	O
)	O
.	O

These	O
diseases	O
include	O
the	O
premature	O
ageing	O
or	O
progeric	O
diseases	O
Hutchinson	O
-	O
Gilford	O
progeria	O
and	O
atypical	O
Werner	O
's	O
syndrome	O
,	O
diseases	O
affecting	O
striated	O
and	O
cardiac	O
muscle	O
including	O
muscular	O
dystrophies	O
and	O
dilated	O
cardiomyopathies	O
,	O
lipodystrophies	O
affecting	O
white	O
fat	O
deposition	O
and	O
skeletal	O
development	O
and	O
a	O
peripheral	O
neuropathy	O
resulting	O
in	O
motor	O
neuron	O
demyelination	O
.	O

To	O
understand	O
how	O
these	O
diseases	O
arise	O
from	O
different	O
mutations	O
in	O
the	O
same	O
protein	O
,	O
we	O
established	O
mouse	O
lines	O
carrying	O
some	O
of	O
the	O
same	O
mutations	O
found	O
in	O
the	O
human	O
LMNA	O
gene	O
,	O
as	O
both	O
mouse	O
and	O
human	O
lamin	O
genes	O
show	O
a	O
very	O
high	O
degree	O
of	O
sequence	O
conservation	O
.	O

We	O
have	O
generated	O
mice	O
with	O
different	O
mutations	O
resulting	O
in	O
progeria	O
,	O
muscular	O
dystrophy	O
and	O
dilated	O
cardiomyopathy	O
.	O

Our	O
mouse	O
lines	O
are	O
providing	O
novel	O
insights	O
into	O
how	O
changes	O
to	O
the	O
nuclear	O
lamina	O
affect	O
the	O
mechanical	O
integrity	O
of	O
the	O
nucleus	O
and	O
in	O
turn	O
intracellular	O
signalling	O
,	O
such	O
as	O
the	O
NF	O
-	O
kappaB	O
pathway	O
,	O
as	O
well	O
as	O
cell	O
proliferation	O
and	O
survival	O
,	O
cellular	O
functions	O
that	O
,	O
when	O
disrupted	O
,	O
may	O
be	O
the	O
basis	O
for	O
the	O
origin	O
of	O
such	O
diseases	O
.	O

A	O
novel	O
mutation	B-Var
of	O
the	O
cathepsin	B-Gene
C	I-Gene
gene	O
in	O
a	O
thai	O
family	O
with	B-Reg
Papillon	B-Disease
-	I-Disease
Lefevre	I-Disease
syndrome	I-Disease
.	O

BACKGROUND	O
:	O
Papillon	O
-	O
Lefevre	O
syndrome	O
(	O
PLS	O
)	O
is	O
a	O
rare	O
autosomal	O
recessive	O
disorder	O
characterized	O
by	O
palmar-	O
plantar	O
hyperkeratosis	O
and	O
rapid	O
periodontal	O
destruction	O
of	O
both	O
primary	O
and	O
permanent	O
dentitions	O
.	O

It	O
has	O
been	O
shown	O
that	O
the	O
disease	O
is	O
caused	O
by	O
cathepsin	O
C	O
gene	O
(	B-Gene
CTSC	I-Gene
)	I-Gene
mutation	B-Var
leading	O
to	O
the	O
deficiency	B-NegReg
of	O
cathepsin	B-Enzyme
C	I-Enzyme
enzymatic	I-Enzyme
activity	B-MPA
.	O

This	O
study	O
demonstrates	O
the	O
clinical	O
manifestations	O
and	O
CTSC	O
mutational	O
and	O
enzymatic	O
activity	O
analyses	O
in	O
a	O
5-year	O
-	O
old	O
Thai	O
male	O
PLS	O
patient	O
and	O
his	O
parents	O
.	O

METHODS	O
:	O
Peripheral	O
blood	O
samples	O
were	O
obtained	O
for	O
genomic	O
DNA	O
isolation	O
.	O

All	O
exons	O
of	O
the	O
CTSC	O
gene	O
were	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
using	O
specific	O
primers	O
.	O

Mutations	O
were	O
identified	O
by	O
DNA	O
sequencing	O
.	O

Verification	O
of	O
the	O
mutation	O
was	O
performed	O
by	O
digestion	O
of	O
PCR	O
products	O
by	O
restriction	O
endonucleases	O
.	O

The	O
cathepsin	O
C	O
enzymatic	O
activity	O
was	O
determined	O
using	O
the	O
synthetic	O
substrate	O
glycyl-	O
L	O
-	O
arginine-7-amino-4-methylcoumarin	O
.	O

RESULTS	O
:	O
The	O
patient	O
demonstrated	O
classical	O
characteristics	O
of	O
PLS	O
,	O
including	O
hyperkeratotic	O
skin	O
lesions	O
.	O

By	O
the	O
age	O
of	O
5	O
,	O
all	O
of	O
his	O
primary	O
teeth	O
were	O
extracted	O
due	O
to	O
severe	O
periodontal	O
infection	O
.	O

The	O
parents	O
had	O
no	O
physical	O
abnormalities	O
.	O

The	O
periodontal	O
examination	O
revealed	O
localized	O
mild	O
periodontal	O
destruction	O
.	O

Sequence	O
analysis	O
showed	O
a	O
nucleotide	O
change	O
at	O
position	O
90	O
from	O
C	O
>	O
A	O
(	B-Var
c.90C	I-Var
>	I-Var
A	I-Var
)	I-Var
which	O
resulted	B-Reg
in	I-Reg
a	O
change	O
from	O
cysteine	O
residue	O
to	O
a	O
premature	B-MPA
stop	I-MPA
codon	I-MPA
at	O
the	O
amino	O
acid	O
position	O
30	O
in	O
the	O
exon	O
1	O
.	O

The	O
HpyCH4V	O
digestion	O
revealed	O
that	O
the	O
patient	O
was	O
homozygous	O
,	O
whereas	O
both	O
the	O
father	O
and	O
mother	O
were	O
heterozygous	O
carriers	O
of	O
this	O
mutation	O
.	O

The	O
cathepsin	O
C	O
activity	O
was	O
reduced	O
in	O
the	O
patient	O
's	O
mother	O
,	O
and	O
the	O
activity	O
in	O
the	O
patient	O
was	O
almost	O
completely	O
lost	O
.	O

CONCLUSIONS	O
:	O
This	O
is	O
the	O
first	O
study	O
to	O
demonstrate	O
a	O
CTSC	B-Gene
gene	O
mutation	O
in	O
a	O
Thai	O
family	O
with	O
PLS	O
.	O

The	O
identified	O
mutation	B-Var
is	O
novel	O
and	O
potentially	O
leads	O
to	O
the	O
drastic	O
reduction	B-NegReg
of	O
the	O
cathepsin	B-Enzyme
C	I-Enzyme
enzymatic	I-Enzyme
activity	B-MPA
.	O

This	O
suggests	O
that	O
the	O
mutation	O
is	O
pathogenetic	O
,	O
causing	B-Reg
the	O
PLS	B-Disease
.	O

Mutational	O
analysis	O
in	O
more	O
members	O
of	O
the	O
family	O
is	O
warranted	O
to	O
identify	O
whether	O
the	O
mutation	O
is	O
inherited	O
from	O
a	O
common	O
ancestor	O
.	O

Mutations	O
of	O
COL10A1	O
in	O
Schmid	O
metaphyseal	O
chondrodysplasia	O
.	O

Schmid	B-Disease
metaphyseal	I-Disease
chondrodysplasia	I-Disease
(	O
SMCD	O
)	O
is	O
a	O
dominantly	O
inherited	O
cartilage	O
disorder	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
gene	O
for	O
the	O
hypertrophic	O
cartilage	O
extracellular	O
matrix	O
structural	O
protein	O
,	O
collagen	O
X	O
(	B-Gene
COL10A1	I-Gene
)	I-Gene
.	O

Thirty	O
heterozygous	O
mutations	O
have	O
been	O
described	O
,	O
about	O
equally	O
divided	O
into	O
two	O
mutation	O
types	O
,	O
missense	O
mutations	O
,	O
and	O
mutations	O
that	O
introduce	O
premature	O
termination	O
signals	O
.	O

The	O
COL10A1	O
mutations	O
are	O
clustered	O
(	O
33/36	O
)	O
in	O
the	O
3	O
'	O
region	O
of	O
exon	O
3	O
,	O
which	O
codes	O
for	O
the	O
C	O
-	O
terminal	O
NC1	O
trimerization	O
domain	O
.	O

The	O
effect	O
of	O
COL10A1	O
missense	O
mutations	O
have	O
been	O
examined	O
by	O
in	O
vitro	O
expression	O
and	O
assembly	O
assays	O
and	O
cell	O
transfection	O
studies	O
,	O
which	O
suggest	O
that	O
a	O
common	O
consequence	O
is	O
the	O
disruption	O
of	O
collagen	O
X	O
trimerization	O
and	O
secretion	O
,	O
with	O
consequent	O
intracellular	O
degradation	O
.	O

The	O
effect	O
of	O
COL10A1	B-Gene
nonsense	B-Var
mutations	I-Var
in	O
cartilage	O
tissue	O
has	O
been	O
examined	O
in	O
two	O
patients	O
,	O
demonstrating	O
that	O
the	O
mutant	B-Var
mRNA	B-MPA
is	O
completely	O
removed	B-NegReg
by	O
nonsense	B-MPA
mediated	I-MPA
mRNA	I-MPA
decay	B-NegReg
.	O

Thus	O
for	O
both	O
classes	O
of	O
mutations	O
,	O
functional	O
haploinsufficiency	O
is	O
the	O
most	O
probable	O
cause	O
of	O
the	O
clinical	O
phenotype	O
in	O
SMCD	O
.	O

Sjögren	B-Disease
-	I-Disease
Larsson	I-Disease
syndrome	I-Disease
:	I-Disease
diversity	O
of	B-Reg
mutations	B-Var
and	O
polymorphisms	O
in	O
the	O
fatty	O
aldehyde	O
dehydrogenase	O
gene	O
(	B-Gene
ALDH3A2	I-Gene
)	I-Gene
.	O

Sjögren	B-Disease
-	I-Disease
Larsson	I-Disease
syndrome	I-Disease
(	O
SLS	O
)	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
characterized	O
by	O
ichthyosis	O
,	O
mental	O
retardation	O
,	O
and	O
spastic	O
diplegia	O
or	O
tetraplegia	O
.	O

The	O
disease	O
is	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
ALDH3A2	B-Gene
gene	O
(	O
also	O
known	O
as	O
FALDH	B-Gene
and	O
ALDH10	B-Gene
)	I-Gene
on	O
chromosome	O
17p11.2	O
that	O
encodes	O
fatty	O
aldehyde	O
dehydrogenase	O
(	O
FALDH	O
)	O
,	O
an	O
enzyme	O
that	O
catalyzes	O
the	O
oxidation	O
of	O
long	O
-	O
chain	O
aldehydes	O
derived	O
from	O
lipid	O
metabolism	O
.	O

In	O
SLS	O
patients	O
,	O
72	O
mutations	O
have	O
been	O
identified	O
,	O
with	O
a	O
distribution	O
that	O
is	O
scattered	O
throughout	O
the	O
ALDH3A2	O
gene	O
.	O

Most	O
mutations	O
are	O
private	O
but	O
several	O
common	O
mutations	O
have	O
been	O
detected	O
,	O
which	O
probably	O
reflect	O
founder	O
effects	O
or	O
recurrent	O
mutational	O
events	O
.	O

Missense	O
mutations	B-Var
comprise	O
the	O
most	O
abundant	O
class	O
(	O
38	O
%	O
)	O
and	O
expression	O
studies	O
indicate	O
that	O
most	O
of	O
these	O
result	O
in	O
a	O
profound	O
reduction	B-NegReg
in	O
enzyme	B-Enzyme
activity	B-MPA
.	O

Deletions	O
account	O
for	O
about	O
25	O
%	O
of	O
the	O
mutations	O
and	O
range	O
from	O
single	O
nucleotides	O
to	O
entire	O
exons	O
.	O

Twelve	O
splice	O
-	O
site	O
mutations	B-Var
have	O
been	O
demonstrated	O
to	O
cause	B-Reg
aberrant	B-MPA
splicing	I-MPA
in	O
cultured	O
fibroblasts	O
.	O

To	O
date	O
,	O
more	O
than	O
a	O
dozen	O
intragenic	O
ALDH3A2	O
polymorphisms	O
consisting	O
of	O
SNPs	O
and	O
one	O
microsatellite	O
marker	O
have	O
been	O
characterized	O
,	O
although	O
none	O
of	O
them	O
alter	O
the	O
FALDH	O
protein	O
sequence	O
.	O

The	O
striking	O
mutational	O
diversity	O
in	O
SLS	O
offers	O
a	O
challenge	O
for	O
DNA	O
-	O
based	O
diagnosis	O
,	O
but	O
promises	O
to	O
provide	O
a	O
wealth	O
of	O
information	O
about	O
enzyme	O
structure	O
-	O
function	O
correlations	O
.	O

Genetic	O
screening	O
of	O
familial	O
Mediterranean	O
fever	O
mutations	O
in	O
the	O
Palestinian	O
population	O
.	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
spectrum	O
of	O
mutations	B-Var
and	O
genotypes	O
in	O
the	O
pyrin	B-Gene
gene	O
in	B-Reg
familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
(	O
FMF	O
)	O
patients	O
.	O

METHODS	O
:	O
Blood	O
samples	O
of	O
511	O
suspected	O
FMF	O
patients	O
,	O
received	O
from	O
the	O
Molecular	O
Genetics	O
Laboratory	O
,	O
Makassed	O
Islamic	O
Charitable	O
Hospital	O
,	O
Mount	O
Olives	O
,	O
Jerusalem	O
during	O
the	O
period	O
from	O
June	O
1999	O
to	O
August	O
2004	O
,	O
were	O
investigated	O
by	O
genotyping	O
24	O
different	O
MEFV	O
mutations	O
.	O

RESULTS	O
:	O
Our	O
work	O
revealed	O
the	O
presence	O
of	O
14	O
different	O
mutations	O
from	O
the	O
identified	O
24	O
mutations	O
in	O
the	O
gene	O
which	O
are	O
assembled	O
in	O
6	O
homozygous	O
,	O
9	O
heterozygous	O
and	O
16	O
compound	O
heterozygous	O
genotypes	O
.	O

The	O
homozygous	O
genotypes	O
represent	O
the	O
predominant	O
format	O
among	O
our	O
patients	O
representing	O
approximately	O
38	O
%	O
of	O
the	O
revealed	O
genotypes	O
.	O

Interestingly	O
,	O
in	O
94	O
(	O
31.4	O
%	O
)	O
of	O
the	O
tested	O
subjects	O
,	O
only	O
one	O
mutation	O
in	O
the	O
pyrin	O
gene	O
could	O
be	O
identified	O
while	O
the	O
other	O
mutant	O
allele	O
remains	O
unidentified	O
.	O

Moreover	O
,	O
the	O
genotype	O
of	O
3	O
(	O
1	O
%	O
)	O
patients	O
revealed	O
the	O
presence	O
of	O
triplet	O
mutations	O
in	O
the	O
pyrin	O
gene	O
.	O

CONCLUSION	O
:	O
The	O
results	O
of	O
our	O
study	O
clearly	O
suggest	O
that	O
the	O
origin	O
of	O
FMF	O
among	O
the	O
Palestinian	O
population	O
is	O
mostly	O
homozygous	O
.	O

The	O
identification	O
of	O
a	O
significant	O
number	O
of	O
patients	O
with	O
one	O
known	O
mutation	O
indicates	O
potentially	O
the	O
presence	O
of	O
new	O
mutations	O
in	O
the	O
gene	O
which	O
will	O
be	O
investigated	O
in	O
the	O
future	O
.	O

Novel	O
CLN3	B-Gene
mutation	B-Var
predicted	O
to	O
cause	O
complete	O
loss	B-NegReg
of	O
protein	B-Protein
function	B-MPA
does	O
not	O
modify	O
the	O
classical	O
JNCL	O
phenotype	O
.	O

Juvenile	B-Disease
Neuronal	I-Disease
Ceroid	I-Disease
Lipofuscinosis	I-Disease
(	O
JNCL	O
)	O
,	O
or	O
Batten	O
disease	O
,	O
is	O
a	O
childhood	O
neurodegenerative	O
disease	O
that	O
is	O
characterized	O
clinically	O
by	O
progressive	O
visual	O
loss	O
,	O
seizures	O
,	O
dementia	O
,	O
and	O
motor	O
incoordination	O
.	O

Children	O
affected	O
with	O
this	O
disease	O
tend	O
to	O
develop	O
normally	O
for	O
the	O
first	O
5	O
years	O
of	O
life	O
.	O

However	O
,	O
once	O
disease	O
onset	O
occurs	O
,	O
they	O
decline	O
rapidly	O
and	O
die	O
in	O
their	O
late	O
20s	O
to	O
early	O
30s	O
.	O

Though	O
this	O
represents	O
the	O
typical	O
disease	O
course	O
,	O
the	O
onset	O
and	O
severity	O
of	O
disease	O
symptoms	O
can	O
vary	O
.	O

This	O
variability	O
is	O
presumed	O
to	O
be	O
the	O
result	O
of	O
both	O
differences	O
in	O
the	O
causative	O
genetic	O
mutation	O
in	O
the	O
CLN3	O
gene	O
as	O
well	O
as	O
environmental	O
influences	O
.	O

Most	O
cases	O
of	O
JNCL	B-Disease
are	O
caused	B-Reg
by	I-Reg
a	O
1	O
kb	O
deletion	B-Var
in	O
the	O
CLN3	B-Gene
gene	O
,	O
resulting	B-Reg
in	I-Reg
a	O
frameshift	B-Var
mutation	I-Var
predicted	O
to	O
leave	O
the	O
first	O
153	O
amino	O
acids	O
of	O
the	O
CLN3	O
protein	O
intact	O
,	O
followed	O
by	O
the	O
addition	O
of	O
28	O
novel	O
amino	O
acids	O
.	O

Here	O
we	O
report	O
the	O
discovery	O
of	O
a	O
novel	O
mutation	O
identified	O
as	O
a	O
G	O
to	O
T	O
transversion	O
at	O
nucleotide	O
49	O
(	B-Var
G49	I-Var
T	I-Var
)	I-Var
in	O
exon	O
2	O
of	O
CLN3	B-Gene
,	O
introducing	B-Reg
a	O
premature	O
stop	O
codon	O
(	B-Var
E17X	I-Var
)	I-Var
near	O
the	O
N	O
-	O
terminus	O
.	O

This	O
mutation	O
represents	O
the	O
most	O
5	O
'	O
mutation	O
described	O
to	O
date	O
.	O

The	O
patient	O
examined	O
in	O
this	O
study	O
was	O
heterozygous	O
for	O
the	O
common	O
1	O
kb	O
deletion	O
and	O
E17X.	O
She	O
had	O
classical	O
disease	O
progression	O
,	O
suggesting	O
that	O
this	O
mutation	O
in	O
CLN3	O
mimics	O
the	O
more	O
prevalent	O
1	O
kb	O
deletion	O
and	O
that	O
progression	O
of	O
JNCL	O
is	O
predominantly	O
the	O
result	O
of	O
loss	O
of	O
CLN3	O
function	O
.	O

Identification	O
of	O
a	O
novel	O
founder	O
mutation	O
in	O
the	O
DYSF	O
gene	O
causing	O
clinical	O
variability	O
in	O
the	O
Spanish	O
population	O
.	O

BACKGROUND	O
:	O
Mutations	B-Var
in	O
the	O
dysferlin	O
(	B-Gene
DYSF	I-Gene
)	I-Gene
gene	O
cause	B-Reg
3	O
different	O
phenotypes	O
of	O
muscular	O
dystrophies	O
:	O
Miyoshi	B-Disease
myopathy	I-Disease
,	O
limb	B-Disease
-	I-Disease
girdle	I-Disease
muscular	I-Disease
dystrophy	I-Disease
type	I-Disease
2B	I-Disease
,	O
and	O
distal	B-Disease
anterior	I-Disease
compartment	I-Disease
myopathy	I-Disease
.	O

OBJECTIVE	O
:	O
To	O
present	O
the	O
results	O
of	O
clinical	O
and	O
molecular	O
analysis	O
of	O
8	O
patients	O
with	O
dysferlinopathy	O
from	O
5	O
unrelated	O
families	O
.	O

DESIGN	O
:	O
Clinical	O
assessment	O
was	O
performed	O
with	O
a	O
standardized	O
protocol	O
.	O

A	O
muscle	O
biopsy	O
specimen	O
was	O
obtained	O
and	O
studied	O
by	O
immunohistochemistry	O
.	O

Genetic	O
analysis	O
was	O
performed	O
using	O
single	O
-	O
stranded	O
conformation	O
polymorphism	O
and	O
direct	O
sequencing	O
of	O
genomic	O
DNA	O
.	O

RESULTS	O
:	O
All	O
the	O
patients	O
presented	O
the	O
R1905X	O
mutation	O
in	O
the	O
DYSF	O
gene	O
in	O
homozygosity	O
,	O
and	O
the	O
haplotype	O
analysis	O
at	O
the	O
DYSF	O
locus	O
revealed	O
that	O
it	O
was	O
a	O
novel	O
and	O
founder	O
mutation	O
.	O

A	O
C	B-Var
-	I-Var
to	I-Var
-	I-Var
T	I-Var
transition	I-Var
at	O
nucleotide	O
position	O
6086	O
changes	O
an	O
arginine	O
into	O
a	O
stop	O
codon	O
,	O
leading	B-Reg
to	I-Reg
premature	B-MPA
termination	I-MPA
of	I-MPA
translation	I-MPA
.	O

This	O
mutation	O
was	O
expressed	O
as	O
3	O
different	O
clinical	O
phenotypes	O
(	O
limb	O
-	O
girdle	O
muscular	O
dystrophy	O
type	O
2B	O
,	O
Miyoshi	O
distal	O
myopathy	O
,	O
and	O
distal	O
anterior	O
dysferlinopathy	O
)	O
,	O
but	O
only	O
1	O
phenotype	O
was	O
found	O
in	O
the	O
same	O
family	O
.	O

CONCLUSIONS	O
:	O
The	O
new	O
R1905X	O
DYSF	O
founder	O
mutation	O
produced	O
the	O
3	O
possible	O
dysferlinopathy	O
phenotypes	O
without	O
intrafamilial	O
heterogeneity	O
.	O

This	O
homogeneous	O
population	O
in	O
Sueca	O
,	O
Spain	O
,	O
should	O
be	O
helpful	O
in	O
studying	O
the	O
modifying	O
factors	O
responsible	O
for	O
the	O
phenotypic	O
variability	O
.	O

A	O
novel	O
frameshift	B-Var
mutation	O
(	O
+	O
G	O
)	O
at	O
codons	O
15/16	O
in	O
a	O
beta0	B-Gene
thalassaemia	I-Gene
gene	I-Gene
results	O
in	O
a	O
significant	O
reduction	B-NegReg
of	O
beta	B-MPA
globin	I-MPA
mRNA	I-MPA
values	O
.	O

AIMS	O
:	O
To	O
identify	O
a	O
novel	O
beta	O
globin	O
gene	O
mutation	O
found	O
in	O
a	O
Chinese	O
family	O
,	O
and	O
also	O
to	O
assess	O
its	O
functional	O
consequences	O
.	O

METHODS	O
:	O
Haematological	O
analysis	O
was	O
performed	O
on	O
all	O
family	O
members	O
.	O

The	O
23	O
common	O
mutations	O
of	O
beta	O
thalassaemia	O
found	O
in	O
Chinese	O
populations	O
were	O
detected	O
by	O
means	O
of	O
a	O
reverse	O
dot	O
blot	O
method	O
.	O

Direct	O
DNA	O
sequencing	O
of	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplified	O
complete	O
beta	O
globin	O
gene	O
was	O
carried	O
out	O
to	O
identify	O
the	O
novel	O
mutation	O
.	O

A	O
real	O
time	O
,	O
one	O
step	O
reverse	O
transcription	O
PCR	O
assay	O
was	O
used	O
to	O
measure	O
beta	O
globin	O
mRNA	O
in	O
the	O
reticulocytes	O
of	O
heterozygous	O
patients	O
.	O

RESULTS	O
:	O
A	O
novel	O
frameshift	O
mutation	O
-	O
an	O
insertion	B-Var
of	O
G	O
between	O
codons	O
15	O
and	O
16	O
in	O
a	O
homonucleotide	O
run	O
of	O
four	O
guanines	O
-	O
was	O
determined	O
,	O
which	O
generates	B-Reg
a	O
new	O
premature	B-MPA
chain	I-MPA
terminator	I-MPA
at	O
the	O
22nd	O
codon	O
.	O

Relative	O
quantitative	O
analysis	O
of	O
the	O
beta	O
globin	O
mRNA	O
in	O
heterozygous	O
subjects	O
demonstrated	O
a	O
39.83	O
%	O
reduction	O
compared	O
normal	O
controls	O
.	O

CONCLUSIONS	O
:	O
The	O
significantly	O
lower	B-NegReg
amounts	B-MPA
of	I-MPA
beta	I-MPA
globin	I-MPA
mRNA	I-MPA
found	O
in	O
mutation	B-Var
carriers	O
is	O
probably	O
caused	B-Reg
by	I-Reg
the	O
rapid	O
nonsense	O
mediated	O
degradation	B-MPA
of	O
the	O
mutant	O
mRNA	O
.	O

These	O
data	O
,	O
combined	O
with	O
haematological	O
analysis	O
,	O
suggest	O
that	O
this	O
novel	O
mutation	B-Var
of	O
CDs	O
15/16	O
(	O
+	O
G	O
)	O
results	B-Reg
in	I-Reg
a	O
beta(0	B-Disease
)	I-Disease
thalassaemia	I-Disease
phenotype	O
.	O

Increased	O
risk	O
of	O
idiopathic	O
chronic	O
pancreatitis	O
in	O
cystic	O
fibrosis	O
carriers	O
.	O

Cystic	B-Disease
fibrosis	I-Disease
(	O
CF	O
)	O
is	O
a	O
recessive	O
disease	O
caused	B-Reg
by	I-Reg
mutations	B-Var
of	O
the	O
CF	O
transmembrane	O
conductance	O
regulator	O
(	B-Gene
CFTR	I-Gene
)	I-Gene
gene	O
.	O

The	O
risk	O
of	O
idiopathic	O
chronic	O
pancreatitis	O
(	O
ICP	O
)	O
is	O
increased	O
in	O
individuals	O
who	O
have	O
CFTR	O
genotypes	O
containing	O
a	O
CF	O
-	O
causing	O
mutation	O
plus	O
a	O
second	O
pathogenic	O
allele	O
.	O

It	O
is	O
unknown	O
whether	O
the	O
risk	O
of	O
ICP	O
is	O
increased	O
in	O
CF	O
carriers	O
who	O
have	O
one	O
CF	O
-	O
causing	O
mutation	O
plus	O
one	O
normal	O
allele	O
.	O

In	O
this	O
study	O
,	O
52	O
sporadic	O
cases	O
of	O
ICP	O
were	O
ascertained	O
through	O
the	O
European	O
Registry	O
of	O
Hereditary	O
Pancreatitis	O
and	O
Familial	O
Pancreatic	O
Cancer	O
.	O

Individuals	O
with	O
pathogenic	O
cationic	O
trypsinogen	O
mutations	O
were	O
excluded	O
.	O

DNA	O
was	O
comprehensively	O
tested	O
for	O
CFTR	O
mutations	O
using	O
a	O
robotically	O
enhanced	O
,	O
multiplexed	O
,	O
and	O
highly	O
redundant	O
form	O
of	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
analysis	O
followed	O
by	O
DNA	O
sequencing	O
.	O

Fifteen	O
subjects	O
had	O
a	O
total	O
of	O
18	O
pathogenic	O
CFTR	O
alleles	O
.	O

Eight	O
subjects	O
had	O
common	O
CF	O
-	O
causing	O
mutations	O
.	O

This	O
group	O
included	O
seven	O
CF	O
carriers	O
in	O
whom	O
the	O
second	O
CFTR	O
allele	O
was	O
normal	O
(	O
4.3	O
times	O
the	O
expected	O
frequency	O
,	O
P=0.0002	O
)	O
.	O

Three	O
subjects	O
had	O
compound	O
heterozygotes	O
genotypes	O
containing	O
two	O
pathogenic	O
alleles	O
(	O
31	O
times	O
the	O
expected	O
frequency	O
,	O
P<0.0001	O
)	O
.	O

A	O
variant	O
allele	O
of	O
uncertain	O
significance	O
(	O
p	O
.	O
R75Q	O
)	O
was	O
detected	O
in	O
eight	O
of	O
the	O
52	O
ICP	O
subjects	O
and	O
at	O
a	O
similar	O
frequency	O
(	O
13/96	O
)	O
in	O
random	O
donors	O
.	O

ICP	O
differs	O
from	O
other	O
established	O
CFTR	O
-	O
related	O
conditions	O
in	O
that	O
ICP	O
risk	O
is	O
increased	O
in	O
CF	O
carriers	O
who	O
have	O
one	O
documented	O
normal	O
CFTR	O
allele	O
.	O

Having	O
two	O
CFTR	O
mutations	O
imparts	O
a	O
higher	O
relative	O
risk	O
,	O
while	O
having	O
only	O
one	O
mutation	O
imparts	O
a	O
higher	O
attributable	O
risk	O
.	O

Mutation	O
identification	O
in	O
a	O
canine	O
model	O
of	O
X	O
-	O
linked	O
ectodermal	O
dysplasia	O
.	O

X	B-Disease
-	I-Disease
linked	I-Disease
hypohidrotic	I-Disease
ectodermal	I-Disease
dysplasia	I-Disease
(	O
XHED	O
)	O
,	O
an	O
inherited	O
disease	O
recognized	O
in	O
humans	O
,	O
mice	O
,	O
and	O
cattle	O
,	O
is	O
characterized	O
by	O
hypotrichosis	O
,	O
a	O
reduced	O
number	O
or	O
absence	O
of	O
sweat	O
glands	O
,	O
and	O
missing	O
or	O
malformed	O
teeth	O
.	O

In	O
a	O
subset	O
of	O
affected	O
individuals	O
and	O
animals	O
,	O
mutations	B-Var
in	O
the	O
EDA	B-Gene
gene	O
(	O
formerly	O
EDI	O
)	O
,	O
coding	O
for	O
ectodysplasin	O
,	O
have	O
been	O
found	O
to	O
cause	B-Reg
this	O
phenotype	O
.	O

Ectodysplasin	O
is	O
a	O
homotrimeric	O
transmembrane	O
protein	O
with	O
an	O
extracellular	O
TNF	O
-	O
like	O
domain	O
,	O
which	O
has	O
been	O
shown	O
to	O
be	O
involved	O
in	O
the	O
morphogenesis	O
of	O
hair	O
follicles	O
and	O
tooth	O
buds	O
during	O
fetal	O
development	O
.	O

Some	O
human	O
XHED	B-Disease
patients	O
also	O
have	O
concurrent	O
immunodeficiency	O
,	O
due	B-Reg
to	I-Reg
mutations	B-Var
in	O
the	O
NF	O
-	O
kappaB	O
essential	O
modulator	O
protein	O
(	B-Gene
IKBKG	I-Gene
;	I-Gene
formerly	O
NEMO	O
)	O
,	O
which	O
is	O
also	O
encoded	O
on	O
the	O
X	O
chromosome	O
.	O

In	O
a	O
breeding	O
colony	O
of	O
dogs	O
with	O
XHED	O
,	O
immune	O
system	O
defects	O
had	O
been	O
suspected	O
because	O
of	O
frequent	O
pulmonary	O
infections	O
and	O
unexpected	O
deaths	O
resulting	O
from	O
pneumonia	O
.	O

To	O
determine	O
if	O
defects	O
in	O
EDA	O
or	O
IKBKG	O
cause	O
XHED	O
in	O
the	O
dogs	O
,	O
linkage	O
analysis	O
and	O
sequencing	O
experiments	O
were	O
performed	O
.	O

A	O
polymorphic	O
marker	O
near	O
the	O
canine	O
EDA	O
gene	O
showed	O
significant	O
linkage	O
to	O
XHED	O
.	O

The	O
canine	O
EDA	B-Gene
gene	O
was	O
sequenced	O
and	O
a	O
nucleotide	B-Var
substitution	I-Var
(	O
G	O
to	O
A	O
)	O
in	O
the	O
splice	O
acceptor	O
site	O
of	O
intron	O
8	O
was	O
detected	O
in	O
affected	O
dogs	O
.	O

In	O
the	O
presence	O
of	O
the	O
A	O
residue	O
,	O
a	O
cryptic	O
acceptor	O
site	O
within	O
exon	O
9	O
is	O
used	O
,	O
leading	B-Reg
to	I-Reg
a	O
frame	B-MPA
shift	I-MPA
and	O
use	O
of	O
a	O
premature	B-MPA
stop	I-MPA
codon	I-MPA
that	O
truncates	B-NegReg
the	O
translation	B-MPA
of	O
both	O
isoforms	O
,	O
EDA	O
-	O
A1	O
and	O
EDA	O
-	O
A2	O
,	O
resulting	O
in	O
the	O
absence	B-NegReg
of	O
the	O
TNF	B-MPA
-	I-MPA
like	I-MPA
homology	I-MPA
domain	I-MPA
,	O
the	O
receptor	O
-	O
binding	O
site	O
of	O
ectodysplasin	O
.	O

Familial	O
Mediterranean	O
fever	O
(	O
FMF	O
)	O
in	O
Lebanon	O
and	O
Jordan	O
:	O
a	O
population	O
genetics	O
study	O
and	O
report	O
of	O
three	O
novel	O
mutations	O
.	O

Familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
(	O
FMF	O
)	O
is	O
an	O
autosomal	O
recessive	O
disease	O
mostly	O
frequent	O
in	O
Mediterranean	O
populations	O
.	O

Over	O
50	O
mutations	B-Var
have	O
been	O
identified	O
in	O
the	O
gene	O
responsible	B-Reg
for	I-Reg
the	O
disease	O
,	O
MEFV	B-Gene
.	O

The	O
present	O
study	O
reports	O
the	O
frequencies	O
of	O
MEFV	B-Gene
mutations	B-Var
in	B-Reg
558	O
Lebanese	O
and	O
55	O
Jordanian	O
FMF	B-Disease
patients	O
and	O
points	O
out	O
the	O
severity	O
of	O
the	O
M694V	O
frequently	O
observed	O
mutation	O
among	O
these	O
patients	O
.	O

Three	O
novel	O
mutations	O
,	O
T177I	O
,	O
S108R	O
and	O
E474	O
K	O
were	O
also	O
identified	O
in	O
the	O
Lebanese	O
group	O
.	O

An	O
excess	O
of	O
homozygotes	O
and	O
a	O
deficit	O
of	O
heterozygotes	O
were	O
observed	O
in	O
both	O
samples	O
when	O
compared	O
to	O
the	O
expected	O
number	O
of	O
observed	O
genotypes	O
under	O
the	O
Hardy	O
-	O
Weinberg	O
hypothesis	O
.	O

Homozygotes	O
for	O
M694V	O
and	O
M694I	O
were	O
still	O
in	O
excess	O
in	O
the	O
Lebanese	O
group	O
of	O
patients	O
,	O
even	O
after	O
consanguinous	O
homozygotes	O
were	O
removed	O
,	O
or	O
population	O
structure	O
was	O
considered	O
.	O

This	O
excess	O
is	O
therefore	O
neither	O
due	O
to	O
consanguinity	O
nor	O
to	O
subgroups	O
in	O
the	O
Lebanese	O
population	O
,	O
but	O
rather	O
to	O
more	O
remote	O
consanguinity	O
or	O
to	O
a	O
selection	O
bias	O
favoring	O
the	O
census	O
of	O
these	O
genotypes	O
.	O

The	O
fact	O
that	O
FMF	O
female	O
patients	O
were	O
less	O
censed	O
than	O
male	O
patients	O
may	O
be	O
due	O
to	O
the	O
greater	O
resistance	O
of	O
females	O
to	O
pain	O
and	O
to	O
the	O
possibility	O
of	O
confusing	O
abdominal	O
and	O
gynecological	O
pain	O
.	O

The	O
phenotypic	O
heterogeneity	O
of	O
the	O
FMF	O
could	O
then	O
originate	O
both	O
from	O
genetic	O
causes	O
like	O
allelic	O
heterogeneity	O
or	O
modulating	O
genes	O
,	O
and	O
cultural	O
background	O
facing	O
the	O
physiological	O
consequences	O
of	O
genotypes	O
at	O
risk	O
.	O

[	O
Mutational	O
and	O
clinical	O
features	O
of	O
Japanese	O
patients	O
with	O
dysferlinopathy	O
(	O
Miyoshi	O
myopathy	O
and	O
limb	O
girdle	O
muscular	O
dystrophy	O
type	O
2B	O
)	O
]	O
.	O

Mutations	B-Var
in	O
the	O
dysferlin	B-Gene
gene	O
cause	B-Reg
both	O
Miyoshi	B-Disease
myopathy	I-Disease
(	O
MM	O
)	O
and	O
limb	B-Disease
girdle	I-Disease
muscular	I-Disease
dystrophy	I-Disease
2B	I-Disease
(	O
LGMD2B	O
)	O
.	O

We	O
examined	O
patients	O
with	O
dysferlinopathy	O
in	O
Japan	O
,	O
and	O
identified	O
28	O
and	O
12	O
different	O
mutations	O
respectively	O
in	O
MM	O
and	O
LGMD2B	O
patients	O
.	O

The	O
mean	O
age	O
at	O
onset	O
of	O
the	O
patients	O
with	O
MM	O
was	O
22	O
+	O
/-	O
9	O
years	O
(	O
range	O
12	O
-	O
48	O
years	O
)	O
and	O
that	O
of	O
the	O
patients	O
with	O
LGMD2B	O
was	O
26	O
+	O
/-	O
10	O
years	O
(	O
range	O
11	O
-	O
43	O
years	O
)	O
.	O

On	O
the	O
average	O
,	O
the	O
first	O
use	O
of	O
a	O
cane	O
was	O
at	O
33	O
years	O
(	O
14	O
years	O
after	O
the	O
onset	O
)	O
for	O
MM	O
and	O
39	O
years	O
(	O
15	O
years	O
after	O
onset	O
)	O
for	O
LGMD	O
2B.	O
Patients	O
became	O
wheelchair	O
-	O
bound	O
at	O
41	O
years	O
(	O
21	O
years	O
after	O
onset	O
)	O
in	O
MM	O
and	O
45	O
years	O
(	O
21	O
years	O
after	O
onset	O
)	O
for	O
LGMD2B.	O
The	O
mean	O
maximum	O
serum	O
CK	O
level	O
at	O
any	O
age	O
of	O
the	O
patients	O
was	O
5,829	O
+	O
/-	O
4,273	O
IU	O
/	O
l	O
(	O
range	O
1,289	O
-	O
12,566	O
IU	O
/	O
l	O
)	O
for	O
MM	O
and	O
3,787	O
+	O
/-	O
2,493	O
IU	O
/	O
l	O
(	O
627	O
-	O
10,000	O
IU	O
/	O
l	O
)	O
for	O
LGMD2B	O
:	O
in	O
both	O
disorders	O
,	O
the	O
serum	O
CK	O
level	O
fell	O
in	O
proportion	O
to	O
the	O
duration	O
of	O
the	O
illness	O
.	O

We	O
have	O
identified	O
four	O
common	O
four	O
mutations	O
(	O
C1939	O
G	O
,	O
G3370	O
T	O
,	O
3746delG	O
,	O
and	O
4870delT	O
)	O
in	O
Japanese	O
patients	O
with	O
MM	O
,	O
accounting	O
for	O
48	O
percent	O
of	O
all	O
MM	O
mutations	O
in	O
this	O
population	O
.	O

Two	O
of	O
the	O
four	O
mutations	O
(	O
G3370	O
T	O
,	O
and	O
4870delT	O
)	O
accounted	O
for	O
52	O
percent	O
of	O
the	O
mutations	O
in	O
LGMD2B	O
patients	O
,	O
while	O
the	O
3746delG	O
mutation	O
was	O
not	O
found	O
in	O
patients	O
with	O
LGMD2B.	O
The	O
G3370	B-Var
T	I-Var
mutation	O
may	O
be	O
associated	B-Reg
with	I-Reg
a	O
milder	O
form	O
of	O
MM	B-Disease
and	O
LGMD2B.	B-Disease
By	O
contrast	O
,	O
the	O
G3510A	B-Var
mutation	O
appears	O
to	O
be	O
associated	B-Reg
with	I-Reg
a	O
severe	O
form	O
of	O
MM	B-Disease
.	O

[	O
Molecular	O
pathomechanism	O
of	O
distal	O
myopathy	O
with	O
rimmed	O
vacuoles	O
]	O
.	O

Distal	B-Disease
myopathy	I-Disease
with	I-Disease
rimmed	I-Disease
vacuoles	I-Disease
(	O
DMRV	O
)	O
and	O
hereditary	B-Disease
inclusion	I-Disease
body	I-Disease
myopathy	I-Disease
(	O
HIBM	O
)	O
are	O
genetically	O
identical	O
autosomal	O
recessive	O
muscle	O
disorders	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
GNE	B-Gene
gene	O
.	O

This	O
gene	O
encodes	O
a	O
bifunctional	O
protein	O
with	O
UDP	O
-	O
GlcNAc	O
2-epimerase	O
and	O
ManNAc	O
kinase	O
activities	O
that	O
catalyze	O
the	O
rate	O
limiting	O
step	O
and	O
the	O
succeeding	O
step	O
,	O
respectively	O
,	O
in	O
the	O
sialic	O
acid	O
biosynthetic	O
pathway	O
.	O

V572L	O
mutation	O
is	O
the	O
most	O
prevalent	O
among	O
Japanese	O
DMRV	O
patients	O
and	O
accounts	O
for	O
about	O
60	O
%	O
of	O
mutant	O
alleles	O
.	O

Clinical	O
spectrum	O
of	O
DMRV	O
/	O
HIBM	O
seems	O
to	O
be	O
wider	O
than	O
previously	O
thought	O
in	O
terms	O
of	O
both	O
the	O
severity	O
of	O
the	O
disease	O
and	O
the	O
range	O
of	O
affected	O
organs	O
.	O

There	O
are	O
rare	O
asymptomatic	O
homozygotes	O
with	O
missense	O
GNE	O
mutations	O
,	O
indicating	O
the	O
presence	O
of	O
mitigating	O
factors	O
.	O

Surprisingly	O
,	O
more	O
than	O
10	O
%	O
of	O
the	O
patients	O
had	O
a	O
variety	O
of	O
cardiac	O
abnormalities	O
,	O
suggesting	O
that	O
skeletal	O
muscle	O
may	O
not	O
be	O
the	O
only	O
organ	O
involved	O
.	O

Studies	O
on	O
recombinant	O
GNE	B-Gene
demonstrate	O
a	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
nature	O
of	O
the	O
missense	O
mutations	B-Var
identified	O
.	O

Patients	O
'	O
cells	O
show	O
decreased	B-NegReg
sialylation	B-MPA
status	I-MPA
which	O
can	O
be	O
recovered	O
by	O
adding	O
GNE	O
metabolites	O
,	O
such	O
as	O
ManNAc	O
and	O
NeuAc	O
.	O

This	O
indicates	O
the	O
possibility	O
of	O
developing	O
a	O
therapy	O
for	O
DMRV	O
/	O
HIBM	O
by	O
giving	O
these	O
metabolites	O
to	O
patients	O
although	O
we	O
have	O
to	O
await	O
the	O
model	O
mice	O
that	O
are	O
currently	O
being	O
produced	O
at	O
several	O
laboratories	O
.	O

X	B-Disease
linked	I-Disease
cone	I-Disease
-	I-Disease
rod	I-Disease
dystrophy	I-Disease
,	O
CORDX3	O
,	O
is	O
caused	B-Reg
by	I-Reg
a	O
mutation	B-Var
in	O
the	O
CACNA1F	B-Gene
gene	O
.	O

BACKGROUND	O
:	O
X	B-Disease
linked	I-Disease
cone	I-Disease
-	I-Disease
rod	I-Disease
dystrophy	I-Disease
(	O
CORDX	O
)	O
is	O
a	O
recessive	O
retinal	O
disease	O
characterised	O
by	O
progressive	O
dysfunction	O
of	O
photoreceptors	O
.	O

It	O
is	O
genetically	O
heterogeneous	O
,	O
showing	O
linkage	O
to	O
three	O
X	O
chromosomal	O
loci	O
.	O

CORDX1	B-Disease
is	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
RPGR	B-Gene
gene	O
(	O
Xp21.1	O
)	O
,	O
CORDX2	O
is	O
located	O
on	O
Xq27.2	O
-	O
28	O
,	O
and	O
we	O
recently	O
localised	O
CORDX3	O
to	O
Xp11.4-q13.1	O
.	O

We	O
aimed	O
to	O
identify	O
the	O
causative	O
gene	O
behind	O
the	O
CORDX3	O
phenotype	O
.	O

METHODS	O
:	O
All	O
48	O
exons	O
of	O
the	O
CACNA1F	O
gene	O
were	O
screened	O
for	O
mutations	O
by	O
DNA	O
sequencing	O
.	O

RNA	O
from	O
cultured	O
lymphoblasts	O
and	O
peripheral	O
blood	O
activated	O
T	O
lymphocytes	O
was	O
analysed	O
by	O
RT	O
-	O
PCR	O
and	O
sequencing	O
.	O

RESULTS	O
:	O
A	O
novel	O
CACNA1F	O
mutation	O
,	O
IVS28	O
-	O
1	O
GCGTC	O
>	O
TGG	O
,	O
in	O
the	O
splice	O
acceptor	O
site	O
of	O
intron	O
28	O
was	O
identified	O
.	O

Messenger	O
RNA	O
studies	O
indicated	O
that	O
the	O
identified	O
mutation	B-Var
leads	O
to	O
altered	B-Reg
splicing	B-MPA
of	O
the	O
CACNA1F	B-Gene
transcript	B-MPA
.	O

Aberrant	B-Var
splice	I-Var
variants	I-Var
are	O
predicted	O
to	O
result	B-Reg
in	I-Reg
premature	B-MPA
termination	I-MPA
and	O
deletions	B-Var
of	O
the	O
encoded	B-Protein
protein	I-Protein
,	O
Ca(v)1.4	O
alpha1	O
subunit	O
.	O

CONCLUSION	O
:	O
CACNA1F	B-Gene
mutations	B-Var
cause	B-Reg
the	O
retinal	B-Disease
disorder	I-Disease
,	O
incomplete	O
congenital	B-Disease
stationary	I-Disease
night	I-Disease
blindness	I-Disease
(	O
CSNB2	O
)	O
,	O
although	O
mutations	O
have	O
also	O
been	O
detected	O
in	O
patients	O
with	O
divergent	O
diagnoses	O
.	O

Our	O
results	O
indicate	O
that	O
yet	O
another	O
phenotype	O
,	O
CORDX3	B-Disease
,	O
is	O
caused	B-Reg
by	I-Reg
a	O
mutation	B-Var
in	O
CACNA1F.	B-Gene
Clinically	O
,	O
CORDX3	O
shares	O
some	O
features	O
with	O
CSNB2	O
but	O
is	O
distinguishable	O
from	O
CSNB2	O
in	O
that	O
it	O
is	O
progressive	O
,	O
can	O
begin	O
in	O
adulthood	O
,	O
has	O
no	O
nystagmus	O
or	O
hyperopic	O
refraction	O
,	O
has	O
only	O
low	O
grade	O
astigmatism	O
,	O
and	O
in	O
dark	O
adaptation	O
lacks	O
cone	O
threshold	O
and	O
has	O
small	O
or	O
no	O
elevation	O
of	O
rod	O
threshold	O
.	O

Considering	O
all	O
features	O
,	O
CORDX3	O
is	O
more	O
similar	O
to	O
other	O
X	O
chromosomal	O
cone	O
-	O
rod	O
dystrophies	O
than	O
to	O
CSNB2	O
.	O

Novel	O
JARID1C	O
/	O
SMCX	O
mutations	O
in	O
patients	O
with	O
X	O
-	O
linked	O
mental	O
retardation	O
.	O

X	B-Disease
-	I-Disease
linked	I-Disease
mental	I-Disease
retardation	I-Disease
(	O
XLMR	O
)	O
is	O
a	O
heterogeneous	O
disorder	O
that	O
affects	O
approximately	O
2	O
in	O
1000	O
males	O
.	O

JARID1C	O
/	O
SMCX	O
is	O
relatively	O
new	O
among	O
the	O
known	O
XLMR	O
genes	O
,	O
and	O
seven	O
different	O
mutations	O
have	O
been	O
identified	O
previously	O
in	O
this	O
gene	O
[	O
Jensen	O
LR	O
et	O
al	O
.	O

,	O
Am	O
.	O

J.	O
Hum	O
.	O

Genet	O
.	O

76:227	O
-	O
236	O
,	O
2005	O
]	O
.	O

Here	O
,	O
we	O
report	O
five	O
novel	O
JARID1C	B-Gene
mutations	O
in	B-Reg
five	O
XLMR	B-Disease
families	O
.	O

The	O
changes	O
comprise	O
one	O
nonsense	O
mutation	O
(	B-Var
p	I-Var
.	I-Var
Arg332X	I-Var
)	I-Var
and	O
four	O
missense	O
mutations	O
(	B-Var
p	I-Var
.	I-Var
Asp87Gly	I-Var
;	I-Var
p	B-Var
.	I-Var
Phe642Leu	I-Var
;	I-Var
p	B-Var
.	I-Var
Arg750Trp	I-Var
;	I-Var
p	B-Var
.	I-Var
Tyr751Cys	I-Var
)	I-Var
affecting	O
evolutionarily	O
conserved	O
amino	O
acids	O
.	O

The	O
degree	O
of	O
mental	O
retardation	O
in	O
the	O
affected	O
males	O
ranged	O
from	O
mild	O
to	O
severe	O
,	O
and	O
some	O
patients	O
suffered	O
from	O
additional	O
disorders	O
such	O
as	O
epilepsy	O
,	O
short	O
stature	O
,	O
or	O
behavioral	O
problems	O
.	O

This	O
study	O
brings	O
the	O
total	O
number	O
of	O
reported	O
JARID1C	O
mutations	O
to	O
twelve	O
.	O

In	O
contrast	O
to	O
other	O
XLMR	O
genes	O
in	O
which	O
mutations	O
were	O
found	O
only	O
in	O
single	O
or	O
very	O
few	O
families	O
,	O
JARID1C	O
appears	O
to	O
be	O
one	O
of	O
the	O
more	O
frequently	O
mutated	O
genes	O
in	O
this	O
disorder	O
.	O

Missense	B-Var
mutations	I-Var
in	O
SH2D1A	B-Gene
identified	O
in	O
patients	O
with	B-Reg
X	B-Disease
-	I-Disease
linked	I-Disease
lymphoproliferative	I-Disease
disease	I-Disease
differentially	O
affect	O
the	O
expression	O
and	O
function	O
of	O
SAP	O
.	O

X	B-Disease
-	I-Disease
linked	I-Disease
lymphoproliferative	I-Disease
disease	I-Disease
(	O
XLP	O
)	O
is	O
an	O
immunodeficiency	O
resulting	B-Reg
from	I-Reg
mutations	B-Var
in	O
SH2D1A	B-Gene
,	O
which	O
encodes	O
signalling	O
lymphocytic	O
activation	O
molecule	O
(	O
SLAM)-associated	O
protein	O
(	O
SAP	O
)	O
.	O

In	O
addition	O
to	O
SLAM	O
,	O
SAP	O
associates	O
with	O
several	O
other	O
cell	O
-	O
surface	O
receptors	O
including	O
2B4	O
(	O
CD244	O
)	O
,	O
Ly9	O
(	O
CD229	O
)	O
,	O
CD84	O
and	O
NTB	O
-	O
A.	O
SAP	O
contains	O
a	O
single	O
src	O
-	O
homology-2	O
domain	O
and	O
acts	O
as	O
an	O
intracellular	O
adaptor	O
protein	O
by	O
recruiting	O
the	O
protein	O
tyrosine	O
kinase	O
FynT	O
to	O
the	O
cytoplasmic	O
domains	O
of	O
some	O
of	O
these	O
receptors	O
,	O
which	O
results	O
in	O
the	O
initiation	O
of	O
specific	O
downstream	O
signal	O
transduction	O
pathways	O
.	O

XLP	O
is	O
likely	O
to	O
result	O
from	O
perturbed	O
signalling	O
through	O
one	O
or	O
more	O
of	O
these	O
SAP	O
-	O
associating	O
receptors	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
missense	O
(	O
Y54C	O
,	O
I84	O
T	O
and	O
F87S	O
)	O
and	O
insertion	O
(	O
fs82	O
--	O
>	O
X103	O
)	O
mutations	O
in	O
four	O
different	O
kindreds	O
affected	O
by	O
XLP	O
.	O

Each	O
mutation	B-Var
dramatically	O
reduced	B-NegReg
the	O
half	B-MPA
-	I-MPA
life	I-MPA
of	O
SAP	B-Protein
,	O
thus	O
diminishing	B-NegReg
its	O
expression	B-MPA
in	O
primary	O
lymphocytes	O
as	O
well	O
as	O
in	O
transfected	O
cell	O
lines	O
.	O

Interestingly	O
,	O
although	O
the	O
Y54C	B-Var
and	O
F87S	B-Var
mutations	O
compromised	B-NegReg
the	O
ability	B-MPA
of	O
SAP	B-Protein
to	O
associate	B-Interaction
with	O
different	O
receptors	O
,	O
the	O
I84	O
T	O
mutation	O
had	O
no	O
effect	O
on	O
the	O
ability	O
of	O
SAP	O
to	O
bind	O
SLAM	O
,	O
CD84	O
or	O
2B4	O
.	O

However	O
,	O
signalling	B-MPA
downstream	I-MPA
of	I-MPA
SLAM	I-MPA
was	O
reduced	B-NegReg
in	O
the	O
presence	O
of	O
SAP	B-Protein
bearing	O
the	O
I84	B-Var
T	I-Var
mutation	O
.	O

These	O
findings	O
indicate	O
that	O
,	O
irrespective	O
of	O
the	O
type	O
of	O
mutation	O
,	O
signalling	O
through	O
SAP	O
-	O
associating	O
receptors	O
in	O
XLP	O
can	O
be	O
impaired	O
by	O
reducing	O
the	O
expression	O
of	O
SAP	O
,	O
the	O
ability	O
of	O
SAP	O
to	O
bind	O
surface	O
receptors	O
and/or	O
its	O
ability	O
to	O
activate	O
signal	O
transduction	O
downstream	O
of	O
the	O
SLAM	O
-	O
SAP	O
complex	O
.	O

The	O
R110C	B-Var
mutation	O
in	O
Notch3	B-Gene
causes	B-Reg
variable	O
clinical	O
features	O
in	O
two	O
Turkish	O
families	O
with	O
CADASIL	B-Disease
syndrome	I-Disease
.	O

Mutations	B-Var
in	O
Notch3	B-Gene
gene	O
are	O
responsible	B-Reg
for	O
the	O
cerebral	B-Disease
autosomal	I-Disease
dominant	I-Disease
arteriopathy	I-Disease
with	I-Disease
subcortical	I-Disease
infarcts	I-Disease
and	I-Disease
leukoencephalopathy	I-Disease
(	O
CADASIL	O
)	O
.	O

It	O
is	O
a	O
late	O
onset	O
neurological	O
disorder	O
recognized	O
by	O
recurrent	O
strokes	O
and	O
dementia	O
.	O

We	O
describe	O
here	O
the	O
clinical	O
and	O
molecular	O
findings	O
of	O
three	O
unrelated	O
Turkish	O
families	O
with	O
CADASIL	O
syndrome	O
.	O

Two	O
of	O
the	O
families	O
were	O
identified	O
to	O
have	O
the	O
same	O
mutation	O
,	O
p	O
.	O
R110C	O
(	O
c	O
.	O

C328	O
T	O
)	O
,	O
located	O
in	O
exon	O
3	O
of	O
the	O
Notch3	O
gene	O
.	O

Interestingly	O
,	O
the	O
phenotypic	O
expression	O
of	O
the	O
disease	O
in	O
these	O
two	O
families	O
was	O
markedly	O
different	O
in	O
severity	O
and	O
age	O
of	O
onset	O
implicating	O
additional	O
genetic	O
and/or	O
non	O
-	O
genetic	O
modulating	O
factors	O
involved	O
in	O
the	O
pathogenesis	O
.	O

In	O
addition	O
,	O
we	O
identified	O
the	O
novel	O
p	O
.	O
C201R	O
(	O
c	O
.	O

T601C	O
)	O
mutation	O
in	O
exon	O
4	O
of	O
the	O
Notch3	O
gene	O
in	O
a	O
proband	O
of	O
the	O
third	O
family	O
with	O
two	O
consecutive	O
stroke	O
-	O
like	O
episodes	O
and	O
typical	O
MRI	O
findings	O
.	O

Mutations	B-Var
described	O
here	O
cause	B-Reg
an	O
odd	B-MPA
number	I-MPA
of	I-MPA
cysteines	I-MPA
in	I-MPA
the	I-MPA
N	I-MPA
-	I-MPA
terminal	I-MPA
of	I-MPA
the	I-MPA
EGF	I-MPA
domain	I-MPA
of	O
Notch3	B-Gene
protein	B-Protein
,	O
which	O
seems	O
to	O
have	O
an	O
important	O
functional	O
effect	B-Reg
in	O
the	O
pathophysiology	O
of	O
CADASIL	B-Disease
.	O

The	O
phenotypic	O
variability	O
in	O
families	O
carrying	O
the	O
same	O
molecular	O
defect	O
as	O
presented	O
here	O
makes	O
the	O
prediction	O
of	O
prognosis	O
inconceivable	O
.	O

Although	O
DNA	O
analysis	O
is	O
effective	O
and	O
valuable	O
in	O
diagnosing	O
approximately	O
90	O
%	O
of	O
the	O
CADASIL	O
patients	O
,	O
lack	O
of	O
genotype	O
-	O
phenotype	O
correlation	O
and	O
prognostic	O
parameters	O
makes	O
the	O
presymptomatic	O
genetic	O
counseling	O
very	O
difficult	O
.	O

Entries	O
in	O
the	O
Leiden	O
Duchenne	O
muscular	O
dystrophy	O
mutation	O
database	O
:	O
an	O
overview	O
of	O
mutation	O
types	O
and	O
paradoxical	O
cases	O
that	O
confirm	O
the	O
reading	O
-	O
frame	O
rule	O
.	O

The	O
severe	O
Duchenne	B-Disease
and	O
milder	O
Becker	B-Disease
muscular	I-Disease
dystrophy	I-Disease
are	O
both	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
DMD	B-Gene
gene	O
.	O

This	O
gene	O
codes	O
for	O
dystrophin	O
,	O
a	O
protein	O
important	O
for	O
maintaining	O
the	O
stability	O
of	O
muscle	O
-	O
fiber	O
membranes	O
.	O

In	O
1988	O
,	O
Monaco	O
and	O
colleagues	O
postulated	O
an	O
explanation	O
for	O
the	O
phenotypic	O
difference	O
between	O
Duchenne	O
and	O
Becker	O
patients	O
in	O
the	O
reading	O
-	O
frame	O
rule	O
:	O
In	O
Duchenne	B-Disease
patients	O
,	O
mutations	B-Var
induce	B-Reg
a	B-MPA
shift	I-MPA
in	I-MPA
the	I-MPA
reading	I-MPA
frame	I-MPA
leading	B-Reg
to	O
prematurely	B-MPA
truncated	I-MPA
,	O
dysfunctional	B-NegReg
dystrophins	B-Protein
.	O

In	O
Becker	B-Disease
patients	O
,	O
in	B-Var
-	I-Var
frame	I-Var
mutations	I-Var
allow	B-Reg
the	O
synthesis	B-MPA
of	I-MPA
internally	I-MPA
deleted	I-MPA
,	O
but	O
largely	B-PosReg
functional	I-PosReg
dystrophins	B-Protein
.	O

Currently	O
,	O
over	O
4700	O
mutations	O
have	O
been	O
reported	O
in	O
the	O
Leiden	O
DMD	O
mutation	O
database	O
,	O
of	O
which	O
91	O
%	O
are	O
in	O
agreement	O
with	O
this	O
rule	O
.	O

In	O
this	O
study	O
we	O
provide	O
an	O
update	O
of	O
the	O
mutational	O
variability	O
in	O
the	O
DMD	O
gene	O
,	O
particularly	O
focusing	O
on	O
genotype	O
-	O
phenotype	O
correlations	O
and	O
mutations	O
that	O
appear	O
to	O
be	O
exceptions	O
to	O
the	O
reading	O
-	O
frame	O
rule	O
.	O

Prevalence	O
of	O
disease	O
-	O
causing	O
mutations	O
in	O
families	O
with	O
autosomal	O
dominant	O
retinitis	O
pigmentosa	O
:	O
a	O
screen	O
of	O
known	O
genes	O
in	O
200	O
families	O
.	O

PURPOSE	O
:	O
To	O
survey	O
families	O
with	O
clinical	O
evidence	O
of	O
autosomal	B-Disease
dominant	I-Disease
retinitis	I-Disease
pigmentosa	I-Disease
(	O
adRP	O
)	O
for	O
mutations	O
in	O
genes	O
known	O
to	O
cause	O
adRP	O
.	O

METHODS	O
:	O
Two	O
hundred	O
adRP	O
families	O
,	O
drawn	O
from	O
a	O
cohort	O
of	O
more	O
than	O
400	O
potential	O
families	O
,	O
were	O
selected	O
by	O
analysis	O
of	O
pedigrees	O
.	O

Minimum	O
criteria	O
for	O
inclusion	O
in	O
the	O
adRP	O
cohort	O
included	O
either	O
evidence	O
of	O
at	O
least	O
three	O
generations	O
of	O
affected	O
individuals	O
or	O
two	O
generations	O
with	O
evidence	O
of	O
male	O
-	O
to	O
-	O
male	O
transmission	O
.	O

Probands	O
from	O
each	O
family	O
were	O
screened	O
for	O
mutations	B-Var
in	O
13	O
genes	O
known	O
to	O
cause	B-Reg
adRP	B-Disease
:	I-Disease
CA4	B-Gene
,	O
CRX	B-Gene
,	O
FSCN2	B-Gene
,	O
IMPDH1	B-Gene
,	O
NRL	B-Gene
,	O
PRPF3	B-Gene
(	O
RP18	O
)	O
,	O
PRPF8	B-Gene
(	O
RP13	O
)	O
,	O
PRPF31	B-Gene
(	O
RP11	O
)	O
,	O
RDS	B-Gene
,	O
RHO	B-Gene
,	O
ROM1	B-Gene
,	O
RP1	B-Gene
,	O
and	O
RP9	B-Gene
.	O

Families	O
without	O
mutations	O
in	O
autosomal	O
genes	O
and	O
in	O
which	O
an	O
X	O
-	O
linked	O
mode	O
of	O
inheritance	O
could	O
not	O
be	O
excluded	O
were	O
tested	O
for	O
mutations	O
in	O
ORF	O
15	O
of	O
X	O
-	O
linked	O
RPGR	O
.	O

Potentially	O
pathogenic	O
variants	O
were	O
evaluated	O
based	O
on	O
a	O
variety	O
of	O
genetic	O
and	O
computational	O
criteria	O
,	O
to	O
confirm	O
or	O
exclude	O
pathogenicity	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
82	O
distinct	O
,	O
rare	O
(	O
nonpolymorphic	O
)	O
variants	O
were	O
detected	O
among	O
the	O
genes	O
tested	O
.	O

Of	O
these	O
,	O
57	O
are	O
clearly	O
pathogenic	O
based	O
on	O
multiple	O
criteria	O
,	O
10	O
are	O
probably	O
pathogenic	O
,	O
and	O
15	O
are	O
probably	O
benign	O
.	O

In	O
the	O
cohort	O
of	O
200	O
families	O
,	O
94	O
(	O
47	O
%	O
)	O
have	O
one	O
of	O
the	O
clearly	O
pathogenic	O
variants	O
and	O
10	O
(	O
5	O
%	O
)	O
have	O
one	O
of	O
the	O
probably	O
pathogenic	O
variants	O
.	O

One	O
family	O
(	O
0.5	O
%	O
)	O
has	O
digenic	O
RDS	O
-	O
ROM1	O
mutations	O
.	O

Two	O
families	O
(	O
1	O
%	O
)	O
have	O
a	O
pathogenic	O
RPGR	O
mutation	O
,	O
indicating	O
that	O
families	O
with	O
apparent	O
autosomal	O
transmission	O
of	O
RP	O
may	O
actually	O
have	O
X	O
-	O
linked	O
genetic	O
disease	O
.	O

Thus	O
,	O
107	O
families	O
(	O
53.5	O
%	O
)	O
have	O
mutations	O
in	O
known	O
genes	O
,	O
leaving	O
93	O
whose	O
underlying	O
cause	O
is	O
still	O
unknown	O
.	O

CONCLUSIONS	O
:	O
Together	O
,	O
the	O
known	O
adRP	O
genes	O
account	O
for	O
retinal	O
disease	O
in	O
approximately	O
half	O
of	O
the	O
families	O
in	O
this	O
survey	O
,	O
mostly	O
Americans	O
of	O
European	O
origin	O
.	O

Among	O
the	O
adRP	O
genes	O
,	O
IMPDH1	O
,	O
PRPF8	O
,	O
PRPF31	O
,	O
RDS	O
,	O
RHO	O
,	O
and	O
RP1	O
each	O
accounts	O
for	O
more	O
than	O
2	O
%	O
of	O
the	O
total	O
;	O
CRX	O
,	O
PRPF3	O
,	O
and	O
RPGR	O
each	O
accounts	O
for	O
roughly	O
1	O
%	O
.	O

Disease	O
-	O
causing	O
mutations	O
were	O
not	O
found	O
in	O
CA4	O
,	O
FSCN2	O
,	O
NRL	O
,	O
or	O
RP9	O
.	O

Because	O
some	O
mutations	O
are	O
frequent	O
and	O
some	O
regions	O
are	O
more	O
likely	O
to	O
harbor	O
mutations	O
than	O
others	O
,	O
more	O
than	O
two	O
thirds	O
of	O
the	O
detected	O
mutations	O
can	O
be	O
found	O
by	O
screening	O
less	O
than	O
10	O
%	O
of	O
the	O
total	O
gene	O
sequences	O
.	O

Among	O
the	O
remaining	O
families	O
,	O
mutations	O
may	O
lie	O
in	O
regions	O
of	O
known	O
genes	O
that	O
were	O
not	O
tested	O
,	O
mutations	O
may	O
not	O
be	O
detectable	O
by	O
PCR	O
-	O
based	O
sequencing	O
,	O
or	O
other	O
loci	O
may	O
be	O
involved	O
.	O

Clinical	O
and	O
genetic	O
analysis	O
of	O
Korean	O
patients	O
with	O
Miyoshi	O
myopathy	O
:	O
identification	O
of	O
three	O
novel	O
mutations	O
in	O
the	O
DYSF	O
gene	O
.	O

Miyoshi	B-Disease
myopathy	I-Disease
(	O
MM	O
)	O
is	O
an	O
autosomal	O
recessive	O
distal	O
muscular	O
dystrophy	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
dysferlin	O
gene	O
(	B-Gene
DYSF	I-Gene
)	I-Gene
on	O
chromosome	O
2p13	O
.	O

Although	O
MM	O
patients	O
and	O
their	O
mutations	O
in	O
the	O
DYSF	O
gene	O
have	O
been	O
found	O
from	O
all	O
over	O
the	O
world	O
,	O
there	O
is	O
only	O
one	O
report	O
of	O
genetically	O
confirmed	O
case	O
of	O
MM	O
in	O
Korea	O
.	O

Recently	O
,	O
we	O
encountered	O
three	O
unrelated	O
Korean	O
patients	O
with	O
MM	O
and	O
two	O
of	O
them	O
have	O
previously	O
been	O
considered	O
as	O
having	O
a	O
type	O
of	O
inflammatory	O
myopathy	O
.	O

The	O
clinical	O
and	O
laboratory	O
evaluation	O
showed	O
typical	O
features	O
of	O
muscle	O
involvement	O
in	O
MM	O
in	O
all	O
patients	O
but	O
one	O
patient	O
initially	O
had	O
moderate	O
proximal	O
muscle	O
involvement	O
and	O
another	O
showed	O
incomplete	O
quadriparesis	O
with	O
rapid	O
progression	O
.	O

Direct	O
sequencing	O
analysis	O
of	O
the	O
DYSF	O
gene	O
revealed	O
that	O
each	O
patient	O
had	O
compound	O
heterozygous	O
mutations	O
(	O
Gln832X	O
and	O
Trp992Arg	O
,	O
Gln832X	O
and	O
Trp999Cys	O
,	O
and	O
Lys1103X	O
and	O
Ile1401HisfsX8	O
,	O
respectively	O
)	O
among	O
which	O
three	O
were	O
novel	O
.	O

Although	O
MM	O
has	O
been	O
thought	O
to	O
be	O
quite	O
rare	O
in	O
Korea	O
,	O
it	O
should	O
be	O
considered	O
in	O
a	O
differential	O
diagnosis	O
of	O
patients	O
exhibiting	O
distal	O
myopathy	O
.	O

UBE2A	B-Gene
,	O
which	O
encodes	O
a	O
ubiquitin	O
-	O
conjugating	O
enzyme	O
,	O
is	O
mutated	B-Var
in	B-Reg
a	O
novel	O
X	B-Disease
-	I-Disease
linked	I-Disease
mental	I-Disease
retardation	I-Disease
syndrome	I-Disease
.	O

We	O
report	O
a	O
mutation	B-Var
of	O
UBE2A	B-Gene
/	I-Gene
HR6A	I-Gene
,	O
which	O
encodes	O
a	O
ubiquitin	O
-	O
conjugating	O
enzyme	O
(	O
E2	O
)	O
,	O
a	O
member	O
of	O
the	O
ubiquitin	O
proteasome	O
pathway	O
,	O
as	O
the	O
cause	B-Reg
of	O
a	O
novel	O
X	B-Disease
-	I-Disease
linked	I-Disease
mental	I-Disease
retardation	I-Disease
(	I-Disease
XLMR	I-Disease
)	I-Disease
syndrome	I-Disease
that	O
affects	O
three	O
males	O
in	O
a	O
two	O
-	O
generation	O
family	O
.	O

A	O
single	O
-	O
nucleotide	O
substitution	O
,	O
c.382C-->T	B-Var
in	O
UBE2A	B-Gene
,	O
led	B-Reg
to	I-Reg
a	O
premature	O
UAG	O
stop	O
codon	O
(	B-Var
Q128X	I-Var
)	I-Var
.	O

As	O
a	O
consequence	O
,	O
the	O
predicted	O
polypeptide	O
lacks	O
the	O
25	O
C	O
-	O
terminal	O
amino	O
acid	O
residues	O
.	O

The	O
importance	O
of	O
this	O
terminal	O
sequence	O
for	O
UBE2	O
function	O
is	O
inferred	O
by	O
its	O
conservation	O
in	O
vertebrates	O
and	O
in	O
Drosophila	O
.	O

UBE2A	O
mutations	O
do	O
not	O
appear	O
to	O
significantly	O
contribute	O
to	O
XLMR	O
,	O
since	O
no	O
UBE2A	O
mutations	O
were	O
identified	O
in	O
15	O
families	O
with	O
nonsyndromic	O
and	O
4	O
families	O
with	O
syndromic	O
idiopathic	O
XLMR	O
previously	O
mapped	O
to	O
intervals	O
encompassing	O
this	O
gene	O
.	O

This	O
is	O
the	O
first	O
description	O
of	O
a	O
mutation	O
in	O
a	O
ubiquitin	O
-	O
conjugating	O
enzyme	O
gene	O
as	O
the	O
cause	O
of	O
a	O
human	O
disease	O
.	O

Twenty	O
-	O
one	O
novel	O
mutations	B-Var
in	O
the	O
GLB1	B-Gene
gene	O
identified	O
in	B-Reg
a	O
large	O
group	O
of	O
GM1-gangliosidosis	B-Disease
and	O
Morquio	B-Disease
B	I-Disease
patients	O
:	O
possible	O
common	O
origin	O
for	O
the	O
prevalent	O
p	O
.	O
R59H	O
mutation	O
among	O
gypsies	O
.	O

GM1-gangliosidosis	B-Disease
and	O
Morquio	B-Disease
B	I-Disease
disease	O
are	O
rare	O
lysosomal	O
storage	O
disorders	O
caused	B-Reg
by	I-Reg
beta	B-MPA
-	I-MPA
galactosidase	I-MPA
deficiency	B-NegReg
due	O
to	O
mutations	B-Var
in	O
the	O
GLB1	B-Gene
gene	O
.	O

Three	O
major	O
clinical	O
forms	O
of	O
GM1-gangliosidosis	O
have	O
been	O
established	O
on	O
the	O
basis	O
of	O
age	O
of	O
onset	O
and	O
severity	O
of	O
symptoms	O
:	O
infantile	O
,	O
late	O
infantile	O
/	O
juvenile	O
,	O
and	O
adult	O
.	O

We	O
performed	O
mutation	O
analysis	O
on	O
30	O
GM1-gangliosidosis	O
and	O
five	O
Morquio	O
B	O
patients	O
,	O
mainly	O
of	O
Spanish	O
origin	O
,	O
and	O
all	O
the	O
causative	O
mutations	O
were	O
identified	O
.	O

Thirty	O
different	O
mutations	O
were	O
found	O
,	O
21	O
of	O
which	O
were	O
novel	O
.	O

With	O
the	O
exception	O
of	O
two	O
adults	O
and	O
one	O
juvenile	O
patient	O
,	O
all	O
the	O
GM1-gangliosidosis	O
patients	O
were	O
affected	O
by	O
the	O
infantile	O
form	O
.	O

Clinical	O
findings	O
are	O
presented	O
for	O
all	O
patients	O
.	O

We	O
report	O
the	O
association	O
of	O
the	O
novel	O
mutations	O
p	O
.	O
T420	O
K	O
and	O
p	O
.	O
L264S	O
with	O
the	O
adult	O
form	O
and	O
the	O
juvenile	O
form	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
the	O
novel	O
mutation	O
p	B-Var
.	I-Var
Y83C	I-Var
was	O
associated	B-Reg
with	I-Reg
Morquio	B-Disease
B	I-Disease
disease	O
.	O

Among	O
the	O
30	O
GM1-gangliosidosis	O
patients	O
,	O
6	O
were	O
of	O
Gypsy	O
origin	O
(	O
Roma	O
)	O
.	O

Moreover	O
,	O
those	O
six	O
Gypsy	O
patients	O
shared	O
not	O
only	O
the	O
same	O
mutation	O
(	O
p	O
.	O
R59H	O
)	O
but	O
also	O
a	O
common	O
haplotype	O
.	O

This	O
observation	O
indicates	O
a	O
possible	O
founder	O
effect	O
in	O
this	O
group	O
and	O
suggests	O
that	O
screening	O
of	O
the	O
p	O
.	O
R59H	O
mutation	O
may	O
be	O
appropriate	O
in	O
GM1-gangliosidosis	O
patients	O
of	O
Gypsy	O
origin	O
.	O

This	O
is	O
the	O
first	O
exhaustive	O
mutational	O
analysis	O
performed	O
in	O
a	O
large	O
group	O
of	O
Iberian	O
GM1-gangliosidosis	O
and	O
Morquio	O
B	O
patients	O
.	O

Misregulation	O
of	O
alternative	O
splicing	O
causes	O
pathogenesis	O
in	O
myotonic	O
dystrophy	O
.	O

Myotonic	B-Disease
dystrophy	I-Disease
(	O
DM	O
)	O
,	O
the	O
most	O
common	O
form	O
of	O
adult	O
onset	O
muscular	O
dystrophy	O
,	O
affects	O
skeletal	O
muscle	O
,	O
heart	O
,	O
and	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
.	O

Mortality	O
results	O
primarily	O
from	O
muscle	O
wasting	O
and	O
cardiac	O
arrhythmias	O
.	O

There	O
are	O
two	O
forms	O
of	O
the	O
disease	O
:	O
DM1	O
and	O
DM2	O
.	O

DM1	O
,	O
which	O
constitutes	O
98	O
%	O
of	O
cases	O
,	O
is	O
caused	O
by	O
a	O
CTG	O
expansion	O
in	O
the	O
3	O
'	O
untranslated	O
region	O
(	O
UTR	O
)	O
of	O
the	O
DMPK	O
gene	O
.	O

DM2	B-Disease
is	O
caused	B-Reg
by	I-Reg
a	O
CCTG	B-Var
expansion	I-Var
in	O
the	O
first	O
intron	O
of	O
the	O
ZNF9	B-Gene
gene	O
.	O

RNA	O
containing	O
CUG-	O
or	O
CCUG	O
-	O
expanded	O
repeats	O
are	O
transcribed	O
but	O
are	O
retained	O
in	O
the	O
nucleus	O
in	O
foci	O
.	O

Disease	O
pathogenesis	O
results	O
primarily	O
from	O
a	O
gain	B-PosReg
of	I-PosReg
function	I-PosReg
of	O
the	O
expanded	B-MPA
RNAs	I-MPA
,	O
which	O
alter	B-Reg
developmentally	B-MPA
regulated	I-MPA
alternative	I-MPA
splicing	I-MPA
as	O
well	O
as	O
pathways	B-Pathway
of	I-Pathway
muscle	I-Pathway
differentiation	I-Pathway
.	O

The	O
toxic	O
RNA	O
has	O
been	O
implicated	O
in	O
sequestration	O
of	O
splicing	O
regulators	O
and	O
transcription	O
factors	O
thereby	O
causing	O
specific	O
symptoms	O
of	O
the	O
disease	O
.	O

Here	O
we	O
review	O
the	O
proposed	O
mechanisms	O
for	O
the	O
toxic	O
effects	O
of	O
the	O
expanded	O
repeats	O
and	O
discuss	O
the	O
molecular	O
mechanisms	O
of	O
splicing	O
misregulation	O
and	O
disease	O
pathogenesis	O
.	O

Clinical	O
aspects	O
and	O
physiopathology	O
of	O
Brugada	O
syndrome	O
:	O
review	O
of	O
current	O
concepts	O
.	O

Brugada	B-Disease
syndrome	I-Disease
(	O
BS	O
)	O
is	O
an	O
inherited	O
cardiac	O
disorder	O
characterized	O
by	O
typical	O
electrocardiographic	O
patterns	O
of	O
ST	O
segment	O
elevation	O
in	O
the	O
precordial	O
leads	O
,	O
right	O
bundle	O
branch	O
block	O
,	O
fast	O
polymorphic	O
ventricular	O
tachycardia	O
in	O
patients	O
without	O
any	O
structural	O
heart	O
disease	O
,	O
and	O
a	O
high	O
risk	O
of	O
sudden	O
cardiac	O
death	O
.	O

The	O
incidence	O
of	O
BS	O
is	O
high	O
in	O
male	O
vs.	O
female	O
(	O
i.e.	O
,	O
8	O
-	O
10/1	O
:	O
male	O
/	O
female	O
)	O
.	O

The	O
disorder	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
SCN5A	O
gene	O
encoding	O
Nav1.5	O
,	O
the	O
cardiac	O
sodium	O
channel	O
,	O
which	O
is	O
the	O
only	O
gene	O
in	O
which	O
mutations	O
were	O
found	O
to	O
cause	O
the	O
disease	O
.	O

Mutations	B-Var
in	O
SCN5A	B-Gene
associated	O
with	O
the	O
BS	B-Disease
phenotype	O
usually	O
result	O
in	O
a	O
loss	B-NegReg
of	O
channel	B-CPA
function	I-CPA
by	O
a	O
reduction	B-NegReg
in	O
Na+	B-CPA
currents	I-CPA
.	O

We	O
review	O
the	O
clinical	O
aspects	O
,	O
risk	O
stratification	O
,	O
and	O
therapeutic	O
management	O
of	O
this	O
important	O
syndrome	O
.	O

[	O
McLeod	O
syndrome	O
:	O
Multisystem	O
involvement	O
associated	O
with	O
neuroacanthocytosis	O
linked	O
to	O
X	O
chromosome	O
.	O

report	O
of	O
two	O
related	O
cases	O
]	O
.	O

Síndrome	O
de	O
McLeod	O
:	O
compromiso	O
multisistémico	O
asociado	O
a	O
neuroacantocitosis	O
ligada	O
al	O
cromosoma	O
X	O
,	O
en	O
una	O
familia	O
chilena	O
.	O

Neurological	O
abnormalities	O
associated	O
with	O
spiculated	O
,	O
"	O
acanthocytic	O
"	O
red	O
cells	O
in	O
blood	O
have	O
been	O
described	O
as	O
neuroacanthocytosis	O
.	O

This	O
is	O
a	O
heterogeneous	O
group	O
of	O
conditions	O
that	O
can	O
be	O
clearly	O
subdivided	O
on	O
the	O
basis	O
of	O
recent	O
genetic	O
findings	O
.	O

The	O
McLeod	B-Disease
Syndrome	I-Disease
,	O
one	O
of	O
the	O
core	O
neuroacanthocytosis	B-Disease
syndromes	I-Disease
,	O
is	O
a	O
rare	O
X	O
-	O
linked	O
disorder	O
caused	B-Reg
by	I-Reg
mutations	B-Var
of	O
the	O
XK	B-Gene
gene	O
,	O
an	O
X	O
-	O
chromosomal	O
gene	O
of	O
unknown	O
function	O
characterized	O
by	O
haemopoietic	O
abnormalities	O
and	O
late	O
-	O
onset	O
neurological	O
and	O
muscular	O
defects	O
.	O

We	O
report	O
two	O
Chilean	O
brothers	O
with	O
the	O
McLeod	O
phenotype	O
who	O
showed	O
important	O
psychiatric	O
features	O
.	O

The	O
diagnosis	O
may	O
be	O
elusive	O
if	O
the	O
presence	O
of	O
acanthocytosis	O
is	O
not	O
properly	O
studied	O
.	O

We	O
describe	O
a	O
method	O
which	O
allowed	O
the	O
diagnosis	O
that	O
unmasked	O
acanthocytosis	O
.	O

Otherwise	O
the	O
condition	O
could	O
have	O
remained	O
undiagnosed	O
as	O
it	O
had	O
been	O
for	O
decades	O
in	O
this	O
family	O
.	O

This	O
syndrome	O
must	O
be	O
considered	O
when	O
assessing	O
a	O
familial	O
movement	O
disorder	O
,	O
specially	O
affecting	O
males	O
with	O
relevant	O
psychiatric	O
features	O
.	O

A	O
reliable	O
test	O
for	O
acanthocytosis	O
assessment	O
is	O
available	O
.	O

A	O
new	O
variant	O
database	O
for	O
mismatch	O
repair	O
genes	O
associated	O
with	O
Lynch	O
syndrome	O
.	O

Mutations	B-Var
in	O
some	O
mismatch	O
repair	O
(	B-Gene
MMR	I-Gene
)	I-Gene
genes	O
are	O
associated	B-Reg
with	I-Reg
Lynch	B-Disease
syndrome	I-Disease
(	O
LS	O
;	O
also	O
called	O
hereditary	O
nonpolyposis	O
colorectal	O
cancer	O
[	O
HNPCC	O
]	O
)	O
,	O
an	O
autosomal	O
dominant	O
cancer	O
susceptibility	O
syndrome	O
.	O

Colorectal	O
cancer	O
(	O
CRC	O
)	O
is	O
the	O
most	O
frequent	O
cancer	O
observed	O
in	O
LS	O
.	O

However	O
,	O
tumors	O
occur	O
at	O
a	O
variety	O
of	O
extracolonic	O
sites	O
and	O
individuals	O
may	O
have	O
multiple	O
primary	O
cancers	O
.	O

LS	O
is	O
the	O
most	O
common	O
hereditary	O
form	O
of	O
CRC	O
,	O
accounting	O
for	O
approximately	O
1	O
%	O
of	O
all	O
CRC	O
.	O

Since	O
the	O
first	O
account	O
of	O
mutations	B-Var
in	O
MSH2	B-Gene
causing	B-Reg
this	O
cancer	B-Disease
susceptibility	O
syndrome	O
in	O
1993	O
,	O
mutations	B-Var
in	O
three	O
additional	O
MMR	O
genes	O
,	O
MLH1	B-Gene
,	O
MSH6	B-Gene
,	O
and	O
PMS2	B-Gene
,	O
have	O
been	O
shown	O
to	O
cause	B-Reg
LS	B-Disease
.	O

More	O
than	O
1,500	O
different	O
variants	O
have	O
been	O
identified	O
in	O
these	O
four	O
genes	O
and	O
approximately	O
80	O
%	O
of	O
the	O
alterations	O
have	O
been	O
identified	O
in	O
MLH1	O
and	O
MSH2	O
.	O

There	O
have	O
been	O
a	O
few	O
previous	O
attempts	O
to	O
systematically	O
record	O
MMR	O
variants	O
associated	O
with	O
LS	O
patients	O
;	O
however	O
,	O
they	O
were	O
not	O
complete	O
nor	O
were	O
they	O
continuously	O
updated	O
.	O

Thus	O
,	O
it	O
was	O
our	O
goal	O
to	O
generate	O
and	O
maintain	O
a	O
comprehensive	O
catalogue	O
of	O
MMR	O
variants	O
from	O
genes	O
known	O
to	O
be	O
mutated	O
in	O
LS	O
(	O
;	O
last	O
accessed	O
8	O
February	O
2007	O
)	O
.	O

Providing	O
such	O
a	O
resource	O
should	O
aid	O
investigators	O
in	O
understanding	O
the	O
significance	O
of	O
the	O
variants	O
.	O

Complete	O
androgen	O
insensitivity	O
without	O
Wolffian	O
duct	O
development	O
:	O
the	O
AR	O
-	O
A	O
form	O
of	O
the	O
androgen	O
receptor	O
is	O
not	O
sufficient	O
for	O
male	O
genital	O
development	O
.	O

BACKGROUND	O
:	O
The	O
androgen	O
receptor	O
(	O
AR	O
)	O
is	O
essential	O
for	O
the	O
differentiation	O
of	O
male	O
external	O
and	O
internal	O
genitalia	O
.	O

It	O
is	O
normally	O
present	O
in	O
two	O
forms	O
,	O
a	O
full	O
-	O
length	O
form	O
B	O
and	O
an	O
N	O
-	O
terminal	O
truncated	O
form	O
A	O
with	O
still	O
unknown	O
function	O
.	O

Mutations	B-Var
in	O
the	O
AR	B-Gene
gene	O
cause	B-Reg
androgen	B-Disease
insensitivity	I-Disease
syndrome	I-Disease
(	O
AIS	O
)	O
,	O
which	O
is	O
divided	O
into	O
subgroups	O
according	O
to	O
the	O
degree	O
of	O
undermasculinization	O
.	O

Patients	O
with	O
completely	O
female	O
external	O
genitalia	O
are	O
classified	O
as	O
complete	O
AIS	O
(	O
CAIS	O
)	O
.	O

However	O
,	O
a	O
recent	O
study	O
has	O
shown	O
that	O
some	O
CAIS	O
patients	O
have	O
signs	O
of	O
internal	O
male	O
genital	O
differentiation	O
due	O
to	O
missense	O
mutations	O
that	O
show	O
some	O
degree	O
of	O
residual	O
function	O
.	O

OBJECTIVE	O
:	O
We	O
aimed	O
to	O
study	O
the	O
expression	O
of	O
the	O
different	O
forms	O
of	O
the	O
AR	O
in	O
two	O
CAIS	O
patients	O
in	O
relation	O
to	O
the	O
development	O
of	O
male	O
internal	O
genital	O
structures	O
.	O

One	O
patient	O
had	O
a	O
mutation	O
(	O
L7fsX33	O
)	O
that	O
affects	O
only	O
the	O
full	O
-	O
length	O
AR	O
-	O
B	O
form	O
of	O
the	O
AR	O
,	O
whereas	O
the	O
other	O
had	O
a	O
nonsense	O
mutation	O
(	O
Q733X	O
)	O
affecting	O
both	O
isoforms	O
.	O

MEASUREMENTS	O
AND	O
RESULTS	O
:	O
We	O
thoroughly	O
analysed	O
internal	O
genitalia	O
at	O
surgery	O
and	O
by	O
histological	O
examination	O
.	O

No	O
signs	O
of	O
Wolffian	O
duct	O
(	O
WD	O
)	O
development	O
were	O
present	O
in	O
any	O
of	O
the	O
patients	O
.	O

Western	O
blotting	O
of	O
proteins	O
from	O
gonadal	O
and	O
genital	O
skin	O
fibroblasts	O
was	O
performed	O
with	O
AR	O
antibodies	O
directed	O
against	O
different	O
AR	O
epitopes	O
.	O

The	O
N	O
-	O
terminally	O
truncated	O
A	O
form	O
was	O
expressed	O
in	O
normal	O
amounts	O
in	O
the	O
patient	O
with	O
the	O
L7fsX33	O
mutation	O
while	O
no	O
AR	O
was	O
detected	O
in	O
the	O
other	O
patient	O
.	O

CONCLUSION	O
:	O
The	O
presence	O
of	O
the	O
AR	O
-	O
A	O
form	O
does	O
not	O
seem	O
to	O
be	O
sufficient	O
for	O
WD	O
maintenance	O
and	O
differentiation	O
.	O

Comprehensive	O
analysis	O
of	O
the	O
gene	O
encoding	O
filaggrin	O
uncovers	O
prevalent	O
and	O
rare	O
mutations	O
in	O
ichthyosis	O
vulgaris	O
and	O
atopic	O
eczema	O
.	O

We	O
recently	O
reported	O
two	O
common	O
filaggrin	O
(	B-Gene
FLG	I-Gene
)	I-Gene
null	O
mutations	B-Var
that	O
cause	B-Reg
ichthyosis	B-Disease
vulgaris	I-Disease
and	O
predispose	B-Disease
to	I-Disease
eczema	I-Disease
and	O
secondary	B-Disease
allergic	I-Disease
diseases	I-Disease
.	O

We	O
show	O
here	O
that	O
these	O
common	O
European	O
mutations	O
are	O
ancestral	O
variants	O
carried	O
on	O
conserved	O
haplotypes	O
.	O

To	O
facilitate	O
comprehensive	O
analysis	O
of	O
other	O
populations	O
,	O
we	O
report	O
a	O
strategy	O
for	O
full	O
sequencing	O
of	O
this	O
large	O
,	O
highly	O
repetitive	O
gene	O
,	O
and	O
we	O
describe	O
15	O
variants	O
,	O
including	O
seven	O
that	O
are	O
prevalent	O
.	O

All	O
the	O
variants	B-Var
are	O
either	O
nonsense	O
or	O
frameshift	O
mutations	O
that	O
,	O
in	O
representative	O
cases	O
,	O
resulted	O
in	O
loss	B-NegReg
of	O
filaggrin	B-MPA
production	I-MPA
in	O
the	O
epidermis	O
.	O

In	O
an	O
Irish	O
case	O
-	O
control	O
study	O
,	O
the	O
five	O
most	O
common	O
European	O
mutations	O
showed	O
a	O
strong	O
association	O
with	O
moderate	O
-	O
to	O
-	O
severe	O
childhood	O
eczema	O
(	O
chi2	O
test	O
:	O
P	O
=	O
2.12	O
x	O
10(-51	O
)	O
;	O
Fisher	O
's	O
exact	O
test	O
:	O
heterozygote	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
7.44	O
(	O
95	O
%	O
confidence	O
interval	O
(	O
c.i	O
.	O

)	O
=	O
4.9	O
-	O
11.3	O
)	O
,	O
and	O
homozygote	O
OR	O
=	O
151	O
(	O
95	O
%	O
c.i	O
.	O

=	O
20	O
-	O
1,136	O
)	O
)	O
.	O

We	O
found	O
three	O
additional	O
rare	O
null	O
mutations	O
in	O
this	O
case	O
series	O
,	O
suggesting	O
that	O
the	O
genetic	O
architecture	O
of	O
filaggrin	O
-	O
related	O
atopic	O
dermatitis	O
consists	O
of	O
both	O
prevalent	O
and	O
rare	O
risk	O
alleles	O
.	O

Increased	O
chromosome	O
instability	O
and	O
accumulation	O
of	O
DNA	O
double	O
-	O
strand	O
breaks	O
in	O
Werner	O
syndrome	O
cells	O
.	O

Werner	B-Disease
syndrome	I-Disease
(	O
WS	O
)	O
is	O
a	O
premature	O
aging	O
syndrome	O
caused	B-Reg
by	I-Reg
mutations	B-Var
of	O
the	O
WRN	B-Gene
gene	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
a	O
strain	O
of	O
WS	O
fibroblast	O
cells	O
shows	O
abnormal	O
karyotypes	O
characterized	O
by	O
several	O
complex	O
translocations	O
and	O
50-fold	O
more	O
frequency	O
of	O
abnormal	O
metaphases	O
including	O
dicentric	O
chromosomes	O
without	O
fragments	O
than	O
normal	O
cells	O
when	O
examined	O
at	O
a	O
similar	O
culture	O
stage	O
.	O

Further	O
,	O
telomere	O
fluorescence	O
in	O
situ	O
hybridization	O
indicates	O
that	O
the	O
abnormal	O
signals	O
,	O
extra	O
telomere	O
signal	O
and	O
loss	O
of	O
telomere	O
signal	O
,	O
emerge	O
two-	O
to	O
three	O
-	O
fold	O
more	O
frequently	O
in	O
WS	O
cells	O
than	O
in	O
normal	O
cells	O
.	O

Taken	O
together	O
,	O
these	O
results	O
indicate	O
that	O
chromosome	O
instability	O
including	O
dysfunction	O
of	O
telomere	O
maintenance	O
is	O
more	O
prominent	O
in	O
WS	O
cells	O
than	O
in	O
normal	O
cells	O
.	O

In	O
addition	O
,	O
the	O
accumulation	O
of	O
DNA	O
double	O
-	O
strand	O
breaks	O
(	O
DSBs	O
)	O
at	O
the	O
G(1	O
)	O
phase	O
,	O
including	O
those	O
at	O
telomeres	O
,	O
detected	O
by	O
phosphorylated	O
ATM	O
(	O
ataxia	O
telangiectasia	O
mutated	O
)	O
foci	O
is	O
accelerated	O
in	O
WS	O
cells	O
even	O
at	O
a	O
low	O
senescence	O
level	O
.	O

The	O
increased	O
accumulation	O
of	O
DSBs	O
in	O
WS	O
cells	O
is	O
reduced	O
in	O
the	O
presence	O
of	O
anti	O
-	O
oxidative	O
agents	O
,	O
suggesting	O
that	O
enhanced	O
oxidative	O
stress	O
in	O
WS	O
cells	O
is	O
involved	O
in	O
accelerated	O
accumulation	O
of	O
DSBs	O
.	O

These	O
results	O
indicate	O
that	O
WS	O
cells	O
are	O
prone	O
to	O
accumulate	B-PosReg
DSBs	B-MPA
spontaneously	O
due	O
to	O
a	O
defect	B-Var
of	O
WRN	B-Gene
,	O
which	O
leads	O
to	O
increased	B-PosReg
chromosome	B-MPA
instability	I-MPA
that	O
could	O
activate	B-PosReg
checkpoints	B-MPA
,	O
resulting	O
in	O
accelerated	B-PosReg
senescence	B-CPA
.	O

A	O
novel	O
mutation	B-Var
in	O
TRIM37	B-Gene
is	O
associated	B-Reg
with	I-Reg
mulibrey	B-Disease
nanism	I-Disease
in	O
a	O
Turkish	O
boy	O
.	O

Mulibrey	O
nanism	O
is	O
a	O
rare	O
autosomal	O
-	O
recessive	O
disorder	O
characterized	O
by	O
prenatal	O
onset	O
severe	O
growth	O
retardation	O
and	O
pericardial	O
constriction	O
associated	O
with	O
abnormalities	O
of	O
muscle	O
,	O
liver	O
,	O
brain	O
and	O
eye	O
.	O

More	O
than	O
80	O
%	O
of	O
previously	O
reported	O
patients	O
are	O
of	O
Finnish	O
origin	O
in	O
whom	O
a	O
founder	O
mutation	O
in	O
the	O
TRIM37	O
gene	O
have	O
been	O
described	O
.	O

We	O
report	O
on	O
a	O
7-year	O
-	O
old	O
Turkish	O
boy	O
who	O
presented	O
with	O
classical	O
phenotypic	O
features	O
of	O
mulibrey	O
nanism	O
.	O

Mutation	O
screening	O
of	O
the	O
TRIM37	O
gene	O
revealed	O
that	O
the	O
proband	O
had	O
a	O
homozygous	O
two	O
base	O
pair	O
deletion	O
,	O
c.1894_1895delGA	B-Var
,	O
resulting	B-Reg
in	I-Reg
a	O
frame	B-Var
-	I-Var
shift	I-Var
and	O
a	O
premature	B-MPA
termination	I-MPA
codon	O
.	O

Our	O
proband	O
is	O
one	O
of	O
the	O
rare	O
examples	O
of	O
mulibrey	O
nanism	O
outside	O
Finland	O
and	O
extends	O
the	O
mutation	O
spectrum	O
in	O
this	O
disorder	O
.	O

Phenotype	O
-	O
genotype	O
correlation	O
in	O
eight	O
Polish	O
patients	O
with	O
inherited	O
Factor	O
XIII	O
deficiency	O
:	O
identification	O
of	O
three	O
novel	O
mutations	O
.	O

Inherited	B-Disease
factor	I-Disease
XIII	I-Disease
(	O
FXIII	O
)	O
deficiency	O
is	O
known	O
as	O
one	O
of	O
the	O
most	O
rare	O
blood	O
coagulation	O
disorder	O
in	O
humans	O
.	O

In	O
the	O
present	O
study	O
,	O
phenotype	O
and	O
genotype	O
of	O
eight	O
FXIII	O
deficient	O
Polish	O
patients	O
from	O
five	O
unrelated	O
families	O
were	O
compared	O
.	O

The	O
patients	O
presented	O
with	O
a	O
severe	O
phenotype	O
demonstrated	O
by	O
a	O
high	O
incidence	O
of	O
intracerebral	O
haemorrhages	O
(	O
seven	O
of	O
eight	O
patients	O
)	O
,	O
haemarthrosis	O
(	O
six	O
patients	O
)	O
and	O
bleeding	O
due	O
to	O
trauma	O
(	O
five	O
patients	O
)	O
.	O

Introduction	O
of	O
regular	O
substitution	O
with	O
FXIII	O
concentrate	O
prevented	O
spontaneous	O
bleeding	O
in	O
seven	O
patients	O
.	O

In	O
all	O
patients	O
,	O
mutations	O
within	O
the	O
F13A	B-Gene
gene	O
have	O
been	O
identified	O
revealing	O
four	O
missense	O
mutations	O
(	B-Var
Arg77Cys	I-Var
,	O
Arg260Cys	B-Var
,	O
Ala378Pro	B-Var
,	O
Gly420Ser	B-Var
)	I-Var
,	O
one	O
nonsense	O
mutation	O
(	B-Var
Arg661X	I-Var
)	I-Var
,	O
one	O
splice	O
site	O
mutation	O
(	B-Var
IVS5	I-Var
-	I-Var
1	I-Var
G	I-Var
>	I-Var
A	I-Var
)	I-Var
and	O
one	O
small	O
deletion	O
(	B-Var
c.499	I-Var
-	I-Var
512del	I-Var
)	I-Var
.	O

One	O
homozygous	O
large	O
deletion	O
involving	O
exon	O
15	O
was	O
detected	O
by	O
failure	O
of	O
PCR	O
product	O
.	O

The	O
corresponding	O
mutations	B-Var
resulted	O
in	O
severely	O
reduced	B-NegReg
FXIII	B-MPA
activity	I-MPA
and	O
FXIII	B-MPA
A	I-MPA
-	I-MPA
subunit	I-MPA
antigen	I-MPA
concentration	I-MPA
,	O
while	O
FXIII	O
B	O
-	O
subunit	O
antigen	O
remained	O
normal	O
or	O
mildly	O
decreased	O
.	O

Structural	O
analysis	O
demonstrated	O
that	O
the	O
novel	O
Ala378Pro	B-Var
mutation	O
may	O
cause	O
a	O
disruption	B-NegReg
of	O
the	O
FXIII	B-MPA
catalytic	I-MPA
triad	I-MPA
leading	O
to	O
a	O
non	B-NegReg
-	I-NegReg
functional	I-NegReg
protein	B-Protein
which	O
presumably	O
undergoes	O
premature	B-MPA
degradation	I-MPA
.	O

In	O
conclusion	O
,	O
the	O
severe	O
phenotype	O
with	O
high	O
incidence	O
of	O
intracranial	O
bleeding	O
and	O
haemarthrosis	O
was	O
in	O
accordance	O
with	O
laboratory	O
findings	O
on	O
FXIII	O
and	O
with	O
severe	O
molecular	O
defects	O
of	O
the	O
F13A	O
gene	O
.	O

Effects	O
of	O
prolonged	O
dark	O
adaptation	O
in	O
patients	O
with	O
retinitis	O
pigmentosa	O
of	O
Bothnia	O
type	O
:	O
an	O
electrophysiological	O
study	O
.	O

Bothnia	B-Disease
dystrophy	I-Disease
(	O
BD	O
)	O
is	O
a	O
variant	O
of	O
recessive	O
retinitis	O
punctata	O
albescens	O
(	O
RPA	O
)	O
,	O
caused	B-Reg
by	I-Reg
the	O
missense	O
mutation	O
R233W	B-Var
in	O
cellular	O
retinaldehyde	O
-	O
binding	O
protein	O
(	B-Protein
CRALBP	I-Protein
)	I-Protein
,	O
which	O
is	O
localized	O
in	O
the	O
retinal	O
pigment	O
epithelium	O
(	O
RPE	O
)	O
and	O
Müller	O
cells	O
of	O
the	O
retina	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
,	O
by	O
examining	O
the	O
electrophysiological	O
responses	O
of	O
the	O
retina	O
,	O
to	O
evaluate	O
the	O
capacity	O
of	O
recovery	O
of	O
the	O
whole	O
retinal	O
area	O
and	O
different	O
cell	O
types	O
induced	O
by	O
extremely	O
prolonged	O
dark	O
adaptation	O
(	O
DA	O
)	O
in	O
BD	O
disease	O
and	O
to	O
gain	O
further	O
understanding	O
of	O
the	O
pathogenesis	O
of	O
BD	O
.	O

Six	O
young	O
patients	O
underwent	O
bilateral	O
full	O
-	O
field	O
ERGs	O
after	O
24	O
h	O
of	O
DA	O
in	O
one	O
eye	O
and	O
standard	O
DA	O
in	O
the	O
fellow	O
eye	O
.	O

The	O
results	O
were	O
also	O
compared	O
with	O
the	O
effect	O
of	O
prolonged	O
DA	O
(	O
10	O
h	O
)	O
,	O
previously	O
studied	O
in	O
the	O
same	O
patients	O
.	O

After	O
extremely	O
prolonged	O
DA	O
(	O
24	O
h	O
)	O
the	O
rod	O
b	O
-	O
wave	O
and	O
the	O
mixed	O
rod	O
-	O
cone	O
a	O
-	O
wave	O
responses	O
reached	O
normal	O
though	O
delayed	O
amplitudes	O
.	O

An	O
increase	O
,	O
up	O
to	O
normal	O
level	O
,	O
in	O
the	O
oscillatory	O
response	O
was	O
found	O
.	O

There	O
was	O
no	O
obvious	O
recovery	O
of	O
the	O
cone	O
response	O
.	O

We	O
conclude	O
that	O
in	O
young	O
BD	O
patients	O
during	O
extremely	O
prolonged	O
DA	O
there	O
is	O
a	O
significant	O
additional	O
capacity	O
of	O
recovery	O
of	O
rod	O
function	O
and	O
also	O
significant	O
gain	O
of	O
activity	O
in	O
the	O
inner	O
retinal	O
layer	O
.	O

A	O
continuous	O
but	O
slow	O
regeneration	O
of	O
rod	O
photopigment	O
seems	O
to	O
occur	O
at	O
least	O
up	O
to	O
24	O
h.	O
The	O
visual	O
process	O
in	O
the	O
RPE	O
is	O
retarded	O
and	O
CRALBP	O
acts	O
in	O
this	O
process	O
;	O
also	O
,	O
the	O
Müller	O
cells	O
of	O
the	O
retina	O
seem	O
to	O
be	O
involved	O
.	O

The	O
findings	O
also	O
support	O
an	O
extremely	O
slow	O
synthesis	O
of	O
photopigments	O
and	O
irreversibly	O
disturbed	O
cone	O
function	O
early	O
in	O
BD	O
.	O

A	O
case	O
of	O
lethal	O
hypophosphatasia	O
providing	O
new	O
insights	O
into	O
the	O
perinatal	O
benign	O
form	O
of	O
hypophosphatasia	O
and	O
expression	O
of	O
the	O
ALPL	O
gene	O
.	O

Hypophosphatasia	B-Disease
is	O
a	O
rare	O
inherited	O
bone	O
disease	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
alkaline	O
phosphatase	O
liver	O
-	O
type	O
gene	O
(	B-Gene
ALPL	I-Gene
)	I-Gene
gene	O
,	O
with	O
extensive	O
allelic	O
heterogeneity	O
leading	O
to	O
a	O
range	O
of	O
clinical	O
phenotypes	O
.	O

We	O
report	O
here	O
a	O
patient	O
who	O
died	O
from	O
severe	O
lethal	O
hypophosphatasia	O
,	O
who	O
was	O
compound	O
heterozygous	O
for	O
the	O
mutation	O
c.1133A	O
>	O
T	O
(	O
D361V	O
)	O
and	O
the	O
newly	O
detected	O
missense	O
mutation	O
c791A	O
>	O
G	O
,	O
and	O
whose	O
parents	O
were	O
both	O
healthy	O
.	O

Because	O
the	O
c.1133A	O
>	O
T	O
(	O
D361V	O
)	O
mutation	O
was	O
previously	O
reported	O
to	O
have	O
a	O
dominant	O
-	O
negative	O
effect	O
and	O
to	O
be	O
responsible	O
for	O
the	O
uncommon	O
perinatal	O
benign	O
form	O
of	O
the	O
disease	O
,	O
we	O
studied	O
the	O
expression	O
of	O
the	O
ALPL	O
gene	O
in	O
this	O
family	O
.	O

Analysis	O
at	O
the	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
level	O
,	O
both	O
quantitative	O
and	O
qualitative	O
,	O
showed	O
that	O
the	O
paternal	O
c.1133A	B-Var
>	I-Var
T	I-Var
(	O
D361V	O
)	O
mutation	O
was	O
associated	O
with	O
over	B-MPA
-	I-MPA
expression	I-MPA
of	O
the	O
ALPL	B-Gene
gene	O
and	O
that	O
the	O
maternal	O
c.791A	B-Var
>	I-Var
G	I-Var
mutation	O
lead	B-Reg
to	I-Reg
complete	O
skipping	B-Var
of	I-Var
exon	I-Var
7	I-Var
.	O

The	O
results	O
provide	O
an	O
explanation	O
of	O
the	O
lethal	O
phenotype	O
in	O
the	O
patient	O
where	O
the	O
two	O
ALPL	O
alleles	O
are	O
non	O
-	O
functional	O
and	O
in	O
the	O
asymptomatic	O
father	O
where	O
over	O
-	O
expression	O
of	O
the	O
normal	O
allele	O
could	O
counteract	O
the	O
effect	O
of	O
the	O
c.1133A	O
>	O
T	O
(	O
D361V	O
)	O
mutation	O
by	O
providing	O
an	O
increased	O
level	O
of	O
normal	O
mRNA	O
.	O

This	O
may	O
also	O
explain	O
the	O
variable	O
expression	O
of	O
hypophosphatasia	O
observed	O
in	O
parents	O
of	O
patients	O
with	O
the	O
perinatal	O
benign	O
form	O
.	O

Choreoacanthocytosis	O
in	O
a	O
Mexican	O
family	O
.	O

BACKGROUND	O
:	O
Choreoacanthocytosis	B-Disease
(	O
CHAC	O
)	O
(	O
Online	O
Mendelian	O
Inheritance	O
in	O
Man	O
accession	O
No	O
.	O

200150	O
)	O
is	O
a	O
hereditary	O
neurodegenerative	O
syndrome	O
characterized	O
by	O
movement	O
disorders	O
,	O
cognitive	O
decline	O
,	O
myopathy	O
,	O
behavioral	O
changes	O
,	O
and	O
acanthocytosis	O
and	O
is	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
VPS13A	B-Gene
gene	O
.	O

OBJECTIVE	O
:	O
To	O
describe	O
the	O
cases	O
of	O
2	O
Mexican	O
women	O
with	O
clinical	O
and	O
molecular	O
characteristics	O
compatible	O
with	O
CHAC	O
.	O

DESIGN	O
:	O
Case	O
reports	O
.	O

Patients	O
Choreoacanthocytosis	O
was	O
identified	O
in	O
2	O
Mexican	O
mestizo	O
sisters	O
with	O
healthy	O
consanguineous	O
parents	O
.	O

Clinical	O
manifestations	O
began	O
at	O
different	O
ages	O
.	O

RESULTS	O
:	O
The	O
onset	O
of	O
signs	O
and	O
symptoms	O
of	O
CHAC	O
in	O
the	O
proband	O
was	O
at	O
age	O
32	O
years	O
and	O
was	O
characterized	O
by	O
balancing	O
problems	O
followed	O
by	O
chorea	O
,	O
compulsive	O
lip	O
and	O
tongue	O
biting	O
with	O
buccolingual	O
self	O
-	O
mutilation	O
,	O
dysarthria	O
,	O
dysphagia	O
,	O
and	O
weight	O
loss	O
.	O

The	O
first	O
clinical	O
manifestations	O
in	O
the	O
proband	O
's	O
sister	O
occurred	O
at	O
age	O
45	O
years	O
and	O
included	O
multiple	O
motor	O
and	O
verbal	O
tics	O
,	O
with	O
coprolalia	O
,	O
followed	O
by	O
lip	O
and	O
tongue	O
biting	O
,	O
self	O
-	O
mutilation	O
,	O
and	O
chorea	O
.	O

The	O
clinical	O
findings	O
in	O
both	O
sisters	O
were	O
remarkable	O
for	O
acanthocytosis	O
that	O
developed	O
late	O
,	O
when	O
neurologic	O
changes	O
were	O
already	O
evident	O
.	O

Mutation	O
screening	O
of	O
the	O
VPS13A	O
gene	O
revealed	O
homozygosity	O
for	O
the	O
frameshift	O
mutation	O
c.3556_3557dupAC	O
in	O
exon	O
33	O
.	O

Currently	O
,	O
the	O
proband	O
's	O
sister	O
,	O
in	O
whom	O
neurologic	O
defects	O
developed	O
13	O
years	O
after	O
onset	O
of	O
CHAC	O
in	O
the	O
proband	O
,	O
is	O
the	O
least	O
affected	O
.	O

CONCLUSIONS	O
:	O
The	O
same	O
mutation	O
of	O
the	O
VPS13A	O
gene	O
can	O
be	O
expressed	O
differently	O
in	O
the	O
same	O
family	O
.	O

This	O
observation	O
confirms	O
the	O
notion	O
that	O
there	O
is	O
considerable	O
heterogeneity	O
in	O
the	O
clinical	O
manifestation	O
of	O
CHAC	O
.	O

[	O
Phenotype	O
-	O
genotype	O
study	O
in	O
154	O
French	O
NF2	O
mutation	O
carriers	O
]	O
.	O

Analyse	O
phénotypique	O
de	O
154	O
patients	O
porteurs	O
d'une	O
mutation	O
constitutionnelle	O
du	O
gène	O
NF2	O
.	O

INTRODUCTION	O
:	O
Germline	B-Var
mutations	I-Var
in	O
the	O
NF2	B-Gene
gene	O
are	O
responsible	B-Reg
for	O
80	O
p.cent	O
of	O
neurofibromatosis	B-Disease
type	I-Disease
2	I-Disease
typical	O
cases	O
.	O

Mutations	O
are	O
mainly	O
truncating	O
mutations	O
or	O
deletions	O
,	O
missense	O
mutations	O
having	O
been	O
reported	O
in	O
few	O
cases	O
.	O

An	O
important	O
phenotypic	O
variability	O
is	O
observed	O
among	O
gene	O
carriers	O
.	O

To	O
assess	O
whether	O
the	O
phenotypic	O
variability	O
of	O
neurofibromatosis	O
2	O
could	O
be	O
linked	O
to	O
genotype	O
,	O
clinical	O
data	O
of	O
154	O
patients	O
whose	O
NF2	O
germline	O
alteration	O
had	O
been	O
identified	O
in	O
our	O
laboratory	O
have	O
been	O
collected	O
.	O

METHODS	O
:	O
A	O
retrospective	O
questionnaire	O
was	O
sent	O
to	O
the	O
physicians	O
in	O
charge	O
of	O
these	O
patients	O
.	O

Statistical	O
analyses	O
regarding	O
genotypic	O
and	O
phenotypic	O
data	O
were	O
performed	O
by	O
comparisons	O
of	O
average	O
values	O
and	O
correlation	O
tests	O
.	O

RESULTS	O
:	O
In	O
French	O
patients	O
,	O
type	O
of	O
mutation	O
was	O
correlated	O
neither	O
with	O
patients	O
'	O
sex	O
,	O
nor	O
with	O
disease	O
occurrence	O
mode	O
(	O
de	O
novo	O
or	O
inherited	O
mutation	O
)	O
.	O

Disease	O
associated	O
with	O
missense	O
mutations	O
occurred	O
later	O
,	O
with	O
a	O
less	O
severe	O
symptomatology	O
.	O

Patients	O
with	O
nonsense	O
or	O
frameshift	O
mutations	O
were	O
more	O
frequently	O
affected	O
with	O
meningiomas	O
and	O
spinal	O
tumours	O
,	O
in	O
addition	O
to	O
VIII	O
nerve	O
schwannomas	O
,	O
an	O
observation	O
that	O
underlies	O
the	O
genetic	O
determination	O
of	O
the	O
number	O
and	O
type	O
of	O
NF2-related	O
tumours	O
.	O

CONCLUSION	O
:	O
Results	O
from	O
the	O
literature	O
as	O
well	O
as	O
from	O
our	O
study	O
tend	O
to	O
show	O
that	O
only	O
few	O
correlations	O
exist	O
between	O
genotype	O
and	O
phenotype	O
in	O
the	O
NF2	O
disease	O
.	O

It	O
also	O
recognizes	O
that	O
missense	O
mutations	O
have	O
a	O
lower	O
level	O
of	O
evolution	O
,	O
severity	O
and	O
mortality	O
risk	O
.	O

Nonsense	O
and	O
frameshift	O
mutations	O
seem	O
to	O
be	O
associated	O
with	O
a	O
higher	O
number	O
of	O
meningiomas	O
and	O
spinal	O
tumours	O
.	O

Therefore	O
,	O
NF2	O
gene	O
screening	O
keeps	O
its	O
indications	O
in	O
both	O
typical	O
and	O
moderate	O
forms	O
of	O
the	O
disease	O
.	O

Mutations	O
are	O
responsible	O
of	O
80	O
p.cent	O
of	O
typical	O
forms	O
;	O
in	O
moderate	O
forms	O
,	O
identification	O
of	O
a	O
missense	O
mutation	O
seems	O
linked	O
to	O
a	O
lower	O
disease	O
evolution	O
.	O

In	O
any	O
case	O
,	O
assessment	O
and	O
supervision	O
should	O
be	O
identical	O
.	O

Finally	O
,	O
in	O
a	O
small	O
number	O
of	O
cases	O
,	O
the	O
NF2	O
gene	O
appears	O
to	O
be	O
implicated	O
in	O
clinical	O
forms	O
different	O
from	O
those	O
defined	O
by	O
NIH	O
and	O
it	O
might	O
be	O
of	O
interest	O
to	O
enlarge	O
the	O
clinical	O
features	O
suggestive	O
of	O
the	O
disease	O
.	O

Do	O
we	O
know	O
all	O
there	O
is	O
to	O
know	O
about	O
Familial	O
Adenomatous	O
Polyposis	O
?	O
Familial	B-Disease
Adenomatous	I-Disease
Polyposis	I-Disease
(	O
FAP	O
)	O
and	O
Attenuated	B-Disease
FAP	I-Disease
(	O
AFAP	O
)	O
are	O
caused	B-Reg
by	I-Reg
a	O
germline	B-Var
mutation	I-Var
in	O
the	O
Adenomatous	O
polyposis	O
coli	O
(	B-Gene
APC	I-Gene
)	I-Gene
gene	O
.	O

Recently	O
,	O
a	O
new	O
pathway	O
characterized	O
by	O
a	O
biallelic	O
mutation	O
in	O
the	O
MYH	O
gene	O
,	O
with	O
a	O
recessive	O
model	O
of	O
inheritance	O
was	O
discovered	O
for	O
this	O
inherited	O
syndrome	O
.	O

This	O
report	O
describes	O
a	O
Tunisian	O
patient	O
with	O
an	O
attenuated	O
FAP	O
phenotype	O
,	O
presenting	O
seven	O
colon	O
polyps	O
and	O
an	O
adenocarcinoma	O
but	O
no	O
detectable	O
germline	O
mutations	O
in	O
the	O
FAP	O
target	O
genes	O
.	O

A	O
well	O
known	O
somatic	O
mutation	O
was	O
found	O
in	O
the	O
APC	O
mutation	O
cluster	O
region	O
(	O
MCR	O
)	O
.	O

This	O
case	O
shows	O
that	O
further	O
studies	O
are	O
needed	O
to	O
fully	O
understand	O
all	O
the	O
pathways	O
of	O
the	O
FAP	O
syndrome	O
.	O

Mutations	B-Var
in	O
NALP12	B-Gene
cause	B-Reg
hereditary	B-Disease
periodic	I-Disease
fever	I-Disease
syndromes	I-Disease
.	O

NALP	O
proteins	O
,	O
also	O
known	O
as	O
NLRPs	O
,	O
belong	O
to	O
the	O
CATERPILLER	O
protein	O
family	O
involved	O
,	O
like	O
Toll	O
-	O
like	O
receptors	O
,	O
in	O
the	O
recognition	O
of	O
microbial	O
molecules	O
and	O
the	O
subsequent	O
activation	O
of	O
inflammatory	O
and	O
immune	O
responses	O
.	O

Current	O
advances	O
in	O
the	O
function	O
of	O
NALPs	O
support	O
the	O
recently	O
proposed	O
model	O
of	O
a	O
disease	O
continuum	O
bridging	O
autoimmune	O
and	O
autoinflammatory	O
disorders	O
.	O

Among	O
these	O
diseases	O
,	O
hereditary	O
periodic	O
fevers	O
(	O
HPFs	O
)	O
are	O
Mendelian	O
disorders	O
associated	O
with	O
sequence	O
variations	O
in	O
very	O
few	O
genes	O
;	O
these	O
variations	O
are	O
mostly	O
missense	O
mutations	O
whose	O
deleterious	O
effect	O
,	O
which	O
is	O
particularly	O
difficult	O
to	O
assess	O
,	O
is	O
often	O
questionable	O
.	O

The	O
growing	O
number	O
of	O
identified	O
sporadic	O
cases	O
of	O
periodic	O
fever	O
syndrome	O
,	O
together	O
with	O
the	O
lack	O
of	O
discriminatory	O
clinical	O
criteria	O
,	O
has	O
greatly	O
hampered	O
the	O
identification	O
of	O
new	O
disease	O
-	O
causing	O
genes	O
,	O
a	O
step	O
that	O
is	O
,	O
however	O
,	O
essential	O
for	O
appropriate	O
management	O
of	O
these	O
disorders	O
.	O

Using	O
a	O
candidate	O
gene	O
approach	O
,	O
we	O
identified	O
nonambiguous	O
mutations	O
in	O
NALP12	O
(	O
i.e.	O
,	O
nonsense	O
and	O
splice	O
site	O
)	O
in	O
two	O
families	O
with	O
periodic	O
fever	O
syndromes	O
.	O

As	O
shown	O
by	O
means	O
of	O
functional	O
studies	O
,	O
these	O
two	O
NALP12	B-Gene
mutations	B-Var
have	O
a	O
deleterious	O
effect	B-Reg
on	O
NF	B-Pathway
-	I-Pathway
kappaB	I-Pathway
signaling	I-Pathway
.	O

Overall	O
,	O
these	O
data	O
identify	O
a	O
group	O
of	O
HPFs	O
defined	O
by	O
molecular	O
defects	O
in	O
NALP12	O
,	O
opening	O
up	O
new	O
ways	O
to	O
manage	O
these	O
disorders	O
.	O

The	O
identification	O
of	O
these	O
first	O
NALP12	B-Gene
mutations	B-Var
in	O
patients	O
with	B-Reg
autoinflammatory	B-CPA
disorder	I-CPA
also	O
clearly	O
demonstrates	O
the	O
crucial	O
role	O
of	O
NALP12	O
in	O
inflammatory	O
signaling	O
pathways	O
,	O
thereby	O
assigning	O
a	O
precise	O
function	O
to	O
this	O
particular	O
member	O
of	O
an	O
emerging	O
family	O
of	O
proteins	O
whose	O
putative	O
biological	O
properties	O
are	O
currently	O
inferred	O
essentially	O
through	O
in	O
vitro	O
means	O
.	O

ABCA4	O
gene	O
analysis	O
in	O
patients	O
with	O
autosomal	O
recessive	O
cone	O
and	O
cone	O
rod	O
dystrophies	O
.	O

The	O
ATP	O
-	O
binding	O
cassette	O
(	O
ABC	O
)	O
transporters	O
constitute	O
a	O
family	O
of	O
large	O
membrane	O
proteins	O
,	O
which	O
transport	O
a	O
variety	O
of	O
substrates	O
across	O
membranes	O
.	O

The	O
ABCA4	O
protein	O
is	O
expressed	O
in	O
photoreceptors	O
and	O
possibly	O
functions	O
as	O
a	O
transporter	O
for	O
N	O
-	O
retinylidene	O
-	O
phosphatidylethanolamine	O
(	O
N	O
-	O
retinylidene	O
-	O
PE	O
)	O
,	O
the	O
Schiff	O
base	O
adduct	O
of	O
all	O
-	O
trans	O
-	O
retinal	O
with	O
PE	O
.	O

Mutations	B-Var
in	O
the	O
ABCA4	B-Gene
gene	O
have	O
been	O
initially	O
associated	B-Reg
with	I-Reg
autosomal	O
recessive	O
Stargardt	B-Disease
disease	I-Disease
.	O

Subsequent	O
studies	O
have	O
shown	O
that	O
mutations	B-Var
in	O
ABCA4	B-Gene
can	O
also	O
cause	B-Reg
a	O
variety	O
of	O
other	O
retinal	B-Disease
dystrophies	I-Disease
including	O
cone	B-Disease
rod	I-Disease
dystrophy	I-Disease
and	O
retinitis	B-Disease
pigmentosa	I-Disease
.	O

To	O
determine	O
the	O
prevalence	O
and	O
mutation	O
spectrum	O
of	O
ABCA4	O
gene	O
mutations	O
in	O
non	O
-	O
Stargardt	O
phenotypes	O
,	O
we	O
have	O
screened	O
64	O
unrelated	O
patients	O
with	O
autosomal	O
recessive	O
cone	O
(	O
arCD	O
)	O
and	O
cone	O
rod	O
dystrophy	O
(	O
arCRD	O
)	O
applying	O
the	O
Asper	O
Ophthalmics	O
ABCR400	O
microarray	O
followed	O
by	O
DNA	O
sequencing	O
of	O
all	O
coding	O
exons	O
of	O
the	O
ABCA4	O
gene	O
in	O
subjects	O
with	O
single	O
heterozygous	O
mutations	O
.	O

Disease	O
-	O
associated	O
ABCA4	O
alleles	O
were	O
identified	O
in	O
20	O
of	O
64	O
patients	O
with	O
arCD	O
or	O
arCRD	O
.	O

In	O
four	O
of	O
64	O
patients	O
(	O
6	O
%	O
)	O
only	O
one	O
mutant	O
ABCA4	O
allele	O
was	O
detected	O
and	O
in	O
16	O
patients	O
(	O
25	O
%	O
)	O
,	O
mutations	O
on	O
both	O
ABCA4	O
alleles	O
were	O
identified	O
.	O

Based	O
on	O
these	O
data	O
we	O
estimate	O
a	O
prevalence	O
of	O
31	O
%	O
for	O
ABCA4	O
mutations	O
in	O
arCD	O
and	O
arCRD	O
,	O
supporting	O
the	O
concept	O
that	O
the	O
ABCA4	O
gene	O
is	O
a	O
major	O
locus	O
for	O
various	O
types	O
of	O
degenerative	O
retinal	O
diseases	O
with	O
abnormalities	O
in	O
cone	O
or	O
both	O
cone	O
and	O
rod	O
function	O
.	O

Premature	O
termination	O
codons	O
in	O
PRPF31	O
cause	O
retinitis	O
pigmentosa	O
via	O
haploinsufficiency	O
due	O
to	O
nonsense	O
-	O
mediated	O
mRNA	O
decay	O
.	O

Dominant	B-Var
mutations	I-Var
in	O
the	O
gene	O
encoding	O
the	O
mRNA	O
splicing	O
factor	O
PRPF31	B-Gene
cause	B-Reg
retinitis	B-Disease
pigmentosa	I-Disease
,	O
a	O
hereditary	O
form	O
of	O
retinal	O
degeneration	O
.	O

Most	O
of	O
these	O
mutations	O
are	O
characterized	O
by	O
DNA	O
changes	O
that	O
lead	O
to	O
premature	O
termination	O
codons	O
.	O

We	O
investigated	O
6	O
different	O
PRPF31	O
mutations	O
,	O
represented	O
by	O
single	O
-	O
base	O
substitutions	O
or	O
microdeletions	O
,	O
in	O
cell	O
lines	O
derived	O
from	O
9	O
patients	O
with	O
dominant	O
retinitis	O
pigmentosa	O
.	O

Five	O
of	O
these	O
mutations	B-Var
lead	B-Reg
to	I-Reg
premature	B-MPA
termination	I-MPA
codons	I-MPA
,	O
and	O
1	O
leads	B-Reg
to	I-Reg
the	O
skipping	B-MPA
of	I-MPA
exon	I-MPA
2	I-MPA
.	O

Allele	O
-	O
specific	O
measurement	O
of	O
PRPF31	O
transcripts	O
revealed	O
a	O
strong	O
reduction	B-NegReg
in	O
the	O
expression	B-MPA
of	O
mutant	B-Var
alleles	O
.	O

As	O
a	O
consequence	O
,	O
total	O
PRPF31	B-Gene
protein	B-Protein
abundance	B-MPA
was	O
decreased	B-NegReg
,	O
and	O
no	O
truncated	O
proteins	O
were	O
detected	O
.	O

Subnuclear	O
localization	O
of	O
the	O
full	O
-	O
length	O
PRPF31	O
that	O
was	O
present	O
remained	O
unaffected	O
.	O

Blocking	O
nonsense	O
-	O
mediated	O
mRNA	O
decay	O
significantly	O
restored	O
the	O
amount	O
of	O
mutant	O
PRPF31	O
mRNA	O
but	O
did	O
not	O
restore	O
the	O
synthesis	O
of	O
mutant	O
proteins	O
,	O
even	O
in	O
conjunction	O
with	O
inhibitors	O
of	O
protein	O
degradation	O
pathways	O
.	O

Our	O
results	O
indicate	O
that	O
most	O
PRPF31	B-Gene
mutations	B-Var
ultimately	O
result	O
in	O
null	B-NegReg
alleles	B-MPA
through	O
the	O
activation	B-PosReg
of	O
surveillance	B-MPA
mechanisms	I-MPA
that	O
inactivate	B-NegReg
mutant	B-Var
mRNA	I-Var
and	O
,	O
possibly	O
,	O
proteins	B-Protein
.	O

Furthermore	O
,	O
these	O
data	O
provide	O
compelling	O
evidence	O
that	O
the	O
pathogenic	O
effect	O
of	O
PRPF31	O
mutations	O
is	O
likely	O
due	O
to	O
haploinsufficiency	O
rather	O
than	O
to	O
gain	O
of	O
function	O
.	O

Xeroderma	O
pigmentosum	O
-	O
variant	O
patients	O
from	O
America	O
,	O
Europe	O
,	O
and	O
Asia	O
.	O

Xeroderma	B-Disease
pigmentosum	I-Disease
-	I-Disease
variant	I-Disease
(	O
XP	O
-	O
V	O
)	O
patients	O
have	O
sun	O
sensitivity	O
and	O
increased	O
skin	O
cancer	O
risk	O
.	O

Their	O
cells	O
have	O
normal	O
nucleotide	O
excision	O
repair	O
,	O
but	O
have	O
defects	O
in	O
the	O
POLH	O
gene	O
encoding	O
an	O
error	O
-	O
prone	O
polymerase	O
,	O
DNA	O
polymerase	O
eta	O
(	O
pol	O
eta	O
)	O
.	O

To	O
survey	O
the	O
molecular	O
basis	O
of	O
XP	O
-	O
V	O
worldwide	O
,	O
we	O
measured	O
pol	O
eta	O
protein	O
in	O
skin	O
fibroblasts	O
from	O
putative	O
XP	O
-	O
V	O
patients	O
(	O
aged	O
8	O
-	O
66	O
years	O
)	O
from	O
10	O
families	O
in	O
North	O
America	O
,	O
Turkey	O
,	O
Israel	O
,	O
Germany	O
,	O
and	O
Korea	O
.	O

Pol	O
eta	O
was	O
undetectable	O
in	O
cells	O
from	O
patients	O
in	O
eight	O
families	O
,	O
whereas	O
two	O
showed	O
faint	O
bands	O
.	O

DNA	O
sequencing	O
identified	O
10	O
different	O
POLH	O
mutations	O
.	O

There	O
were	O
two	O
splicing	O
,	O
one	O
nonsense	O
,	O
five	O
frameshift	O
(	O
3	O
deletion	O
and	O
2	O
insertion	O
)	O
,	O
and	O
two	O
missense	O
mutations	O
.	O

Nine	O
of	O
these	O
mutations	O
involved	O
the	O
catalytic	O
domain	O
.	O

Although	O
affected	O
siblings	O
had	O
similar	O
clinical	O
features	O
,	O
the	O
relation	O
between	O
the	O
clinical	O
features	O
and	O
the	O
mutations	O
was	O
not	O
clear	O
.	O

POLH	O
mRNA	O
levels	O
were	O
normal	O
or	O
reduced	O
by	O
50	O
%	O
in	O
three	O
cell	O
strains	O
with	O
undetectable	O
levels	O
of	O
pol	O
eta	O
protein	O
,	O
indicating	O
that	O
nonsense	O
-	O
mediated	O
message	O
decay	O
was	O
limited	O
.	O

We	O
found	O
a	O
wide	O
spectrum	O
of	O
mutations	B-Var
in	O
the	O
POLH	B-Gene
gene	O
among	B-Reg
XP	B-Disease
-	I-Disease
V	I-Disease
patients	O
in	O
different	O
countries	O
,	O
suggesting	O
that	O
many	O
of	O
these	O
mutations	O
arose	O
independently	O
.	O

Four	O
novel	O
FXI	B-Gene
gene	O
mutations	B-Var
in	B-Reg
three	O
factor	B-Disease
XI-	I-Disease
deficient	I-Disease
patients	O
.	O

Hereditary	O
factor	O
XI	O
deficiency	O
is	O
a	O
mild	O
bleeding	O
disorder	O
,	O
which	O
is	O
highly	O
prevalent	O
among	O
Ashkenazi	O
Jews	O
,	O
but	O
has	O
been	O
reported	O
in	O
all	O
populations	O
.	O

In	O
Ashkenazi	O
Jews	O
,	O
two	O
factor	O
XI	O
gene	O
mutations	O
Glu	O
117X	O
(	O
type	O
II	O
)	O
and	O
Phe283Leu	O
(	O
type	O
III	O
)	O
are	O
particularly	O
common	O
.	O

In	O
other	O
ethnic	O
groups	O
,	O
factor	B-Disease
XI	I-Disease
deficiency	I-Disease
is	O
a	O
rare	O
bleeding	O
disorder	O
and	O
is	O
related	B-Reg
to	I-Reg
a	O
variety	O
of	O
mutations	B-Var
throughout	O
the	O
factor	B-Gene
XI	I-Gene
gene	O
.	O

Three	O
cases	O
of	O
quantitative	O
factor	O
XI	O
deficiency	O
in	O
relation	O
with	O
four	O
novel	O
missense	O
mutations	O
are	O
reported	O
:	O
a	O
compound	O
heterozygosity	O
for	O
two	O
novel	O
mutations	O
(	B-Var
Ala	I-Var
181	I-Var
Val	I-Var
and	O
Ala	B-Var
412	I-Var
Thr	I-Var
)	I-Var
with	O
a	O
severe	O
factor	O
XI	O
deficiency	O
and	O
two	O
missense	O
mutations	O
(	B-Var
His	I-Var
388	I-Var
Pro	I-Var
and	O
Trp	B-Var
407	I-Var
Cys	I-Var
)	I-Var
in	B-Reg
heterozygous	O
patients	O
with	O
partial	O
factor	B-Disease
XI	I-Disease
deficiency	I-Disease
.	O

[	O
A	O
novel	O
mutation	B-Var
in	O
the	O
SEDL	B-Gene
gene	O
leading	B-Reg
to	I-Reg
X	B-Disease
-	I-Disease
linked	I-Disease
spondyloepiphyseal	I-Disease
dysplasia	I-Disease
tarda	I-Disease
in	O
a	O
large	O
Chinese	O
pedigree	O
]	O
.	O

OBJECTIVE	O
:	O
To	O
identify	O
the	O
genetic	O
defect	O
in	O
a	O
four	O
-	O
generation	O
pedigree	O
with	O
X	O
-	O
linked	O
recessive	O
spondyloepiphyseal	O
dysplasia	O
tarda	O
(	O
SEDT	O
)	O
from	O
Southwest	O
China	O
.	O

METHODS	O
:	O
Linkage	O
analysis	O
with	O
one	O
panel	O
of	O
fluorescently	O
labeled	O
microsatellite	O
markers	O
on	O
chromosome	O
X	O
and	O
mutation	O
screening	O
of	O
SEDL	O
gene	O
by	O
direct	O
sequencing	O
were	O
performed	O
.	O

RESULTS	O
:	O
Linkage	O
between	O
SEDT	O
and	O
Xp22.2-Xp23.1	O
was	O
established	O
with	O
maximum	O
LOD	O
score	O
of	O
3.82	O
(	O
theta	O
=	O
0	O
)	O
between	O
DXS987	O
and	O
DXS8051	O
.	O

Upon	O
sequence	O
analysis	O
,	O
a	O
point	O
mutation	O
within	O
exon	O
4	O
of	O
the	O
SEDL	B-Gene
gene	O
(	B-Var
c.239A	I-Var
to	I-Var
G	I-Var
)	I-Var
was	O
found	O
which	O
resulted	B-Reg
in	I-Reg
substitution	O
of	O
histidine	O
with	O
arginine	O
at	O
codon	O
80	O
(	B-Var
His80Arg	I-Var
)	I-Var
.	O

CONCLUSION	O
:	O
A	O
novel	O
missense	O
mutation	O
(	O
H80R	O
)	O
was	O
identified	O
for	O
SEDL	O
gene	O
in	O
the	O
large	O
Chinese	O
SEDT	O
pedigree	O
.	O

MLPA	O
analysis	O
/	O
complete	O
sequencing	O
of	O
the	O
DMD	O
gene	O
in	O
a	O
group	O
of	O
Bulgarian	O
Duchenne	O
/	O
Becker	O
muscular	O
dystrophy	O
patients	O
.	O

Duchenne	B-Disease
/	I-Disease
Becker	I-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
DMD	O
/	O
BMD	O
)	O
,	O
the	O
most	O
common	O
X	O
-	O
linked	O
muscular	O
dystrophy	O
is	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
enormously	O
large	O
DMD	B-Gene
gene	O
,	O
encoding	O
the	O
protein	O
called	O
dystrophin	O
.	O

This	O
gene	O
was	O
screened	O
in	O
a	O
group	O
of	O
27	O
unrelated	O
Bulgarian	O
DMD	O
/	O
BMD	O
patients	O
by	O
MLPA	O
analysis	O
/	O
complete	O
sequencing	O
.	O

We	O
managed	O
to	O
clarify	O
the	O
disease	O
-	O
causing	O
mutation	O
in	O
96.3	O
%	O
of	O
the	O
analyzed	O
families	O
.	O

The	O
MLPA	O
analysis	O
revealed	O
17	O
deletions	O
(	O
including	O
a	O
deletion	O
of	O
the	O
very	O
last	O
exon	O
79	O
)	O
,	O
6	O
duplications	O
and	O
1	O
point	O
mutation	O
.	O

Two	O
additional	O
point	O
mutations	O
(	O
one	O
of	O
them	O
novel	O
)	O
were	O
detected	O
after	O
complete	O
sequencing	O
of	O
the	O
DMD	O
gene	O
.	O

Altogether	O
,	O
25	O
carriers	O
and	O
11	O
noncarriers	O
were	O
detected	O
in	O
our	O
families	O
.	O

The	O
MLPA	O
test	O
proved	O
to	O
be	O
a	O
powerful	O
tool	O
in	O
detecting	O
deletions	O
/	O
duplications	O
and	O
in	O
some	O
cases	O
point	O
mutations	O
/	O
polymorphisms	O
along	O
the	O
DMD	O
gene	O
.	O

Using	O
this	O
approach	O
in	O
combination	O
with	O
a	O
direct	O
gene	O
sequencing	O
a	O
number	O
of	O
Bulgarian	O
DMD	O
/	O
BMD	O
patients	O
are	O
genetically	O
clarified	O
and	O
prepared	O
for	O
gene	O
therapy	O
in	O
future	O
.	O

A	O
case	O
of	O
Bernard	B-Disease
-	I-Disease
Soulier	I-Disease
Syndrome	I-Disease
due	B-Reg
to	I-Reg
a	O
homozygous	O
four	O
bases	O
deletion	B-Var
(	O
TGAG	O
)	O
of	O
GPIbalpha	B-Gene
gene	I-Gene
:	I-Gene
lack	O
of	O
GPIbalpha	O
but	O
absence	O
of	O
bleeding	O
.	O

More	O
than	O
20	O
DNA	O
mutations	O
with	O
different	O
inheritance	O
pattern	O
have	O
been	O
described	O
in	O
patients	O
with	O
Bernard	O
-	O
Soulier	O
Syndrome	O
(	O
BSS	O
)	O
,	O
leading	O
to	O
abnormal	O
or	O
absent	O
synthesis	O
and/or	O
expression	O
of	O
GPIbalpha	O
.	O

Clinical	O
phenotype	O
shows	O
considerable	O
variation	O
between	O
individuals	O
,	O
such	O
as	O
bleeding	O
,	O
platelet	O
count	O
and	O
the	O
percentage	O
of	O
large	O
platelets	O
.	O

We	O
describe	O
in	O
a	O
BSS	O
patient	O
the	O
first	O
case	O
of	O
homozygous	O
four	O
bases	O
deletion	O
(	O
TGAG	O
)	O
in	O
the	O
gpIbalpha	O
gene	O
coding	O
sequence	O
,	O
leading	O
to	O
a	O
premature	O
stop	O
codon	O
.	O

In	O
the	O
propositus	O
,	O
blood	O
smears	O
revealed	O
giant	O
platelets	O
(	O
30	O
x	O
10(9	O
)	O
platelets	O
/	O
L	O
)	O
,	O
and	O
platelet	O
agglutination	O
to	O
ristocetin	O
was	O
absent	O
.	O

Propositus	O
'	O
parents	O
are	O
consanguineous	O
.	O

His	O
father	O
and	O
paternal	O
grandmother	O
showed	O
a	O
mild	O
thrombocytopenia	O
(	O
108	O
x	O
10(9)/L	O
and	O
120	O
x	O
10(9)/L	O
platelets	O
respectively	O
)	O
while	O
mothers	O
and	O
sister	O
's	O
referred	O
normal	O
platelet	O
counts	O
.	O

The	O
surface	O
expression	O
of	O
GPIbalpha	O
was	O
practically	O
undetectable	O
by	O
flow	O
-	O
cytometry	O
and	O
western	O
blot	O
in	O
the	O
patient	O
and	O
was	O
reduced	O
in	O
the	O
father	O
.	O

Proband	O
's	O
DNA	O
analysis	O
revealed	O
a	O
homozygous	O
four	O
-	O
base	O
-	O
pair	O
deletion	B-Var
(	O
TGAG	O
)	O
,	O
starting	O
from	O
the	O
last	O
base	O
of	O
the	O
codon	O
for	O
Ser39	O
,	O
leading	B-Reg
to	I-Reg
a	O
coding	O
frame	O
shift	O
with	O
a	O
new	O
termination	B-MPA
codon	I-MPA
after	O
11	O
novel	O
amino	O
acids	O
.	O

The	O
same	O
mutation	O
was	O
seen	O
in	O
heterozygosis	O
in	O
both	O
parents	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
GPIbalpha	O
TGAG	O
deletion	O
in	O
homozygous	O
state	O
even	O
if	O
the	O
defect	O
has	O
already	O
been	O
described	O
in	O
a	O
case	O
of	O
compound	O
heterozygosis	O
.	O

Surprisingly	O
,	O
the	O
propositus	O
does	O
not	O
report	O
any	O
spontaneous	O
bleeding	O
tendency	O
.	O

Common	O
mutations	B-Var
in	B-Reg
Cuban	O
cystic	B-Disease
fibrosis	I-Disease
patients	O
.	O

So	O
far	O
,	O
more	O
than	O
1500	O
mutations	O
have	O
been	O
reported	O
in	O
the	O
cystic	O
fibrosis	O
transmembrane	O
conductance	O
regulator	O
(	B-Gene
CFTR	I-Gene
)	I-Gene
gene	O
.	O

Mutational	O
spectrum	O
varies	O
in	O
accordance	O
with	O
geographic	O
and/or	O
ethnic	O
origin	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
analyzed	O
seven	O
common	B-Reg
CF	B-Disease
mutations	O
(	B-Var
p	I-Var
.	I-Var
F508del	I-Var
,	O
p	B-Var
.	I-Var
G542X	I-Var
,	O
p	B-Var
.	I-Var
R1162X	I-Var
,	O
p	B-Var
.	I-Var
N1303	I-Var
K	I-Var
,	O
p	B-Var
.	I-Var
R334W	I-Var
,	O
p	B-Var
.	I-Var
R553X	I-Var
and	O
c.3120	B-Var
+	I-Var
1G	I-Var
>	I-Var
A	I-Var
)	I-Var
taking	O
into	O
account	O
the	O
ethnic	O
origin	O
of	O
the	O
Cuban	O
population	O
which	O
is	O
mainly	O
influenced	O
by	O
Spanish	O
and	O
sub	O
-	O
Sahara	O
African	O
contribution	O
.	O

All	O
but	O
p	O
.	O
N1303	O
K	O
have	O
been	O
detected	O
in	O
our	O
patients	O
,	O
the	O
p	O
.	O
F508del	O
being	O
the	O
most	O
prevalent	O
(	O
37.9	O
%	O
)	O
.	O

Overall	O
,	O
six	O
mutations	O
showed	O
frequencies	O
above	O
1	O
%	O
accounting	O
for	O
55.5	O
%	O
of	O
the	O
Cuban	O
CF	O
alleles	O
.	O

Mutation	B-Var
in	O
BAG3	B-Gene
causes	B-Reg
severe	O
dominant	O
childhood	B-Disease
muscular	I-Disease
dystrophy	I-Disease
.	O

OBJECTIVE	O
:	O
Myofibrillar	O
myopathies	O
(	O
MFMs	O
)	O
are	O
morphologically	O
distinct	O
but	O
genetically	O
heterogeneous	O
muscular	O
dystrophies	O
in	O
which	O
disintegration	O
of	O
Z	O
disks	O
and	O
then	O
of	O
myofibrils	O
is	O
followed	O
by	O
ectopic	O
accumulation	O
of	O
multiple	O
proteins	O
.	O

Cardiomyopathy	O
,	O
neuropathy	O
,	O
and	O
dominant	O
inheritance	O
are	O
frequent	O
associated	O
features	O
.	O

Mutations	O
in	O
alphaB	O
-	O
crystallin	O
,	O
desmin	O
,	O
myotilin	O
,	O
Zasp	O
,	O
or	O
filamin	O
-	O
C	O
can	O
cause	O
MFMs	O
and	O
were	O
detected	O
in	O
32	O
of	O
85	O
patients	O
of	O
the	O
Mayo	O
MFM	O
cohort	O
.	O

Bag3	B-Protein
,	O
another	O
Z	O
-	O
disk	O
-	O
associated	O
protein	O
,	O
has	O
antiapoptotic	O
properties	O
,	O
and	O
its	O
targeted	O
deletion	B-Var
in	O
mice	O
causes	B-Reg
fulminant	B-Disease
myopathy	I-Disease
with	O
early	O
lethality	O
.	O

We	O
therefore	O
searched	O
for	O
mutations	O
in	O
BAG3	O
in	O
53	O
unrelated	O
MFM	O
patients	O
.	O

METHODS	O
:	O
We	O
searched	O
for	O
mutations	O
in	O
BAG3	O
by	O
direct	O
sequencing	O
.	O

We	O
analyzed	O
structural	O
changes	O
in	O
muscle	O
by	O
histochemistry	O
,	O
immunocytochemistry	O
,	O
and	O
electron	O
microscopy	O
,	O
examined	O
mobility	O
of	O
the	O
mutant	O
Bag3	O
by	O
nondenaturing	O
electrophoresis	O
,	O
and	O
searched	O
for	O
abnormal	O
aggregation	O
of	O
the	O
mutant	O
protein	O
in	O
COS-7	O
(	O
SV-40	O
transformed	O
monkey	O
kidney	O
fibroblast-7	O
)	O
cells	O
.	O

RESULTS	O
:	O
We	O
identified	O
a	O
heterozygous	O
p	O
.	O
Pro209Leu	O
mutation	O
in	O
three	O
patients	O
.	O

All	O
presented	O
in	O
childhood	O
,	O
had	O
progressive	O
limb	O
and	O
axial	O
muscle	O
weakness	O
,	O
and	O
experienced	O
development	O
of	O
cardiomyopathy	O
and	O
severe	O
respiratory	O
insufficiency	O
in	O
their	O
teens	O
;	O
two	O
had	O
rigid	O
spines	O
,	O
and	O
one	O
a	O
peripheral	O
neuropathy	O
.	O

Electron	O
microscopy	O
showed	O
disintegration	O
of	O
Z	O
disks	O
,	O
extensive	O
accumulation	O
of	O
granular	O
debris	O
and	O
larger	O
inclusions	O
,	O
and	O
apoptosis	O
of	O
8	O
%	O
of	O
the	O
nuclei	O
.	O

On	O
nondenaturing	O
electrophoresis	O
of	O
muscle	O
extracts	O
,	O
the	O
Bag3	O
complex	O
migrated	O
faster	O
in	O
patient	O
than	O
control	O
extracts	O
,	O
and	O
expression	O
of	O
FLAG	O
-	O
labeled	O
mutant	O
and	O
wild	O
-	O
type	O
Bag3	O
in	O
COS	O
cells	O
showed	O
abnormal	O
aggregation	O
of	O
the	O
mutant	O
protein	O
.	O

INTERPRETATION	O
:	O
We	O
conclude	O
mutation	O
in	O
Bag3	O
defines	O
a	O
novel	O
severe	O
autosomal	O
dominant	O
childhood	O
muscular	O
dystrophy	O
.	O

Network	O
analyses	O
of	O
differentially	O
expressed	O
proteins	O
in	O
amniotic	O
fluid	O
supernatant	O
associated	O
with	O
abnormal	O
human	O
karyotypes	O
.	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
functional	O
roles	O
of	O
differentially	O
expressed	O
proteins	O
in	O
the	O
amniotic	B-Disease
fluid	I-Disease
supernatant	I-Disease
(	O
AFS	O
)	O
with	O
abnormal	O
karyotypes	O
.	O

DESIGN	O
:	O
Basic	O
and	O
clinical	O
research	O
.	O

SETTING	O
:	O
University	O
hospital	O
.	O

PATIENT(S	O
)	O
:	O
Samples	O
of	O
AFS	O
from	O
34	O
fetuses	O
with	O
normal	O
-	O
karyotype	O
,	O
17	O
with	O
trisomy	O
18	O
,	O
and	O
19	O
with	O
trisomy	O
21	O
.	O

INTERVENTION(S	O
)	O
:	O
Two	O
-	O
dimensional	O
chromatography	O
followed	O
by	O
mass	O
spectrometry	O
to	O
identify	O
the	O
proteins	O
differentially	O
expressed	O
in	O
AFS	O
of	O
trisomy-18	O
or	O
trisomy-21	O
fetuses	O
.	O

MAIN	O
OUTCOME	O
MEASURE(S	O
)	O
:	O
Differentially	O
expressed	O
proteins	O
were	O
confirmed	O
with	O
Western	O
blot	O
analysis	O
and	O
ELISA	O
.	O

The	O
roles	O
of	O
biologic	O
networks	O
in	O
the	O
pathophysiology	O
of	O
aneuploidies	O
were	O
analyzed	O
using	O
MetaCore	O
mapping	O
tools	O
.	O

RESULT(S	O
)	O
:	O
Levels	B-MPA
of	O
apolipoprotein	B-Protein
A1	I-Protein
,	O
AP-3mu	B-Protein
,	O
and	O
antitrypsin	B-Protein
were	O
significantly	O
decreased	B-NegReg
in	O
trisomy-18	B-Var
AFS	O
,	O
whereas	O
placental	B-Protein
protein-14	I-Protein
was	O
increased	B-PosReg
.	O

On	O
the	O
other	O
hand	O
,	O
apolipoprotein	B-Protein
A1	I-Protein
was	O
decreased	B-NegReg
in	O
trisomy-21	B-Var
AFS	O
,	O
but	O
antitrypsin	B-Protein
,	O
prealbumin	B-Protein
,	O
and	O
transferrin	B-Protein
were	O
increased	B-PosReg
in	O
trisomy	B-Var
21	I-Var
.	O

Biologic	O
network	O
analyses	O
revealed	O
that	O
the	O
proteins	O
of	O
the	O
trisomy-18	O
AFS	O
network	O
were	O
involved	O
in	O
immune	O
processes	O
,	O
dysfunction	O
of	O
skin	O
pigmentation	O
,	O
and	O
platelet	O
disorders	O
,	O
whereas	O
those	O
of	O
trisomy	O
21	O
were	O
associated	O
with	O
dysfunctional	O
lipid	O
and	O
cholesterol	O
metabolism	O
,	O
processes	O
of	O
metal	O
ion	O
transport	O
,	O
adenosine	O
triphosphate	O
metabolism	O
,	O
and	O
energy	O
-	O
coupled	O
protein	O
transport	O
.	O

CONCLUSION(S	O
)	O
:	O
The	O
combined	O
use	O
of	O
quantitative	O
proteomics	O
and	O
functional	O
network	O
analyses	O
may	O
integrally	O
analyze	O
the	O
pathophysiology	O
of	O
abnormal	O
karyotypes	O
.	O

Canonical	O
WNT	O
signalling	O
determines	O
lineage	O
specificity	O
in	O
Wilms	O
tumour	O
.	O

Wilms	O
tumours	O
(	O
WTs	O
)	O
have	O
two	O
distinct	O
types	O
of	O
histology	O
with	O
or	O
without	O
ectopic	O
mesenchymal	O
elements	O
,	O
suggesting	O
that	O
WTs	O
arise	O
from	O
either	O
the	O
mesenchymal	O
or	O
epithelial	O
nephrogenic	O
lineages	O
.	O

Regardless	O
of	O
the	O
presence	O
or	O
absence	O
of	O
CTNNB1	O
mutations	O
,	O
nuclear	O
accumulation	O
of	O
beta	O
-	O
catenin	O
is	O
often	O
observed	O
in	O
WTs	O
with	O
ectopic	O
mesenchymal	O
elements	O
.	O

Here	O
,	O
we	O
addressed	O
the	O
relationship	O
between	O
the	O
WNT	O
-	O
signalling	O
pathway	O
and	O
lineage	O
in	O
WTs	O
by	O
examining	O
CTNNB1	O
and	O
WT1	O
mutations	O
,	O
nuclear	O
accumulation	O
of	O
beta	O
-	O
catenin	O
,	O
tumour	O
histology	O
and	O
gene	O
expression	O
profiles	O
.	O

In	O
addition	O
,	O
we	O
screened	O
for	O
mutations	B-Var
in	O
WTX	B-Gene
,	O
which	O
has	O
been	O
proposed	O
to	O
be	O
a	O
negative	B-NegReg
regulator	O
of	O
the	O
canonical	O
WNT	B-Pathway
-	I-Pathway
signalling	I-Pathway
pathway	I-Pathway
.	O

Unsupervised	O
clustering	O
analysis	O
identified	O
two	O
classes	O
of	O
tumours	O
:	O
mesenchymal	O
lineage	O
WNT	O
-	O
dependent	O
tumours	O
,	O
and	O
epithelial	O
lineage	O
WNT	O
-	O
independent	O
tumours	O
.	O

In	O
contrast	O
to	O
the	O
mesenchymal	O
lineage	O
specificity	O
of	O
CTNNB1	O
mutations	O
,	O
WTX	O
mutations	O
were	O
surprisingly	O
observed	O
in	O
both	O
lineages	O
.	O

WTX	B-Var
-	I-Var
mutant	I-Var
WTs	O
with	O
ectopic	O
mesenchymal	O
elements	O
had	O
nuclear	O
accumulation	B-PosReg
of	O
beta	B-Protein
-	I-Protein
catenin	I-Protein
,	O
upregulation	B-PosReg
of	O
WNT	B-Gene
target	I-Gene
genes	I-Gene
and	O
an	O
association	B-Reg
with	I-Reg
CTNNB1	B-Gene
mutations	B-Var
in	O
exon	O
7	O
or	O
8	O
.	O

However	O
,	O
epithelial	O
lineage	O
WTs	O
with	O
WTX	O
mutations	O
had	O
no	O
indications	O
of	O
active	O
WNT	O
signalling	O
,	O
suggesting	O
that	O
the	O
involvement	O
of	O
WTX	O
in	O
the	O
WNT	O
-	O
signalling	O
pathway	O
may	O
be	O
lineage	O
dependent	O
,	O
and	O
that	O
WTX	O
may	O
have	O
an	O
alternative	O
function	O
to	O
its	O
role	O
in	O
the	O
canonical	O
WNT	O
-	O
signalling	O
pathway	O
.	O

Apparent	B-Disease
mineralocorticoid	I-Disease
excess	I-Disease
syndrome	I-Disease
in	O
a	O
Brazilian	O
boy	O
caused	B-Reg
by	I-Reg
the	O
homozygous	O
missense	O
mutation	O
p	B-Var
.	I-Var
R186C	I-Var
in	O
the	O
HSD11B2	B-Gene
gene	O
.	O

The	O
apparent	O
mineralocorticoid	O
excess	O
syndrome	O
(	O
AME	O
)	O
is	O
a	O
rare	O
autosomal	O
recessive	O
disorder	O
due	O
to	O
the	O
deficiency	O
of	O
11beta	O
-	O
hydroxysteroid	O
dehydrogenase	O
type	O
2	O
enzyme	O
(	O
11beta	O
-	O
HSD2	O
)	O
.	O

The	O
11beta	O
-	O
HSD2	O
enzyme	O
,	O
encoded	O
by	O
HSD11B2	O
gene	O
,	O
metabolizes	O
active	O
cortisol	O
in	O
cortisone	O
.	O

Mutations	B-Var
on	O
HSD11B2	B-Gene
gene	O
affect	B-Reg
the	O
enzyme	B-Enzyme
activity	B-MPA
by	O
leading	O
to	O
an	O
excess	B-PosReg
of	O
cortisol	B-MPA
,	O
which	O
causes	B-Reg
its	O
inappropriate	O
access	B-MPA
to	I-MPA
mineralocorticoid	I-MPA
receptor	I-MPA
.	O

Therefore	O
,	O
cortisol	O
will	O
bind	O
mineralocorticoid	O
receptor	O
.	O

The	O
human	O
HSD11B2	O
gene	O
maps	O
to	O
chromosome	O
16q22	O
and	O
consists	O
of	O
five	O
exons	O
encoding	O
a	O
protein	O
of	O
405	O
amino	O
acids	O
.	O

We	O
present	O
here	O
clinical	O
and	O
molecular	O
studies	O
on	O
a	O
Brazilian	O
boy	O
who	O
was	O
born	O
pre	O
-	O
term	O
after	O
an	O
oligodramnious	O
pregnancy	O
.	O

He	O
was	O
diagnosed	O
as	O
having	O
AME	O
at	O
the	O
age	O
of	O
26	O
months	O
.	O

His	O
parents	O
are	O
second	O
cousins	O
.	O

Molecular	O
characterization	O
of	O
the	O
HSD11B2	O
gene	O
revealed	O
the	O
homozygous	O
mutation	O
p	O
.	O
R186C.	O
The	O
patient	O
described	O
here	O
is	O
the	O
second	O
case	O
of	O
HDS11B2	B-Gene
gene	O
mutation	B-Var
reported	O
in	O
Brazilian	O
patients	O
with	B-Reg
AME	B-Disease
.	O

[	O
Primary	O
hiperoxaluria	O
:	O
a	O
new	O
mutation	O
in	O
gen	O
AGXT	B-Gene
(	B-Var
R197Q	I-Var
)	I-Var
cause	B-Reg
of	I-Reg
neonatal	B-Disease
convulsions	I-Disease
]	I-Disease
.	O

Hiperoxaluria	O
primaria	O
:	O
una	O
nueva	O
mutación	O
en	O
el	O
gen	O
AGXT	O
(	O
r197q	O
)	O
causante	O
de	O
convulsiones	O
neonatales	O
.	O

Primary	O
hyperoxaluria	O
is	O
a	O
congenital	O
innate	O
error	O
of	O
the	O
metabolism	O
of	O
the	O
amino	O
acids	O
,	O
that	O
is	O
transmitted	O
like	O
an	O
autosomal	O
recessive	O
character	O
.	O

Two	O
types	O
of	O
hyperoxaluria	O
exist	O
:	O
the	O
primary	O
type	O
I	O
,	O
that	O
corresponds	O
to	O
the	O
peroxisomal	O
enzymatic	O
deficit	O
of	O
the	O
alanine	O
glyoxylate	O
aminotransferase	O
in	O
the	O
liver	O
(	O
AGT	O
)	O
and	O
type	O
II	O
,	O
due	O
to	O
the	O
deficit	O
of	O
the	O
glyoxylate	O
reductase	O
/	O
hydroxypyruvate	O
reductase	O
deficiency	O
(	O
GRHPR	O
)	O
.	O

The	O
primary	O
type	O
I	O
(	O
AGT	O
)	O
is	O
the	O
most	O
frequenty	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
female	O
infant	O
of	O
one	O
month	O
of	O
age	O
,	O
that	O
on	O
her	O
first	O
day	O
post	O
birth	O
,	O
presented	O
myoclonic	O
convulsions	O
and	O
tonic	O
spasms	O
,	O
both	O
during	O
wakefullness	O
and	O
sleep	O
periods	O
,	O
that	O
became	O
more	O
frequent	O
and	O
did	O
not	O
respond	O
to	O
the	O
use	O
of	O
anticonvulsants	O
.	O

The	O
ictal	O
Electroencephalogram	O
presented	O
an	O
intermittent	O
activity	O
of	O
spikes	O
and	O
spike	O
-	O
waves	O
of	O
high	O
voltage	O
in	O
the	O
right	O
hemisphere	O
.	O

Eight	O
minutes	O
after	O
the	O
intravenous	O
administration	O
of	O
150	O
mg	O
of	O
pyridoxine	O
,	O
it	O
was	O
observed	O
a	O
diminution	O
of	O
the	O
epileptic	O
activity	O
,	O
as	O
well	O
as	O
the	O
clinical	O
manifestations	O
.	O

The	O
determination	O
of	O
organic	O
acids	O
in	O
urine	O
revealed	O
an	O
increase	O
in	O
the	O
concentration	O
levels	O
of	O
oxalic	O
acid	O
(	O
3064	O
mmol	O
/	O
mol	O
of	O
creatinine	O
)	O
.	O

The	O
molecular	O
genetic	O
study	O
of	O
the	O
AGXT	O
gene	O
,	O
showed	O
the	O
existence	O
of	O
a	O
R197Q	O
mutation	O
in	O
exón	O
5	O
of	O
the	O
patient	O
and	O
her	O
father	O
.	O

She	O
received	O
treatment	O
with	O
pyridoxine	O
at	O
a	O
dose	O
of	O
50	O
mg	O
/	O
day	O
.	O

When	O
she	O
reached	O
the	O
age	O
of	O
three	O
months	O
both	O
a	O
normal	O
electroencephalogram	O
and	O
biochemistry	O
were	O
obtained	O
.	O

Although	O
it	O
is	O
a	O
rare	O
cause	O
of	O
neonatal	O
convulsions	O
,	O
hyperoxaluria	O
,	O
due	O
to	O
new	O
mutations	O
is	O
an	O
underdiagnosed	O
disease	O
by	O
neonatologists	O
and	O
paediatricias	O
.	O

Identification	O
of	O
the	O
CLCN7	B-Gene
gene	O
mutations	B-Var
in	O
two	O
Chinese	O
families	O
with	B-Reg
autosomal	B-Disease
dominant	I-Disease
osteopetrosis	I-Disease
(	I-Disease
type	I-Disease
II	I-Disease
)	I-Disease
.	O

Here	O
we	O
report	O
the	O
identification	O
of	O
two	O
different	O
mutations	O
in	O
chloride	O
channel	O
7	O
gene	O
in	O
two	O
unrelated	O
patients	O
with	O
autosomal	O
dominant	O
osteopetrosis	O
type	O
II	O
.	O

We	O
determined	O
that	O
one	O
patient	O
(	O
a	O
32-year	O
-	O
old	O
woman	O
)	O
carried	O
a	O
heterozygous	O
gene	O
for	O
a	O
R767W	O
mutation	O
in	O
exon	O
24	O
,	O
and	O
another	O
patient	O
(	O
a	O
17-year	O
-	O
old	O
boy	O
)	O
carried	O
a	O
heterozygous	O
gene	O
for	O
a	O
novel	O
frameshift	O
mutation	O
(	O
Glu798FS	O
)	O
in	O
exon	O
25	O
.	O

Recent	O
studies	O
have	O
reported	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
the	O
chloride	O
channel	O
7	O
(	B-Gene
CLCN7	I-Gene
)	I-Gene
gene	O
as	O
a	O
cause	O
of	O
autosomal	B-Disease
dominant	I-Disease
osteopetrosis	I-Disease
type	I-Disease
II	I-Disease
(	I-Disease
ADO	I-Disease
-	I-Disease
II	I-Disease
)	I-Disease
.	O

The	O
identification	O
of	O
gene	O
mutations	O
in	O
Chinese	O
with	O
ADO	O
has	O
not	O
been	O
reported	O
previously	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
mutations	O
of	O
the	O
CLCN7	O
gene	O
in	O
two	O
unrelated	O
Chinese	O
families	O
with	O
ADO	O
-	O
II	O
.	O

Two	O
probands	O
with	O
ADO	O
-	O
II	O
were	O
diagnosed	O
based	O
on	O
their	O
bone	O
characteristics	O
on	O
X	O
-	O
rays	O
and	O
their	O
laboratory	O
results	O
.	O

All	O
25	O
exons	O
of	O
the	O
CLCN7	O
gene	O
,	O
including	O
the	O
exon	O
-	O
intron	O
boundaries	O
,	O
were	O
sequenced	O
.	O

We	O
found	O
in	O
family	O
1	O
that	O
the	O
proband	O
(	O
a	O
32-year	O
-	O
old	O
woman	O
)	O
was	O
heterozygous	O
for	O
a	O
CLCN7	O
mutation	O
.	O

The	O
nonsynonymous	O
mutation	O
consisted	O
of	O
a	O
heterozygous	O
C	O
/	O
T	O
transition	O
at	O
codon	O
2327	O
in	O
exon	O
24	O
,	O
which	O
resulted	O
in	O
an	O
arginine	O
(	O
CGG)-to	O
tryptophan	O
(	O
TGG	O
)	O
substitution	O
at	O
position	O
767	O
(	O
R767W	O
)	O
.	O

The	O
same	O
heterozygous	O
mutation	O
(	O
C	O
/	O
T	O
)	O
was	O
determined	O
in	O
her	O
father	O
and	O
son	O
,	O
who	O
were	O
asymptomatic	O
with	O
normal	O
skeleton	O
radiography	O
.	O

In	O
family	O
2	O
,	O
we	O
found	O
that	O
the	O
proband	O
(	O
a	O
17-year	O
-	O
old	O
boy	O
)	O
carried	O
a	O
novel	O
frameshift	O
mutation	O
(	O
Glu798FS	O
)	O
resulting	O
from	O
a	O
G	O
insertion	O
between	O
codon	O
60	O
and	O
codon	O
61	O
in	O
exon	O
25	O
.	O

The	O
heterozygous	O
-/G	O
insertion	O
is	O
predicted	O
to	O
elongate	O
the	O
peptide	O
of	O
CLCN7	O
by	O
120	O
amino	O
acids	O
after	O
position	O
797	O
amino	O
acids	O
.	O

Similarly	O
,	O
some	O
individuals	O
of	O
this	O
family	O
carried	O
the	O
same	O
heterozygous	O
mutation	O
,	O
but	O
they	O
are	O
all	O
asymptomatic	O
.	O

Furthermore	O
,	O
the	O
R767W	O
and	O
Glu798FS	O
mutations	O
were	O
not	O
found	O
in	O
100	O
unrelated	O
controls	O
.	O

Our	O
present	O
findings	O
suggest	O
that	O
the	O
novel	O
Glu798FS	B-Var
mutation	O
in	O
exon	O
25	O
and	O
R767W	B-Var
in	O
exon	O
24	O
in	O
the	O
CLCN7	B-Gene
gene	O
were	O
responsible	B-Reg
for	O
ADO	B-Disease
-	I-Disease
II	I-Disease
in	O
these	O
Chinese	O
patients	O
.	O

A	O
case	O
of	O
factor	B-Disease
XI	I-Disease
deficiency	I-Disease
caused	B-Reg
by	I-Reg
compound	O
heterozygous	O
F11	B-Gene
gene	O
mutation	B-Var
.	O

Inherited	O
factor	O
XI	O
(	O
FXI	O
)	O
deficiency	O
is	O
a	O
rare	O
autosomal	O
recessive	O
bleeding	O
disorder	O
in	O
most	O
populations	O
except	O
for	O
Ashkenazi	O
Jews	O
.	O

In	O
this	O
report	O
,	O
a	O
25-year	O
-	O
old	O
Chinese	O
female	O
FXI	O
deficiency	O
case	O
has	O
been	O
studied	O
.	O

Routine	O
clotting	O
tests	O
showed	O
significantly	O
prolonged	O
activated	O
partial	O
thromboplastin	O
time	O
(	O
69.5	O
s	O
,	O
control	O
35	O
+	O
/-	O
10	O
s	O
)	O
while	O
prothrombin	O
time	O
(	O
12.3	O
s	O
,	O
control	O
13	O
+	O
/-	O
3	O
s)was	O
normal	O
.	O

FXI	O
:	O
C	O
and	O
FXI	O
:	O
Ag	O
were	O
2.6	O
%	O
and	O
2.5	O
%	O
,	O
respectively	O
,	O
indicating	O
that	O
this	O
case	O
was	O
cross	O
-	O
reacting	O
material	O
negative	O
.	O

The	O
activities	O
of	O
other	O
coagulation	O
factors	O
and	O
liver	O
function	O
were	O
in	O
normal	O
range	O
.	O

The	O
DNA	O
sequence	O
results	O
of	O
the	O
15	O
exons	O
and	O
their	O
boundaries	O
of	O
F11	O
gene	O
revealed	O
a	O
novel	O
G3733C	O
missense	O
mutation	O
in	O
exon	O
2	O
,	O
and	O
a	O
recurrent	O
C16642	O
T	O
nonsense	O
mutation	O
in	O
exon	O
8	O
.	O

The	O
G3733C	B-Var
mutation	O
caused	B-Reg
G-1R	B-Var
substitution	I-Var
in	O
FXI	B-Protein
signal	I-Protein
peptide	I-Protein
,	O
which	O
might	O
impair	B-NegReg
the	O
protein	B-MPA
's	I-MPA
secretion	I-MPA
and	O
introduced	B-PosReg
a	O
new	O
BssSI	O
enzyme	B-Enzyme
digestion	B-MPA
site	O
.	O

The	O
C16642	B-Var
T	I-Var
mutation	O
led	B-Reg
a	O
premature	B-MPA
stop	I-MPA
codon	I-MPA
at	O
amino	O
acid	O
position	O
263(Q263Term	B-Var
)	I-Var
.	O

G-1R	B-Var
and	O
Q263Term	B-Var
compound	O
heterozygous	O
mutations	O
in	O
F11	B-Gene
gene	O
were	O
the	O
cause	B-Reg
of	O
FXI	B-Disease
deficiency	I-Disease
for	O
this	O
proband	O
.	O

G-1R	B-Var
mutation	O
was	O
a	O
novel	O
F11	B-Gene
gene	O
mutation	O
causing	B-Reg
inherited	O
FXI	B-Disease
deficiency	I-Disease
.	O

Accelerated	O
inactivation	O
of	O
the	O
L	O
-	O
type	O
calcium	O
current	O
due	O
to	O
a	O
mutation	O
in	O
CACNB2b	O
underlies	O
Brugada	O
syndrome	O
.	O

Recent	O
studies	O
have	O
demonstrated	O
an	O
association	B-Reg
between	O
mutations	B-Var
in	O
CACNA1c	B-Gene
or	O
CACNB2b	B-Gene
and	O
Brugada	B-Disease
syndrome	I-Disease
(	O
BrS	O
)	O
.	O

Previously	O
described	O
mutations	O
all	O
caused	O
a	O
loss	O
of	O
function	O
secondary	O
to	O
a	O
reduction	O
of	O
peak	O
calcium	O
current	O
(	O
I(Ca	O
)	O
)	O
.	O

We	O
describe	O
a	O
novel	O
CACNB2b	B-Gene
mutation	B-Var
associated	O
with	O
BrS	O
in	O
which	O
loss	O
of	O
function	O
is	O
caused	O
by	O
accelerated	O
inactivation	B-NegReg
of	O
I(Ca	B-MPA
)	I-MPA
.	O

The	O
proband	O
,	O
a	O
32	O
year	O
old	O
male	O
,	O
displayed	O
a	O
Type	O
I	O
ST	O
segment	O
elevation	O
in	O
two	O
right	O
precordial	O
ECG	O
leads	O
following	O
a	O
procainamide	O
challenge	O
.	O

EP	O
study	O
was	O
positive	O
with	O
induction	O
of	O
polymorphic	O
VT	O
/	O
VF	O
.	O

Interrogation	O
of	O
implanted	O
ICD	O
revealed	O
brief	O
episodes	O
of	O
very	O
rapid	O
ventricular	O
tachycardia	O
.	O

He	O
was	O
also	O
diagnosed	O
with	O
vasovagal	O
syncope	O
.	O

Genomic	O
DNA	O
was	O
isolated	O
from	O
lymphocytes	O
.	O

All	O
exons	O
and	O
intron	O
borders	O
of	O
15	O
ion	O
channel	O
genes	O
were	O
amplified	O
and	O
sequenced	O
.	O

The	O
only	O
mutation	O
uncovered	O
was	O
a	O
missense	O
mutation	O
(	O
T11I	O
)	O
in	O
CACNB2b	O
.	O

We	O
expressed	O
WT	O
or	O
T11I	O
CACNB2b	O
in	O
TSA201	O
cells	O
co	O
-	O
transfected	O
with	O
WT	O
CACNA1c	O
and	O
CACNA2d	O
.	O

Patch	O
clamp	O
analysis	O
showed	O
no	O
significant	O
difference	O
between	O
WT	O
and	O
T11I	O
in	O
peak	O
I(Ca	O
)	O
density	O
,	O
steady	O
-	O
state	O
inactivation	O
or	O
recovery	O
from	O
inactivation	O
.	O

However	O
,	O
both	O
fast	O
and	O
slow	O
decays	O
of	O
I(Ca	O
)	O
were	O
significantly	O
faster	O
in	O
mutant	O
channels	O
between	O
0	O
and	O
+	O
20	O
mV.	O
Action	O
potential	O
voltage	O
clamp	O
experiments	O
showed	O
that	O
total	O
charge	O
was	O
reduced	O
by	O
almost	O
half	O
compared	O
to	O
WT	O
.	O

We	O
report	O
the	O
first	O
BrS	O
mutation	O
in	O
CaCNB2b	O
resulting	O
in	O
accelerated	O
inactivation	O
of	O
L	O
-	O
type	O
calcium	O
channel	O
current	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
faster	O
current	O
decay	O
results	O
in	O
a	O
loss	O
-	O
of	O
-	O
function	O
responsible	O
for	O
the	O
Brugada	O
phenotype	O
Electrophysiological	O
studies	O
in	O
a	O
mouse	O
model	O
of	O
Schwartz	O
-	O
Jampel	O
syndrome	O
demonstrate	O
muscle	O
fiber	O
hyperactivity	O
of	O
peripheral	O
nerve	O
origin	O
.	O

Schwartz	B-Disease
-	I-Disease
Jampel	I-Disease
syndrome	I-Disease
(	O
SJS	O
)	O
is	O
an	O
autosomal	O
-	O
recessive	O
condition	O
characterized	O
by	O
muscle	O
stiffness	O
and	O
chondrodysplasia	O
.	O

It	O
is	O
due	O
to	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
hypomorphic	O
mutations	B-Var
in	O
the	O
HSPG2	B-Gene
gene	O
that	O
encodes	O
for	O
perlecan	O
,	O
a	O
proteoglycan	O
secreted	O
into	O
the	O
basement	O
membrane	O
.	O

The	O
origin	O
of	O
muscle	O
stiffness	O
in	O
SJS	O
is	O
debated	O
.	O

To	O
resolve	O
this	O
issue	O
,	O
we	O
performed	O
an	O
electrophysiological	O
investigation	O
of	O
an	O
SJS	O
mouse	O
model	O
with	O
a	O
missense	O
mutation	O
in	O
the	O
HSPG2	O
gene	O
.	O

Compound	O
muscle	O
action	O
potential	O
amplitudes	O
,	O
distal	O
motor	O
latencies	O
,	O
repetitive	O
nerve	O
stimulation	O
tests	O
,	O
and	O
sensory	O
nerve	O
conduction	O
velocities	O
of	O
SJS	O
mice	O
were	O
normal	O
.	O

On	O
electromyography	O
(	O
EMG	O
)	O
,	O
neuromyotonic	O
discharges	O
,	O
that	O
is	O
,	O
bursts	O
of	O
motor	O
unit	O
action	O
potentials	O
firing	O
at	O
high	O
rates	O
(	O
120	O
-	O
300	O
HZ	O
)	O
,	O
were	O
constantly	O
observed	O
in	O
SJS	O
mice	O
in	O
all	O
muscles	O
,	O
except	O
in	O
the	O
diaphragm	O
.	O

Neuromyotonic	O
discharges	O
were	O
not	O
influenced	O
by	O
general	O
anesthesia	O
and	O
disappeared	O
with	O
curare	O
administration	O
.	O

They	O
persisted	O
after	O
complete	O
motor	O
nerve	O
section	O
,	O
terminating	O
only	O
with	O
Wallerian	O
degeneration	O
.	O

These	O
results	O
demonstrate	O
that	O
perlecan	O
deficiency	O
in	O
SJS	O
provokes	O
a	O
neuromyotonic	O
syndrome	O
.	O

The	O
findings	O
further	O
suggest	O
a	O
distal	O
axonal	O
localization	O
of	O
the	O
generator	O
of	O
neuromyotonic	O
discharges	O
.	O

SJS	O
should	O
now	O
be	O
considered	O
as	O
an	O
inherited	O
disorder	O
with	O
peripheral	O
nerve	O
hyperexcitability	O
.	O

MEFV	B-Gene
mutation	B-Var
carriage	O
in	O
Israeli	O
Jewish	O
individuals	O
from	O
ethnicities	O
with	O
low	O
risk	O
for	B-Reg
familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
.	O

Familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
(	O
FMF	O
)	O
is	O
a	O
disease	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
MEditerranean	O
FeVer	O
gene	O
(	B-Gene
MEFV	I-Gene
)	I-Gene
,	O
and	O
in	O
Israel	O
it	O
most	O
commonly	O
affects	O
Jews	O
of	O
North	O
African	O
extraction	O
,	O
in	O
whom	O
the	O
mutation	O
carrier	O
rate	O
is	O
as	O
high	O
as	O
1	O
in	O
5	O
.	O

To	O
assess	O
the	O
protective	O
as	O
well	O
as	O
the	O
modulating	O
affect	O
of	O
MEFV	O
mutation	O
carriage	O
on	O
various	O
inflammatory	O
disease	O
states	O
,	O
we	O
sought	O
to	O
define	O
the	O
frequency	O
of	O
MEFV	O
mutations	O
in	O
Israeli	O
Jewish	O
individuals	O
of	O
various	O
ethnicities	O
,	O
including	O
those	O
with	O
low	O
frequency	O
of	O
FMF	O
,	O
which	O
were	O
not	O
in	O
the	O
focus	O
of	O
our	O
attention	O
hitherto	O
.	O

A	O
total	O
of	O
163	O
adults	O
of	O
Bucharian	O
,	O
Turkish	O
,	O
Georgian	O
,	O
Yemenite	O
and	O
Bulgarian	O
origin	O
comprised	O
the	O
study	O
group	O
.	O

The	O
prevalence	O
of	O
the	O
most	O
frequent	O
MEFV	O
mutations	O
in	O
the	O
Israeli	O
Jewish	O
population	O
,	O
namely	O
:	O
M694V	O
,	O
V726A	O
and	O
E148Q	O
,	O
was	O
assessed	O
.	O

The	O
association	O
of	O
mutation	O
carriage	O
with	O
a	O
personal	O
history	O
of	O
FMF	O
-	O
like	O
phenomena	O
,	O
as	O
well	O
as	O
various	O
inflammatory	O
and	O
non	O
-	O
inflammatory	O
diseases	O
,	O
was	O
evaluated	O
.	O

A	O
high	O
MEFV	O
mutation	O
frequency	O
was	O
found	O
among	O
Jews	O
of	O
Bucharian	O
,	O
Georgian	O
and	O
Bulgarian	O
origin	O
(	O
20	O
%	O
)	O
,	O
whereas	O
intermediate	O
and	O
low	O
rates	O
were	O
detected	O
in	O
Jews	O
of	O
Turkish	O
and	O
Yemenite	O
extraction	O
(	O
14	O
and	O
8	O
%	O
,	O
respectively	O
)	O
.	O

FMF	O
-	O
like	O
manifestations	O
and	O
related	O
diseases	O
were	O
observed	O
more	O
often	O
in	O
MEFV	O
mutation	O
carriers	O
than	O
in	O
their	O
counterparts	O
.	O

MEFV	O
mutation	O
frequency	O
,	O
directly	O
assessed	O
by	O
DNA	O
analysis	O
,	O
exceeds	O
the	O
rate	O
calculated	O
from	O
disease	O
prevalence	O
in	O
Israeli	O
Jewish	O
individuals	O
originated	O
from	O
ethnicities	O
with	O
a	O
low	O
prevalence	O
of	O
FMF	O
.	O

MEFV	O
mutation	O
carriage	O
in	O
this	O
subgroup	O
is	O
associated	O
with	O
various	O
inflammatory	O
disorders	O
.	O

In	O
vivo	O
laser	O
confocal	O
microscopy	O
findings	O
and	O
mutational	O
analysis	O
for	O
Schnyder	O
's	O
crystalline	O
corneal	O
dystrophy	O
.	O

OBJECTIVE	O
:	O
To	O
identify	O
any	O
mutation	O
of	O
the	O
UbiA	O
prenyltransferase	O
domain	O
-	O
containing	O
protein	O
1	O
(	O
UBIAD1	O
)	O
gene	O
in	O
Japanese	O
patients	O
with	O
Schnyder	B-Disease
's	I-Disease
crystalline	I-Disease
corneal	I-Disease
dystrophy	I-Disease
(	O
SCCD	O
)	O
and	O
to	O
investigate	O
in	O
vivo	O
microstructural	O
phenotype	O
and	O
genotype	O
correlations	O
using	O
laser	O
scanning	O
confocal	O
microscopy	O
(	O
Heidelberg	O
Retina	O
Tomograph	O
2	O
Rostock	O
Cornea	O
Module	O
;	O
Heidelberg	O
Engineering	O
GmbH	O
,	O
Dossenheim	O
,	O
Germany	O
)	O
.	O

DESIGN	O
:	O
Small	O
,	O
comparative	O
case	O
series	O
.	O

PARTICIPANTS	O
:	O
Three	O
patients	O
from	O
3	O
pedigrees	O
(	O
3	O
males	O
)	O
with	O
clinically	O
diagnosed	O
SCCD	O
and	O
their	O
relatives	O
(	O
2	O
males	O
,	O
1	O
female	O
)	O
participated	O
in	O
this	O
study	O
.	O

TESTING	O
:	O
All	O
participants	O
were	O
examined	O
genetically	O
and	O
by	O
slit	O
-	O
lamp	O
biomicroscopy	O
and	O
in	O
vivo	O
laser	O
confocal	O
microscopy	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
:	O
Genomic	O
DNA	O
from	O
the	O
patients	O
and	O
100	O
unrelated	O
healthy	O
volunteers	O
(	O
200	O
chromosomes	O
)	O
was	O
isolated	O
from	O
blood	O
samples	O
and	O
used	O
for	O
mutation	O
screening	O
of	O
the	O
UBIAD1	O
gene	O
.	O

Selected	O
confocal	O
images	O
of	O
corneal	O
layers	O
were	O
evaluated	O
qualitatively	O
for	O
shape	O
and	O
degree	O
of	O
light	O
reflection	O
of	O
deposits	O
.	O

RESULTS	O
:	O
Novel	O
mutations	O
in	O
the	O
UBIAD1	O
gene	O
(	O
Y174C	O
,	O
K181R	O
,	O
and	O
N233H	O
)	O
were	O
identified	O
.	O

Additionally	O
,	O
cosegregation	O
of	O
the	O
mutation	O
(	B-Var
Y174C	I-Var
)	I-Var
and	O
SCCD	O
was	O
confirmed	O
in	O
1	O
pedigree	O
,	O
indicating	O
that	O
the	O
mutation	O
of	O
the	O
UBIAD1	B-Gene
gene	O
is	O
causative	B-Reg
for	O
SCCD	B-Disease
.	O

The	O
3	O
mutations	O
were	O
absent	O
in	O
all	O
200	O
control	O
chromosomes	O
.	O

In	O
vivo	O
laser	O
confocal	O
microscopy	O
demonstrated	O
subepithelial	O
highly	O
reflective	O
crystals	O
in	O
4	O
cases	O
;	O
the	O
shapes	O
of	O
the	O
crystals	O
were	O
needle	O
-	O
shaped	O
(	O
3	O
cases	O
)	O
or	O
rectangular	O
(	O
1	O
case	O
)	O
.	O

A	O
phenotype	O
and	O
genotype	O
correlation	O
was	O
demonstrated	O
in	O
1	O
pedigree	O
,	O
and	O
phenotypic	O
heterogeneity	O
(	O
SCCD	O
with	O
or	O
without	O
crystals	O
caused	O
by	O
a	O
same	O
mutation	O
of	O
Y174C	O
in	O
the	O
UBIAD1	O
gene	O
)	O
also	O
was	O
demonstrated	O
in	O
1	O
pedigree	O
.	O

CONCLUSIONS	O
:	O
Nonsynonymous	O
novel	O
mutations	O
in	O
the	O
UBIAD1	O
gene	O
were	O
detected	O
in	O
3	O
unrelated	O
Japanese	O
pedigrees	O
with	O
SCCD	O
,	O
confirming	O
the	O
genetic	O
heterogeneity	O
of	O
this	O
disorder	O
.	O

In	O
vivo	O
laser	O
confocal	O
microscopy	O
is	O
capable	O
of	O
identifying	O
characteristic	O
corneal	O
microstructural	O
changes	O
related	O
to	O
genetically	O
mapped	O
SCCD	O
with	O
high	O
resolution	O
,	O
and	O
phenotypic	O
heterogeneity	O
was	O
presented	O
.	O

Further	O
confocal	O
and	O
mutational	O
analysis	O
using	O
a	O
larger	O
number	O
of	O
patients	O
with	O
SCCD	O
is	O
required	O
to	O
elucidate	O
in	O
vivo	O
microstructural	O
phenotype	O
and	O
genotype	O
correlations	O
.	O

FINANCIAL	O
DISCLOSURE(S	O
)	O
:	O
The	O
author(s	O
)	O
have	O
no	O
proprietary	O
or	O
commercial	O
interest	O
in	O
any	O
materials	O
discussed	O
in	O
this	O
article	O
.	O

Neutral	B-Disease
lipid	I-Disease
storage	I-Disease
disease	I-Disease
:	I-Disease
genetic	O
disorders	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
adipose	B-Enzyme
triglyceride	I-Enzyme
lipase	B-Gene
/	I-Gene
PNPLA2	I-Gene
or	O
CGI-58	B-Gene
/	I-Gene
ABHD5	I-Gene
.	O

Neutral	O
lipid	O
storage	O
disease	O
(	O
NLSD	O
)	O
is	O
a	O
group	O
of	O
autosomal	O
recessive	O
disorders	O
characterized	O
by	O
the	O
excessive	O
accumulation	O
of	O
neutral	O
lipids	O
in	O
multiple	O
tissues	O
.	O

Recently	O
,	O
two	O
genes	O
,	O
adipose	O
triglyceride	O
lipase	O
(	O
ATGL	O
/	O
PNPLA2	O
)	O
and	O
comparative	O
gene	O
identification-58	O
(	O
CGI-58	O
/	O
ABHD5	O
)	O
,	O
have	O
been	O
shown	O
to	O
cause	O
NLSD	O
.	O

ATGL	O
specifically	O
hydrolyzes	O
the	O
first	O
fatty	O
acid	O
from	O
triacylglycerols	O
(	O
TG	O
)	O
and	O
CGI-58	O
/	O
ABHD5	O
stimulates	O
ATGL	O
activity	O
by	O
a	O
currently	O
unknown	O
mechanism	O
.	O

Mutations	B-Var
in	O
both	O
the	O
ATGL	B-Gene
and	O
the	O
CGI-58	B-Gene
genes	O
are	O
associated	B-Reg
with	I-Reg
systemic	B-MPA
TG	I-MPA
accumulation	I-MPA
,	O
yet	O
the	O
resulting	O
clinical	O
manifestations	O
are	O
not	O
identical	O
.	O

Patients	O
with	O
defective	O
ATGL	O
function	O
suffer	O
from	O
more	O
severe	O
myopathy	O
(	O
NLSDM	O
)	O
than	O
patients	O
with	O
defective	O
CGI-58	O
function	O
.	O

On	O
the	O
other	O
hand	O
,	O
CGI-58	B-Gene
mutations	B-Var
are	O
always	O
associated	B-Reg
with	I-Reg
ichthyosis	O
(	B-Disease
NLSDI	I-Disease
)	I-Disease
,	O
which	O
was	O
not	O
observed	O
in	O
patients	O
with	O
defective	O
ATGL	O
function	O
.	O

These	O
observations	O
indicate	O
an	O
ATGL	O
-	O
independent	O
function	O
of	O
CGI-58	O
.	O

This	O
review	O
summarizes	O
recent	O
findings	O
with	O
the	O
goal	O
of	O
relating	O
structural	O
variants	O
of	O
ATGL	O
and	O
CGI-58	O
to	O
functional	O
consequences	O
in	O
lipid	O
metabolism	O
.	O

A	O
heterozygous	B-Var
null	I-Var
mutation	I-Var
combined	O
with	O
the	O
G1258A	B-Var
polymorphism	O
of	O
SPINK5	B-Gene
causes	O
impaired	B-NegReg
LEKTI	B-MPA
function	I-MPA
and	O
abnormal	B-MPA
expression	I-MPA
of	I-MPA
skin	I-MPA
barrier	I-MPA
proteins	I-MPA
.	O

BACKGROUND	O
:	O
Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
the	O
Kazal	O
-	O
type	O
serine	O
protease	O
inhibitor	O
,	O
LEKTI	O
,	O
encoded	O
by	O
the	O
SPINK5	B-Gene
gene	O
cause	O
the	O
rare	O
autosomal	O
recessive	O
skin	O
disease	O
Netherton	B-Disease
syndrome	I-Disease
(	O
NS	O
)	O
.	O

G1258A	O
polymorphism	O
in	O
SPINK5	O
may	O
be	O
associated	O
with	O
atopic	O
dermatitis	O
,	O
which	O
shares	O
several	O
clinical	O
features	O
with	O
NS	O
.	O

OBJECTIVES	O
:	O
To	O
determine	O
if	O
the	O
phenotype	O
of	O
NS	O
can	O
be	O
caused	O
by	O
a	O
single	O
null	O
mutation	O
in	O
SPINK5	O
combined	O
with	O
the	O
homozygous	O
G1258A	O
polymorphism	O
.	O

METHODS	O
:	O
We	O
screened	O
mutations	O
in	O
the	O
gene	O
SPINK5	O
by	O
direct	O
DNA	O
sequencing	O
and	O
position	O
cloning	O
and	O
examined	O
the	O
expressions	O
of	O
the	O
SPINK5-encoded	O
protein	O
LEKTI	O
and	O
other	O
relevant	O
proteins	O
by	O
immunostaining	O
and	O
immunoblot	O
.	O

RESULTS	O
:	O
We	O
describe	O
here	O
a	O
patient	O
who	O
was	O
clinically	O
diagnosed	O
with	O
NS	O
and	O
carried	O
a	O
single	O
null	O
mutation	O
in	O
SPINK5	O
combined	O
with	O
the	O
homozygous	O
G1258A	O
polymorphism	O
.	O

SPINK5	O
mRNA	O
was	O
present	O
at	O
normal	O
levels	O
and	O
LEKTI	O
was	O
expressed	O
in	O
the	O
epidermis	O
.	O

Nonetheless	O
,	O
the	O
putative	O
downstream	O
LEKTI	O
substrates	O
stratum	O
corneum	O
trypsin	O
-	O
like	O
enzyme	O
(	O
SCTE	O
)	O
,	O
desmoglein	O
1	O
and	O
protein	O
markers	O
of	O
keratinocyte	O
differentiation	O
were	O
expressed	O
abnormally	O
,	O
similar	O
to	O
that	O
seen	O
in	O
NS	O
if	O
two	O
null	O
mutant	O
alleles	O
are	O
present	O
.	O

CONCLUSION	O
:	O
This	O
finding	O
indicates	O
that	O
haploinsufficiency	O
of	O
SPINK5	O
can	O
cause	O
the	O
NS	O
phenotype	O
in	O
the	O
presence	O
of	O
one	O
null	O
mutation	O
with	O
homozygous	O
G1258A	O
polymorphisms	O
in	O
SPINK5	O
,	O
and	O
this	O
could	O
impair	O
the	O
function	O
of	O
LEKTI	O
and	O
therefore	O
acts	O
as	O
a	O
true	O
mutation	O
.	O

MEFV	B-Gene
mutations	B-Var
in	O
patients	O
with	B-Reg
Familial	B-Disease
Mediterranean	I-Disease
Fever	I-Disease
from	O
the	O
Aegean	O
region	O
of	O
Turkey	O
.	O

Familial	B-Disease
Mediterranean	I-Disease
Fever	I-Disease
(	O
FMF	O
)	O
which	O
is	O
frequently	O
present	O
in	O
Mediterranean	O
populations	O
is	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
MEFV	B-Gene
gene	O
.	O

According	O
to	O
recent	O
data	O
,	O
MEFV	O
mutations	O
are	O
not	O
the	O
only	O
cause	O
of	O
FMF	O
,	O
but	O
these	O
are	O
major	O
genetic	O
determinants	O
which	O
cause	O
FMF	O
.	O

It	O
has	O
also	O
been	O
suggested	O
that	O
there	O
may	O
be	O
a	O
number	O
of	O
other	O
genes	O
causing	O
FMF	O
.	O

The	O
MEFV	O
gene	O
is	O
located	O
at	O
16p13.3	O
and	O
encodes	O
a	O
protein	O
,	O
pyrin	O
/	O
marenostrin	O
.	O

More	O
than	O
70	O
disease	O
associated	O
mutations	O
and	O
totally	O
186	O
mutations	O
and	O
polymorphisms	O
have	O
been	O
defined	O
in	O
affected	O
individuals	O
.	O

We	O
have	O
retrospectively	O
evaluated	O
the	O
molecular	O
test	O
results	O
of	O
1,201	O
patients	O
identified	O
as	O
having	O
FMF	O
clinical	O
symptoms	O
referred	O
to	O
the	O
Molecular	O
Genetics	O
Laboratory	O
of	O
the	O
Department	O
of	O
Medical	O
Genetics	O
,	O
Faculty	O
of	O
Medicine	O
,	O
Ege	O
University	O
,	O
Izmir	O
/	O
Turkey	O
over	O
the	O
last	O
4	O
years	O
.	O

Patients	O
were	O
tested	O
for	O
12	O
common	O
mutations	O
in	O
the	O
MEFV	O
gene	O
using	O
a	O
strip	O
assay	O
method	O
(	O
Innogenetics	O
,	O
Belgium	O
)	O
.	O

Out	O
of	O
the	O
1,201	O
patients	O
tested	O
(	O
2,402	O
chromosomes	O
)	O
in	O
the	O
Aegean	O
region	O
in	O
Turkey	O
,	O
654	O
(	O
54.45	O
%	O
)	O
did	O
not	O
carry	O
any	O
mutations	O
,	O
among	O
the	O
547	O
(	O
45.55	O
%	O
)	O
patients	O
with	O
mutations	O
246	O
patients	O
were	O
either	O
homozygous	O
(	O
101	O
)	O
or	O
compound	O
heterozygous	O
(	O
145	O
)	O
,	O
296	O
carried	O
only	O
one	O
detected	O
mutation	O
,	O
and	O
five	O
patients	O
had	O
three	O
mutations	O
.	O

Allelic	O
frequencies	O
for	O
the	O
four	O
most	O
common	O
mutations	O
in	O
the	O
mutation	O
positive	O
groups	O
were	O
47.60	O
%	O
(	O
M694V	O
)	O
,	O
16.75	O
%	O
(	O
E148Q	O
)	O
,	O
12.95	O
%	O
(	O
V726A	O
)	O
,	O
11.94	O
%	O
(	O
M680I	O
G	O
/	O
C).The	O
remaining	O
alleles	O
(	O
10.76	O
%	O
)	O
showed	O
rare	O
mutations	O
which	O
were	O
R761H	O
,	O
P369S	O
,	O
A744S	O
,	O
K695R	O
,	O
F479L	O
,	O
M694I.	O
When	O
the	O
frequencies	O
of	O
mutations	O
detected	O
in	O
our	O
group	O
were	O
compared	O
to	O
the	O
frequencies	O
reported	O
in	O
the	O
other	O
regions	O
of	O
Turkey	O
,	O
an	O
increase	O
in	O
V726A	O
mutation	O
frequency	O
was	O
observed	O
.	O

No	O
patient	O
showed	O
a	O
I692del	O
mutation	O
which	O
is	O
sometimes	O
evident	O
in	O
other	O
Mediterranean	O
populations	O
.	O

Factor	B-Protein
VIII	I-Protein
mutations	B-Var
in	B-Reg
42	O
Moldovan	O
haemophilia	B-Disease
A	I-Disease
families	O
,	O
including	O
12	O
that	O
are	O
novel	O
.	O

Haemophilia	B-Disease
A	I-Disease
(	O
HA	O
)	O
is	O
a	O
bleeding	O
disorder	O
caused	B-Reg
by	I-Reg
mutations	B-Var
within	O
the	O
X	O
-	O
linked	O
F8	B-Gene
gene	O
.	O

A	O
series	O
of	O
42	O
unrelated	O
Moldovan	O
patients	O
with	O
HA	O
had	O
their	O
disease	O
-	O
causative	O
mutation	O
determined	O
to	O
provide	O
clinically	O
valuable	O
genotyping	O
information	O
for	O
a	O
historically	O
underserved	O
population	O
and	O
to	O
utilize	O
factor	O
VIII	O
(	O
FVIII	O
)	O
structural	O
information	O
to	O
analyse	O
the	O
effects	O
of	O
haemophilic	O
missense	O
substitutions	O
.	O

DNA	O
samples	O
were	O
analysed	O
to	O
detect	O
intron	O
22	O
and	O
intron	O
1	O
inversions	O
followed	O
by	O
heteroduplex	O
analysis	O
of	O
PCR	O
-	O
amplified	O
fragments	O
containing	O
all	O
exonic	O
sequences	O
.	O

Missense	O
sites	O
identified	O
by	O
DNA	O
sequencing	O
were	O
visualized	O
in	O
the	O
recently	O
described	O
crystal	O
structures	O
of	O
human	O
FVIII	O
.	O

Of	O
the	O
26	O
different	O
point	O
mutations	O
,	O
12	O
were	O
novel	O
.	O

Gel	O
electrophoresis	O
identified	O
samples	O
with	O
a	O
second	O
major	O
DNA	O
band	O
that	O
migrated	O
abnormally	O
;	O
these	O
amplified	O
products	O
were	O
sequenced	O
.	O

Thirteen	O
intron	O
22	O
inversions	O
and	O
one	O
intron	O
1	O
inversion	O
were	O
found	O
.	O

Two	O
patients	O
had	O
large	O
,	O
partial	O
gene	O
deletions	O
and	O
there	O
were	O
six	O
frameshift	O
,	O
two	O
non	O
-	O
sense	O
,	O
two	O
splicing	O
and	O
16	O
missense	O
genotypes	O
.	O

Two	O
subjects	O
with	O
an	O
intron	O
22	O
inversion	O
and	O
one	O
with	O
a	O
large	O
,	O
partial	O
gene	O
deletion	O
developed	O
an	O
alloimmune	O
inhibitor	O
.	O

Their	O
localization	O
suggests	O
intra-	O
and	O
possibly	O
inter	O
-	O
molecular	O
interactions	O
that	O
are	O
important	O
for	O
the	O
structural	O
integrity	O
and/or	O
procoagulant	O
function	O
of	O
FVIII	O
.	O

Investigation	O
of	O
C5a	O
receptor	O
gene	O
450	O
C	O
/	O
T	O
polymorphism	O
in	O
Turkish	O
patients	O
with	O
familial	O
Mediterranean	O
fever	O
.	O

Familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
(	O
FMF	O
)	O
is	O
a	O
genetic	O
disorder	O
with	O
acute	O
inflammatory	O
serosal	O
attacks	O
due	B-Reg
to	I-Reg
MEFV	B-Gene
gene	O
mutations	B-Var
which	O
resides	O
in	O
chromosome	O
16	O
.	O

Lack	O
of	O
a	O
C5a	O
inhibitor	O
activity	O
in	O
the	O
peritoneum	O
has	O
previously	O
been	O
proposed	O
in	O
part	O
to	O
contribute	O
in	O
propagation	O
of	O
the	O
serosal	O
inflammation	O
in	O
FMF	O
attacks	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
C5a	O
receptor	O
(	O
C5aR	O
)	O
gene	O
polymorphism	O
in	O
patients	O
with	O
FMF	O
and	O
its	O
relation	O
to	O
the	O
main	O
features	O
of	O
the	O
disease	O
.	O

A	O
polymorphism	O
in	O
the	O
coding	O
region	O
of	O
C5aR	O
gene	O
leading	O
to	O
C	O
to	O
T	O
transition	O
at	O
nucleotide	O
position	O
450	O
has	O
been	O
investigated	O
in	O
85	O
non	O
-	O
related	O
Turkish	O
FMF	O
patients	O
and	O
160	O
non	O
-	O
related	O
healthy	O
controls	O
by	O
using	O
PCR	O
-	O
RFLP	O
.	O

The	O
frequencies	O
of	O
C5aR	O
gene	O
450	O
CT	O
genotype	O
and	O
T	O
allele	O
were	O
not	O
significantly	O
different	O
between	O
Turkish	O
FMF	O
patients	O
and	O
healthy	O
subjects	O
(	O
14.12	O
and	O
8.24	O
%	O
for	O
FMF	O
vs.	O
10	O
and	O
5	O
%	O
for	O
controls	O
,	O
respectively	O
)	O
.	O

C5aR	O
gene	O
450	O
CT	O
genotype	O
tended	O
to	O
associate	O
with	O
the	O
presence	O
Henoch	O
-	O
Schonlein	O
purpura	O
(	O
OR	O
:	O
1.25	O
,	O
95	O
%	O
CI	O
:	O
0.917	O
-	O
1.704	O
,	O
P	O
=	O
0.017	O
)	O
but	O
with	O
no	O
other	O
clinical	O
findings	O
of	O
the	O
disease	O
.	O

C5aR	O
polymorphism	O
might	O
be	O
searched	O
in	O
populations	O
having	O
high	O
prevalence	O
of	O
FMF	O
.	O

Expression	O
of	O
the	O
familial	O
Mediterranean	O
fever	O
gene	O
is	O
regulated	O
by	O
nonsense	O
-	O
mediated	O
decay	O
.	O

Mutations	B-Var
in	O
the	O
MEditerranean	O
FeVer	O
(	B-Gene
MEFV	I-Gene
)	I-Gene
gene	O
are	O
responsible	B-Reg
for	O
familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
(	O
FMF	O
)	O
,	O
a	O
recessively	O
inherited	O
auto	O
-	O
inflammatory	O
disease	O
.	O

Cases	O
of	O
dominant	O
inheritance	O
and	O
phenotype	O
-	O
genotype	O
heterogeneity	O
have	O
been	O
reported	O
;	O
however	O
,	O
the	O
underlying	O
molecular	O
mechanism	O
is	O
not	O
currently	O
understood	O
.	O

The	O
FMF	O
protein	O
named	O
pyrin	O
or	O
marenostrin	O
(	O
P	O
/	O
M	O
)	O
is	O
thought	O
to	O
be	O
involved	O
in	O
regulating	O
innate	O
immunity	O
but	O
its	O
function	O
remains	O
subject	O
to	O
controversy	O
.	O

Recent	O
studies	O
postulate	O
that	O
a	O
defect	O
in	O
MEFV	O
expression	O
regulation	O
may	O
play	O
a	O
role	O
in	O
FMF	O
physiopathology	O
.	O

Our	O
group	O
,	O
along	O
with	O
others	O
,	O
has	O
identified	O
several	O
alternatively	O
spliced	O
MEFV	O
transcripts	O
in	O
leukocytes	O
.	O

Since	O
alternative	O
splicing	O
and	O
nonsense	O
-	O
mediated	O
decay	O
(	O
NMD	O
)	O
pathways	O
are	O
usually	O
coupled	O
in	O
the	O
post	O
-	O
transcriptional	O
regulation	O
of	O
gene	O
expression	O
,	O
we	O
hypothesized	O
that	O
NMD	O
could	O
contribute	O
to	O
the	O
regulation	O
of	O
the	O
MEFV	O
gene	O
.	O

To	O
address	O
this	O
issue	O
,	O
we	O
examined	O
the	O
effect	O
of	O
indirect	O
and	O
direct	O
inhibition	O
of	O
NMD	O
on	O
expression	O
of	O
the	O
MEFV	O
transcripts	O
in	O
THP1	O
,	O
monocyte	O
and	O
neutrophil	O
cells	O
.	O

We	O
showed	O
that	O
MEFV	O
is	O
the	O
first	O
auto	O
-	O
inflammatory	O
gene	O
regulated	O
by	O
NMD	O
in	O
both	O
a	O
cell-	O
and	O
transcript	O
-	O
specific	O
manner	O
.	O

These	O
results	O
and	O
preliminary	O
western	O
-	O
blot	O
analyses	O
suggest	O
the	O
possible	O
translation	O
of	O
alternatively	O
spliced	O
MEFV	O
transcripts	O
into	O
several	O
P	O
/	O
M	O
variants	O
according	O
to	O
cell	O
type	O
and	O
inflammatory	O
state	O
.	O

Our	O
results	O
introduce	O
the	O
novel	O
hypothesis	O
that	O
variation	O
of	O
NMD	O
efficiency	O
could	O
play	O
an	O
important	O
role	O
in	O
FMF	O
physiopathology	O
as	O
a	O
potent	O
phenotypic	O
modifier	O
.	O

Novel	O
PORCN	B-Gene
mutations	B-Var
in	B-Reg
focal	B-Disease
dermal	I-Disease
hypoplasia	I-Disease
.	O

Focal	O
dermal	O
hypoplasia	O
(	O
FDH	O
)	O
,	O
Goltz	O
or	O
Goltz	O
-	O
Gorlin	O
syndrome	O
,	O
is	O
an	O
X	O
-	O
linked	O
dominant	O
multisystem	O
disorder	O
characterized	O
primarily	O
by	O
involvement	O
of	O
the	O
skin	O
,	O
skeletal	O
system	O
and	O
eyes	O
.	O

We	O
screened	O
for	O
mutations	B-Var
in	O
the	O
PORCN	B-Gene
gene	O
in	B-Reg
eight	O
patients	O
of	O
Belgian	O
and	O
Finnish	O
origin	O
with	O
firm	O
clinical	O
suspicion	O
of	O
FDH	B-Disease
.	O

First	O
,	O
we	O
performed	O
quantitative	O
PCR	O
(	O
qPCR	O
)	O
analysis	O
to	O
define	O
the	O
copy	O
number	O
at	O
this	O
locus	O
.	O

Next	O
,	O
we	O
sequenced	O
the	O
coding	O
regions	O
and	O
flanking	O
intronic	O
sequences	O
of	O
the	O
PORCN	O
gene	O
.	O

Three	O
de	O
novo	O
mutations	O
were	O
identified	O
in	O
our	O
patients	O
with	O
FDH	O
:	O
a	O
150-kb	O
deletion	O
removing	O
six	O
genes	O
including	O
PORCN	O
,	O
as	O
defined	O
by	O
qPCR	O
and	O
X	O
-	O
array	O
-	O
CGH	O
,	O
and	O
two	O
heterozygous	O
missense	O
mutations	O
;	O
c.992T	O
>	O
G	O
(	O
p	O
.	O
L331R	O
)	O
in	O
exon	O
11	O
and	O
c.1094G	O
>	O
A	O
(	O
p	O
.	O
R365Q	O
)	O
in	O
exon	O
13	O
of	O
the	O
gene	O
.	O

Both	O
point	O
mutations	O
changed	O
highly	O
conserved	O
amino	O
acids	O
and	O
were	O
not	O
found	O
in	O
300	O
control	O
X	O
chromosomes	O
.	O

The	O
three	O
patients	O
in	O
whom	O
mutations	O
were	O
identified	O
all	O
present	O
with	O
characteristic	O
dermal	O
findings	O
together	O
with	O
limb	O
manifestations	O
,	O
which	O
were	O
not	O
seen	O
in	O
our	O
mutation	O
-	O
negative	O
patients	O
.	O

The	O
clinical	O
characteristics	O
of	O
our	O
patients	O
with	O
PORCN	O
mutations	O
were	O
compared	O
with	O
the	O
previously	O
reported	O
mutation	O
-	O
positive	O
cases	O
.	O

In	O
this	O
report	O
,	O
we	O
summarize	O
the	O
literature	O
on	O
PORCN	O
mutations	O
and	O
associated	O
phenotypes	O
.	O

Longitudinal	O
course	O
of	O
cognitive	O
,	O
adaptive	O
,	O
and	O
behavioral	O
characteristics	O
in	O
Costello	O
syndrome	O
.	O

Costello	B-Disease
syndrome	I-Disease
is	O
a	O
rare	O
rasopathy	O
caused	B-Reg
by	I-Reg
germline	O
mutations	B-Var
in	O
the	O
oncogene	O
HRAS	B-Gene
resulting	O
in	O
increased	B-PosReg
signal	B-MPA
transduction	I-MPA
through	O
the	O
Ras	B-Pathway
/	I-Pathway
mitogen	I-Pathway
-	I-Pathway
activated	I-Pathway
protein	I-Pathway
kinase	I-Pathway
pathway	I-Pathway
.	O

In	O
contrast	O
to	O
the	O
more	O
common	O
rasopathies	O
,	O
such	O
as	O
neurofibromatosis	O
type	O
1	O
and	O
Noonan	O
syndrome	O
,	O
limited	O
information	O
is	O
available	O
on	O
standardized	O
cognitive	O
testing	O
in	O
this	O
cohort	O
.	O

Past	O
research	O
indicated	O
a	O
mean	O
average	O
IQ	O
in	O
the	O
mild	O
mental	O
retardation	O
range	O
,	O
with	O
strengths	O
in	O
fluid	O
reasoning	O
(	O
FR	O
)	O
and	O
weakness	O
in	O
expressive	O
language	O
,	O
as	O
well	O
as	O
static	O
skills	O
over	O
time	O
.	O

Here	O
we	O
report	O
on	O
standardized	O
IQ	O
and	O
adaptive	O
functioning	O
in	O
18	O
individuals	O
with	O
Costello	O
syndrome	O
,	O
nine	O
males	O
and	O
nine	O
females	O
,	O
and	O
longitudinal	O
development	O
for	O
11	O
who	O
had	O
previous	O
testing	O
.	O

The	O
overall	O
IQ	O
,	O
ranging	O
from	O
severe	O
mental	O
retardation	O
to	O
the	O
average	O
range	O
,	O
with	O
a	O
mean	O
in	O
the	O
mildly	O
mentally	O
retarded	O
range	O
,	O
was	O
again	O
found	O
to	O
be	O
stable	O
,	O
but	O
an	O
interesting	O
pattern	O
in	O
the	O
development	O
of	O
nonverbal	O
FR	O
was	O
identified	O
.	O

Participants	O
showed	O
an	O
improvement	O
in	O
nonverbal	O
FR	O
,	O
followed	O
by	O
stable	O
skills	O
thereafter	O
,	O
suggesting	O
a	O
"	O
late	O
bloomer	O
"	O
effect	O
in	O
late	O
childhood	O
/	O
early	O
adolescence	O
.	O

Overall	O
adaptive	O
functioning	O
fell	O
into	O
the	O
range	O
of	O
Intellectual	O
Disability	O
for	O
70	O
%	O
of	O
subjects	O
,	O
with	O
Socialization	O
as	O
a	O
relative	O
strength	O
and	O
Daily	O
Living	O
Skills	O
an	O
area	O
of	O
relative	O
difficulty	O
.	O

Interestingly	O
,	O
females	O
were	O
found	O
to	O
be	O
higher	O
functioning	O
than	O
males	O
in	O
all	O
domains	O
,	O
including	O
Communication	O
,	O
Daily	O
Living	O
Skills	O
and	O
Socialization	O
.	O

Caregivers	O
reported	O
significantly	O
more	O
behavioral	O
concerns	O
in	O
males	O
,	O
including	O
internalizing	O
,	O
externalizing	O
,	O
and	O
other	O
maladaptive	O
behaviors	O
.	O

In	O
contrast	O
,	O
no	O
gender	O
differences	O
were	O
found	O
in	O
cognitive	O
or	O
visuomotor	O
functioning	O
.	O

Molecular	O
analysis	O
of	O
42	O
patients	O
with	B-Reg
congenital	B-Disease
dyserythropoietic	I-Disease
anemia	I-Disease
type	I-Disease
II	I-Disease
:	I-Disease
new	O
mutations	B-Var
in	O
the	O
SEC23B	B-Gene
gene	O
and	O
a	O
search	O
for	O
a	O
genotype	O
-	O
phenotype	O
relationship	O
.	O

BACKGROUND	O
:	O
The	O
most	O
frequent	O
form	O
of	O
congenital	O
dyserythropoietic	O
anemia	O
is	O
the	O
type	O
II	O
form	O
.	O

Recently	O
it	O
was	O
shown	O
that	O
the	O
vast	O
majority	O
of	O
patients	O
with	O
congenital	B-Disease
dyserythropoietic	I-Disease
anemia	I-Disease
type	I-Disease
II	I-Disease
carry	B-Reg
mutations	B-Var
in	O
the	O
SEC23B	B-Gene
gene	O
.	O

Here	O
we	O
established	O
the	O
molecular	O
basis	O
of	O
42	O
cases	O
of	O
congenital	O
dyserythropoietic	O
anemia	O
type	O
II	O
and	O
attempted	O
to	O
define	O
a	O
genotype	O
-	O
phenotype	O
relationship	O
.	O

DESIGN	O
AND	O
METHODS	O
:	O
SEC23B	O
gene	O
sequencing	O
analysis	O
was	O
performed	O
to	O
assess	O
the	O
diversity	O
and	O
incidence	O
of	O
each	O
mutation	O
in	O
42	O
patients	O
with	O
congenital	O
dyserythropoietic	O
anemia	O
type	O
II	O
(	O
25	O
described	O
exclusively	O
in	O
this	O
work	O
)	O
,	O
from	O
the	O
Italian	O
and	O
the	O
French	O
Registries	O
,	O
and	O
the	O
relationship	O
of	O
these	O
mutations	O
with	O
the	O
clinical	O
presentation	O
.	O

To	O
this	O
purpose	O
,	O
we	O
divided	O
the	O
patients	O
into	O
two	O
groups	O
:	O
(	O
i	O
)	O
patients	O
with	O
two	O
missense	O
mutations	O
and	O
(	O
ii	O
)	O
patients	O
with	O
one	O
nonsense	O
and	O
one	O
missense	O
mutation	O
.	O

RESULTS	O
:	O
We	O
found	O
22	O
mutations	O
of	O
uneven	O
frequency	O
,	O
including	O
seven	O
novel	O
mutations	O
.	O

Compound	O
heterozygosity	O
for	O
a	O
missense	O
and	O
a	O
nonsense	O
mutation	O
tended	O
to	O
produce	O
a	O
more	O
severe	O
clinical	O
presentation	O
,	O
a	O
lower	O
reticulocyte	O
count	O
,	O
a	O
higher	O
serum	O
ferritin	O
level	O
,	O
and	O
,	O
in	O
some	O
cases	O
,	O
more	O
pronounced	O
transfusion	O
needs	O
,	O
than	O
homozygosity	O
or	O
compound	O
heterozygosity	O
for	O
two	O
missense	O
mutations	O
.	O

Homozygosity	O
or	O
compound	O
heterozygosity	O
for	O
two	O
nonsense	O
mutations	O
was	O
never	O
found	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
allowed	O
us	O
to	O
determine	O
the	O
most	O
frequent	O
mutations	O
in	O
patients	O
with	O
congenital	O
dyserythropoietic	O
anemia	O
type	O
II	O
.	O

Correlations	O
between	O
the	O
mutations	O
and	O
various	O
biological	O
parameters	O
suggested	O
that	O
the	O
association	O
of	O
one	O
missense	O
mutation	O
and	O
one	O
nonsense	O
mutation	O
was	O
significantly	O
more	O
deleterious	O
that	O
the	O
association	O
of	O
two	O
missense	O
mutations	O
.	O

However	O
,	O
there	O
was	O
an	O
overlap	O
between	O
the	O
two	O
categories	O
.	O

Identification	O
and	O
characterization	O
of	O
novel	O
sequence	O
variations	O
in	O
MECP2	O
gene	O
in	O
Rett	O
syndrome	O
patients	O
.	O

Rett	B-Disease
syndrome	I-Disease
(	O
RS	O
)	O
is	O
a	O
neurodevelopmental	O
disorder	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
MECP2	B-Gene
gene	O
.	O

Exons	O
2	O
,	O
3	O
,	O
and	O
4	O
,	O
in	O
addition	O
to	O
intronic	O
and	O
3'UTR	O
adjacent	O
regions	O
,	O
were	O
sequenced	O
in	O
80	O
patients	O
with	O
RS	O
.	O

Twenty	O
-	O
nine	O
sequence	O
variations	O
were	O
detected	O
in	O
49	O
patients	O
,	O
34	O
(	O
69.4	O
%	O
)	O
patients	O
with	O
the	O
classic	O
form	O
of	O
RS	O
,	O
and	O
15	O
(	O
30.6	O
%	O
)	O
patients	O
with	O
atypical	O
forms	O
of	O
RS	O
.	O

Thirteen	O
of	O
the	O
29	O
detected	O
mutations	O
represent	O
novel	O
sequence	O
variations	O
.	O

Missense	O
mutation	O
T158	O
M	O
was	O
the	O
most	O
commonly	O
observed	O
mutation	O
,	O
detected	O
in	O
nine	O
patients	O
(	O
11.2	O
%	O
)	O
.	O

Six	O
hotspot	O
pathogenic	O
mutations	O
(	O
R133C	O
,	O
T158	O
M	O
,	O
R168X	O
,	O
R255X	O
,	O
R270X	O
,	O
and	O
R294X	O
)	O
were	O
responsible	O
for	O
the	O
phenotype	O
in	O
26/80	O
patients	O
(	O
32.5	O
%	O
)	O
.	O

Ribosomal	O
protein	O
genes	O
RPS10	B-Gene
and	O
RPS26	B-Gene
are	O
commonly	O
mutated	B-Var
in	B-Reg
Diamond	B-Disease
-	I-Disease
Blackfan	I-Disease
anemia	I-Disease
.	O

Diamond	O
-	O
Blackfan	O
anemia	O
(	O
DBA	O
)	O
,	O
an	O
inherited	O
bone	O
marrow	O
failure	O
syndrome	O
characterized	O
by	O
anemia	O
that	O
usually	O
presents	O
before	O
the	O
first	O
birthday	O
or	O
in	O
early	O
childhood	O
,	O
is	O
associated	O
with	O
birth	O
defects	O
and	O
an	O
increased	O
risk	O
of	O
cancer	O
.	O

Although	O
anemia	O
is	O
the	O
most	O
prominent	O
feature	O
of	O
DBA	O
,	O
the	O
disease	O
is	O
also	O
characterized	O
by	O
growth	O
retardation	O
and	O
congenital	O
malformations	O
,	O
in	O
particular	O
craniofacial	O
,	O
upper	O
limb	O
,	O
heart	O
,	O
and	O
urinary	O
system	O
defects	O
that	O
are	O
present	O
in	O
approximately	O
30%-50	O
%	O
of	O
patients	O
.	O

DBA	O
has	O
been	O
associated	O
with	O
mutations	O
in	O
seven	O
ribosomal	O
protein	O
(	O
RP	O
)	O
genes	O
,	O
RPS19	O
,	O
RPS24	O
,	O
RPS17	O
,	O
RPL35A	O
,	O
RPL5	O
,	O
RPL11	O
,	O
and	O
RPS7	O
,	O
in	O
about	O
43	O
%	O
of	O
patients	O
.	O

To	O
continue	O
our	O
large	O
-	O
scale	O
screen	O
of	O
RP	O
genes	O
in	O
a	O
DBA	O
population	O
,	O
we	O
sequenced	O
35	O
ribosomal	O
protein	O
genes	O
,	O
RPL15	O
,	O
RPL24	O
,	O
RPL29	O
,	O
RPL32	O
,	O
RPL34	O
,	O
RPL9	O
,	O
RPL37	O
,	O
RPS14	O
,	O
RPS23	O
,	O
RPL10A	O
,	O
RPS10	O
,	O
RPS12	O
,	O
RPS18	O
,	O
RPL30	O
,	O
RPS20	O
,	O
RPL12	O
,	O
RPL7A	O
,	O
RPS6	O
,	O
RPL27A	O
,	O
RPLP2	O
,	O
RPS25	O
,	O
RPS3	O
,	O
RPL41	O
,	O
RPL6	O
,	O
RPLP0	O
,	O
RPS26	O
,	O
RPL21	O
,	O
RPL36AL	O
,	O
RPS29	O
,	O
RPL4	O
,	O
RPLP1	O
,	O
RPL13	O
,	O
RPS15A	O
,	O
RPS2	O
,	O
and	O
RPL38	O
,	O
in	O
our	O
DBA	O
patient	O
cohort	O
of	O
117	O
probands	O
.	O

We	O
identified	O
three	O
distinct	O
mutations	O
of	O
RPS10	O
in	O
five	O
probands	O
and	O
nine	O
distinct	O
mutations	O
of	O
RPS26	O
in	O
12	O
probands	O
.	O

Pre	O
-	O
rRNA	O
analysis	O
in	O
lymphoblastoid	O
cells	O
from	O
patients	O
bearing	O
mutations	B-Var
in	O
RPS10	B-Gene
and	O
RPS26	B-Gene
showed	O
elevated	B-PosReg
levels	B-MPA
of	I-MPA
18S	I-MPA
-	I-MPA
E	I-MPA
pre	I-MPA
-	I-MPA
rRNA	I-MPA
.	O

This	O
accumulation	O
is	O
consistent	O
with	O
the	O
phenotype	O
observed	O
in	O
HeLa	O
cells	O
after	O
knockdown	O
of	O
RPS10	O
or	O
RPS26	O
expression	O
with	O
siRNAs	O
,	O
which	O
indicates	O
that	O
mutations	B-Var
in	O
the	O
RPS10	B-Gene
and	O
RPS26	B-Gene
genes	O
in	O
DBA	O
patients	O
affect	B-Reg
the	O
function	B-MPA
of	I-MPA
the	I-MPA
proteins	I-MPA
in	I-MPA
rRNA	I-MPA
processing	O
.	O

Clinical	O
and	O
molecular	O
aspects	O
of	O
aniridia	O
.	O

Aniridia	O
is	O
a	O
severe	O
,	O
congenital	O
ocular	O
malformation	O
inherited	O
in	O
an	O
autosomal	O
-	O
dominant	O
fashion	O
with	O
high	O
penetrance	O
and	O
variable	O
expression	O
.	O

Eye	O
morphogenesis	O
in	O
humans	O
involves	O
a	O
molecular	O
genetic	O
cascade	O
in	O
which	O
a	O
number	O
of	O
developmental	O
genes	O
interact	O
in	O
a	O
highly	O
organized	O
process	O
during	O
the	O
embryonic	O
period	O
to	O
produce	O
functional	O
ocular	O
structures	O
.	O

Among	O
these	O
genes	O
,	O
paired	O
box	O
gene	O
6	O
(	O
PAX6	O
)	O
has	O
an	O
essential	O
role	O
as	O
it	O
encodes	O
a	O
phylogenetically	O
conserved	O
transcription	O
factor	O
almost	O
universally	O
employed	O
for	O
eye	O
formation	O
in	O
animals	O
with	O
bilateral	O
symmetry	O
,	O
despite	O
widely	O
different	O
embryological	O
origins	O
.	O

To	O
direct	O
eye	O
development	O
,	O
PAX6	O
regulates	O
the	O
tissue	O
-	O
specific	O
expression	O
of	O
diverse	O
molecules	O
,	O
hormones	O
,	O
and	O
structural	O
proteins	O
.	O

In	O
humans	O
,	O
PAX6	B-Gene
is	O
located	O
in	O
chromosome	O
11p13	O
,	O
and	O
its	O
mutations	B-Var
lead	B-Reg
to	I-Reg
a	O
variety	O
of	O
hereditary	B-CPA
ocular	I-CPA
malformations	I-CPA
of	O
the	O
anterior	O
and	O
posterior	O
segment	O
,	O
among	O
which	O
aniridia	O
and	O
most	O
probably	O
foveal	O
hypoplasia	O
are	O
the	O
major	O
signs	O
.	O

Aniridia	B-Disease
occurs	O
due	B-Reg
to	I-Reg
decreased	B-NegReg
dosage	B-MPA
of	O
the	O
PAX6	B-Gene
gene	O
and	O
exists	O
in	O
both	O
sporadic	O
and	O
familial	O
forms	O
.	O

The	O
mutations	O
are	O
scattered	O
throughout	O
the	O
gene	O
and	O
the	O
vast	O
majority	O
of	O
those	O
reported	O
so	O
far	O
are	O
nonsense	B-Var
mutations	I-Var
,	O
frameshift	B-Var
mutations	I-Var
,	O
or	O
splicing	B-Var
errors	I-Var
that	O
are	O
predicted	O
to	O
cause	B-Reg
pre	B-MPA
-	I-MPA
mature	I-MPA
truncation	I-MPA
of	O
the	O
PAX6	B-Gene
protein	B-Protein
,	O
causing	B-Reg
haploinsufficiency	B-MPA
.	O

Here	O
we	O
review	O
the	O
data	O
regarding	O
the	O
mechanisms	O
and	O
the	O
mutations	O
that	O
relate	O
to	O
aniridia	B-Disease
.	O

GARS	O
axonopathy	O
:	O
not	O
every	O
neuron	O
's	O
cup	O
of	O
tRNA	O
.	O

Charcot	B-Disease
-	I-Disease
Marie	I-Disease
-	I-Disease
Tooth	I-Disease
disease	I-Disease
type	I-Disease
2D	I-Disease
,	O
a	O
hereditary	O
axonal	O
neuropathy	O
,	O
is	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
glycyl	O
-	O
tRNA	O
synthetase	O
(	B-Gene
GARS	I-Gene
)	I-Gene
.	O

The	O
mutations	O
are	O
distributed	O
throughout	O
the	O
protein	O
in	O
multiple	O
functional	O
domains	O
.	O

In	O
biochemical	O
and	O
cell	O
culture	O
experiments	O
,	O
some	O
mutant	O
forms	O
of	O
GARS	O
have	O
been	O
indistinguishable	O
from	O
wild	O
-	O
type	O
protein	O
,	O
suggesting	O
that	O
these	O
in	O
vitro	O
tests	O
might	O
not	O
adequately	O
assess	O
the	O
aberrant	O
activity	O
responsible	O
for	O
axonal	O
degeneration	O
.	O

Recently	O
,	O
mouse	O
and	O
fly	O
models	O
have	O
offered	O
new	O
insights	O
into	O
the	O
disease	O
mechanism	O
.	O

There	O
are	O
still	O
gaps	O
in	O
our	O
understanding	O
of	O
how	O
mutations	O
in	O
a	O
ubiquitously	O
expressed	O
component	O
of	O
the	O
translation	O
machinery	O
result	O
in	O
axonal	O
neuropathy	O
.	O

Here	O
,	O
we	O
review	O
recent	O
reports	O
,	O
weigh	O
the	O
evidence	O
for	O
and	O
against	O
possible	O
mechanisms	O
and	O
suggest	O
areas	O
of	O
focus	O
for	O
future	O
work	O
.	O

Genotype	O
-	O
phenotype	O
correlation	O
in	O
a	O
large	O
population	O
of	O
muscular	B-Disease
dystrophy	I-Disease
patients	O
with	B-Reg
LAMA2	B-Gene
mutations	B-Var
.	O

Merosin	B-Disease
deficient	I-Disease
congenital	I-Disease
muscular	I-Disease
dystrophy	I-Disease
1A	I-Disease
(	O
MDC1A	O
)	O
results	B-Reg
from	I-Reg
mutations	B-Var
in	O
the	O
LAMA2	B-Gene
gene	O
.	O

We	O
report	O
51	O
patients	O
with	O
MDC1A	O
and	O
examine	O
the	O
relationship	O
between	O
degree	O
of	O
merosin	O
expression	O
,	O
genotype	O
and	O
clinical	O
features	O
.	O

Thirty	O
-	O
three	O
patients	O
had	O
absence	O
of	O
merosin	O
and	O
13	O
showed	O
some	O
residual	O
merosin	O
.	O

Compared	O
to	O
the	O
residual	O
merosin	O
group	O
,	O
patients	O
with	O
absent	O
merosin	O
had	O
an	O
earlier	O
presentation	O
(	O
<	O
7days	O
)	O
(	O
P=0.0073	O
)	O
,	O
were	O
more	O
likely	O
to	O
lack	O
independent	O
ambulation	O
(	O
P=0.0215	O
)	O
,	O
or	O
require	O
enteral	O
feeding	O
(	O
P=0.0099	O
)	O
and	O
ventilatory	O
support	O
(	O
P=0.0354	O
)	O
.	O

We	O
identified	O
33	O
novel	O
LAMA2	O
mutations	O
;	O
these	O
were	O
distributed	O
throughout	O
the	O
gene	O
in	O
patients	O
with	O
absent	O
merosin	O
,	O
with	O
minor	O
clusters	O
in	O
exon	O
27	O
,	O
14	O
,	O
25	O
and	O
26	O
(	O
55	O
%	O
of	O
mutations	O
)	O
.	O

Patients	O
with	O
residual	O
merosin	O
often	O
carried	O
at	O
least	O
one	O
splice	O
site	O
mutation	O
and	O
less	O
frequently	O
frameshift	O
mutations	O
.	O

This	O
large	O
study	O
identified	O
novel	O
LAMA2	O
mutations	O
and	O
highlights	O
the	O
role	O
of	O
immunohistochemical	O
studies	O
for	O
merosin	O
status	O
in	O
predicting	O
clinical	O
severity	O
of	O
MDC1A.	O
Novel	O
and	O
recurrent	O
mutations	O
in	O
the	O
filaggrin	O
gene	O
in	O
Chinese	O
patients	O
with	O
ichthyosis	O
vulgaris	O
.	O

BACKGROUND	O
:	O
Ichthyosis	B-Disease
vulgaris	I-Disease
(	O
IV	O
)	O
is	O
a	O
common	O
inherited	O
skin	O
disorder	O
,	O
and	O
the	O
filament	O
aggregating	O
protein	O
(	O
filaggrin	O
)	O
is	O
a	O
key	O
protein	O
involved	O
in	O
skin	O
barrier	O
function	O
.	O

Mutations	B-Var
in	O
the	O
filaggrin	O
gene	O
(	B-Gene
FLG	I-Gene
)	I-Gene
have	O
recently	O
been	O
identified	O
as	O
the	O
cause	B-Reg
of	O
IV	B-Disease
.	O

However	O
,	O
there	O
have	O
been	O
no	O
reports	O
of	O
FLG	O
mutations	O
in	O
mainland	O
Chinese	O
families	O
with	O
IV	O
.	O

OBJECTIVES	O
:	O
To	O
identify	O
FLG	O
mutations	O
in	O
Chinese	O
patients	O
with	O
IV	O
.	O

METHODS	O
:	O
Eleven	O
unrelated	O
Chinese	O
families	O
with	O
IV	O
were	O
examined	O
for	O
FLG	O
mutations	O
with	O
denaturing	O
high	O
-	O
performance	O
liquid	O
chromatography	O
prescreening	O
and	O
sequencing	O
.	O

SNaPShot	O
was	O
employed	O
to	O
obtain	O
a	O
high	O
-	O
throughput	O
screening	O
for	O
the	O
identified	O
mutations	O
.	O

RESULTS	O
:	O
Three	O
mutations	O
-	O
one	O
novel	O
mutation	O
(	O
Q1256X	O
)	O
and	O
two	O
known	O
mutations	O
(	O
3321delA	O
and	O
E2422X	O
)	O
-	O
were	O
identified	O
in	O
these	O
families	O
.	O

The	O
novel	O
mutation	O
,	O
Q1256X	O
,	O
found	O
in	O
a	O
Chinese	O
family	O
with	O
IV	O
,	O
was	O
located	O
in	O
filaggrin	O
repeat	O
3	O
.	O

Mutation	O
3321delA	O
,	O
previously	O
found	O
in	O
Japanese	O
patients	O
,	O
was	O
present	O
in	O
eight	O
Chinese	O
families	O
with	O
IV	O
.	O

Mutation	O
E2422X	O
,	O
previously	O
found	O
in	O
a	O
Dutch	O
patient	O
of	O
Chinese	O
origin	O
,	O
was	O
present	O
in	O
two	O
Chinese	O
families	O
with	O
IV	O
.	O

Neither	O
of	O
the	O
null	O
mutations	O
,	O
Q1256X	O
and	O
E2422X	O
,	O
were	O
found	O
in	O
100	O
unrelated	O
control	O
cases	O
from	O
the	O
Chinese	O
population	O
;	O
however	O
,	O
the	O
mutation	O
ratio	O
for	O
3321delA	O
was	O
3	O
%	O
in	O
these	O
controls	O
.	O

CONCLUSIONS	O
:	O
Our	O
study	O
suggests	O
that	O
each	O
population	O
may	O
have	O
a	O
unique	O
and	O
prevalent	O
set	O
of	O
FLG	O
mutations	O
.	O

Genetic	O
analysis	O
of	O
haemophilia	O
A	O
in	O
Taiwan	O
.	O

Haemophilia	B-Disease
A	I-Disease
(	O
HA	O
)	O
is	O
an	O
X	O
-	O
linked	O
bleeding	O
disorder	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
factor	O
VIII	O
(	B-Gene
FVIII	I-Gene
)	I-Gene
gene	O
.	O

Identification	O
of	O
these	O
mutations	O
is	O
becoming	O
increasingly	O
important	O
in	O
a	O
variety	O
of	O
clinical	O
settings	O
.	O

The	O
purpose	O
of	O
this	O
report	O
is	O
to	O
describe	O
our	O
experience	O
of	O
FVIII	O
gene	O
mutation	O
analysis	O
in	O
the	O
largest	O
cohort	O
of	O
patients	O
in	O
Taiwan	O
including	O
the	O
discovery	O
of	O
21	O
novel	O
mutations	O
.	O

We	O
tested	O
115	O
HA	O
patients	O
from	O
91	O
unrelated	O
families	O
,	O
including	O
79	O
severe	O
,	O
15	O
moderate	O
and	O
21	O
mild	O
types	O
starting	O
with	O
an	O
assay	O
for	O
the	O
intron	O
22	O
inversion	O
by	O
long	O
range	O
-	O
PCR	O
followed	O
if	O
necessary	O
by	O
additional	O
genetic	O
studies	O
.	O

Intron	O
22	O
inversion	O
accounted	O
for	O
27.8	O
%	O
of	O
the	O
total	O
and	O
36.7	O
%	O
of	O
severe	O
HA	O
patients	O
respectively	O
while	O
intron	O
1	O
inversion	O
comprised	O
7.6	O
%	O
of	O
severe	O
patients	O
.	O

These	O
were	O
clearly	O
different	O
from	O
the	O
known	O
data	O
in	O
caucasian	O
populations	O
.	O

Of	O
75	O
patients	O
without	O
intron	O
22	O
or	O
1	O
inversion	O
,	O
70	O
from	O
62	O
unrelated	O
families	O
revealed	O
56	O
different	O
mutations	O
by	O
denaturing	O
high	O
-	O
performance	O
liquid	O
chromatography	O
(	O
DHPLC	O
)	O
,	O
of	O
which	O
21	O
were	O
novel	O
.	O

Also	O
,	O
the	O
only	O
female	O
patient	O
with	O
severe	O
HA	O
was	O
found	O
to	O
have	O
heterozygous	O
non	O
-	O
sense	O
mutation	O
(	O
c.6683G	O
>	O
A	O
)	O
of	O
exon	O
24	O
.	O

Seven	O
patients	O
,	O
including	O
five	O
without	O
amplified	O
PCR	O
product	O
and	O
two	O
without	O
encoded	O
DNA	O
defect	O
turned	O
out	O
to	O
have	O
exon(s	O
)	O
deletion	O
or	O
insertion	O
by	O
reverse	O
transcript	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
.	O

In	O
our	O
study	O
,	O
the	O
combination	O
of	O
various	O
molecular	O
techniques	O
including	O
LR	O
-	O
PCR	O
,	O
multiplex	O
PCR	O
,	O
DHPLC	O
and	O
RT	O
-	O
PCR	O
analysis	O
enabled	O
definitive	O
detection	O
of	O
the	O
causative	O
FVIII	O
gene	O
defects	O
in	O
112	O
of	O
113	O
(	O
99	O
%	O
)	O
HA	O
patients	O
.	O

Mutation	O
spectra	O
in	O
autosomal	O
dominant	O
and	O
recessive	O
retinitis	O
pigmentosa	O
in	O
northern	O
Sweden	O
.	O

Retinal	O
degenerations	O
represent	O
a	O
heterogeneous	O
group	O
of	O
disorders	O
affecting	O
the	O
function	O
of	O
the	O
retina	O
.	O

The	O
frequency	O
of	O
retinitis	O
pigmentosa	O
(	O
RP	O
)	O
is	O
1/3500	O
worldwide	O
,	O
however	O
,	O
in	O
northern	O
Sweden	O
it	O
is	O
1/2000	O
due	O
to	O
limited	O
migration	O
and	O
a	O
'	O
founder	O
'	O
effect	O
.	O

In	O
this	O
study	O
we	O
identified	O
genetic	O
mechanisms	O
underlying	O
autosomal	O
dominant	O
and	O
recessive	O
RP	O
present	O
in	O
northern	O
Sweden	O
.	O

Several	O
novel	O
mutations	O
unique	O
for	O
this	O
region	O
were	O
found	O
.	O

In	O
an	O
autosomal	O
recessive	O
form	O
of	O
RP	O
,	O
Bothnia	B-Disease
dystrophy	I-Disease
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
RLBP1	B-Gene
gene	O
,	O
bi	O
-	O
allelic	O
mutations	O
R234W	O
,	O
M226	O
K	O
and	O
compound	O
heterozygosity	O
,	O
M226K+R234W	O
was	O
detected	O
.	O

In	O
dominant	O
form	O
of	O
RP	O
mapped	O
to	O
19q13.42	O
a	O
59	O
kb	O
genomic	O
deletion	O
including	O
the	O
PRPF31	O
and	O
three	O
other	O
genes	O
was	O
found	O
.	O

These	O
data	O
provide	O
additional	O
information	O
on	O
the	O
molecular	O
mechanisms	O
of	O
RP	O
evolvement	O
and	O
in	O
the	O
future	O
might	O
be	O
useful	O
in	O
development	O
of	O
therapeutic	O
strategies	O
.	O

Identification	O
of	O
the	O
disease	O
-	O
causing	O
mutations	O
allowed	O
introducing	O
molecular	O
genetic	O
testing	O
of	O
the	O
patients	O
and	O
their	O
families	O
into	O
the	O
clinical	O
practice	O
.	O

Sequence	O
variants	B-Var
of	O
the	O
DFNB31	B-Gene
gene	O
among	B-Reg
Usher	B-Disease
syndrome	I-Disease
patients	O
of	O
diverse	O
origin	O
.	O

PURPOSE	O
:	O
It	O
has	O
been	O
demonstrated	O
that	O
mutations	B-Var
in	O
deafness	O
,	O
autosomal	O
recessive	O
31	O
(	B-Gene
DFNB31	I-Gene
)	I-Gene
,	O
the	O
gene	O
encoding	O
whirlin	O
,	O
is	O
responsible	B-Reg
for	O
nonsyndromic	B-Disease
hearing	I-Disease
loss	I-Disease
(	O
NSHL	O
;	O
DFNB31	O
)	O
and	O
Usher	B-Disease
syndrome	I-Disease
type	I-Disease
II	I-Disease
(	O
USH2D	O
)	O
.	O

We	O
screened	O
DFNB31	O
in	O
a	O
large	O
cohort	O
of	O
patients	O
with	O
different	O
clinical	O
subtypes	O
of	O
Usher	O
syndrome	O
(	O
USH	O
)	O
to	O
determine	O
the	O
prevalence	O
of	O
DFNB31	O
mutations	O
among	O
USH	O
patients	O
.	O

METHODS	O
:	O
DFNB31	O
was	O
screened	O
in	O
149	O
USH2	O
,	O
29	O
USH1	O
,	O
six	O
atypical	O
USH	O
,	O
and	O
11	O
unclassified	O
USH	O
patients	O
from	O
diverse	O
ethnic	O
backgrounds	O
.	O

Mutation	O
detection	O
was	O
performed	O
by	O
direct	O
sequencing	O
of	O
all	O
coding	O
exons	O
.	O

RESULTS	O
:	O
We	O
identified	O
38	O
different	O
variants	O
among	O
195	O
patients	O
.	O

Most	O
variants	O
were	O
clearly	O
polymorphic	O
,	O
but	O
at	O
least	O
two	O
out	O
of	O
the	O
15	O
nonsynonymous	O
variants	O
(	B-Var
p	I-Var
.	I-Var
R350W	I-Var
and	O
p	B-Var
.	I-Var
R882S	I-Var
)	I-Var
are	O
predicted	O
to	O
impair	B-NegReg
whirlin	B-Protein
structure	B-MPA
and	O
function	B-MPA
,	O
suggesting	O
eventual	O
pathogenicity	O
.	O

No	O
putatively	O
pathogenic	O
mutation	O
was	O
found	O
in	O
the	O
second	O
allele	O
of	O
patients	O
with	O
these	O
mutations	O
.	O

CONCLUSIONS	O
:	O
DFNB31	O
is	O
not	O
a	O
major	O
cause	O
of	O
USH	O
.	O

Partial	O
depletion	O
of	O
CREB	O
-	O
binding	O
protein	O
reduces	O
life	O
expectancy	O
in	O
a	O
mouse	O
model	O
of	O
Huntington	O
disease	O
.	O

Previous	O
studies	O
have	O
reported	O
that	O
mutant	B-Var
huntingtin	B-Gene
(	O
htt	O
)	O
interferes	B-Reg
with	O
cyclic	B-Protein
AMP	I-Protein
response	I-Protein
element	I-Protein
binding	I-Protein
protein	I-Protein
binding	B-Interaction
protein	B-Protein
(	O
CBP)-mediated	O
transcription	B-MPA
,	O
possibly	O
by	O
inhibiting	B-NegReg
the	O
acetylation	B-MPA
of	O
histones	B-Protein
.	O

In	O
Drosophila	O
models	O
that	O
express	O
fragments	O
of	O
mutant	O
htt	O
,	O
histone	O
deacetylase	O
inhibitors	O
reverse	O
deficits	O
in	O
histone	O
acetylation	O
,	O
rescue	O
photoreceptor	O
degeneration	O
,	O
and	O
prolong	O
their	O
survival	O
.	O

These	O
compounds	O
also	O
improve	O
motor	O
deficits	O
in	O
a	O
transgenic	O
mouse	O
model	O
of	O
Huntington	O
disease	O
(	O
HD	O
)	O
.	O

To	O
determine	O
whether	O
endogenous	O
CBP	O
depletion	O
contributes	O
to	O
HD	O
pathogenesis	O
,	O
we	O
crossed	O
HD	O
-	O
N171	O
-	O
82Q	O
transgenic	O
mice	O
with	O
mice	O
harboring	O
a	O
disrupted	O
CBP	O
gene	O
and	O
produced	O
mice	O
with	O
partial	O
(	O
50	O
%	O
)	O
depletion	O
of	O
CBP	O
.	O

This	O
reduction	O
of	O
CBP	O
levels	O
decreased	O
the	O
life	O
expectancy	O
of	O
the	O
HD	O
-	O
N171	O
-	O
82Q	O
Line	O
6	O
mouse	O
model	O
.	O

The	O
loss	O
of	O
CBP	O
had	O
no	O
obvious	O
impact	O
on	O
the	O
severity	O
of	O
motor	O
impairment	O
,	O
degeneration	O
of	O
the	O
striatum	O
,	O
mutant	O
htt	O
inclusion	O
formation	O
,	O
or	O
global	O
levels	O
of	O
acetylated	O
histones	O
H3	O
or	O
H4	O
in	O
brain	O
.	O

In	O
cell	O
models	O
,	O
we	O
confirmed	O
that	O
mutant	O
htt	O
inclusions	O
recruit	O
human	O
CBP	O
but	O
found	O
no	O
evidence	O
for	O
interactions	O
between	O
soluble	O
forms	O
of	O
mutant	O
htt	O
and	O
CBP	O
.	O

Although	O
we	O
identified	O
no	O
neurological	O
explanation	O
for	O
the	O
decreased	O
life	O
expectancy	O
of	O
HD	O
-	O
N171	O
-	O
82Q	O
mice	O
with	O
partial	O
depletion	O
of	O
CBP	O
,	O
the	O
data	O
are	O
consistent	O
with	O
the	O
notion	O
that	O
CBP	O
function	O
mitigates	O
mutant	O
htt	O
toxicity	O
by	O
a	O
currently	O
unidentified	O
mechanism	O
.	O

Type	O
I	O
hyperprolinemia	O
:	O
genotype	O
/	O
phenotype	O
correlations	O
.	O

Type	B-Disease
I	I-Disease
hyperprolinemia	I-Disease
(	O
HPI	O
)	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
associated	O
with	O
cognitive	O
and	O
psychiatric	O
troubles	O
,	O
caused	O
by	O
alterations	O
of	O
the	O
Proline	O
Dehydrogenase	O
gene	O
(	O
PRODH	O
)	O
at	O
22q11	O
.	O

HPI	B-Disease
results	B-Reg
from	I-Reg
PRODH	B-Gene
deletion	B-Var
and/or	O
missense	B-Var
mutations	I-Var
reducing	B-NegReg
proline	B-Enzyme
oxidase	I-Enzyme
(	O
POX	O
)	O
activity	B-MPA
.	O

The	O
goals	O
of	O
this	O
study	O
were	O
first	O
to	O
measure	O
in	O
controls	O
the	O
frequency	O
of	O
PRODH	O
variations	O
described	O
in	O
HPI	O
patients	O
,	O
second	O
to	O
assess	O
the	O
functional	O
effect	O
of	O
PRODH	O
mutations	O
on	O
POX	O
activity	O
,	O
and	O
finally	O
to	O
establish	O
genotype	O
/	O
enzymatic	O
activity	O
correlations	O
in	O
a	O
new	O
series	O
of	O
HPI	O
patients	O
.	O

Eight	O
of	O
14	O
variants	O
occurred	O
at	O
polymorphic	O
frequency	O
in	O
114	O
controls	O
.	O

POX	O
activity	O
was	O
determined	O
for	O
six	O
novel	O
mutations	O
and	O
two	O
haplotypes	O
.	O

The	O
c.1331G	O
>	O
A	O
,	O
p	O
.	O
G444D	O
allele	O
has	O
a	O
drastic	O
effect	O
,	O
whereas	O
the	O
c.23C	B-Var
>	I-Var
T	I-Var
,	O
p	B-Var
.	I-Var
P8L	I-Var
allele	O
and	O
the	O
c.[56C	B-Var
>	I-Var
A	I-Var
;	I-Var
172G	I-Var
>	I-Var
A	I-Var
]	I-Var
,	O
p.[Q19P	B-Var
;	I-Var
A58	I-Var
T	I-Var
]	I-Var
haplotype	O
result	O
in	O
a	O
moderate	O
decrease	B-NegReg
in	O
activity	B-MPA
.	O

Among	O
the	O
19	O
HPI	O
patients	O
,	O
10	O
had	O
a	O
predicted	O
residual	O
activity	O
<	O
50	O
%	O
.	O

Eight	O
out	O
of	O
nine	O
subjects	O
with	O
a	O
predicted	O
residual	O
activity	O
>	O
or	O
=	O
50	O
%	O
bore	O
at	O
least	O
one	O
c.824C	O
>	O
A	O
,	O
p	O
.	O
T275N	O
allele	O
,	O
which	O
has	O
no	O
detrimental	O
effect	O
on	O
activity	O
but	O
whose	O
frequency	O
in	O
controls	O
is	O
only	O
3	O
%	O
.	O

Our	O
results	O
suggest	O
that	O
PRODH	B-Gene
mutations	B-Var
lead	O
to	O
a	O
decreased	B-NegReg
POX	B-Enzyme
activity	B-MPA
or	O
affect	B-Reg
other	B-MPA
biological	I-MPA
parameters	I-MPA
causing	B-Reg
hyperprolinemia	B-Disease
.	O

Dihydropyrimidine	B-Disease
dehydrogenase	I-Disease
deficiency	I-Disease
caused	B-Reg
by	I-Reg
a	O
novel	O
genomic	O
deletion	O
c.505_513del	B-Var
of	O
DPYD	B-Gene
.	O

Dihydropyrimidine	O
dehydrogenase	O
(	O
DPD	O
)	O
deficiency	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
of	O
the	O
pyrimidine	O
degradation	O
pathway	O
.	O

In	O
a	O
patient	O
presenting	O
with	O
convulsions	O
,	O
psychomotor	O
retardation	O
and	O
Reye	O
like	O
syndrome	O
,	O
strongly	O
elevated	O
levels	O
of	O
uracil	O
and	O
thymine	O
were	O
detected	O
in	O
urine	O
.	O

No	O
DPD	O
activity	O
could	O
be	O
detected	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

Analysis	O
of	O
the	O
gene	O
encoding	O
DPD	O
(	O
DPYD	O
)	O
showed	O
that	O
the	O
patient	O
was	O
homozygous	O
for	O
a	O
novel	O
c.505_513del	O
(	O
p.169_171del	O
)	O
mutation	O
in	O
exon	O
6	O
of	O
DPYD	O
.	O

Analysis	O
of	O
mutations	B-Var
causing	B-Reg
biotinidase	B-Disease
deficiency	I-Disease
.	O

Biotinidase	O
deficiency	O
is	O
an	O
inherited	O
disorder	O
in	O
which	O
the	O
vitamin	O
,	O
biotin	O
,	O
is	O
not	O
recycled	O
.	O

Individuals	O
with	O
biotinidase	O
deficiency	O
can	O
develop	O
neurological	O
and	O
cutaneous	O
symptoms	O
if	O
they	O
are	O
not	O
treated	O
with	O
biotin	O
.	O

Biotinidase	O
deficiency	O
screening	O
has	O
been	O
incorporated	O
into	O
essentially	O
all	O
newborn	O
screening	O
programs	O
in	O
the	O
United	O
States	O
and	O
in	O
many	O
countries	O
.	O

We	O
now	O
report	O
140	O
known	O
mutations	B-Var
in	O
the	O
biotinidase	O
gene	O
(	B-Gene
BTD	I-Gene
)	I-Gene
that	O
cause	B-Reg
biotinidase	B-Disease
deficiency	I-Disease
.	O

All	O
types	O
of	O
mutations	B-Var
have	O
been	O
found	O
to	O
cause	B-Reg
biotinidase	B-Disease
deficiency	I-Disease
.	O

Variants	O
have	O
been	O
identified	O
throughout	O
the	O
coding	O
sequence	O
.	O

Essentially	O
all	O
the	O
variants	B-Var
result	O
in	O
enzymatic	B-Enzyme
activities	B-MPA
with	O
less	B-NegReg
than	O
10	O
%	O
of	O
mean	O
normal	O
enzyme	O
activity	O
(	O
profound	O
biotinidase	O
deficiency	O
)	O
with	O
the	O
exception	O
of	O
the	O
c.1330G	B-Var
>	I-Var
C	I-Var
(	O
p	O
.	O
D444H	O
)	O
mutation	O
,	O
which	O
results	O
in	O
an	O
enzyme	B-Enzyme
having	O
50	B-NegReg
%	I-NegReg
of	O
mean	O
normal	O
serum	B-MPA
activity	I-MPA
.	O

The	O
putative	O
three	O
-	O
dimensional	O
structure	O
of	O
biotinidase	O
has	O
been	O
predicted	O
by	O
homology	O
to	O
that	O
of	O
nitrilases	O
/	O
amidases	O
.	O

The	O
effect	O
of	O
the	O
various	O
missense	O
mutations	O
can	O
be	O
predicted	O
to	O
affect	O
various	O
important	O
sites	O
within	O
the	O
structure	O
of	O
the	O
enzyme	O
.	O

This	O
compilation	O
of	O
variants	O
causing	O
biotinidase	O
deficiency	O
will	O
be	O
useful	O
to	O
clinical	O
laboratories	O
that	O
are	O
performing	O
mutation	O
analysis	O
for	O
confirmational	O
testing	O
when	O
the	O
enzymatic	O
results	O
are	O
equivocal	O
for	O
children	O
identified	O
through	O
newborn	O
screening	O
.	O

N88S	B-Var
mutation	O
in	O
the	O
BSCL2	B-Gene
gene	O
in	B-Reg
a	O
Serbian	O
family	O
with	O
distal	B-Disease
hereditary	I-Disease
motor	I-Disease
neuropathy	I-Disease
type	I-Disease
V	I-Disease
or	O
Silver	B-Disease
syndrome	I-Disease
.	O

BACKGROUND	O
:	O
Distal	B-Disease
hereditary	I-Disease
motor	I-Disease
neuropathy	I-Disease
type	I-Disease
V	I-Disease
(	O
dHMN	O
-	O
V	O
)	O
and	O
Silver	B-Disease
syndrome	I-Disease
are	O
rare	O
phenotypically	O
overlapping	O
diseases	O
which	O
can	O
be	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
Berardinelli	O
-	O
Seip	O
Congenital	O
Lipodystrophy	O
2	O
(	B-Gene
BSCL2	I-Gene
)	I-Gene
gene	O
or	O
Seipin	B-Gene
.	O

AIM	O
:	O
To	O
report	O
the	O
first	O
Serbian	O
family	O
with	O
a	O
BSCL2	O
mutation	O
showing	O
variable	O
expression	O
within	O
the	O
family	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
A	O
55-year	O
-	O
old	O
woman	O
presented	O
with	O
weakness	O
of	O
both	O
hands	O
at	O
the	O
age	O
of	O
45	O
.	O

At	O
age	O
47	O
,	O
she	O
noticed	O
distal	O
muscle	O
weakness	O
and	O
atrophy	O
in	O
her	O
legs	O
.	O

Physical	O
examination	O
revealed	O
atrophy	O
and	O
weakness	O
of	O
small	O
hand	O
muscles	O
and	O
mild	O
atrophy	O
and	O
weakness	O
of	O
the	O
lower	O
limbs	O
.	O

There	O
was	O
generalized	O
hyperreflexia	O
with	O
the	O
exception	O
of	O
ankle	O
reflexes	O
which	O
were	O
diminished	O
.	O

Her	O
25year	O
-	O
old	O
son	O
had	O
only	O
stiffness	O
of	O
both	O
legs	O
at	O
the	O
age	O
of	O
22	O
.	O

Physical	O
examination	O
revealed	O
only	O
generalized	O
hyporeflexia	O
.	O

The	O
third	O
affected	O
member	O
in	O
this	O
family	O
was	O
her	O
55year	O
-	O
old	O
cousin	O
who	O
showed	O
a	O
more	O
prominent	O
involvement	O
of	O
leg	O
muscles	O
with	O
mild	O
asymmetrical	O
weakness	O
of	O
hand	O
muscles	O
and	O
no	O
pyramidal	O
tract	O
features	O
.	O

RESULTS	O
:	O
In	O
all	O
three	O
patients	O
sensory	O
nerve	O
conduction	O
velocities	O
(	O
NCV	O
)	O
were	O
normal	O
in	O
all	O
extremities	O
.	O

Compound	O
muscle	O
action	O
potential	O
(	O
CMAP	O
)	O
amplitudes	O
were	O
markedly	O
reduced	O
in	O
all	O
patients	O
.	O

Concentric	O
needle	O
EMG	O
showed	O
evidence	O
of	O
chronic	O
denervation	O
in	O
distal	O
muscles	O
.	O

DNA	O
sequencing	O
of	O
BSCL2	O
was	O
performed	O
and	O
a	O
heterozygous	O
N88S	O
missense	O
mutation	O
in	O
BSCL2	O
gene	O
was	O
detected	O
in	O
all	O
three	O
patients	O
.	O

CONCLUSION	O
:	O
This	O
report	O
is	O
further	O
confirmation	O
of	O
phenotypic	O
heterogenity	O
due	O
to	O
the	O
N88S	O
mutation	O
of	O
BSCL2	O
gene	O
in	O
the	O
same	O
family	O
.	O

DOK7	B-Gene
mutations	B-Var
presenting	B-Reg
as	I-Reg
a	O
proximal	B-Disease
myopathy	I-Disease
in	O
French	O
Canadians	O
.	O

DOK7	B-Gene
mutations	B-Var
cause	B-Reg
a	O
congenital	B-Disease
myasthenic	I-Disease
syndrome	I-Disease
(	O
OMIM	O
254300	O
)	O
characterized	O
by	O
a	O
"	O
limb	O
-	O
girdle	O
"	O
phenotype	O
.	O

We	O
identified	O
7	O
French	O
-	O
Canadian	O
patients	O
with	O
a	O
previously	O
undiagnosed	O
proximal	O
myopathy	O
.	O

A	O
genome	O
wide	O
scan	O
was	O
performed	O
.	O

Homozygosity	O
mapping	O
identified	O
a	O
locus	O
on	O
chromosome	O
4p16.2	O
containing	O
DOK7	O
.	O

Sequencing	O
of	O
DOK7	O
revealed	O
homozygous	O
1124_1127dupTGCC	O
mutations	O
in	O
all	O
individuals	O
.	O

SNP	O
genotyping	O
of	O
42	O
kb	O
surrounding	O
DOK7	O
in	O
our	O
cohort	O
and	O
in	O
9	O
patients	O
of	O
various	O
European	O
origins	O
demonstrated	O
a	O
shared	O
haplotype	O
suggesting	O
a	O
common	O
ancestral	O
European	O
mutation	O
.	O

In	O
our	O
cohort	O
,	O
fatigability	O
was	O
not	O
prominent	O
;	O
rather	O
patients	O
reported	O
prolonged	O
periods	O
of	O
increased	O
weakness	O
.	O

Abnormalities	O
on	O
repetitive	O
nerve	O
stimulation	O
and	O
single	O
fiber	O
EMG	O
were	O
not	O
invariably	O
present	O
.	O

There	O
was	O
considerable	O
intra	O
-	O
familial	O
phenotypic	O
variability	O
,	O
and	O
we	O
report	O
an	O
asymptomatic	O
individual	O
.	O

DOK7	O
mutations	O
should	O
be	O
considered	O
in	O
patients	O
with	O
early	O
-	O
onset	O
myopathy	O
,	O
even	O
in	O
the	O
absence	O
of	O
symptoms	O
suggesting	O
a	O
possible	O
myasthenia	O
.	O

Identification	O
of	O
known	O
and	O
novel	O
PTCH	B-Gene
mutations	B-Var
in	B-Reg
both	O
syndromic	O
and	O
non	O
-	O
syndromic	O
keratocystic	B-Disease
odontogenic	I-Disease
tumors	I-Disease
.	O

AIM	O
:	O
To	O
clarify	O
the	O
role	O
of	O
PTCH	O
in	O
patients	O
with	O
NBCCS	O
-	O
related	O
and	O
non	O
-	O
sydromic	O
keratocystic	O
odontogenic	O
tumors	O
.	O

METHODOLOGY	O
:	O
Mutation	O
analysis	O
was	O
undertaken	O
in	O
8	O
sporadic	O
and	O
4	O
NBCCS	O
-	O
associated	O
KCOTs	O
.	O

RESULTS	O
:	O
Four	O
novel	O
and	O
two	O
known	O
mutations	O
were	O
identified	O
in	O
2	O
sporadic	O
and	O
3	O
syndromic	O
cases	O
,	O
two	O
of	O
which	O
being	O
germline	O
mutations	O
(	O
c.2179delT	O
,	O
c.2824delC	O
)	O
and	O
4	O
somatic	O
mutations	O
(	O
c.3162dupG	O
,	O
c.1362	O
-	O
1374dup	O
,	O
c.1012	O
C	O
>	O
T	O
,	O
c.403C	O
>	O
T	O
)	O
.	O

CONCLUSION	O
:	O
Our	O
findings	O
suggest	O
that	O
defects	O
of	O
PTCH	O
are	O
associated	O
with	O
the	O
pathogenesis	O
of	O
syndromic	O
as	O
well	O
as	O
a	O
subset	O
of	O
non	O
-	O
syndromic	O
KCOTs	O
.	O

NOTCH3	B-Gene
mutations	B-Var
and	O
clinical	O
features	O
in	O
33	O
mainland	O
Chinese	O
families	O
with	B-Reg
CADASIL	B-Disease
.	O

BACKGROUND	O
:	O
Cerebral	B-Disease
autosomal	I-Disease
dominant	I-Disease
arteriopathy	I-Disease
with	I-Disease
subcortical	I-Disease
infarcts	I-Disease
and	I-Disease
leucoencephalopathy	I-Disease
(	O
CADASIL	O
)	O
is	O
an	O
inherited	O
small	O
-	O
vessel	O
disease	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
NOTCH3	B-Gene
.	O

Although	O
CADASIL	O
cases	O
have	O
been	O
identified	O
worldwide	O
,	O
the	O
data	O
from	O
mainland	O
China	O
are	O
still	O
limited	O
.	O

OBJECTIVE	O
:	O
To	O
identify	O
NOTCH3	O
mutations	O
and	O
analyse	O
the	O
clinical	O
and	O
MRI	O
findings	O
in	O
a	O
large	O
series	O
of	O
CADASIL	O
patients	O
from	O
mainland	O
China	O
.	O

METHODS	O
:	O
Direct	O
sequencing	O
of	O
NOTCH3	O
and/or	O
skin	O
or	O
sural	O
nerve	O
biopsies	O
were	O
performed	O
on	O
48	O
unrelated	O
suspected	O
CADASIL	O
cases	O
of	O
Chinese	O
descent	O
.	O

The	O
clinical	O
manifestations	O
and	O
MRI	O
features	O
were	O
retrospectively	O
collected	O
and	O
analysed	O
in	O
the	O
33	O
index	O
patients	O
with	O
confirmed	O
diagnosis	O
and	O
their	O
available	O
affected	O
family	O
members	O
.	O

RESULTS	O
:	O
20	O
different	O
NOTCH3	O
mutations	O
were	O
identified	O
in	O
33	O
families	O
,	O
including	O
seven	O
novel	O
mutations	O
.	O

The	O
highest	O
mutation	O
frequency	O
was	O
in	O
exons	O
4	O
(	O
55	O
%	O
)	O
and	O
3	O
(	O
30	O
%	O
)	O
.	O

Granular	O
osmiophilic	O
material	O
in	O
smooth	O
muscle	O
cells	O
was	O
found	O
in	O
30	O
cases	O
who	O
were	O
biopsied	O
.	O

Clinical	O
presentation	O
included	O
TIA	O
/	O
stroke	O
in	O
82	O
%	O
,	O
cognitive	O
decline	O
in	O
60	O
%	O
,	O
and	O
migraine	O
with	O
aura	O
in	O
only	O
5	O
%	O
of	O
57	O
symptomatic	O
cases	O
.	O

MRI	O
detected	O
multiple	O
lacunar	O
infarcts	O
and	O
leucoaraiosis	O
in	O
all	O
symptomatic	O
cases	O
,	O
brainstem	O
lesions	O
in	O
64	O
%	O
of	O
symptomatic	O
cases	O
and	O
white	O
-	O
matter	O
lesions	O
in	O
the	O
temporal	O
pole	O
in	O
46	O
%	O
of	O
affected	O
members	O
.	O

CONCLUSIONS	O
:	O
The	O
mutational	O
spectrum	O
and	O
primary	O
clinical	O
features	O
of	O
patients	O
with	O
CADASIL	O
from	O
mainland	O
China	O
are	O
similar	O
to	O
those	O
in	O
Caucasians	O
.	O

However	O
,	O
migraine	O
with	O
aura	O
and	O
abnormal	O
white	O
matter	O
in	O
the	O
temporal	O
pole	O
are	O
less	O
common	O
than	O
among	O
Caucasians	O
,	O
while	O
brainstem	O
involvement	O
is	O
more	O
common	O
than	O
among	O
Caucasians	O
.	O

Prevalence	O
,	O
mutation	O
spectrum	O
and	O
phenotypic	O
variability	O
in	O
Norwegian	O
patients	O
with	O
Limb	O
Girdle	O
Muscular	O
Dystrophy	O
2I.	O
Mutations	B-Var
in	O
the	O
FKRP	B-Gene
(	O
Fukutin	O
Related	O
Protein	O
)	O
gene	O
produce	B-Reg
a	O
range	O
of	O
phenotypes	O
including	O
Limb	B-Disease
Girdle	I-Disease
Muscular	I-Disease
Dystrophy	I-Disease
Type	I-Disease
2I	I-Disease
(	O
LGMD2I	O
)	O
.	O

In	O
order	O
to	O
investigate	O
the	O
prevalence	O
,	O
the	O
mutation	O
spectrum	O
and	O
possible	O
genotype	O
-	O
phenotype	O
correlation	O
,	O
we	O
studied	O
a	O
cohort	O
of	O
Norwegian	O
patients	O
with	O
LGMD2I	O
,	O
ascertained	O
in	O
a	O
4-year	O
period	O
.	O

In	O
this	O
retrospective	O
study	O
of	O
genetically	O
tested	O
patients	O
,	O
we	O
identified	O
88	O
patients	O
from	O
69	O
families	O
,	O
who	O
were	O
either	O
homozygous	O
or	O
compound	O
heterozygous	O
for	O
FKRP	O
mutations	O
.	O

This	O
gives	O
a	O
minimum	O
prevalence	O
of	O
1/54,000	O
and	O
a	O
corresponding	O
carrier	O
frequency	O
of	O
1/116	O
in	O
the	O
Norwegian	O
population	O
.	O

Seven	O
different	O
FKRP	O
mutations	O
,	O
including	O
three	O
novel	O
changes	O
,	O
were	O
detected	O
.	O

Seventy	O
-	O
six	O
patients	O
were	O
homozygous	O
for	O
the	O
common	O
c.826C	O
>	O
A	O
mutation	O
.	O

These	O
patients	O
had	O
later	O
disease	O
onset	O
than	O
patients	O
who	O
were	O
compound	O
heterozygous	O
-	O
14.0	O
vs.	O
6.1	O
years	O
.	O

We	O
detected	O
substantial	O
variability	O
in	O
disease	O
severity	O
among	O
homozygous	O
patients	O
.	O

Novel	O
and	O
recurrent	O
connexin	O
30.3	O
and	O
connexin	O
31	O
mutations	O
associated	O
with	O
erythrokeratoderma	O
variabilis	O
.	O

Erythrokeratoderma	B-Disease
variabilis	I-Disease
(	O
EKV	O
)	O
is	O
characterized	O
by	O
fixed	O
hyperkeratotic	O
plaques	O
and	O
transient	O
erythema	O
.	O

Mutations	B-Var
in	O
the	O
genes	O
GJB3	B-Gene
and	O
GJB4	B-Gene
,	O
which	O
encode	O
connexin	O
(	O
Cx)31	O
and	O
Cx30.3	O
,	O
are	O
associated	B-Reg
with	O
EKV	B-Disease
.	O

We	O
report	O
one	O
novel	O
mutation	O
in	O
Cx31	O
and	O
one	O
recurrent	O
mutation	O
in	O
Cx30.3	O
in	O
two	O
different	O
families	O
.	O

One	O
novel	O
rare	O
sequence	O
variant	O
of	O
unknown	O
clinical	O
significance	O
was	O
also	O
identified	O
.	O

This	O
finding	O
extends	O
the	O
spectrum	O
of	O
known	O
EKV	O
-	O
associated	O
mutations	O
.	O

Thyroid	O
pathology	O
in	O
PTEN	O
-	O
hamartoma	O
tumor	O
syndrome	O
:	O
characteristic	O
findings	O
of	O
a	O
distinct	O
entity	O
.	O

BACKGROUND	O
:	O
Phosphatase	O
and	O
tensin	O
homolog	O
deleted	O
on	O
chromosome	O
ten	O
(	B-Disease
PTEN)-hamartoma	I-Disease
tumor	I-Disease
syndrome	I-Disease
(	O
PHTS	O
)	O
is	O
a	O
complex	O
disorder	O
caused	O
by	O
germline	O
inactivating	B-NegReg
mutations	B-Var
of	O
the	O
PTEN	B-Gene
tumor	O
suppressor	O
gene	O
.	O

PHTS	O
includes	O
Cowden	O
syndrome	O
(	O
CS	O
)	O
,	O
Bannayan	O
-	O
Riley	O
-	O
Ruvalcaba	O
syndrome	O
(	O
BRRS	O
)	O
,	O
and	O
Proteus	O
-	O
like	O
syndromes	O
.	O

Affected	O
individuals	O
develop	O
both	O
benign	O
and	O
malignant	O
tumors	O
in	O
a	O
variety	O
of	O
tissues	O
,	O
including	O
the	O
thyroid	O
.	O

This	O
study	O
is	O
to	O
better	O
characterize	O
and	O
describe	O
the	O
thyroid	O
pathology	O
within	O
the	O
different	O
entities	O
of	O
this	O
syndrome	O
,	O
and	O
examine	O
whether	O
there	O
is	O
an	O
association	O
between	O
specific	O
thyroid	O
findings	O
and	O
different	O
PTEN	O
mutations	O
.	O

METHODS	O
:	O
Twenty	O
patients	O
with	O
known	O
PTEN	O
mutations	O
,	O
and/or	O
clinical	O
diagnosis	O
of	O
PHTS	O
,	O
and	O
thyroid	O
pathology	O
were	O
identified	O
:	O
14	O
with	O
CS	O
and	O
6	O
with	O
BRRS	O
.	O

RESULTS	O
:	O
Thyroid	O
pathology	O
findings	O
were	O
as	O
follows	O
:	O
multiple	O
adenomatous	O
nodules	O
in	O
a	O
background	O
of	O
lymphocytic	O
thyroiditis	O
(	O
LT	O
)	O
in	O
75	O
%	O
,	O
papillary	O
carcinoma	O
in	O
60	O
%	O
,	O
LT	O
alone	O
in	O
55	O
%	O
,	O
follicular	O
carcinoma	O
in	O
45	O
%	O
,	O
C	O
-	O
cell	O
hyperplasia	O
in	O
55	O
%	O
,	O
and	O
follicular	O
adenomas	O
in	O
25	O
%	O
.	O

Within	O
the	O
papillary	O
carcinoma	O
group	O
,	O
there	O
were	O
6	O
microcarcinomas	O
,	O
5	O
follicular	O
variants	O
,	O
and	O
1	O
classical	O
type	O
.	O

CONCLUSIONS	O
:	O
There	O
were	O
no	O
morphologic	O
differences	O
between	O
the	O
thyroid	O
findings	O
in	O
CS	O
and	O
BRRS	O
.	O

Also	O
,	O
there	O
was	O
no	O
correlation	O
between	O
specific	O
PTEN	O
germline	O
mutations	O
(	O
exons	O
5	O
,	O
6	O
,	O
and	O
8)	O
and	O
pathologic	O
findings	O
.	O

Distinctive	O
and	O
characteristic	O
findings	O
in	O
PHTS	O
include	O
multiple	O
unique	O
adenomatous	O
nodules	O
in	O
a	O
background	O
of	O
LT	O
,	O
and	O
C	O
-	O
cell	O
hyperplasia	O
;	O
it	O
is	O
vital	O
that	O
pathologists	O
recognize	O
the	O
classical	O
histologic	O
features	O
of	O
this	O
syndrome	O
to	O
alert	O
clinicians	O
to	O
the	O
possibility	O
of	O
this	O
syndrome	O
in	O
their	O
patients	O
.	O

Variable	O
phenotypes	O
are	O
associated	O
with	O
PMP22	O
missense	O
mutations	O
.	O

Charcot	B-Disease
-	I-Disease
Marie	I-Disease
-	I-Disease
Tooth	I-Disease
disease	I-Disease
(	O
CMT	O
)	O
is	O
the	O
commonest	O
hereditary	O
neuropathy	O
encompassing	O
a	O
large	O
group	O
of	O
clinically	O
and	O
genetically	O
heterogeneous	O
disorders	O
.	O

The	O
commonest	O
form	O
of	O
CMT	B-Disease
,	O
CMT1A	B-Disease
,	O
is	O
usually	O
caused	B-Reg
by	I-Reg
a	O
1.4	O
megabase	O
duplication	B-Var
of	O
chromosome	O
17	O
containing	O
the	O
PMP22	B-Gene
gene	O
.	O

Mutations	B-Var
of	O
PMP22	B-Gene
are	O
a	O
less	O
common	O
cause	B-Reg
of	O
CMT	B-Disease
.	O

We	O
describe	O
clinical	O
,	O
electrophysiological	O
and	O
molecular	O
findings	O
of	O
10	O
patients	O
carrying	O
PMP22	O
missense	O
mutations	O
.	O

The	O
phenotype	O
varied	O
from	O
mild	O
hereditary	O
neuropathy	O
with	O
liability	O
to	O
pressure	O
palsies	O
(	O
HNPP	O
)	O
to	O
severe	O
CMT1	O
.	O

We	O
identified	O
six	O
different	O
point	O
mutations	O
,	O
including	O
two	O
novel	O
mutations	O
.	O

Three	O
families	O
were	O
also	O
found	O
to	O
harbour	O
a	O
Thr118Met	O
mutation	O
.	O

Although	O
PMP22	O
point	O
mutations	O
are	O
not	O
common	O
,	O
our	O
findings	O
highlight	O
the	O
importance	O
of	O
sequencing	O
the	O
PMP22	O
gene	O
in	O
patients	O
with	O
variable	O
CMT	O
phenotypes	O
and	O
also	O
confirm	O
that	O
the	O
PMP22	B-Gene
Thr118Met	B-Var
mutation	O
is	O
associated	B-Reg
with	I-Reg
a	O
neuropathy	B-CPA
albeit	O
with	O
reduced	O
penetrance	O
.	O

Genotype	O
-	O
phenotype	O
analysis	O
of	O
the	O
branchio	O
-	O
oculo	O
-	O
facial	O
syndrome	O
.	O

Branchio	B-Disease
-	I-Disease
oculo	I-Disease
-	I-Disease
facial	I-Disease
syndrome	I-Disease
(	O
BOFS	O
;	O
OMIM#113620	O
)	O
is	O
a	O
rare	O
autosomal	O
dominant	O
craniofacial	O
disorder	O
with	O
variable	O
expression	O
.	O

Major	O
features	O
include	O
cutaneous	O
and	O
ocular	O
abnormalities	O
,	O
characteristic	O
facies	O
,	O
renal	O
,	O
ectodermal	O
,	O
and	O
temporal	O
bone	O
anomalies	O
.	O

Having	O
determined	O
that	O
mutations	B-Var
involving	O
TFAP2A	B-Gene
result	B-Reg
in	I-Reg
BOFS	B-Disease
,	O
we	O
studied	O
a	O
total	O
of	O
30	O
families	O
(	O
41	O
affected	O
individuals	O
)	O
;	O
26/30	O
(	O
87	O
%	O
)	O
fulfilled	O
our	O
cardinal	O
diagnostic	O
criteria	O
.	O

The	O
original	O
family	O
with	O
the	O
3.2	O
Mb	O
deletion	O
including	O
the	O
TFAP2A	O
gene	O
remains	O
the	O
only	O
BOFS	O
family	O
without	O
the	O
typical	O
CL	O
/	O
P	O
and	O
the	O
only	O
family	O
with	O
a	O
deletion	O
.	O

We	O
have	O
identified	O
a	O
hotspot	O
region	O
in	O
the	O
highly	O
conserved	O
exons	O
4	O
and	O
5	O
of	O
TFAP2A	O
that	O
harbors	O
missense	O
mutations	O
in	O
27/30	O
(	O
90	O
%	O
)	O
families	O
.	O

Several	O
of	O
these	O
mutations	O
are	O
recurrent	O
.	O

Mosaicism	O
was	O
detected	O
in	O
one	O
family	O
.	O

To	O
date	O
,	O
genetic	O
heterogeneity	O
has	O
not	O
been	O
observed	O
.	O

Although	O
the	O
cardinal	O
criteria	O
for	O
BOFS	O
have	O
been	O
based	O
on	O
the	O
presence	O
of	O
each	O
of	O
the	O
core	O
defects	O
,	O
an	O
affected	O
family	O
member	O
or	O
thymic	O
remnant	O
,	O
we	O
documented	O
TFAP2A	O
mutations	O
in	O
three	O
(	O
10	O
%	O
)	O
probands	O
in	O
our	O
series	O
without	O
a	O
classic	O
cervical	O
cutaneous	O
defect	O
or	O
ectopic	O
thymus	O
.	O

Temporal	O
bone	O
anomalies	O
were	O
identified	O
in	O
3/5	O
patients	O
investigated	O
.	O

The	O
occurrence	O
of	O
CL	O
/	O
P	O
,	O
premature	O
graying	O
,	O
coloboma	O
,	O
heterochromia	O
irides	O
,	O
and	O
ectopic	O
thymus	O
,	O
are	O
evidence	O
for	O
BOFS	O
as	O
a	O
neurocristopathy	O
.	O

Intrafamilial	O
clinical	O
variability	O
can	O
be	O
marked	O
.	O

Although	O
there	O
does	O
not	O
appear	O
to	O
be	O
mutation	O
-	O
specific	O
genotype	O
-	O
phenotype	O
correlations	O
at	O
this	O
time	O
,	O
more	O
patients	O
need	O
to	O
be	O
studied	O
.	O

Clinical	O
testing	O
for	O
TFAP2A	O
mutations	O
is	O
now	O
available	O
and	O
will	O
assist	O
geneticists	O
in	O
confirming	O
the	O
typical	O
cases	O
or	O
excluding	O
the	O
diagnosis	O
in	O
atypical	O
cases	O
.	O

Twenty	O
-	O
five	O
novel	O
mutations	O
including	O
duplications	O
in	O
the	O
ATP7A	O
gene	O
.	O

Twenty	O
-	O
five	O
novel	O
mutations	O
including	O
duplications	O
in	O
the	O
ATP7A	O
gene	O
.	O

Menkes	B-Disease
disease	I-Disease
(	O
MD	O
)	O
and	O
occipital	B-Disease
horn	I-Disease
syndrome	I-Disease
(	O
OHS	O
)	O
are	O
allelic	O
X	O
-	O
linked	O
recessive	O
copper	O
deficiency	O
disorders	O
resulting	B-Reg
from	I-Reg
ATP7A	B-Gene
gene	O
mutations	B-Var
.	O

MD	O
is	O
a	O
severe	O
condition	O
leading	O
to	O
progressive	O
neurological	O
degeneration	O
and	O
death	O
in	O
early	O
childhood	O
,	O
whereas	O
OHS	O
has	O
a	O
milder	O
phenotype	O
with	O
mainly	O
connective	O
tissue	O
abnormalities	O
.	O

Until	O
now	O
,	O
molecular	O
analyses	O
have	O
revealed	O
only	O
deletions	O
and	O
point	O
mutations	O
in	O
both	O
diseases	O
.	O

This	O
study	O
reports	O
new	O
molecular	O
data	O
in	O
a	O
series	O
of	O
40	O
patients	O
referred	O
for	O
either	O
MD	O
or	O
OHS	O
.	O

We	O
describe	O
23	O
point	O
mutations	O
(	O
9	O
missense	O
mutations	O
,	O
7	O
splice	O
site	O
variants	O
,	O
4	O
nonsense	O
mutations	O
,	O
and	O
3	O
small	O
insertions	O
or	O
deletions	O
)	O
and	O
7	O
intragenic	O
deletions	O
.	O

Of	O
these	O
,	O
18	O
point	O
mutations	O
and	O
3	O
deletions	O
are	O
novel	O
.	O

Furthermore	O
,	O
our	O
finding	O
of	O
four	O
whole	O
exon	O
duplications	O
enlarges	O
the	O
mutation	O
spectrum	O
in	O
the	O
ATP7A	O
gene	O
.	O

ATP7A	O
alterations	O
were	O
found	O
in	O
85	O
%	O
of	O
cases	O
.	O

Of	O
these	O
alterations	O
,	O
two	O
thirds	O
were	O
point	O
mutations	O
and	O
the	O
remaining	O
one	O
third	O
consisted	O
of	O
large	O
rearrangements	O
.	O

We	O
found	O
that	O
66.6	O
%	O
of	O
point	O
mutations	B-Var
resulted	O
in	O
impaired	B-NegReg
ATP7A	B-Gene
transcript	B-MPA
splicing	I-MPA
,	O
a	O
phenomenon	O
more	O
frequent	O
than	O
expected	O
.	O

This	O
finding	O
enabled	O
us	O
to	O
confirm	O
the	O
pathogenic	O
role	O
of	O
ATP7A	O
mutations	O
,	O
particularly	O
in	O
missense	O
and	O
splice	O
site	O
variants	O
.	O

Phenotypic	O
heterogeneity	O
in	O
a	O
large	O
Thai	O
slow	O
-	O
channel	O
congenital	O
myasthenic	O
syndrome	O
kinship	O
.	O

The	O
slow	B-Disease
-	I-Disease
channel	I-Disease
congenital	I-Disease
myasthenic	I-Disease
syndrome	I-Disease
(	O
SCCMS	O
)	O
is	O
an	O
autosomal	O
dominant	O
neuromuscular	O
disorder	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
different	O
subunits	O
of	O
the	O
acetylcholine	O
receptor	O
(	B-Gene
AChR	I-Gene
)	I-Gene
.	O

We	O
here	O
report	O
our	O
clinical	O
findings	O
in	O
three	O
generations	O
of	O
a	O
large	O
Thai	O
kinship	O
suffering	O
from	O
SCCMS	O
and	O
trace	O
the	O
disease	O
to	O
the	O
p	O
.	O
Gly153Ser	O
mutation	O
in	O
the	O
AChR	O
α	O
subunit	O
.	O

The	O
same	O
mutation	O
had	O
previously	O
been	O
reported	O
only	O
in	O
Caucasian	O
but	O
not	O
in	O
Asian	O
patients	O
.	O

The	O
clinical	O
features	O
include	O
ptosis	O
,	O
ophthalmoparesis	O
,	O
and	O
weakness	O
of	O
the	O
cervical	O
and	O
finger	O
extensor	O
muscles	O
as	O
well	O
as	O
marked	O
phenotypic	O
heterogeneity	O
.	O

[	O
Anaemia	O
caused	O
by	O
a	O
congenital	O
haemoglobin	O
defect	O
can	O
also	O
occur	O
in	O
native	O
Dutch	O
patients	O
]	O
.	O

Anemie	O
door	O
aangeboren	O
afwijkingen	O
van	O
het	O
hemoglobine	O
,	O
ook	O
bij	O
autochtone	O
Nederlanders	O
.	O

An	O
11-year	O
-	O
old	O
boy	O
of	O
Dutch	O
descent	O
had	O
suffered	O
from	O
tiredness	O
,	O
pallor	O
and	O
poor	O
appetite	O
for	O
many	O
years	O
.	O

There	O
was	O
no	O
indication	O
of	O
chronic	O
infection	O
.	O

Iron	O
supplements	O
did	O
not	O
produce	O
sufficient	O
improvement	O
in	O
the	O
symptoms	O
.	O

Following	O
analysis	O
using	O
fast	O
protein	O
liquid	O
chromatography	O
and	O
DNA	O
sequencing	O
analysis	O
,	O
it	O
appeared	O
that	O
this	O
was	O
a	O
case	O
of	O
β	B-Disease
-	I-Disease
thalassaemia	I-Disease
intermedia	I-Disease
,	O
caused	B-Reg
by	I-Reg
a	O
point	B-Var
mutation	I-Var
in	O
the	O
promotor	O
region	O
of	O
the	O
β	B-Gene
-	I-Gene
globulin	I-Gene
gene	O
.	O

The	O
boy	O
's	O
parents	O
both	O
proved	O
to	O
be	O
heterozygotes	O
for	O
this	O
point	O
mutation	O
.	O

A	O
second	O
patient	O
,	O
a	O
5-year	O
-	O
old	O
girl	O
of	O
Dutch	O
descent	O
,	O
suffered	O
from	O
an	O
icterus	O
following	O
a	O
respiratory	O
tract	O
infection	O
.	O

Splenomegaly	O
,	O
hyperbilirubinaemia	O
and	O
microcytic	O
anaemia	O
with	O
raised	O
reticulocyte	O
values	O
were	O
observed	O
.	O

Because	O
of	O
the	O
presence	O
of	O
spherocytes	O
,	O
hereditary	O
spherocytosis	O
was	O
initially	O
suspected	O
.	O

On	O
further	O
analysis	O
Heinz	O
bodies	O
were	O
also	O
seen	O
,	O
following	O
which	O
DNA	O
sequencing	O
analysis	O
showed	O
a	O
de	O
novo	O
Hb	O
Köln	O
mutation	O
.	O

Congenital	O
haemoglobin	O
defects	O
are	O
usually	O
associated	O
with	O
people	O
originating	O
from	O
Africa	O
,	O
the	O
Mediterranean	O
,	O
the	O
Middle	O
-	O
East	O
or	O
South	O
-	O
East	O
Asia	O
.	O

That	O
such	O
abnormalities	O
can	O
also	O
occur	O
in	O
children	O
of	O
Dutch	O
descent	O
is	O
demonstrated	O
by	O
these	O
two	O
cases	O
.	O

Mild	O
recessive	O
dystrophic	B-Disease
epidermolysis	I-Disease
bullosa	I-Disease
associated	B-Reg
with	I-Reg
two	O
compound	O
heterozygous	O
COL7A1	B-Gene
mutations	B-Var
.	O

Dystrophic	B-Disease
epidermolysis	I-Disease
bullosa	I-Disease
is	O
a	O
group	O
of	O
inherited	O
skin	O
blistering	O
disorders	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
COL7A1	B-Gene
gene	O
coding	O
for	O
type	O
VII	O
collagen	O
.	O

More	O
than	O
500	O
different	O
COL7A1	B-Gene
mutations	B-Var
have	O
been	O
detected	B-Reg
in	O
dystrophic	B-Disease
epidermolysis	I-Disease
bullosa	I-Disease
to	O
date	O
.	O

Clarification	O
of	O
genotype	O
-	O
phenotype	O
correlations	O
is	O
of	O
particular	O
importance	O
for	O
the	O
development	O
of	O
novel	O
therapeutic	O
approaches	O
.	O

Here	O
we	O
report	O
a	O
female	O
patient	O
with	O
mild	O
dystrophic	O
epidermolysis	O
bullosa	O
harbouring	O
two	O
compound	O
heterozygous	O
COL7A1	O
mutations	O
,	O
namely	O
the	O
intronic	O
splice	O
site	O
mutation	O
c.3832	O
-	O
2A	O
>	O
G	O
and	O
the	O
glycine	O
substitution	O
p	O
.	O
G1347W.	O
Our	O
data	O
extend	O
the	O
current	O
knowledge	O
on	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
dystrophic	O
epidermolysis	O
bullosa	O
.	O

[	O
Association	O
of	O
mutation	O
types	O
and	O
distribution	O
characteristics	O
of	O
dystrophin	O
gene	O
with	O
clinical	O
symptoms	O
in	O
Chinese	O
population	O
]	O
.	O

Duchenne	O
muscular	O
dystrophy	O
(	O
DMD	O
)	O
is	O
X	O
-	O
linked	O
disorder	O
caused	O
by	O
mutations	O
in	O
the	O
dystrophin	O
gene	O
.	O

To	O
investigate	O
mutation	O
types	O
and	O
distribution	O
characteristics	O
of	O
dystrophin	O
gene	O
in	O
Chinese	O
DMD	O
patients	O
,	O
we	O
used	O
Multiplex	O
Ligation	O
-	O
Dependent	O
Probe	O
Amplification	O
(	O
MLPA	O
)	O
to	O
analyze	O
the	O
dystrophin	O
gene	O
in	O
720	O
DMD	O
patients	O
,	O
their	O
mothers	O
,	O
and	O
20	O
normal	O
adult	O
males	O
.	O

Results	O
showed	O
that	O
detection	O
rate	O
was	O
64.9	O
%	O
(	O
467/720	O
)	O
in	O
all	O
the	O
patients	O
,	O
gene	O
deletion	O
rate	O
was	O
54.3	O
%	O
(	O
391/720	O
)	O
,	O
and	O
gene	O
duplication	O
rate	O
was	O
10.6	O
%	O
(	O
76/720	O
)	O
.	O

The	O
rate	O
of	O
deletion	O
mutant	O
occurred	O
in	O
Exon	O
45	O
-	O
54	O
was	O
71.9	O
%	O
(	O
281/391	O
)	O
in	O
all	O
gene	O
deletion	O
patients	O
;	O
meanwhile	O
,	O
the	O
rate	O
of	O
gene	O
duplication	O
occurred	O
in	O
Exon	O
1	O
-	O
40	O
was	O
82.9	O
%	O
(	O
63/76	O
)	O
in	O
all	O
gene	O
duplication	O
ones	O
.	O

In	O
all	O
the	O
patients	O
with	O
gene	O
deletion	O
and	O
duplication	O
,	O
the	O
rate	O
of	O
DMD	O
and	O
IMD	O
was	O
90.6	O
%	O
(	O
423/467	O
)	O
,	O
and	O
BMD	O
,	O
9.4	O
%	O
(	O
44/467	O
)	O
.	O

This	O
indicates	O
that	O
the	O
main	O
reason	B-Reg
of	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
is	O
dystrophin	B-Gene
gene	I-Gene
deletion	B-Var
mutation	O
,	O
which	O
would	O
occur	O
in	O
any	O
gene	O
unevenly	O
with	O
hot	O
spots	O
of	O
mutation	O
.	O

The	O
location	O
and	O
fragment	O
length	O
of	O
gene	O
deletion	O
and	O
duplication	O
can	O
not	O
decide	O
the	O
severity	O
of	O
clinical	O
symptoms	O
directly	O
.	O

AXIN2-associated	O
autosomal	O
dominant	O
ectodermal	O
dysplasia	O
and	O
neoplastic	O
syndrome	O
.	O

We	O
describe	O
a	O
family	O
with	O
a	O
novel	O
,	O
inherited	O
AXIN2	O
mutation	O
(	O
c.1989G	O
>	O
A	O
)	O
segregating	O
in	O
an	O
autosomal	O
dominant	O
pattern	O
with	O
oligodontia	O
and	O
variable	O
other	O
findings	O
including	O
colonic	O
polyposis	O
,	O
gastric	O
polyps	O
,	O
a	O
mild	O
ectodermal	O
dysplasia	O
phenotype	O
with	O
sparse	O
hair	O
and	O
eyebrows	O
,	O
and	O
early	O
onset	O
colorectal	O
and	O
breast	O
cancers	O
.	O

This	O
novel	O
mutation	O
predicts	O
p	O
.	O
Trp663X	O
,	O
which	O
is	O
a	O
truncated	O
protein	O
that	O
is	O
missing	O
the	O
last	O
three	O
exons	O
,	O
including	O
the	O
DIX	O
(	O
Disheveled	O
and	O
AXIN	O
interacting	O
)	O
domain	O
.	O

This	O
nonsense	O
mutation	B-Var
is	O
predicted	O
to	O
destroy	B-NegReg
the	O
inhibitory	B-MPA
action	I-MPA
of	O
AXIN2	B-Gene
on	O
WNT	B-Pathway
signaling	I-Pathway
.	O

Previous	O
authors	O
have	O
described	O
an	O
unrelated	O
family	O
with	O
autosomal	O
dominant	O
oligodontia	O
and	O
a	O
variable	O
colorectal	O
phenotype	O
segregating	O
with	O
a	O
nonsense	O
mutation	O
of	O
AXIN2	O
,	O
as	O
well	O
as	O
a	O
frameshift	O
AXIN2	O
mutation	O
in	O
an	O
unrelated	O
individual	O
with	O
oligodontia	O
.	O

Our	O
report	O
provides	O
additional	O
evidence	O
supporting	O
an	O
autosomal	B-Var
dominant	I-Var
AXIN2-associated	B-Reg
ectodermal	B-Disease
dysplasia	I-Disease
and	O
neoplastic	B-Disease
syndrome	I-Disease
.	O

The	O
Down	O
syndrome	O
critical	O
region	O
regulates	O
retinogeniculate	O
refinement	O
.	O

Down	B-Disease
syndrome	I-Disease
(	O
DS	O
)	O
is	O
a	O
developmental	O
disorder	O
caused	B-Reg
by	I-Reg
a	O
third	O
chromosome	O
21	O
in	O
humans	O
(	B-Var
Trisomy	I-Var
21	I-Var
)	I-Var
,	O
leading	O
to	O
neurological	O
deficits	O
and	O
cognitive	O
impairment	O
.	O

Studies	O
in	O
mouse	O
models	O
of	O
DS	O
suggest	O
that	O
cognitive	O
deficits	O
in	O
the	O
adult	O
are	O
associated	O
with	O
deficits	O
in	O
synaptic	O
learning	O
and	O
memory	O
mechanisms	O
,	O
but	O
it	O
is	O
unclear	O
whether	O
alterations	O
in	O
the	O
early	O
wiring	O
and	O
refinement	O
of	O
neuronal	O
circuits	O
contribute	O
to	O
these	O
deficits	O
.	O

Here	O
,	O
we	O
show	O
that	O
early	O
developmental	O
refinement	O
of	O
visual	O
circuits	O
is	O
perturbed	O
in	O
mouse	O
models	O
of	O
Down	O
syndrome	O
.	O

Specifically	O
,	O
we	O
find	O
excessive	O
eye	O
-	O
specific	O
segregation	O
of	O
retinal	O
axons	O
in	O
the	O
dorsal	O
lateral	O
geniculate	O
nucleus	O
.	O

Indeed	O
,	O
the	O
degree	O
of	O
refinement	O
scales	O
with	O
defects	O
in	O
the	O
"	O
Down	O
syndrome	O
critical	O
region	O
"	O
(	O
DSCR	O
)	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

We	O
further	O
identify	O
Dscam	O
(	O
Down	O
syndrome	O
cell	O
adhesion	O
molecule	O
)	O
,	O
a	O
gene	O
within	O
the	O
DSCR	O
,	O
as	O
a	O
regulator	O
of	O
eye	O
-	O
specific	O
segregation	O
of	O
retinogeniculate	O
projections	O
.	O

Although	O
Dscam	O
is	O
not	O
the	O
sole	O
gene	O
in	O
the	O
DSCR	O
contributing	O
to	O
enhanced	O
refinement	O
in	O
trisomy	O
,	O
Dscam	O
dosage	O
clearly	O
regulates	O
cell	O
spacing	O
and	O
dendritic	O
fasciculation	O
in	O
a	O
specific	O
class	O
of	O
retinal	O
ganglion	O
cells	O
.	O

Thus	O
,	O
altered	O
developmental	O
refinement	O
of	O
visual	O
circuits	O
that	O
occurs	O
before	O
sensory	O
experience	O
is	O
likely	O
to	O
contribute	O
to	O
visual	O
impairment	O
in	O
individuals	O
with	O
Down	O
syndrome	O
.	O

Identification	O
and	O
functional	O
consequences	O
of	O
a	O
recurrent	O
NLRP12	B-Gene
missense	B-Var
mutation	I-Var
in	B-Reg
periodic	B-Disease
fever	I-Disease
syndromes	I-Disease
.	O

OBJECTIVE	O
:	O
To	O
gain	O
insight	O
into	O
the	O
molecular	O
bases	O
of	O
genetically	O
unexplained	O
periodic	O
fever	O
syndromes	O
(	O
PFS	O
)	O
by	O
screening	O
NLRP12	O
,	O
a	O
gene	O
in	O
which	O
only	O
a	O
nonsense	O
and	O
a	O
splice	O
site	O
mutation	O
have	O
so	O
far	O
been	O
identified	O
,	O
and	O
to	O
assess	O
the	O
functional	O
consequences	O
of	O
the	O
identified	O
missense	O
variation	O
.	O

METHODS	O
:	O
NLRP12	O
was	O
screened	O
for	O
mutations	O
by	O
direct	O
sequencing	O
.	O

Functional	O
assays	O
were	O
performed	O
in	O
HEK	O
293	O
T	O
cells	O
stably	O
expressing	O
the	O
proapoptotic	O
protein	O
ASC	O
and	O
procaspase	O
1	O
,	O
in	O
order	O
to	O
determine	O
the	O
effects	O
of	O
normal	O
and	O
mutated	O
NLRP12	O
proteins	O
on	O
speck	O
formation	O
,	O
caspase	O
1	O
signaling	O
,	O
and	O
NF	O
-	O
κB	O
activation	O
.	O

RESULTS	O
:	O
A	O
heterozygous	O
NLRP12	B-Gene
missense	O
mutation	O
involving	O
a	O
CpG	O
site	O
(	B-Var
c.1054C	I-Var
>	I-Var
T	I-Var
;	I-Var
p	O
.	O
Arg352Cys	O
)	O
was	O
identified	O
in	O
exon	O
3	O
,	O
which	O
encodes	B-Reg
the	O
nucleotide	B-Interaction
-	I-Interaction
binding	I-Interaction
site	O
(	O
NBS	O
)	O
of	O
the	O
protein	B-Protein
,	O
in	O
2	O
patients	O
from	O
different	O
countries	O
and	O
carrying	O
different	O
NLRP12	O
haplotypes	O
.	O

The	O
mutation	B-Var
,	O
which	O
does	O
not	O
alter	O
the	O
inhibitory	O
effect	O
of	O
NLRP12	O
on	O
NF	O
-	O
κB	O
activation	O
,	O
increases	B-PosReg
speck	B-MPA
formation	I-MPA
and	O
activates	B-PosReg
caspase	B-MPA
1	I-MPA
signaling	I-MPA
.	O

To	O
define	O
this	O
new	O
class	O
of	O
PFS	O
,	O
we	O
propose	O
the	O
term	O
NLRP12-associated	O
disorders	O
(	O
NLRP12AD	O
)	O
.	O

CONCLUSION	O
:	O
Given	O
the	O
rarity	O
of	O
known	O
NLRP12-associated	O
disorders	O
,	O
the	O
identification	O
of	O
this	O
NLRP12	O
molecular	O
defect	O
contributes	O
to	O
the	O
delineation	O
of	O
the	O
clinical	O
spectrum	O
associated	O
with	O
mutations	O
in	O
this	O
gene	O
and	O
highlights	O
the	O
importance	O
of	O
screening	O
NLRP12	O
in	O
patients	O
presenting	O
with	O
unexplained	O
PFS	O
.	O

This	O
study	O
also	O
demonstrates	O
,	O
by	O
means	O
of	O
functional	O
assays	O
,	O
the	O
deleterious	O
effect	O
of	O
this	O
recurrent	O
missense	O
mutation	O
;	O
the	O
gain	B-PosReg
of	I-PosReg
function	I-PosReg
for	O
speck	B-MPA
formation	I-MPA
and	O
caspase	B-MPA
1	I-MPA
signaling	I-MPA
associated	O
with	O
this	O
NBS	O
mutation	B-Var
is	O
consistent	O
with	O
the	O
inflammatory	O
phenotype	O
of	O
PFS	O
.	O

New	O
homozygous	O
SPINK5	O
mutation	O
,	O
p	O
.	O
Gln333X	O
,	O
in	O
a	O
Turkish	O
pedigree	O
with	O
Netherton	O
syndrome	O
.	O

Netherton	B-Disease
syndrome	I-Disease
(	O
NS	O
)	O
is	O
a	O
rare	O
autosomal	O
recessive	O
genodermatosis	O
caused	O
by	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
the	O
SPINK5	B-Gene
gene	O
.	O

The	O
clinical	O
features	O
include	O
congenital	O
ichthyosis	O
,	O
trichorrhexis	O
invaginata	O
and	O
atopy	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
a	O
new	O
homozygous	O
SPINK5	B-Gene
mutation	O
,	O
p	B-Var
.	I-Var
Gln333X	I-Var
,	O
responsible	B-Reg
for	O
NS	B-Disease
in	O
affected	O
members	O
of	O
two	O
closely	O
related	O
Turkish	O
families	O
,	O
and	O
provide	O
an	O
overview	O
of	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
in	O
this	O
condition	O
.	O

Severer	O
phenotype	O
in	O
Unverricht	B-Disease
-	I-Disease
Lundborg	I-Disease
disease	I-Disease
(	O
EPM1	O
)	O
patients	O
compound	O
heterozygous	O
for	B-Reg
the	O
dodecamer	O
repeat	O
expansion	O
and	O
the	O
c.202C	B-Var
>	I-Var
T	I-Var
mutation	O
in	O
the	O
CSTB	B-Gene
gene	O
.	O

BACKGROUND	O
/	O
AIMS	O
:	O
Unverricht	B-Disease
-	I-Disease
Lundborg	I-Disease
disease	I-Disease
(	O
EPM1	O
)	O
is	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
cystatin	O
B	O
(	B-Gene
CSTB	I-Gene
)	I-Gene
gene	O
.	O

Most	O
patients	O
are	O
homozygous	O
for	O
the	O
expanded	O
dodecamer	O
repeat	O
mutation	O
alleles	O
,	O
but	O
9	O
other	O
EPM1-associated	O
mutations	O
have	O
also	O
been	O
identified	O
.	O

We	O
describe	O
the	O
clinical	O
,	O
cognitive	O
and	O
imaging	O
characteristics	O
of	O
5	O
Finnish	O
EPM1	O
patients	O
who	O
are	O
compound	O
heterozygous	O
for	O
the	O
dodecamer	O
repeat	O
expansion	O
and	O
the	O
c.202C	O
>	O
T	O
mutations	O
.	O

METHODS	O
:	O
Five	O
compound	O
heterozygous	O
patients	O
and	O
21	O
patients	O
homozygous	O
for	O
the	O
expansion	O
mutation	O
,	O
participating	O
in	O
an	O
ongoing	O
nationwide	O
clinical	O
and	O
molecular	O
genetics	O
study	O
,	O
were	O
evaluated	O
using	O
the	O
Unified	O
Myoclonus	O
Rating	O
Scale	O
test	O
and	O
comprehensive	O
neuropsychological	O
testing	O
.	O

All	O
patients	O
underwent	O
MR	O
imaging	O
.	O

The	O
MR	O
data	O
were	O
also	O
compared	O
with	O
those	O
of	O
24	O
healthy	O
control	O
subjects	O
.	O

RESULTS	O
:	O
Age	O
at	O
onset	O
of	O
symptoms	O
was	O
significantly	O
lower	O
in	O
the	O
compound	O
heterozygotes	O
than	O
in	O
the	O
homozygous	O
EPM1	O
patients	O
.	O

They	O
also	O
had	O
severer	O
myoclonus	O
and	O
drug	O
-	O
resistant	O
tonic	O
-	O
clonic	O
seizures	O
.	O

Moreover	O
,	O
they	O
had	O
lower	O
cognitive	O
performance	O
.	O

In	O
MRI	O
a	O
voxel	O
-	O
based	O
morphometry	O
analysis	O
of	O
primary	O
and	O
premotor	O
cortex	O
,	O
supplementary	O
motor	O
cortex	O
and	O
thalami	O
revealed	O
gray	O
matter	O
volume	O
loss	O
when	O
compared	O
with	O
the	O
healthy	O
controls	O
,	O
similar	O
to	O
patients	O
homozygous	O
for	O
the	O
expansion	O
mutation	O
.	O

CONCLUSION	O
:	O
Patients	O
compound	O
heterozygous	O
for	O
the	O
dodecamer	O
repeat	O
expansion	O
and	O
the	O
c.202C	O
>	O
T	O
mutations	O
seem	O
to	O
have	O
a	O
severer	O
form	O
of	O
EPM1	O
than	O
patients	O
homozygous	O
for	O
the	O
expansion	O
mutation	O
.	O

These	O
findings	O
have	O
implications	O
for	O
counseling	O
of	O
EPM1	O
patients	O
with	O
different	O
genetic	O
defects	O
.	O

Acquisition	O
of	O
steady	O
-	O
state	O
operant	O
behavior	O
in	O
long	O
-	O
living	O
Ames	O
Dwarf	O
mice	O
.	O

Ames	O
dwarf	O
mice	O
have	O
a	O
Prop-1	B-Gene
mutation	B-Var
that	O
has	O
been	O
identified	O
with	O
increased	B-PosReg
levels	B-MPA
of	I-MPA
IGF	I-MPA
-	I-MPA
I	I-MPA
in	O
the	O
central	O
nervous	O
system	O
,	O
upregulation	B-PosReg
of	O
neuroprotective	B-CPA
systems	I-CPA
,	O
and	O
increased	O
lifespan	O
.	O

To	O
elucidate	O
the	O
behavioral	O
effects	O
of	O
the	O
Prop-1	O
mutation	O
,	O
8	O
Ames	O
dwarf	O
and	O
7	O
normal	O
mice	O
(	O
all	O
of	O
whom	O
were	O
8	O
months	O
of	O
age	O
or	O
younger	O
)	O
were	O
compared	O
on	O
a	O
differential	O
-	O
reinforcement	O
-	O
of	O
-	O
low	O
-	O
rate	O
-	O
of	O
-	O
responding	O
schedule	O
of	O
reinforcement	O
and	O
a	O
matching	O
-	O
to	O
-	O
sample	O
task	O
.	O

On	O
both	O
tasks	O
,	O
nosepokes	O
were	O
reinforced	O
with	O
access	O
to	O
a	O
saccharin	O
solution	O
.	O

Comparisons	O
were	O
based	O
on	O
several	O
measures	O
of	O
behavioral	O
efficiency	O
:	O
pause	O
durations	O
,	O
intertrial	O
intervals	O
,	O
and	O
numbers	O
of	O
responses	O
.	O

Ames	O
dwarf	O
mice	O
were	O
generally	O
less	O
efficient	O
than	O
normal	O
mice	O
.	O

One	O
possible	O
cause	O
of	O
this	O
outcome	O
is	O
that	O
relatively	O
young	O
Ames	O
dwarf	O
mice	O
show	O
less	O
cognitive	O
development	O
than	O
age	O
-	O
matched	O
normal	O
mice	O
.	O

[	B-Gene
GNE	I-Gene
gene	O
mutation	B-Var
analysis	O
in	O
5	O
patients	O
with	B-Reg
distal	B-Disease
myopathy	I-Disease
with	I-Disease
rimmed	I-Disease
vacuoles	I-Disease
]	I-Disease
.	O

OBJECTIVE	O
:	O
To	O
investigate	O
GNE	O
gene	O
mutations	O
in	O
5	O
Chinese	O
patients	O
with	O
distal	O
myopathy	O
with	O
rimmed	O
vacuoles	O
(	O
DMRV	O
)	O
.	O

METHODS	O
:	O
Five	O
patients	O
with	O
typical	O
clinical	O
and	O
pathological	O
features	O
of	O
DMRV	O
were	O
studied	O
.	O

All	O
the	O
11	O
coding	O
exons	O
and	O
the	O
flanking	O
intron	O
sequences	O
of	O
GNE	O
gene	O
were	O
amplified	O
by	O
PCR	O
and	O
sequenced	O
.	O

Four	O
family	O
members	O
of	O
case	O
5	O
were	O
also	O
examined	O
for	O
GNE	O
gene	O
mutations	O
.	O

RESULTS	O
:	O
All	O
the	O
patients	O
were	O
identified	O
to	O
have	O
different	O
GNE	O
gene	O
mutations	O
:	O
Cases	O
1	O
-	O
4	O
had	O
complex	O
heterozygous	O
mutations	O
and	O
case	O
5	O
had	O
homozygous	O
mutation	O
.	O

Six	O
reported	O
mutations	O
had	O
been	O
identified	O
,	O
including	O
1	O
nonsense	O
mutation	O
(	O
p	O
.	O
R8X	O
)	O
and	O
5	O
missense	O
mutations	O
(	O
p	O
.	O
D176V	O
,	O
p	O
.	O
I298	O
T	O
,	O
p	O
.	O
A591	O
T	O
,	O
P.A631V	O
,	O
and	O
p	O
.	O
V696	O
M	O
)	O
.	O

A	O
novel	O
mutation	O
(	O
c.317T	O
>	O
C	O
,	O
p	O
.	O
I106	O
T	O
)	O
was	O
identified	O
in	O
case	O
2	O
.	O

CONCLUSION	O
:	O
This	O
is	O
the	O
first	O
report	O
of	O
p	B-Var
.	I-Var
R8X	I-Var
,	O
p	B-Var
.	I-Var
I298	I-Var
T	I-Var
,	O
p	B-Var
.	I-Var
A591	I-Var
T	I-Var
and	O
p	B-Var
.	I-Var
V696	I-Var
M	I-Var
mutations	O
in	O
GNE	B-Gene
gene	O
in	O
Chinese	O
population	O
,	O
and	O
a	O
novel	O
mutation	O
p	B-Var
.	I-Var
I106	I-Var
T	I-Var
was	O
identified	O
.	O

These	O
findings	O
further	O
expand	O
the	O
clinical	O
and	O
genetic	O
spectrum	O
of	B-Reg
DMRV	B-Disease
in	O
China	O
.	O

Congenital	O
variant	O
of	O
Rett	O
syndrome	O
due	O
to	O
an	O
intragenic	O
large	O
deletion	O
in	O
MECP2	O
.	O

Rett	B-Disease
syndrome	I-Disease
(	O
RTT	O
)	O
is	O
a	O
neurodevelopmental	O
disorder	O
that	O
is	O
one	O
of	O
the	O
most	O
common	O
causes	O
of	O
mental	O
retardation	O
in	O
females	O
.	O

RTT	O
diagnosis	O
is	O
based	O
on	O
distinct	O
clinical	O
criteria	O
.	O

We	O
describe	O
here	O
a	O
female	O
patient	O
with	O
severe	O
phenotype	O
of	O
congenital	O
variant	O
RTT	O
.	O

The	O
patient	O
originally	O
presented	O
with	O
severe	O
developmental	O
delay	O
prior	O
to	O
the	O
age	O
of	O
6	O
months	O
and	O
later	O
exhibited	O
characteristic	O
features	O
of	O
RTT	O
that	O
included	O
air	O
swallowing	O
,	O
bruxism	O
,	O
and	O
hand	O
stereotypies	O
.	O

Results	O
of	O
an	O
array	O
-	O
based	O
comparative	O
genomic	O
hybridization	O
analysis	O
indicated	O
there	O
was	O
a	O
very	O
small	O
microdeletion	O
in	O
Xq28	O
.	O

Multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
analysis	O
further	O
confirmed	O
there	O
were	O
heterozygous	O
deletions	O
of	O
intron	O
2	O
,	O
exon	O
3	O
,	O
intron	O
3	O
,	O
and	O
part	O
of	O
exon	O
4	O
in	O
MECP2	O
.	O

Findings	O
in	O
the	O
present	O
patient	O
confirm	O
the	O
view	O
that	O
large	O
MECP2	B-Gene
deletions	B-Var
are	O
an	O
important	O
cause	B-Reg
of	O
severe	O
congenital	O
variant	O
RTT	B-Disease
.	O

To	O
ensure	O
an	O
accurate	O
diagnosis	O
of	O
congenital	O
variant	O
RTT	O
,	O
a	O
multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
analysis	O
of	O
MECP2	O
should	O
be	O
performed	O
in	O
patients	O
suspected	O
of	O
having	O
this	O
disorder	O
.	O

A	O
new	O
frame	B-Var
-	I-Var
shifting	I-Var
mutation	O
of	O
UGT1A1	B-Gene
gene	O
causes	B-Reg
type	B-Disease
I	I-Disease
Crigler	I-Disease
-	I-Disease
Najjar	I-Disease
syndrome	I-Disease
.	O

We	O
present	O
a	O
case	O
of	O
severe	O
persisting	O
unconjugated	O
hyperbilirubinemia	O
in	O
a	O
Uigur	O
infant	O
boy	O
,	O
eventually	O
diagnosed	O
as	O
Crigler	O
-	O
Najjar	O
syndrome	O
type	O
I.	O
DNA	O
analysis	O
of	O
his	O
blood	O
of	O
the	O
UGT1A1	O
gene	O
sequence	O
demonstrated	O
that	O
he	O
was	O
homozygous	O
for	O
an	O
insertion	O
mutation	O
causing	O
a	O
change	O
of	O
the	O
coding	O
exons	O
with	O
a	O
frame	O
-	O
shift	O
,	O
resulting	O
in	O
the	O
substitution	O
of	O
27	O
abnormal	O
amino	O
acid	O
residues	O
in	O
his	O
hepatic	O
bilirubin	O
uridine	O
diphosphoglucuronyl	O
transferase	O
enzyme	O
.	O

Both	O
of	O
his	O
parents	O
were	O
heterozygous	O
for	O
the	O
same	O
mutation	O
.	O

A	O
novel	O
frame	O
-	O
shifting	O
mutation	O
of	O
the	O
UGT1A1	O
gene	O
was	O
found	O
,	O
confirming	O
the	O
diagnosis	O
of	O
Crigler	O
-	O
Najjar	O
syndrome	O
type	O
I	O
for	O
this	O
patient	O
.	O

X	O
inactivation	O
in	O
females	O
with	O
X	O
-	O
linked	O
Charcot	O
-	O
Marie	O
-	O
Tooth	O
disease	O
.	O

X	B-Disease
-	I-Disease
linked	I-Disease
Charcot	I-Disease
-	I-Disease
Marie	I-Disease
-	I-Disease
Tooth	I-Disease
disease	I-Disease
(	O
CMT1X	O
)	O
is	O
the	O
second	O
most	O
common	O
inherited	O
neuropathy	O
,	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
gap	O
junction	O
beta-1	O
(	B-Gene
GJB1	I-Gene
)	I-Gene
.	O

Males	O
have	O
a	O
uniformly	O
moderately	O
severe	O
phenotype	O
while	O
females	O
have	O
a	O
variable	O
phenotype	O
,	O
suggested	O
to	O
be	O
due	O
to	O
X	O
inactivation	O
.	O

We	O
aimed	O
to	O
assess	O
X	O
inactivation	O
pattern	O
in	O
females	O
with	O
CMT1X	O
and	O
correlate	O
this	O
with	O
phenotype	O
using	O
the	O
CMT	O
examination	O
score	O
to	O
determine	O
whether	O
the	O
X	O
inactivation	O
pattern	O
accounted	O
for	O
the	O
variable	O
phenotype	O
in	O
females	O
with	O
CMT1X.	O
We	O
determined	O
X	O
inactivation	O
pattern	O
in	O
67	O
females	O
with	O
CMT1X	O
and	O
24	O
controls	O
using	O
the	O
androgen	O
receptor	O
assay	O
.	O

We	O
were	O
able	O
to	O
determine	O
which	O
X	O
chromosome	O
carried	O
the	O
GJB1	O
mutation	O
in	O
30	O
females	O
.	O

There	O
was	O
no	O
difference	O
in	O
X	O
inactivation	O
pattern	O
between	O
patients	O
and	O
controls	O
.	O

In	O
addition	O
,	O
there	O
was	O
no	O
correlation	O
between	O
X	O
inactivation	O
pattern	O
in	O
blood	O
and	O
phenotype	O
.	O

A	O
possible	O
explanation	O
for	O
these	O
findings	O
is	O
that	O
the	O
X	O
inactivation	O
pattern	O
in	O
Schwann	O
cells	O
rather	O
than	O
in	O
blood	O
may	O
explain	O
the	O
variable	O
phenotype	O
in	O
females	O
with	O
CMT1X.	O
Autosomal	B-Disease
dominant	I-Disease
polycystic	I-Disease
kidney	I-Disease
disease	I-Disease
:	I-Disease
comprehensive	O
mutation	B-Var
analysis	O
of	O
PKD1	B-Gene
and	O
PKD2	B-Gene
in	B-Reg
700	O
unrelated	O
patients	O
.	O

Autosomal	B-Disease
dominant	I-Disease
polycystic	I-Disease
kidney	I-Disease
disease	I-Disease
(	O
ADPKD	O
)	O
,	O
the	O
most	O
common	O
inherited	O
kidney	O
disorder	O
,	O
is	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
PKD1	B-Gene
or	O
PKD2	B-Gene
.	O

The	O
molecular	O
diagnosis	O
of	O
ADPKD	O
is	O
complicated	O
by	O
extensive	O
allelic	O
heterogeneity	O
and	O
particularly	O
by	O
the	O
presence	O
of	O
six	O
highly	O
homologous	O
sequences	O
of	O
PKD1	O
exons	O
1	O
-	O
33	O
.	O

Here	O
,	O
we	O
screened	O
PKD1	O
and	O
PKD2	O
for	O
both	O
conventional	O
mutations	O
and	O
gross	O
genomic	O
rearrangements	O
in	O
up	O
to	O
700	O
unrelated	O
ADPKD	O
patients	O
--	O
the	O
largest	O
patient	O
cohort	O
to	O
date	O
--	O
by	O
means	O
of	O
direct	O
sequencing	O
,	O
followed	O
by	O
quantitative	O
fluorescent	O
multiplex	O
polymerase	O
chain	O
reaction	O
or	O
array	O
-	O
comparative	O
genomic	O
hybridization	O
.	O

This	O
resulted	O
in	O
the	O
identification	O
of	O
the	O
largest	O
number	O
of	O
new	O
pathogenic	O
mutations	O
(	O
n	O
=	O
351	O
)	O
in	O
a	O
single	O
publication	O
,	O
expanded	O
the	O
spectrum	O
of	O
known	O
ADPKD	O
pathogenic	O
mutations	O
by	O
41.8	O
%	O
for	O
PKD1	O
and	O
by	O
23.8	O
%	O
for	O
PKD2	O
,	O
and	O
provided	O
new	O
insights	O
into	O
several	O
issues	O
,	O
such	O
as	O
the	O
population	O
-	O
dependent	O
distribution	O
of	O
recurrent	O
mutations	O
compared	O
with	O
founder	O
mutations	O
and	O
the	O
relative	O
paucity	O
of	O
pathogenic	O
missense	O
mutations	O
in	O
the	O
PKD2	O
gene	O
.	O

Our	O
study	O
,	O
together	O
with	O
others	O
,	O
highlights	O
the	O
importance	O
of	O
developing	O
novel	O
approaches	O
for	O
both	O
mutation	O
detection	O
and	O
functional	O
validation	O
of	O
nondefinite	O
pathogenic	O
mutations	O
to	O
increase	O
the	O
diagnostic	O
value	O
of	O
molecular	O
testing	O
for	O
ADPKD	O
.	O

A	O
novel	O
classification	O
system	O
to	O
predict	O
the	O
pathogenic	O
effects	O
of	O
CHD7	B-Gene
missense	B-Var
variants	I-Var
in	B-Reg
CHARGE	B-Disease
syndrome	I-Disease
.	O

CHARGE	B-Disease
syndrome	I-Disease
is	O
characterized	O
by	O
the	O
variable	O
occurrence	O
of	O
multisensory	O
impairment	O
,	O
congenital	O
anomalies	O
,	O
and	O
developmental	O
delay	O
,	O
and	O
is	O
caused	B-Reg
by	I-Reg
heterozygous	B-Var
mutations	I-Var
in	O
the	O
CHD7	B-Gene
gene	O
.	O

Correct	O
interpretation	O
of	O
CHD7	O
variants	O
is	O
essential	O
for	O
genetic	O
counseling	O
.	O

This	O
is	O
particularly	O
difficult	O
for	O
missense	O
variants	O
because	O
most	O
variants	O
in	O
the	O
CHD7	O
gene	O
are	O
private	O
and	O
a	O
functional	O
assay	O
is	O
not	O
yet	O
available	O
.	O

We	O
have	O
therefore	O
developed	O
a	O
novel	O
classification	O
system	O
to	O
predict	O
the	O
pathogenic	O
effects	O
of	O
CHD7	O
missense	O
variants	O
that	O
can	O
be	O
used	O
in	O
a	O
diagnostic	O
setting	O
.	O

Our	O
classification	O
system	O
combines	O
the	O
results	O
from	O
two	O
computational	O
algorithms	O
(	O
PolyPhen-2	O
and	O
Align	O
-	O
GVGD	O
)	O
and	O
the	O
prediction	O
of	O
a	O
newly	O
developed	O
structural	O
model	O
of	O
the	O
chromo-	O
and	O
helicase	O
domains	O
of	O
CHD7	O
with	O
segregation	O
and	O
phenotypic	O
data	O
.	O

The	O
combination	O
of	O
different	O
variables	O
will	O
lead	O
to	O
a	O
more	O
confident	O
prediction	O
of	O
pathogenicity	O
than	O
was	O
previously	O
possible	O
.	O

We	O
have	O
used	O
our	O
system	O
to	O
classify	O
145	O
CHD7	O
missense	O
variants	O
.	O

Our	O
data	O
show	O
that	O
pathogenic	O
missense	O
mutations	O
are	O
mainly	O
present	O
in	O
the	O
middle	O
of	O
the	O
CHD7	O
gene	O
,	O
whereas	O
benign	O
variants	O
are	O
mainly	O
clustered	O
in	O
the	O
5	O
'	O
and	O
3	O
'	O
regions	O
.	O

Finally	O
,	O
we	O
show	O
that	O
CHD7	O
missense	O
mutations	O
are	O
,	O
in	O
general	O
,	O
associated	O
with	O
a	O
milder	O
phenotype	O
than	O
truncating	O
mutations	O
.	O

Novel	O
mutation	O
in	O
SLC9A6	O
gene	O
in	O
a	O
patient	O
with	O
Christianson	O
syndrome	O
and	O
retinitis	O
pigmentosum	O
.	O

Mutations	B-Var
in	O
the	O
SLC9A6	B-Gene
gene	O
cause	B-Reg
Christianson	B-Disease
syndrome	I-Disease
in	O
boys	O
.	O

This	O
X	O
-	O
linked	O
syndrome	O
is	O
characterized	O
by	O
profound	O
mental	O
retardation	O
with	O
autistic	O
behavior	O
,	O
microcephaly	O
,	O
epilepsy	O
,	O
ophthalmoplegia	O
,	O
and	O
ataxia	O
.	O

Progressive	O
cerebellar	O
atrophy	O
with	O
motor	O
regression	O
is	O
a	O
remarkable	O
feature	O
in	O
some	O
patients	O
.	O

We	O
report	O
on	O
a	O
22year	O
-	O
old	O
male	O
patient	O
with	O
Christianson	O
syndrome	O
carrying	O
the	O
novel	O
p	O
.	O
Gln306X	O
mutation	O
.	O

The	O
infantile	O
phenotype	O
suggested	O
pervasive	O
developmental	O
disorder	O
,	O
then	O
profound	O
mental	O
retardation	O
ensued	O
.	O

In	O
later	O
childhood	O
,	O
progressive	O
cerebellar	O
atrophy	O
was	O
diagnosed	O
on	O
serial	O
brain	O
MRIs	O
and	O
motor	O
regression	O
occurred	O
.	O

Furthermore	O
,	O
ophthalmological	O
evaluations	O
showed	O
a	O
retinitis	O
pigmentosum	O
previously	O
unreported	O
in	O
this	O
condition	O
.	O

We	O
conclude	O
that	O
the	O
natural	O
history	O
of	O
the	O
disease	O
in	O
this	O
patient	O
tends	O
to	O
confirm	O
the	O
degenerative	O
nature	O
of	O
Christianson	O
syndrome	O
,	O
and	O
that	O
retinal	O
degeneration	O
may	O
be	O
part	O
of	O
the	O
condition	O
.	O

Before	O
the	O
onset	O
of	O
degeneration	O
,	O
the	O
syndromic	O
association	O
of	O
severe	O
mental	O
retardation	O
,	O
autistic	O
behavior	O
,	O
external	O
ophthalmoplegia	O
,	O
and	O
facial	O
dysmorphism	O
in	O
male	O
patients	O
is	O
a	O
clue	O
to	O
the	O
diagnosis	O
.	O

Mutation	B-Var
analysis	O
in	O
two	O
Chinese	O
families	O
with	B-Reg
multiple	B-Disease
endocrine	I-Disease
neoplasia	I-Disease
type	I-Disease
1	I-Disease
.	O

OBJECTIVE	O
:	O
This	O
study	O
aimed	O
at	O
identifing	O
mutations	O
in	O
two	O
Chinese	O
genealogies	O
with	O
MEN1	B-Gene
.	O

SUBJECTS	O
AND	O
METHODS	O
:	O
Three	O
members	O
of	O
two	O
Chinese	O
families	O
with	O
MEN1	O
were	O
enrolled	O
in	O
this	O
study	O
,	O
and	O
all	O
of	O
the	O
coding	O
regions	O
and	O
adjacent	O
sequences	O
of	O
the	O
MEN1	O
gene	O
were	O
amplified	O
and	O
sequenced	O
.	O

RESULTS	O
:	O
A	O
recurrent	O
mutation	O
of	O
heterozygous	O
change	O
T	O
>	O
A	O
at	O
IVS	O
4	O
+	O
1	O
was	O
found	O
in	O
family	O
I	O
,	O
and	O
a	O
novel	O
insGAGGTGG	O
mutation	O
(	O
c.703	O
-	O
709dup7bp	O
)	O
resulted	O
in	O
a	O
frameshift	O
(	O
p	O
.	O
A237Gfsx13	O
)	O
in	O
family	O
II	O
.	O

CONCLUSION	O
:	O
We	O
are	O
able	O
to	O
add	O
a	O
new	O
mutation	O
of	O
MEN1	O
gene	O
in	O
Chinese	O
patients	O
with	O
MEN1	O
that	O
will	O
be	O
useful	O
for	O
the	O
diagnosis	O
and	O
treatment	O
of	O
the	O
disease	O
.	O

Two	O
novel	O
mutations	O
in	O
the	O
lactase	O
gene	O
in	O
a	O
Japanese	O
infant	O
with	O
congenital	O
lactase	O
deficiency	O
.	O

Intestinal	O
lactase	O
is	O
required	O
for	O
the	O
hydrolysis	O
of	O
lactose	O
that	O
is	O
the	O
most	O
essential	O
carbohydrate	O
in	O
milk	O
and	O
the	O
primary	O
diet	O
source	O
of	O
newborn	O
.	O

Congenital	B-Disease
lactase	I-Disease
deficiency	I-Disease
[	O
CLD	O
(	O
MIM	O
223000	O
)	O
]	O
is	O
a	O
severe	O
gastrointestinal	O
disorder	O
and	O
is	O
characterized	O
by	O
watery	O
diarrhea	O
due	O
to	O
an	O
extremely	O
low	O
or	O
the	O
lack	O
of	O
lactase	O
activity	O
in	O
the	O
intestinal	O
wall	O
from	O
birth	O
.	O

CLD	O
is	O
a	O
rare	O
disease	O
and	O
occurs	O
more	O
frequently	O
in	O
Finland	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
mutations	B-Var
in	O
the	O
coding	O
region	O
of	O
the	O
lactase	O
(	B-Gene
LCT	I-Gene
)	I-Gene
gene	O
underlie	B-Reg
CLD	B-Disease
in	O
patients	O
from	O
Finland	O
and	O
other	O
European	O
countries	O
.	O

Here	O
,	O
we	O
report	O
two	O
novel	O
mutations	O
in	O
the	O
LCT	O
gene	O
in	O
a	O
Japanese	O
female	O
infant	O
with	O
clinical	O
features	O
consistent	O
with	O
those	O
of	O
CLD	O
.	O

She	O
suffered	O
from	O
severe	O
watery	O
diarrhea	O
from	O
the	O
age	O
of	O
2	O
days	O
on	O
breast	O
milk	O
/	O
lactose	O
containing	O
cow	O
's	O
milk	O
formula	O
.	O

With	O
the	O
lactose	O
-	O
free	O
hydrolyzed	O
cow	O
's	O
milk	O
formula	O
,	O
diarrhea	O
was	O
stopped	O
,	O
and	O
she	O
has	O
now	O
developed	O
well	O
on	O
a	O
lactose	O
-	O
free	O
diet	O
.	O

She	O
shows	O
a	O
lactose	O
-	O
intolerance	O
pattern	O
on	O
the	O
lactose	O
challenge	O
test	O
.	O

Sequence	O
analysis	O
revealed	O
the	O
two	O
mutations	O
in	O
her	O
LCT	B-Gene
gene	O
:	O
c.4419C	B-Var
>	I-Var
G	I-Var
(	O
p	O
.	O
Y1473X	O
)	O
in	O
exon	O
10	O
transmitted	O
from	O
her	O
mother	O
and	O
c.5387delA	B-Var
(	O
p	O
.	O
D1796fs	O
)	O
in	O
exon	O
16	O
transmitted	O
from	O
her	O
father	O
.	O

Both	O
mutations	O
cause	B-Reg
premature	B-MPA
truncation	I-MPA
of	O
lactase	B-Protein
polypeptide	I-Protein
and	O
are	O
supposed	O
to	O
be	B-Reg
responsible	I-Reg
for	I-Reg
CLD	B-Disease
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
on	O
mutations	O
in	O
the	O
LCT	O
gene	O
in	O
Japan	O
.	O

We	O
suggest	O
that	O
an	O
increased	O
awareness	O
is	O
required	O
regarding	O
CLD	O
.	O

Analysis	O
of	O
gene	O
mutations	O
in	O
Chinese	O
patients	O
with	O
maple	O
syrup	O
urine	O
disease	O
.	O

OBJECTIVE	O
:	O
Maple	B-Disease
syrup	I-Disease
urine	I-Disease
disease	I-Disease
(	O
MSUD	O
)	O
is	O
predominantly	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
BCKDHA	B-Gene
,	O
BCKDHB	B-Gene
and	O
DBT	B-Gene
genes	O
,	O
which	O
encode	O
for	O
the	O
E1α	O
,	O
E1β	O
and	O
E2	O
subunits	O
of	O
the	O
branched	O
-	O
chain	O
α	O
-	O
keto	O
acid	O
dehydrogenase	O
complex	O
,	O
respectively	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
screen	O
DNA	O
samples	O
from	O
16	O
Chinese	O
MSUD	O
patients	O
and	O
assess	O
a	O
potential	O
correlation	O
between	O
genotype	O
and	O
phenotype	O
.	O

METHODS	O
:	O
BCKDHA	O
,	O
BCKDHB	O
and	O
DBT	O
genes	O
were	O
analyzed	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
direct	O
sequencing	O
.	O

Segments	O
bearing	O
novel	O
mutations	O
were	O
identified	O
by	O
PCR	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
PCR	O
-	O
RFLP	O
)	O
analysis	O
.	O

RESULTS	O
:	O
Within	O
the	O
variant	O
alleles	O
,	O
28	O
mutations	O
(	O
28/32	O
,	O
87.5	O
%	O
)	O
,	O
were	O
detected	O
in	O
15	O
patients	O
,	O
while	O
one	O
patient	O
displayed	O
no	O
mutations	O
.	O

Mutations	O
were	O
comprised	O
of	O
20	O
different	O
:	O
6	O
BCKDHA	O
gene	O
mutations	O
in	O
4	O
cases	O
,	O
10	O
BCKDHB	O
gene	O
mutations	O
in	O
8	O
cases	O
and	O
4	O
DBT	O
gene	O
mutations	O
in	O
3	O
cases	O
.	O

From	O
these	O
,	O
14	O
were	O
novel	O
,	O
which	O
included	O
3	O
mutations	O
in	O
the	O
BCKDHA	O
gene	O
,	O
7	O
in	O
the	O
BCKDHB	O
gene	O
and	O
4	O
in	O
the	O
DBT	O
gene	O
.	O

Only	O
two	O
patients	O
with	O
mutations	O
in	O
the	O
BCKDHB	O
and	O
DBT	O
genes	O
were	O
thiamine	O
-	O
responsive	O
and	O
presented	O
a	O
better	O
clinical	O
outcome	O
.	O

CONCLUSION	O
:	O
We	O
identified	O
20	O
different	O
mutations	O
within	O
the	O
BCKDHA	O
,	O
BCKDHB	O
and	O
DBT	O
genes	O
among	O
16	O
Chinese	O
MSUD	O
patients	O
,	O
including	O
14	O
novel	O
mutations	O
.	O

The	O
majority	O
were	O
non	O
-	O
responsive	O
to	O
thiamine	O
,	O
associating	O
with	O
a	O
worse	O
clinical	O
outcome	O
.	O

Our	O
data	O
provide	O
the	O
basis	O
for	O
further	O
genotype	O
-	O
phenotype	O
correlation	O
studies	O
in	O
these	O
patients	O
,	O
which	O
will	O
be	O
beneficial	O
for	O
early	O
diagnosis	O
and	O
in	O
directing	O
the	O
approach	O
to	O
clinical	O
intervention	O
.	O

Cell	O
models	O
for	O
McArdle	O
disease	O
and	O
aminoglycoside	O
-	O
induced	O
read	O
-	O
through	O
of	O
a	O
premature	O
termination	O
codon	O
.	O

McArdle	B-Disease
disease	I-Disease
results	B-Reg
from	I-Reg
mutations	O
in	O
the	O
gene	O
encoding	O
muscle	O
glycogen	O
phosphorylase	O
(	B-Gene
PYGM	I-Gene
)	I-Gene
protein	O
and	O
the	O
two	O
most	O
common	O
mutations	O
are	O
a	O
premature	O
termination	O
codon	O
(	B-Var
R50X	I-Var
)	I-Var
and	O
a	O
missense	O
mutation	O
(	B-Var
G205S	I-Var
)	I-Var
.	O

Myoblasts	O
from	O
patients	O
can	O
not	O
be	O
used	O
to	O
create	O
a	O
cell	O
model	O
of	O
McArdle	O
disease	O
because	O
even	O
normal	O
myoblasts	O
produce	O
little	O
or	O
no	O
PYGM	O
protein	O
in	O
cell	O
culture	O
.	O

We	O
therefore	O
created	O
cell	O
models	O
by	O
expressing	O
wild	O
-	O
type	O
or	O
mutant	O
(	O
R50X	O
or	O
G205S	O
)	O
PYGM	O
from	O
cDNA	O
integrated	O
into	O
the	O
genome	O
of	O
Chinese	O
hamster	O
ovary	O
cells	O
.	O

These	O
cell	O
lines	O
enable	O
the	O
study	O
of	O
McArdle	O
mutations	O
in	O
the	O
absence	O
of	O
nonsense	O
-	O
mediated	O
decay	O
of	O
mRNA	O
transcripts	O
.	O

Although	O
all	O
cell	O
lines	O
produced	O
stable	O
mRNA	O
,	O
only	O
wild	O
-	O
type	O
produced	O
detectable	O
PYGM	O
protein	O
.	O

Our	O
data	O
suggest	O
that	O
the	O
G205S	B-Var
mutation	O
affects	O
PYGM	B-Gene
by	O
causing	B-Reg
misfolding	B-MPA
and	O
accelerated	B-Reg
protein	B-Protein
turnover	B-MPA
.	O

Using	O
the	O
N	O
-	O
terminal	O
region	O
of	O
PYGM	O
containing	O
the	O
R50X	O
mutation	O
fused	O
to	O
green	O
fluorescent	O
protein	O
,	O
we	O
were	O
able	O
to	O
demonstrate	O
both	O
small	O
amounts	O
of	O
truncated	O
protein	O
production	O
and	O
read	O
-	O
through	O
of	O
the	O
R50X	O
premature	O
termination	O
codon	O
induced	O
by	O
the	O
aminoglycoside	O
,	O
G418	O
.	O

Origins	O
of	O
albino	O
and	O
hooded	O
rats	O
:	O
implications	O
from	O
molecular	O
genetic	O
analysis	O
across	O
modern	O
laboratory	O
rat	O
strains	O
.	O

Albino	O
and	O
hooded	O
(	O
or	O
piebald	O
)	O
rats	O
are	O
one	O
of	O
the	O
most	O
frequently	O
used	O
laboratory	O
animals	O
for	O
the	O
past	O
150	O
years	O
.	O

Despite	O
this	O
fact	O
,	O
the	O
origin	O
of	O
the	O
albino	O
mutation	O
as	O
well	O
as	O
the	O
genetic	O
basis	O
of	O
the	O
hooded	O
phenotype	O
remained	O
unclear	O
.	O

Recently	O
,	O
the	O
albino	B-CPA
mutation	O
has	O
been	O
identified	O
as	B-Reg
the	O
Arg299His	B-Var
missense	I-Var
mutation	I-Var
in	O
the	O
Tyrosinase	B-Gene
gene	I-Gene
and	O
the	O
hooded	O
(	O
H	O
)	O
locus	O
has	O
been	O
mapped	O
to	O
the	O
∼460-kb	O
region	O
in	O
which	O
only	O
the	O
Kit	O
gene	O
exists	O
.	O

Here	O
,	O
we	O
surveyed	O
172	O
laboratory	O
rat	O
strains	O
for	O
the	O
albino	O
mutation	O
and	O
the	O
hooded	O
(	O
h	O
)	O
mutation	O
that	O
we	O
identified	O
by	O
positional	O
cloning	O
approach	O
to	O
investigate	O
possible	O
genetic	O
roots	O
and	O
relationships	O
of	O
albino	O
and	O
hooded	O
rats	O
.	O

All	O
of	O
117	O
existing	O
laboratory	O
albino	O
rats	O
shared	O
the	O
same	O
albino	O
missense	O
mutation	O
,	O
indicating	O
they	O
had	O
only	O
one	O
single	O
ancestor	O
.	O

Genetic	O
fine	O
mapping	O
followed	O
by	O
de	O
novo	O
sequencing	O
of	O
BAC	O
inserts	O
covering	O
the	O
H	O
locus	O
revealed	O
that	O
an	O
endogenous	O
retrovirus	O
(	O
ERV	O
)	O
element	O
was	O
inserted	O
into	O
the	O
first	O
intron	O
of	O
the	O
Kit	O
gene	O
where	O
the	O
hooded	O
allele	O
maps	O
.	O

A	O
solitary	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
was	O
found	O
at	O
the	O
same	O
position	O
to	O
the	O
ERV	O
insertion	O
in	O
another	O
allele	O
of	O
the	O
H	O
locus	O
,	O
which	O
causes	O
the	O
so	O
called	O
Irish	O
(	O
h(i	O
)	O
)	O
phenotype	O
.	O

The	O
ERV	O
and	O
the	O
solitary	O
LTR	O
insertions	O
were	O
completely	O
associated	O
with	O
the	O
hooded	O
and	O
Irish	O
coat	O
patterns	O
,	O
respectively	O
,	O
across	O
all	O
colored	O
rat	O
strains	O
examined	O
.	O

Interestingly	O
,	O
all	O
117	O
albino	O
rat	O
strains	O
shared	O
the	O
ERV	O
insertion	O
without	O
any	O
exception	O
,	O
which	O
strongly	O
suggests	O
that	O
the	O
albino	O
mutation	O
had	O
originally	O
occurred	O
in	O
hooded	O
rats	O
.	O

Identification	O
of	O
a	O
novel	O
arylsulfatase	B-Gene
B	I-Gene
gene	I-Gene
mutation	B-Var
in	B-Reg
three	O
unrelated	O
Iranian	O
mucopolysaccharidosis	B-Disease
type	I-Disease
-	I-Disease
VI	I-Disease
patients	O
with	O
different	O
phenotype	O
severity	O
.	O

BACKGROUND	O
:	O
Mucopolysaccharidosis	B-Disease
type	I-Disease
-	I-Disease
VI	I-Disease
(	O
MPS	O
-	O
VI	O
)	O
,	O
which	O
is	O
inherited	O
as	O
an	O
autosomal	O
recessive	O
trait	O
,	O
results	B-Reg
from	I-Reg
the	O
deficiency	B-NegReg
of	O
N	B-Enzyme
-	I-Enzyme
acetylgalactosamine	I-Enzyme
4-sulfatase	I-Enzyme
(	O
arylsulfatase	O
B	O
)	O
activity	B-MPA
and	O
the	O
lysosomal	B-MPA
accumulation	B-PosReg
of	O
dermatan	O
sulfate	O
.	O

In	O
this	O
study	O
,	O
ARSB	O
mutation	O
analysis	O
was	O
performed	O
on	O
three	O
unrelated	O
patients	O
who	O
were	O
originally	O
from	O
the	O
West	O
Azerbaijan	O
province	O
of	O
Iran	O
.	O

METHODS	O
:	O
After	O
PCR	O
and	O
direct	O
DNA	O
sequencing	O
,	O
DNA	O
extraction	O
was	O
performed	O
.	O

RESULTS	O
:	O
Sequencing	O
analysis	O
revealed	O
a	O
novel	O
homozygous	O
missense	O
mutation	O
in	O
the	O
ARSB	O
gene	O
at	O
c.1457A	O
<	O
G	O
[	O
p.	O
D486V	O
]	O
in	O
three	O
unrelated	O
Iranian	O
MPS	O
-	O
VI	O
patients	O
with	O
different	O
phenotype	O
severity	O
.	O

CONCLUSION	O
:	O
The	O
mutation	O
type	O
in	O
three	O
patients	O
was	O
the	O
same	O
;	O
probably	O
,	O
because	O
of	O
a	O
foundation	O
effect	O
on	O
their	O
population	O
.	O

C.428_451	O
dup(24bp	O
)	O
mutation	O
of	O
the	O
ARX	O
gene	O
detected	O
in	O
a	O
Turkish	O
family	O
.	O

ARX	B-Gene
mutations	B-Var
give	B-Reg
rise	I-Reg
to	I-Reg
both	O
syndromic	O
and	O
nonsyndromic	O
forms	O
of	O
mental	B-Disease
retardation	I-Disease
(	O
MR	O
)	O
.	O

We	O
investigated	O
the	O
most	O
common	O
ARX	O
mutations	O
,	O
c.428_451	O
dup(24bp	O
)	O
and	O
c.333ins	O
(	O
GCG)7	O
in	O
a	O
series	O
of	O
370	O
mentally	O
retarded	O
FMR1	O
(	O
CGG)n	O
expansion	O
mutation	O
negative	O
Turkish	O
patients	O
using	O
PCR	O
amplification	O
and	O
high	O
resolution	O
MetaPhor	O
agarose	O
gel	O
electrophoresis	O
.	O

Sequence	O
analysis	O
was	O
also	O
performed	O
for	O
confirmation	O
and	O
discrimination	O
of	O
the	O
mutations	O
.	O

One	O
patient	O
representing	O
non	O
-	O
syndromic	O
X	O
-	O
linked	O
MR	B-Disease
showed	B-Reg
an	O
abnormal	O
band	O
pattern	O
on	O
agarose	O
gel	O
and	O
sequence	O
analysis	O
of	O
exon	O
2	O
of	O
the	O
ARX	B-Gene
gene	O
revealed	O
that	O
the	O
patient	O
had	O
the	O
c.428_451	B-Var
dup(24bp	I-Var
)	I-Var
mutation	O
.	O

When	O
we	O
screened	O
the	O
family	O
members	O
,	O
we	O
found	O
that	O
his	O
sister	O
and	O
mother	O
were	O
also	O
carrier	O
for	O
the	O
same	O
mutation	O
.	O

The	O
proband	O
showed	O
mild	O
MR	O
and	O
subtle	O
clinical	O
findings	O
like	O
dysarthria	O
and	O
lack	O
of	O
fine	O
motor	O
functions	O
.	O

In	O
conclusion	O
,	O
the	O
patients	O
with	O
weak	O
fine	O
motor	O
skills	O
and	O
positive	O
family	O
history	O
for	O
X	O
-	O
linked	O
MR	O
should	O
be	O
screened	O
for	O
the	O
most	O
common	O
ARX	O
gene	O
mutations	O
.	O

Analysis	O
of	O
a	O
Chinese	O
pedigree	O
with	O
Zellweger	B-Disease
syndrome	I-Disease
reveals	B-Reg
a	O
novel	O
PEX1	B-Gene
mutation	B-Var
by	O
next	O
-	O
generation	O
sequencing	O
.	O

BACKGROUND	O
:	O
Autosomal	O
recessive	O
Zellweger	B-Disease
spectrum	I-Disease
disorder	I-Disease
(	O
ZSD	O
)	O
,	O
the	O
main	O
subgroup	O
of	O
the	O
peroxisome	O
biogenesis	O
disorders	O
(	O
PBDs	O
)	O
,	O
can	O
be	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
any	O
of	O
the	O
13	O
PEX	B-Gene
genes	O
.	O

Zellweger	O
syndrome	O
(	O
ZS	O
)	O
is	O
the	O
most	O
common	O
and	O
severe	O
phenotype	O
in	O
the	O
heterogeneous	O
ZSD	O
.	O

For	O
the	O
large	O
number	O
genes	O
involved	O
,	O
it	O
is	O
difficult	O
to	O
make	O
a	O
precise	O
genetic	O
diagnosis	O
by	O
traditional	O
methods	O
at	O
a	O
time	O
.	O

A	O
combination	O
of	O
enrichment	O
of	O
targeted	O
genes	O
and	O
next	O
-	O
generation	O
sequencing	O
(	O
NGS	O
)	O
would	O
result	O
in	O
both	O
high	O
efficiency	O
and	O
low	O
cost	O
for	O
targeted	O
sequencing	O
of	O
genes	O
of	O
interest	O
.	O

METHODS	O
:	O
To	O
identify	O
potential	O
mutations	O
in	O
a	O
Chinese	O
family	O
associated	O
with	O
Zellweger	O
syndrome	O
,	O
1930	O
kb	O
of	O
all	O
the	O
targeted	O
region	O
of	O
PEX	O
genes	O
were	O
captured	O
and	O
sequenced	O
using	O
NGS	O
.	O

We	O
also	O
performed	O
Sanger	O
sequencing	O
to	O
validate	O
the	O
NGS	O
results	O
.	O

RESULTS	O
:	O
Here	O
,	O
we	O
reported	O
a	O
Chinese	O
patient	O
diagnosed	O
as	O
a	O
severe	O
classic	O
type	O
of	O
PBD	O
based	O
on	O
a	O
clinical	O
investigation	O
.	O

We	O
then	O
performed	O
microarray	O
-	O
based	O
NGS	O
to	O
detect	O
the	O
variants	O
in	O
PEX	O
genes	O
of	O
the	O
whole	O
family	O
.	O

One	O
reported	O
heterozygosis	O
mutation	O
(	O
c.782_783delAA	O
)	O
was	O
identified	O
in	O
the	O
patient	O
's	O
father	O
and	O
one	O
novel	O
heterozygosis	O
missense	O
mutation	O
(	O
c.475G	O
>	O
C	O
)	O
was	O
found	O
in	O
the	O
patient	O
's	O
mother	O
,	O
the	O
patient	O
inherited	O
both	O
mutations	O
.	O

CONCLUSIONS	O
:	O
The	O
results	O
proved	O
that	O
the	O
application	O
of	O
target	O
sequence	O
capture	O
using	O
chip	O
and	O
high	O
-	O
throughput	O
NGS	O
is	O
a	O
valuable	O
tool	O
for	O
the	O
molecular	O
diagnosis	O
of	O
peroxisome	O
biogenesis	O
disorders	O
.	O

The	O
accuracy	O
,	O
high	O
-	O
throughput	O
and	O
speed	O
of	O
the	O
method	O
make	O
it	O
suitable	O
for	O
clinical	O
application	O
.	O

Aspartylglucosaminuria	B-Disease
:	I-Disease
unusual	O
neonatal	O
presentation	O
in	O
Qatari	O
twins	O
with	B-Reg
a	O
novel	O
aspartylglucosaminidase	B-Gene
gene	I-Gene
mutation	B-Var
and	O
3	O
new	O
cases	O
in	O
a	O
Turkish	O
family	O
.	O

Aspartylglucosaminuria	O
is	O
a	O
rare	O
autosomal	O
recessive	O
lysosomal	O
storage	O
disorder	O
leading	O
early	O
to	O
a	O
progressive	O
intellectual	O
disability	O
.	O

Monozygous	O
Qatari	O
twins	O
presented	O
with	O
an	O
unusual	O
perinatal	O
manifestation	O
characterized	O
by	O
severe	O
muscular	O
hypotonia	O
,	O
scarce	O
spontaneous	O
movements	O
,	O
multiple	O
contractures	O
,	O
and	O
respiratory	O
insufficiency	O
.	O

Biochemical	O
investigations	O
suggested	B-Reg
aspartylglucosaminuria	B-Disease
,	O
and	O
a	O
novel	O
homozygous	O
mutation	O
c.439T	B-Var
>	I-Var
C	I-Var
(	O
p	O
.	O
S147P	O
)	O
was	O
found	O
in	O
the	O
aspartylglucosaminidase	B-Gene
gene	I-Gene
.	O

However	O
,	O
it	O
can	O
not	O
be	O
excluded	O
that	O
the	O
unusual	O
neonatal	O
presentation	O
is	O
due	O
to	O
an	O
additional	O
autosomal	O
recessive	O
disease	O
in	O
this	O
multiply	O
consanguineous	O
family	O
.	O

The	O
classical	O
aspartylglucosaminuria	O
phenotype	O
(	O
progressive	O
speech	O
delay	O
,	O
psychomotor	O
retardation	O
,	O
and	O
behavioral	O
abnormalities	O
)	O
was	O
observed	O
in	O
3	O
Turkish	O
siblings	O
.	O

Although	O
aspartylglucosaminuria	O
was	O
suspected	O
early	O
,	O
the	O
definite	O
diagnosis	O
was	O
not	O
confirmed	O
until	O
the	O
age	O
of	O
18	O
years	O
.	O

A	O
novel	O
homozygous	O
mutation	O
c.346C	O
>	O
T	O
(	O
p	O
.	O
R116W	O
)	O
was	O
found	O
.	O

These	O
5	O
cases	O
emphasize	O
that	O
aspartylglucosaminuria	O
is	O
panethnic	O
and	O
may	O
possibly	O
present	O
with	O
prenatal	O
manifestation	O
.	O

Screening	O
for	O
aspartylglucosaminuria	O
should	O
be	O
done	O
in	O
all	O
patients	O
with	O
unexplained	O
psychomotor	O
retardation	O
.	O

Mutations	O
of	O
the	O
thyroid	O
peroxidase	O
gene	O
in	O
Chinese	O
siblings	O
with	O
congenital	O
goitrous	O
hypothyroidism	O
.	O

OBJECTIVES	O
:	O
To	O
investigate	O
thyroid	O
peroxidase	O
gene	O
(	B-Gene
TPO	I-Gene
)	I-Gene
mutations	B-Var
in	B-Reg
a	O
Chinese	O
siblings	O
with	O
congenital	B-Disease
goitrous	I-Disease
hypothyroidism	I-Disease
(	O
CGH	O
)	O
.	O

SUBJECTS	O
AND	O
METHODS	O
:	O
The	O
proband	O
,	O
his	O
sister	O
,	O
and	O
their	O
parents	O
were	O
enrolled	O
.	O

All	O
subjects	O
underwent	O
clinical	O
examination	O
and	O
laboratory	O
tests	O
.	O

Mutation	O
screening	O
of	O
the	O
TPO	O
gene	O
was	O
performed	O
by	O
sequencing	O
fragments	O
amplified	O
from	O
extracted	O
genomic	O
DNA	O
.	O

RESULTS	O
:	O
The	O
siblings	O
were	O
diagnosed	O
as	O
CGH	O
with	O
neurodevelopmental	O
deficits	O
.	O

Two	O
compound	O
heterozygous	O
inactivating	O
mutations	O
were	O
found	O
in	O
the	O
two	O
patients	O
:	O
a	O
frameshift	O
mutation	O
between	O
positions	O
2268	O
and	O
2269	O
(	O
c.2268	O
-	O
2269	O
insT	O
)	O
and	O
a	O
missense	O
mutation	O
at	O
c.2089	O
G	O
>	O
A	O
(	O
p	O
.	O
G667S	O
)	O
of	O
the	O
TPO	O
gene	O
.	O

Their	O
parents	O
,	O
with	O
normal	O
thyroid	O
hormone	O
levels	O
,	O
were	O
heterozygous	O
for	O
mutations	O
c.2268	O
-	O
2269	O
insT	O
and	O
c.2089	O
G	O
>	O
A	O
,	O
respectively	O
.	O

The	O
polymorphisms	O
of	O
c.1207	O
G	O
>	O
T	O
,	O
c.1283	O
G	O
>	O
C	O
,	O
and	O
c.2088	O
C	O
>	O
T	O
were	O
detected	O
in	O
the	O
family	O
.	O

CONCLUSIONS	O
:	O
CGH	B-Disease
of	O
the	O
Chinese	O
siblings	O
was	O
due	B-Reg
to	I-Reg
the	O
TPO	B-Gene
gene	O
mutations	O
(	B-Var
c.2268	I-Var
-	I-Var
2269	I-Var
insT	I-Var
and	O
c.2089	B-Var
G	I-Var
>	I-Var
A	I-Var
)	I-Var
.	O

Nebulin	O
(	O
NEB	O
)	O
mutations	O
in	O
a	O
childhood	O
onset	O
distal	O
myopathy	O
with	O
rods	O
and	O
cores	O
uncovered	O
by	O
next	O
generation	O
sequencing	O
.	O

Recessive	O
nebulin	O
(	B-Gene
NEB	I-Gene
)	I-Gene
mutations	B-Var
are	O
a	O
common	O
cause	B-Reg
of	O
nemaline	B-Disease
myopathy	I-Disease
(	O
NM	O
)	O
,	O
typically	O
characterized	O
by	O
generalized	O
weakness	O
of	O
early	O
-	O
onset	O
and	O
nemaline	O
rods	O
on	O
muscle	O
biopsy	O
.	O

Exceptional	O
adult	O
cases	O
with	O
additional	O
cores	O
and	O
an	O
isolated	O
distal	O
weakness	O
have	O
been	O
reported	O
.	O

The	O
large	O
NEB	O
gene	O
with	O
183	O
exons	O
has	O
been	O
an	O
obstacle	O
for	O
the	O
genetic	O
work	O
-	O
up	O
.	O

Here	O
we	O
report	O
a	O
childhood	O
-	O
onset	O
case	O
with	O
distal	O
weakness	O
and	O
a	O
core	O
-	O
rod	O
myopathy	O
,	O
associated	O
with	O
recessive	O
NEB	O
mutations	O
identified	O
by	O
next	O
generation	O
sequencing	O
(	O
NGS	O
)	O
.	O

This	O
6-year	O
-	O
old	O
boy	O
presented	O
with	O
a	O
history	O
of	O
gross	O
-	O
motor	O
difficulties	O
following	O
a	O
normal	O
early	O
development	O
.	O

He	O
had	O
distal	O
leg	O
weakness	O
with	O
bilateral	O
foot	O
drop	O
,	O
as	O
well	O
as	O
axial	O
muscle	O
weakness	O
,	O
scoliosis	O
and	O
spinal	O
rigidity	O
;	O
additionally	O
he	O
required	O
nocturnal	O
respiratory	O
support	O
.	O

Muscle	O
magnetic	O
resonance	O
(	O
MR	O
)	O
imaging	O
showed	O
distal	O
involvement	O
in	O
the	O
medial	O
and	O
anterior	O
compartment	O
of	O
the	O
lower	O
leg	O
.	O

A	O
muscle	O
biopsy	O
featured	O
both	O
rods	O
and	O
cores	O
.	O

Initial	O
targeted	O
testing	O
identified	O
a	O
heterozygous	O
Nebulin	O
exon	O
55	O
deletion	O
.	O

Further	O
analysis	O
using	O
NGS	O
revealed	O
a	O
frameshifting	O
4	O
bp	O
duplication	O
,	O
c.24372_24375dup	O
(	O
P.Val8126fs	O
)	O
,	O
on	O
the	O
opposite	O
allele	O
.	O

This	O
case	O
illustrates	O
that	O
NEB	B-Gene
mutations	B-Var
can	O
cause	B-Reg
childhood	O
onset	O
distal	O
NM	B-Disease
,	O
with	O
additional	O
cores	O
on	O
muscle	O
biopsy	O
and	O
proves	O
the	O
diagnostic	O
utility	O
of	O
NGS	O
for	O
myopathies	O
,	O
particularly	O
when	O
large	O
genes	O
are	O
implicated	O
.	O

EDM1	O
:	O
a	O
novel	O
point	B-Var
mutation	I-Var
in	O
cartilage	O
oligomeric	O
matrix	O
protein	O
gene	O
in	O
a	O
Chinese	O
family	O
with	B-Reg
multiple	B-Disease
epiphyseal	I-Disease
dysplasia	I-Disease
.	O

BACKGROUND	O
:	O
Multiple	B-Disease
epiphysis	I-Disease
dysplasia	I-Disease
(	O
MED	O
)	O
is	O
a	O
common	O
skeletal	O
dysplasia	O
with	O
a	O
significant	O
locus	O
heterogeneity	O
.	O

In	B-Reg
the	O
majority	O
of	O
clinically	O
defined	O
cases	O
,	O
mutations	B-Var
have	O
been	O
identified	O
in	O
the	O
gene	O
encoding	O
cartilage	O
algometric	O
matrix	O
protein	O
(	B-Gene
COMP	I-Gene
)	I-Gene
.	O

METHODS	O
:	O
Five	O
patients	O
were	O
included	O
in	O
the	O
study	O
.	O

Linkage	O
analysis	O
and	O
mutation	O
analysis	O
of	O
the	O
COMP	O
gene	O
were	O
conducted	O
in	O
the	O
patients	O
and	O
their	O
family	O
members	O
.	O

RESULTS	O
:	O
We	O
have	O
identified	O
a	O
novel	O
mutation	O
in	O
axon	O
14	O
of	O
COMP	O
gene	O
in	O
the	O
family	O
.	O

CONCLUSIONS	O
:	O
This	O
mutation	O
produced	O
a	O
severe	O
MED	O
phenotype	O
with	O
marked	O
short	O
stature	O
,	O
early	O
onset	O
osteoarthritis	O
,	O
and	O
remarkable	O
radiographic	O
changes	O
.	O

Our	O
results	O
extended	O
the	O
range	O
of	O
disease	O
-	O
causing	O
mutations	O
in	O
COMP	O
gene	O
and	O
contributed	O
more	O
information	O
about	O
relationship	O
between	O
mutations	O
and	O
phenotype	O
.	O

A	O
patient	O
with	O
limb	B-Disease
girdle	I-Disease
muscular	I-Disease
dystrophy	I-Disease
carries	B-Reg
a	O
TRIM32	B-Gene
deletion	B-Var
,	O
detected	O
by	O
a	O
novel	O
CGH	O
array	O
,	O
in	O
compound	O
heterozygosis	O
with	O
a	O
nonsense	O
mutation	O
.	O

Limb	B-Disease
girdle	I-Disease
muscular	I-Disease
dystrophy	I-Disease
2H	I-Disease
is	O
a	O
rare	O
autosomal	O
recessive	O
muscular	O
dystrophy	O
,	O
clinically	O
highly	O
variable	O
,	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
TRIM32	B-Gene
gene	O
.	O

Here	O
we	O
describe	O
a	O
35-years	O
-	O
old	O
who	O
experienced	O
progressive	O
muscle	O
weakness	O
.	O

The	O
muscle	O
biopsy	O
revealed	O
an	O
unspecific	O
pattern	O
of	O
atrophic	O
and	O
hypertrophic	O
fibers	O
;	O
the	O
immunohistochemistry	O
for	O
several	O
proteins	O
was	O
normal	O
.	O

Comparative	O
genomic	O
hybridization	O
(	O
CGH	O
)	O
analysis	O
showed	O
a	O
heterozygous	O
deletion	O
of	O
the	O
entire	O
TRIM32	O
gene	O
.	O

On	O
the	O
other	O
allele	O
we	O
identified	O
the	O
R316X	O
nonsense	O
mutation	O
.	O

The	O
genetic	O
diagnosis	O
of	O
LGMD2H	O
in	O
this	O
case	O
was	O
reached	O
by	O
using	O
a	O
novel	O
high	O
throughput	O
diagnostic	O
tool	O
.	O

Epigenetic	O
and	O
genetic	O
alterations	O
of	O
the	O
imprinting	O
disorder	O
Beckwith	O
-	O
Wiedemann	O
syndrome	O
and	O
related	O
disorders	O
.	O

Genomic	O
imprinting	O
is	O
an	O
epigenetic	O
phenomenon	O
that	O
leads	O
to	O
parent	O
-	O
specific	O
differential	O
expression	O
of	O
a	O
subset	O
of	O
genes	O
.	O

Most	O
imprinted	O
genes	O
form	O
clusters	O
,	O
or	O
imprinting	O
domains	O
,	O
and	O
are	O
regulated	O
by	O
imprinting	O
control	O
regions	O
.	O

As	O
imprinted	O
genes	O
have	O
an	O
important	O
role	O
in	O
growth	O
and	O
development	O
,	O
aberrant	O
expression	O
of	O
imprinted	O
genes	O
due	O
to	O
genetic	O
or	O
epigenetic	O
abnormalities	O
is	O
involved	O
in	O
the	O
pathogenesis	O
of	O
human	O
disorders	O
,	O
or	O
imprinting	O
disorders	O
.	O

Beckwith	B-Disease
-	I-Disease
Wiedemann	I-Disease
syndrome	I-Disease
(	O
BWS	O
)	O
is	O
a	O
representative	O
imprinting	O
disorder	O
characterized	O
by	O
macrosomia	O
,	O
macroglossia	O
and	O
abdominal	O
wall	O
defects	O
,	O
and	O
exhibits	O
a	O
predisposition	O
to	O
tumorigenesis	O
.	O

The	O
relevant	O
imprinted	O
chromosomal	O
region	O
in	O
BWS	O
is	O
11p15.5	O
,	O
which	O
consists	O
of	O
two	O
imprinting	O
domains	O
,	O
IGF2	O
/	O
H19	O
and	O
CDKN1C	O
/	O
KCNQ1OT1	O
.	O

BWS	O
has	O
five	O
known	O
causative	O
epigenetic	O
and	O
genetic	O
alterations	O
:	O
loss	O
of	O
methylation	O
(	O
LOM	O
)	O
at	O
KvDMR1	O
,	O
gain	O
of	O
methylation	O
(	O
GOM	O
)	O
at	O
H19DMR	O
,	O
paternal	O
uniparental	O
disomy	O
,	O
CDKN1C	O
mutations	O
and	O
chromosomal	O
rearrangements	O
.	O

Opposite	O
methylation	O
defects	O
,	O
GOM	O
and	O
LOM	O
,	O
at	O
H19DMR	O
are	O
known	O
to	O
cause	O
clinically	O
opposite	O
disorders	O
:	O
BWS	O
and	O
Silver	O
-	O
Russell	O
syndrome	O
,	O
respectively	O
.	O

Interestingly	O
,	O
a	O
recent	O
study	O
discovered	O
that	O
loss	B-NegReg
of	I-NegReg
function	I-NegReg
or	O
gain	B-PosReg
of	I-PosReg
function	I-PosReg
of	O
CDKN1C	B-Gene
also	O
causes	O
clinically	O
opposite	O
disorders	O
,	O
BWS	B-Disease
and	O
IMAGe	B-Disease
(	I-Disease
intrauterine	I-Disease
growth	I-Disease
restriction	I-Disease
,	O
metaphyseal	I-Disease
dysplasia	I-Disease
,	O
adrenal	I-Disease
hypoplasia	I-Disease
congenita	I-Disease
,	O
and	I-Disease
genital	I-Disease
anomalies	I-Disease
)	I-Disease
syndrome	I-Disease
,	O
respectively	O
.	O

Furthermore	O
,	O
several	O
clinical	O
studies	O
have	O
suggested	O
a	O
relationship	O
between	O
assisted	O
reproductive	O
technology	O
(	O
ART	O
)	O
and	O
the	O
risk	O
of	O
imprinting	O
disorders	O
,	O
along	O
with	O
the	O
existence	O
of	O
trans	O
-	O
acting	O
factors	O
that	O
regulate	O
multiple	O
imprinted	O
differentially	O
methylated	O
regions	O
.	O

In	O
this	O
review	O
,	O
we	O
describe	O
the	O
latest	O
knowledge	O
surrounding	O
the	O
imprinting	O
mechanism	O
of	O
11p15.5	O
,	O
in	O
addition	O
to	O
epigenetic	O
and	O
genetic	O
etiologies	O
of	O
BWS	O
,	O
associated	O
childhood	O
tumors	O
,	O
the	O
effects	O
of	O
ART	O
and	O
multilocus	O
hypomethylation	O
disorders	O
.	O

Characterization	O
of	O
seizure	O
-	O
like	O
events	O
recorded	O
in	O
vivo	O
in	O
a	O
mouse	O
model	O
of	O
Rett	O
syndrome	O
.	O

Rett	B-Disease
syndrome	I-Disease
is	O
a	O
neurodevelopmental	O
disorder	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
X	O
-	O
linked	O
gene	O
encoding	O
methyl	O
-	O
CpG	O
-	O
binding	O
protein	O
2	O
(	B-Gene
MECP2	I-Gene
)	I-Gene
.	O

Spontaneous	O
recurrent	O
discharge	O
episodes	O
are	O
displayed	O
in	O
Rett	O
-	O
related	O
seizures	O
as	O
in	O
other	O
types	O
of	O
epilepsies	O
.	O

The	O
aim	O
of	O
this	O
paper	O
is	O
to	O
investigate	O
the	O
seizure	O
-	O
like	O
event	O
(	O
SLE	O
)	O
and	O
inter	O
-	O
SLE	O
states	O
in	O
a	O
female	O
MeCP2-deficient	O
mouse	O
model	O
of	O
Rett	O
syndrome	O
and	O
compare	O
them	O
to	O
those	O
found	O
in	O
other	O
spontaneous	O
recurrent	O
epilepsy	O
models	O
.	O

The	O
study	O
was	O
performed	O
on	O
a	O
small	O
population	O
of	O
female	O
MeCP2-deficient	O
mice	O
using	O
telemetric	O
local	O
field	O
potential	O
(	O
LFP	O
)	O
recordings	O
over	O
a	O
24	O
h	O
period	O
.	O

Durations	O
of	O
SLEs	O
and	O
inter	O
-	O
SLEs	O
were	O
extracted	O
using	O
a	O
rule	O
-	O
based	O
automated	O
SLE	O
detection	O
system	O
for	O
both	O
daytime	O
and	O
nighttime	O
,	O
as	O
well	O
as	O
high	O
and	O
low	O
power	O
levels	O
of	O
the	O
delta	O
frequency	O
range	O
(	O
0.5	O
-	O
4	O
Hz	O
)	O
of	O
the	O
recorded	O
LFPs	O
.	O

The	O
results	O
suggest	O
SLE	O
occurrences	O
are	O
not	O
influenced	O
by	O
circadian	O
rhythms	O
,	O
but	O
had	O
a	O
significantly	O
greater	O
association	O
with	O
delta	O
power	O
.	O

Investigating	O
inter	O
-	O
SLE	O
and	O
SLE	O
states	O
by	O
fitting	O
duration	O
histograms	O
to	O
the	O
gamma	O
distribution	O
showed	O
that	O
SLE	O
initiation	O
and	O
termination	O
were	O
associated	O
with	O
random	O
and	O
deterministic	O
mechanisms	O
,	O
respectively	O
.	O

These	O
findings	O
when	O
compared	O
to	O
reported	O
studies	O
on	O
epilepsy	O
suggest	O
that	O
Rett	O
-	O
related	O
seizures	O
share	O
many	O
similarities	O
with	O
absence	O
epilepsy	O
.	O

Familial	B-Disease
lipoprotein	I-Disease
lipase	I-Disease
deficiency	I-Disease
:	I-Disease
a	O
case	O
of	O
compound	O
heterozygosity	O
of	O
a	O
novel	O
duplication	O
(	O
R44Kfs*4	O
)	O
and	O
a	O
common	O
mutation	O
(	B-Var
N291S	I-Var
)	I-Var
in	B-Reg
the	O
lipoprotein	B-Gene
lipase	I-Gene
gene	I-Gene
.	O

Familial	B-Disease
lipoprotein	I-Disease
lipase	I-Disease
(	I-Disease
LPL	I-Disease
)	I-Disease
deficiency	I-Disease
(	O
FLLD	O
)	O
is	O
a	O
rare	O
autosomal	O
recessive	O
genetic	O
disorder	O
caused	B-Reg
by	I-Reg
homozygous	O
or	O
compound	O
heterozygous	O
mutations	B-Var
in	O
the	O
LPL	B-Gene
gene	O
.	O

FLLD	O
individuals	O
usually	O
express	O
an	O
impaired	O
or	O
non	O
-	O
functional	O
LPL	O
enzyme	O
with	O
low	O
or	O
absent	O
triglyceride	O
(	O
TG	O
)	O
hydrolysis	O
activity	O
causing	O
severe	O
hypertriglyceridaemia	O
.	O

Here	O
we	O
report	O
a	O
case	O
of	O
FLLD	O
in	O
a	O
29-year	O
-	O
old	O
man	O
,	O
who	O
initially	O
presented	O
with	O
eruptive	O
cutaneous	O
xanthomata	O
,	O
elevated	O
plasma	O
TG	O
concentration	O
but	O
no	O
other	O
co	O
-	O
morbidities	O
.	O

Subsequent	O
genetic	O
testing	O
of	O
the	O
patient	O
revealed	O
compound	O
heterozygosity	O
of	O
a	O
novel	O
duplication	O
(	B-Var
p	I-Var
.	I-Var
R44Kfs*4	I-Var
)	I-Var
leading	B-Reg
to	I-Reg
a	O
premature	B-MPA
stop	I-MPA
codon	O
in	O
exon	O
2	O
and	O
a	O
known	O
mutation	O
(	B-Var
N291S	I-Var
)	I-Var
in	O
exon	O
5	O
of	O
the	O
LPL	B-Gene
gene	O
.	O

Further	O
biochemical	O
analysis	O
of	O
the	O
patient	O
's	O
postheparin	O
plasma	O
confirmed	O
a	O
reduction	B-NegReg
of	O
total	O
lipase	B-Enzyme
activity	B-MPA
compared	O
with	O
his	O
heterozygous	O
father	O
carrying	O
the	O
common	O
N291S	B-Var
mutation	O
and	O
to	O
a	O
healthy	O
control	O
.	O

Also	O
the	O
patient	O
showed	O
increased	B-PosReg
(	O
1.85-fold	O
)	O
activity	B-MPA
of	O
hepatic	B-Enzyme
lipase	I-Enzyme
(	O
HL	O
)	O
,	O
indicating	O
a	O
functional	O
link	O
between	O
HL	O
and	O
LPL	O
.	O

In	O
summary	O
,	O
we	O
report	O
a	O
case	O
of	O
FLLD	B-Disease
caused	B-Reg
by	I-Reg
compound	O
heterozygosity	O
of	O
a	O
new	O
duplication	B-Var
and	O
a	O
common	O
mutation	B-Var
in	O
the	O
LPL	B-Gene
gene	O
,	O
resulting	O
in	O
residual	B-NegReg
LPL	B-Enzyme
activity	B-MPA
.	O

With	O
such	O
mutations	O
,	O
individuals	O
may	O
not	O
receive	O
a	O
diagnosis	O
before	O
classical	O
FLLD	O
symptoms	O
appear	O
later	O
in	O
adulthood	O
.	O

Nevertheless	O
,	O
early	O
diagnosis	O
and	O
lipid	O
-	O
lowering	O
treatment	O
may	O
favour	O
a	O
reduced	O
risk	O
of	O
premature	O
cardiovascular	O
disease	O
or	O
acute	O
pancreatitis	O
in	O
such	O
individuals	O
.	O

Microarray	O
analysis	O
of	O
unbalanced	O
translocation	O
in	O
Wolf	O
-	O
Hirschhorn	O
syndrome	O
.	O

Wolf	B-Disease
-	I-Disease
Hirschhorn	I-Disease
syndrome	I-Disease
(	O
WHS	O
)	O
is	O
caused	B-Reg
by	I-Reg
deletions	B-Var
involving	O
chromosome	O
region	O
4p16.3	B-Gene
,	O
which	O
is	O
characterized	O
by	O
growth	O
delay	O
,	O
mild	O
-	O
to	O
-	O
severe	O
mental	O
retardation	O
,	O
hypotonia	O
,	O
facial	O
dysmorphisms	O
and	O
shows	O
extensive	O
phenotypic	O
variability	O
include	O
feeding	O
difficulties	O
,	O
epilepsy	O
and	O
congenital	O
anomalies	O
.	O

Variation	O
in	O
the	O
size	O
of	O
the	O
deletion	O
involving	O
chromosome	O
region	O
4p16.3	O
may	O
explain	O
the	O
clinical	O
variation	O
.	O

However	O
,	O
previous	O
studies	O
indicate	O
that	O
duplication	O
for	O
another	O
chromosome	O
region	O
due	O
to	O
an	O
unbalanced	O
translocation	O
elucidate	O
approximately	O
40	O
-	O
45	O
%	O
WHS	O
patients	O
.	O

Therefore	O
,	O
we	O
used	O
whole	O
genomic	O
cytogenetics	O
array	O
to	O
analyze	O
the	O
entire	O
genome	O
at	O
a	O
significantly	O
higher	O
resolution	O
over	O
conventional	O
cytogenetics	O
to	O
characterize	O
the	O
exact	O
subtelomeric	O
aberration	O
region	O
of	O
one	O
patient	O
with	O
developmental	O
delay	O
and	O
several	O
facial	O
characteristics	O
reminiscent	O
Wolf	O
-	O
Hirschhorn	O
syndrome	O
.	O

Here	O
we	O
report	O
that	O
our	O
patient	O
had	O
3.7	O
Mb	O
deletion	O
at	O
the	O
4p16.2	O
and	O
6.8	O
Mb	O
duplication	O
at	O
8p23.1	O
resulted	O
from	O
the	O
unbalanced	O
translocations	O
der(4)t(4;8)(p16.2;p23.1	O
)	O
.	O

We	O
confirmed	O
that	O
our	O
patient	O
with	O
monosomy	O
4p16.2	O
which	O
is	O
consistent	O
with	O
Wolf	O
-	O
Hirschhorn	O
syndrome	O
and	O
trisomy	O
8p23.1	O
.	O

The	O
combination	O
of	O
the	O
4p	O
deletion	O
with	O
8p	O
partial	O
trisomy	O
explains	O
the	O
complex	O
phenotype	O
presented	O
by	O
our	O
patient	O
.	O

Novel	O
ALPL	O
genetic	O
alteration	O
associated	O
with	O
an	O
odontohypophosphatasia	O
phenotype	O
.	O

Hypophosphatasia	B-Disease
(	O
HPP	O
)	O
is	O
an	O
inherited	O
disorder	O
of	O
mineral	O
metabolism	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
ALPL	B-Gene
,	O
encoding	O
tissue	O
non	O
-	O
specific	O
alkaline	O
phosphatase	O
(	O
TNAP	O
)	O
.	O

Here	O
,	O
we	O
report	O
the	O
molecular	O
findings	O
from	O
monozygotic	O
twins	O
,	O
clinically	O
diagnosed	O
with	O
tooth	O
-	O
specific	O
odontohypophosphatasia	O
(	O
odonto	O
-	O
HPP	O
)	O
.	O

Sequencing	O
of	O
ALPL	O
identified	O
two	O
genetic	O
alterations	O
in	O
the	O
probands	O
,	O
including	O
a	O
heterozygous	O
missense	O
mutation	O
c.454C	B-Var
>	I-Var
T	I-Var
,	O
leading	B-Reg
to	I-Reg
change	O
of	O
arginine	O
152	O
to	O
cysteine	O
(	B-Var
p	I-Var
.	I-Var
R152C	I-Var
)	I-Var
,	O
and	O
a	O
novel	O
heterozygous	O
gene	O
deletion	O
c.1318_1320delAAC	B-Var
,	O
leading	B-Reg
to	I-Reg
the	O
loss	O
of	O
an	O
asparagine	O
residue	O
at	O
codon	O
440	O
(	B-Var
p	I-Var
.	I-Var
N440del	I-Var
)	I-Var
.	O

Clinical	O
identification	O
of	O
low	O
serum	O
TNAP	O
activity	O
,	O
dental	O
abnormalities	O
,	O
and	O
pedigree	O
data	O
strongly	O
suggests	O
a	O
genotype	O
-	O
phenotype	O
correlation	O
between	O
p	O
.	O
N440del	O
and	O
odonto	O
-	O
HPP	O
in	O
this	O
family	O
.	O

Computational	O
analysis	O
of	O
the	O
p	B-Var
.	I-Var
N440del	I-Var
protein	O
structure	O
revealed	O
an	O
alteration	B-Reg
in	O
the	O
tertiary	B-MPA
structure	I-MPA
affecting	B-Reg
the	O
collagen	B-Interaction
-	I-Interaction
binding	I-Interaction
site	I-Interaction
(	O
loop	O
422	O
-	O
452	O
)	O
,	O
which	O
could	O
potentially	O
impair	B-NegReg
the	O
mineralization	B-MPA
process	I-MPA
.	O

Nevertheless	O
,	O
the	O
probands	O
(	O
compound	O
heterozygous	O
:	O
p.[N440del];[R152C	O
]	O
)	O
feature	O
early	O
-	O
onset	O
and	O
severe	O
odonto	O
-	O
HPP	O
phenotype	O
,	O
whereas	O
the	O
father	O
(	O
p.[N440del];[=	O
]	O
)	O
has	O
only	O
moderate	O
symptoms	O
,	O
suggesting	O
p	O
.	O
R152C	O
may	O
contribute	O
or	O
predispose	O
to	O
a	O
more	O
severe	O
dental	O
phenotype	O
in	O
combination	O
with	O
the	O
deletion	O
.	O

These	O
results	O
assist	O
in	O
defining	O
the	O
genotype	O
-	O
phenotype	O
associations	O
for	O
odonto	O
-	O
HPP	O
,	O
and	O
further	O
identify	O
the	O
collagen	O
-	O
binding	O
site	O
as	O
a	O
region	O
of	O
potential	O
structural	O
importance	O
for	O
TNAP	O
function	O
in	O
the	O
biomineralization	O
.	O

Analysis	O
of	O
STK11	O
gene	O
variant	O
in	O
five	O
Chinese	O
patients	O
with	O
Peutz	O
-	O
Jeghers	O
syndrome	O
.	O

BACKGROUND	O
:	O
Peutz	B-Disease
-	I-Disease
Jeghers	I-Disease
syndrome	I-Disease
(	O
PJS	O
)	O
is	O
a	O
rare	O
autosomal	O
dominant	O
inherited	O
disorder	O
characterized	O
by	O
gastrointestinal	O
hamartomatous	O
polyps	O
and	O
mucocutaneous	O
pigmentation	O
.	O

Germline	O
mutation	B-Var
of	O
a	O
serine	O
/	O
threonine	O
kinase	O
11(STK11	B-Gene
)	I-Gene
gene	O
has	O
been	O
identified	O
as	O
a	O
cause	B-Reg
of	O
PJS	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
molecular	O
basis	O
of	O
five	O
Chinese	O
PJS	O
patients	O
.	O

METHODS	O
:	O
Blood	O
samples	O
were	O
collected	O
from	O
five	O
unrelated	O
Chinese	O
PJS	O
patients	O
and	O
their	O
parents	O
.	O

The	O
entire	O
coding	O
region	O
of	O
the	O
STK11	O
gene	O
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
and	O
analyzed	O
by	O
direct	O
sequencing	O
.	O

RESULTS	O
:	O
Three	O
different	O
frameshift	O
mutations	O
(	O
c.519insTGTG	O
,	O
c.792_793insT	O
,	O
and	O
c.334_335insC	O
)	O
,	O
all	O
of	O
which	O
would	O
cause	O
truncation	O
of	O
the	O
gene	O
product	O
,	O
were	O
found	O
in	O
three	O
patients	O
.	O

One	O
missense	O
mutation	O
(	O
p	O
.	O
Ser307Thr	O
)	O
and	O
one	O
3bp	O
deletion	O
mutation	O
(	O
c.228	O
-	O
230del	O
CGT	O
)	O
were	O
identified	O
in	O
the	O
remaining	O
two	O
patients	O
.	O

All	O
of	O
the	O
five	O
investigated	O
patients	O
carried	O
de	O
novo	O
mutations	O
.	O

CONCLUSIONS	O
:	O
The	O
results	O
support	O
that	O
mutation	B-Var
of	O
the	O
LKB1	B-Gene
gene	O
is	O
a	O
cause	B-Reg
of	O
PJS	B-Disease
,	O
and	O
expand	O
the	O
spectrum	O
of	O
the	O
STK11	O
gene	O
mutations	O
.	O

Recurrent	O
de	O
novo	O
c.316G	O
>	O
A	O
mutation	O
in	O
NIPA1	O
hotspot	O
.	O

Mutations	B-Var
in	O
the	O
NIPA1	B-Gene
cause	B-Reg
autosomal	O
dominant	O
form	O
of	O
hereditary	B-Disease
spastic	I-Disease
paraplegia	I-Disease
.	O

Allelic	O
heterogeneity	O
of	O
known	O
NIPA1	B-Gene
mutations	O
is	O
quite	O
limited	O
and	O
the	O
most	O
common	O
mutation	O
is	O
c.316G	B-Var
>	I-Var
A	I-Var
resulting	B-Reg
in	I-Reg
p	B-Protein
.	I-Protein
G106R	I-Protein
protein	O
change	B-MPA
.	O

Here	O
we	O
report	O
the	O
first	O
direct	O
evidence	O
of	O
de	O
novo	O
c.316G	O
>	O
A	O
mutation	O
in	O
the	O
same	O
hotspot	O
of	O
the	O
gene	O
in	O
two	O
unrelated	O
patients	O
who	O
had	O
otherwise	O
a	O
prototypical	O
NIPA1-associated	O
phenotype	O
with	O
a	O
severe	O
form	O
of	O
uncomplicated	O
spastic	O
paraplegia	O
.	O

De	O
novo	O
nature	O
of	O
these	O
mutations	O
was	O
confirmed	O
by	O
sequencing	O
both	O
sets	O
of	O
clinically	O
unaffected	O
parents	O
and	O
confirmation	O
of	O
paternity	O
.	O

We	O
also	O
discuss	O
likely	O
molecular	O
mechanisms	O
accounting	O
for	O
recurrent	O
mutations	O
in	O
this	O
segment	O
of	O
the	O
gene	O
.	O

Apparently	O
sporadic	O
patients	O
without	O
a	O
positive	O
family	O
history	O
of	O
hereditary	O
spastic	O
paraplegia	O
need	O
to	O
be	O
also	O
evaluated	O
for	O
possible	O
disease	O
-	O
causing	O
mutations	O
in	O
genes	O
that	O
are	O
inherited	O
in	O
an	O
autosomal	O
dominant	O
fashion	O
.	O

Late	O
adult	O
-	O
onset	O
of	O
X	O
-	O
linked	O
myopathy	O
with	O
excessive	O
autophagy	O
.	O

INTRODUCTION	O
:	O
X	B-Disease
-	I-Disease
linked	I-Disease
myopathy	I-Disease
with	I-Disease
excessive	I-Disease
autophagy	I-Disease
(	O
XMEA	O
)	O
is	O
characterized	O
by	O
autophagic	O
vacuoles	O
with	O
sarcolemmal	O
features	O
.	O

Mutations	B-Var
in	O
VMA21	B-Gene
result	O
in	O
insufficient	B-NegReg
lysosome	B-MPA
acidification	I-MPA
,	O
causing	B-Reg
progressive	B-CPA
proximal	I-CPA
weakness	I-CPA
with	O
onset	O
before	O
age	O
20	O
years	O
and	O
loss	O
of	O
ambulation	O
by	O
middle	O
age	O
.	O

METHODS	O
:	O
We	O
describe	O
a	O
patient	O
with	O
onset	O
of	O
slowly	O
progressive	O
proximal	O
weakness	O
of	O
the	O
lower	O
limbs	O
after	O
age	O
50	O
,	O
who	O
maintains	O
ambulation	O
with	O
the	O
assistance	O
of	O
a	O
cane	O
at	O
age	O
71	O
.	O

RESULTS	O
:	O
Muscle	O
biopsy	O
at	O
age	O
66	O
showed	O
complex	O
muscle	O
fiber	O
splitting	O
,	O
internalized	O
capillaries	O
,	O
and	O
vacuolar	O
changes	O
characteristic	O
of	O
autophagic	O
vacuolar	O
myopathy	O
.	O

Vacuoles	O
stained	O
positive	O
for	O
sarcolemmal	O
proteins	O
,	O
LAMP2	O
,	O
and	O
complement	O
C5b-9	O
.	O

Ultrastructural	O
evaluation	O
further	O
revealed	O
basal	O
lamina	O
reduplication	O
and	O
extensive	O
autophagosome	O
extrusion	O
.	O

Sanger	O
sequencing	O
identified	O
a	O
known	O
pathologic	O
splice	O
site	O
mutation	O
in	O
VMA21	O
(	O
c.164	O
-	O
7T	O
>	O
G	O
)	O
.	O

CONCLUSIONS	O
:	O
This	O
case	O
expands	O
the	O
clinical	O
phenotype	O
of	O
XMEA	O
and	O
suggests	O
VMA21	O
sequencing	O
be	O
considered	O
in	O
evaluating	O
men	O
with	O
LAMP2-positive	O
autophagic	O
vacuolar	O
myopathy	O
.	O

Novel	O
homozygous	O
PANK2	B-Gene
mutation	B-Var
causing	B-Reg
atypical	O
pantothenate	B-Disease
kinase	I-Disease
-	I-Disease
associated	I-Disease
neurodegeneration	I-Disease
(	O
PKAN	O
)	O
in	O
a	O
Cypriot	O
family	O
.	O

Pantothenate	B-Disease
kinase	I-Disease
-	I-Disease
associated	I-Disease
neurodegeneration	I-Disease
(	O
PKAN	O
)	O
is	O
the	O
commonest	O
,	O
recessively	O
inherited	O
form	O
of	O
neurodegeneration	O
with	O
brain	O
iron	O
accumulation	O
(	O
NBIA	O
)	O
resulting	B-Reg
from	I-Reg
mutations	B-Var
in	O
the	O
pantothenate	O
kinase	O
2	O
(	B-Gene
PANK2	I-Gene
)	I-Gene
gene	O
on	O
chromosome	O
20	O
.	O

PKAN	O
is	O
usually	O
rapidly	O
progressive	O
,	O
presenting	O
in	O
the	O
vast	O
majority	O
in	O
the	O
first	O
decade	O
of	O
life	O
(	O
classic	O
form	O
)	O
.	O

A	O
rarer	O
,	O
later	O
onset	O
and	O
slowly	O
progressive	O
(	O
atypical	O
)	O
PKAN	O
form	O
also	O
exists	O
.	O

We	O
present	O
two	O
siblings	O
of	O
Cypriot	O
descent	O
,	O
a	O
27-year	O
-	O
old	O
man	O
and	O
his	O
clinically	O
asymptomatic	O
younger	O
sister	O
,	O
both	O
of	O
whom	O
were	O
found	O
to	O
be	O
homozygous	O
for	O
a	O
novel	O
c.695A	O
>	O
G	O
(	O
p	O
.	O
Asp232Gly	O
)	O
missense	O
mutation	O
in	O
exon	O
2	O
of	O
the	O
PANK2	O
gene	O
.	O

The	O
index	O
patient	O
presented	O
with	O
a	O
5-year	O
history	O
of	O
slowly	O
progressive	O
gait	O
disturbance	O
,	O
dysarthria	O
,	O
mild	O
axial	O
rigidity	O
and	O
bradykinesia	O
.	O

His	O
brain	O
MRI	O
scan	O
revealed	O
the	O
characteristic	O
"	O
eye	O
-	O
of	O
-	O
the	O
-	O
tiger	O
"	O
sign	O
.	O

Atypical	O
genetically	O
confirmed	O
PKAN	O
cases	O
are	O
sparsely	O
reported	O
and	O
should	O
be	O
considered	O
in	O
the	O
differential	O
diagnosis	O
of	O
patients	O
presenting	O
with	O
a	O
progressive	O
extrapyramidal	O
syndrome	O
particularly	O
if	O
the	O
radiographic	O
findings	O
are	O
suggestive	O
of	O
iron	O
accumulation	O
.	O

Effective	O
treatment	O
strategies	O
for	O
PKAN	O
are	O
not	O
currently	O
available	O
and	O
symptomatic	O
therapy	O
is	O
often	O
unsatisfactory	O
.	O

However	O
,	O
early	O
diagnosis	O
including	O
the	O
presymptomatic	O
stage	O
is	O
important	O
for	O
genetic	O
counseling	O
and	O
will	O
be	O
crucial	O
for	O
testing	O
novel	O
therapeutics	O
in	O
the	O
future	O
.	O

A	O
novel	O
SUCLA2	B-Gene
mutation	B-Var
in	O
a	O
Portuguese	O
child	O
associated	O
with	B-Reg
"	O
mild	O
"	O
methylmalonic	B-Disease
aciduria	I-Disease
.	O

Succinyl	O
-	O
coenzyme	O
A	O
synthase	O
is	O
a	O
mitochondrial	O
matrix	O
enzyme	O
that	O
catalyzes	O
the	O
reversible	O
synthesis	O
of	O
succinate	O
and	O
adenosine	O
triphosphate	O
(	O
ATP	O
)	O
from	O
succinyl	O
-	O
coenzyme	O
A	O
and	O
adenosine	O
diphosphate	O
(	O
ADP	O
)	O
in	O
the	O
tricarboxylic	O
acid	O
cycle	O
.	O

This	O
enzyme	O
is	O
made	O
up	O
of	O
α	O
and	O
β	O
subunits	O
encoded	O
by	O
SUCLG1	O
and	O
SUCLA2	O
,	O
respectively	O
.	O

We	O
present	O
a	O
child	O
with	O
severe	O
muscular	O
hypotonia	O
,	O
dystonia	O
,	O
failure	O
to	O
thrive	O
,	O
sensorineural	O
deafness	O
,	O
and	O
dysmorphism	O
.	O

Metabolic	O
investigations	O
disclosed	O
hyperlactacidemia	O
,	O
moderate	O
urinary	O
excretion	O
of	O
methylmalonic	O
acid	O
,	O
and	O
elevated	O
levels	O
of	O
C4-dicarboxylic	O
carnitine	O
in	O
blood	O
.	O

We	O
identified	O
a	O
novel	O
homozygous	O
p	O
.	O
M329V	O
in	O
SUCLA2	B-Gene
.	O

In	O
cultured	O
cells	O
,	O
the	O
p	B-Var
.	I-Var
M329V	I-Var
resulted	O
in	O
a	O
reduced	B-NegReg
amount	B-MPA
of	O
the	O
SUCLA2	B-Gene
protein	B-Protein
,	O
impaired	B-NegReg
production	B-CPA
of	I-CPA
mitochondrial	I-CPA
ATP	I-CPA
,	O
and	O
enhanced	B-PosReg
production	B-CPA
of	I-CPA
reactive	I-CPA
oxygen	I-CPA
species	I-CPA
,	O
which	O
was	O
partially	O
reduced	O
by	O
using	O
5-aminoimidazole-4-carboxamide	O
ribonucleotide	O
in	O
the	O
culture	O
medium	O
.	O

Expanding	O
the	O
array	O
of	O
SUCLA2	O
mutations	O
,	O
we	O
suggested	O
that	O
reactive	O
oxygen	O
species	O
scavengers	O
are	O
likely	O
to	O
impact	O
on	O
disease	O
prognosis	O
.	O

Molecular	O
profiling	O
of	O
complete	O
congenital	O
stationary	O
night	O
blindness	O
:	O
a	O
pilot	O
study	O
on	O
an	O
Indian	O
cohort	O
.	O

PURPOSE	O
:	O
Congenital	B-Disease
stationary	I-Disease
night	I-Disease
blindness	I-Disease
(	O
CSNB	O
)	O
is	O
a	O
non	O
-	O
progressive	O
retinal	O
disorder	O
that	O
shows	O
genetic	O
and	O
clinical	O
heterogeneity	O
.	O

CSNB	O
is	O
inherited	O
as	O
an	O
autosomal	O
recessive	O
,	O
autosomal	O
dominant	O
,	O
or	O
X	O
-	O
linked	O
recessive	O
trait	O
and	O
shows	O
a	O
good	O
genotype	O
-	O
phenotype	O
correlation	O
.	O

Clinically	O
,	O
CSNB	O
is	O
classified	O
as	O
the	O
Riggs	O
type	O
and	O
the	O
Schubert	O
-	O
Bornschein	O
type	O
.	O

The	O
latter	O
form	O
is	O
further	O
sub	O
-	O
classified	O
into	O
complete	O
and	O
incomplete	O
forms	O
based	O
on	O
specific	O
waveforms	O
on	O
the	O
electroretinogram	O
(	O
ERG	O
)	O
.	O

There	O
are	O
no	O
molecular	O
genetic	O
data	O
for	O
CSNB	O
in	O
the	O
Indian	O
population	O
.	O

Therefore	O
,	O
we	O
present	O
for	O
the	O
first	O
time	O
molecular	O
profiling	O
of	O
eight	O
families	O
with	O
complete	O
CSNB	O
(	O
cCSNB	O
)	O
.	O

METHODS	O
:	O
The	O
index	O
patients	O
and	O
their	O
other	O
affected	O
family	O
members	O
were	O
comprehensively	O
evaluated	O
for	O
the	O
phenotype	O
,	O
including	O
complete	O
ophthalmic	O
evaluation	O
,	O
ERG	O
,	O
fundus	O
autofluorescence	O
,	O
optical	O
coherence	O
tomography	O
,	O
and	O
color	O
vision	O
test	O
.	O

The	O
known	O
gene	O
defects	O
for	O
cCSNB	O
,	O
LRIT3	O
,	O
TRPM1	O
,	O
GRM6	O
,	O
GPR179	O
,	O
and	O
NYX	O
,	O
were	O
screened	O
by	O
PCR	O
direct	O
sequencing	O
.	O

Bioinformatic	O
analyses	O
were	O
performed	O
using	O
SIFT	O
and	O
PolyPhen	O
for	O
the	O
identified	O
missense	O
mutations	O
.	O

RESULTS	O
:	O
All	O
eight	O
affected	O
index	O
patients	O
and	O
affected	O
family	O
members	O
were	O
identified	O
as	O
having	B-Reg
cCSNB	B-Disease
based	O
on	O
their	O
ERG	O
waveforms	O
.	O

Mutations	B-Var
in	O
the	O
TRPM1	B-Gene
gene	O
were	O
identified	O
in	O
six	O
index	O
patients	O
.	O

The	O
two	O
remaining	O
index	O
patients	O
each	O
carried	O
a	O
GPR179	B-Gene
and	O
GRM6	B-Gene
mutation	B-Var
.	O

Seven	O
of	O
the	O
patients	O
revealed	O
homozygous	O
mutations	O
,	O
while	O
one	O
patient	O
showed	O
a	O
compound	O
heterozygous	O
mutation	O
.	O

Six	O
of	O
the	O
eight	O
mutations	O
identified	O
are	O
novel	O
.	O

CONCLUSIONS	O
:	O
This	O
is	O
the	O
first	O
report	O
on	O
molecular	O
profiling	O
of	O
candidate	O
genes	O
in	O
CSNB	O
in	O
an	O
Indian	O
cohort	O
.	O

As	O
shown	O
for	O
other	O
cohorts	O
,	O
TRPM1	B-Gene
seems	O
to	O
be	O
a	O
major	O
gene	O
defect	B-Var
in	O
patients	O
with	B-Reg
cCSNB	B-Disease
in	O
India	O
.	O

UBQLN2	B-Gene
mutation	B-Var
causing	B-Reg
heterogeneous	B-Disease
X	I-Disease
-	I-Disease
linked	I-Disease
dominant	I-Disease
neurodegeneration	I-Disease
.	O

We	O
report	O
a	O
5-generation	O
family	O
with	O
phenotypically	O
diverse	O
neurodegenerative	O
disease	O
including	O
relentlessly	O
progressive	O
choreoathetoid	O
movements	O
,	O
dysarthria	O
,	O
dysphagia	O
,	O
spastic	O
paralysis	O
,	O
and	O
behavioral	O
dementia	O
in	O
descendants	O
of	O
a	O
67-year	O
-	O
old	O
woman	O
with	O
amyotrophic	O
lateral	O
sclerosis	O
.	O

Disease	O
onset	O
varied	O
with	O
gender	O
,	O
occurring	O
in	O
male	O
children	O
and	O
adult	O
women	O
.	O

Exome	O
sequence	O
analyses	O
revealed	O
a	O
novel	O
mutation	O
(	O
c.1490C	O
>	O
T	O
,	O
p	O
.	O
P497L	O
)	O
in	O
the	O
ubiquilin-2	O
gene	O
(	O
UBQLN2	O
)	O
with	O
X	O
-	O
linked	O
inheritance	O
in	O
all	O
studied	O
affected	O
individuals	O
.	O

As	O
ubiquilin-2-positive	O
inclusions	O
were	O
identified	O
in	O
brain	O
,	O
we	O
suggest	O
that	O
mutant	B-Var
peptide	O
predisposes	B-Reg
to	I-Reg
protein	B-Protein
misfolding	B-MPA
and	O
accumulation	B-PosReg
.	O

Our	O
findings	O
expand	O
the	O
spectrum	O
of	O
neurodegenerative	O
phenotypes	O
caused	O
by	O
UBQLN2	O
mutations	O
.	O

Splicing	B-Var
mutation	I-Var
in	O
MVK	B-Gene
is	O
a	O
cause	B-Reg
of	O
porokeratosis	B-Disease
of	I-Disease
Mibelli	I-Disease
.	O

Porokeratosis	O
is	O
a	O
chronic	O
skin	O
disorder	O
characterized	O
by	O
the	O
presence	O
of	O
patches	O
with	O
elevated	O
,	O
thick	O
,	O
keratotic	O
borders	O
,	O
with	O
histological	O
cornoid	O
lamella	O
.	O

Classic	O
porokeratosis	O
of	O
Mibelli	O
(	O
PM	O
)	O
frequently	O
appears	O
in	O
childhood	O
with	O
a	O
risk	O
of	O
malignant	O
transformation	O
.	O

Disseminated	O
superficial	O
actinic	O
porokeratosis	O
(	O
DSAP	O
)	O
is	O
the	O
most	O
common	O
subtype	O
of	O
porokeratosis	O
with	O
genetic	O
heterogeneities	O
,	O
and	O
mevalonate	O
kinase	O
gene	O
(	O
MVK	O
)	O
mutations	O
have	O
been	O
identified	O
in	O
minor	O
portion	O
of	O
DSAP	O
families	O
of	O
Chinese	O
origin	O
.	O

To	O
confirm	O
the	O
previous	O
findings	O
about	O
MVK	O
mutations	O
in	O
DSAP	O
patients	O
and	O
test	O
MVK	O
's	O
role(s	O
)	O
in	O
PM	O
development	O
,	O
we	O
performed	O
genomic	O
sequence	O
analysis	O
for	O
3	O
DSAP	O
families	O
and	O
1	O
PM	O
family	O
of	O
Chinese	O
origin	O
.	O

We	O
identified	O
a	O
splicing	O
mutation	O
of	O
MVK	O
gene	O
,	O
designated	O
as	O
c.1039	O
+	O
1G	O
>	O
A	O
,	O
in	O
the	O
PM	O
family	O
.	O

No	O
MVK	O
mutations	O
were	O
found	O
in	O
three	O
DSAP	O
families	O
.	O

Sequence	O
analysis	O
for	O
complementary	O
DNA	O
templates	O
from	O
PM	O
lesions	O
of	O
all	O
patients	O
revealed	O
a	O
mutation	O
at	O
splice	O
donor	O
site	O
of	O
intron	O
10	O
,	O
designated	O
as	O
c.1039	B-Var
+	I-Var
1G	I-Var
>	I-Var
A	I-Var
,	O
leading	B-Reg
to	I-Reg
the	O
splicing	B-MPA
defect	I-MPA
and	O
termination	B-MPA
codon	I-MPA
52	O
amino	O
acids	O
after	O
exon	O
10	O
.	O

Although	O
no	O
MVK	O
mutations	O
in	O
DSAP	O
patients	O
were	O
found	O
as	O
reported	O
previously	O
,	O
we	O
identified	O
MVK	O
simultaneously	O
responsible	O
for	O
PM	O
development	O
.	O

Whole	O
exome	O
sequencing	O
reveals	O
concomitant	O
mutations	B-Var
of	O
multiple	O
FA	B-Gene
genes	O
in	B-Reg
individual	O
Fanconi	B-Disease
anemia	I-Disease
patients	O
.	O

BACKGROUND	O
:	O
Fanconi	O
anemia	O
(	O
FA	O
)	O
is	O
a	O
rare	O
inherited	O
genetic	O
syndrome	O
with	O
highly	O
variable	O
clinical	O
manifestations	O
.	O

Fifteen	O
genetic	O
subtypes	O
of	O
FA	O
have	O
been	O
identified	O
.	O

Traditional	O
complementation	O
tests	O
for	O
grouping	O
studies	O
have	O
been	O
used	O
generally	O
in	O
FA	O
patients	O
and	O
in	O
stepwise	O
methods	O
to	O
identify	O
the	O
FA	O
type	O
,	O
which	O
can	O
result	O
in	O
incomplete	O
genetic	O
information	O
from	O
FA	O
patients	O
.	O

METHODS	O
:	O
We	O
diagnosed	O
five	O
pediatric	O
patients	O
with	O
FA	O
based	O
on	O
clinical	O
manifestations	O
,	O
and	O
we	O
performed	O
exome	O
sequencing	O
of	O
peripheral	O
blood	O
specimens	O
from	O
these	O
patients	O
and	O
their	O
family	O
members	O
.	O

The	O
related	O
sequencing	O
data	O
were	O
then	O
analyzed	O
by	O
bioinformatics	O
,	O
and	O
the	O
FANC	O
gene	O
mutations	O
identified	O
by	O
exome	O
sequencing	O
were	O
confirmed	O
by	O
PCR	O
re	O
-	O
sequencing	O
.	O

RESULTS	O
:	O
Homozygous	O
and	O
compound	O
heterozygous	O
mutations	O
of	O
FANC	O
genes	O
were	O
identified	O
in	O
all	O
of	O
the	O
patients	O
.	O

The	O
FA	O
subtypes	O
of	O
the	O
patients	O
included	O
FANCA	O
,	O
FANCM	O
and	O
FANCD2	O
.	O

Interestingly	O
,	O
four	O
FA	O
patients	O
harbored	O
multiple	O
mutations	O
in	O
at	O
least	O
two	O
FA	O
genes	O
,	O
and	O
some	O
of	O
these	O
mutations	O
have	O
not	O
been	O
previously	O
reported	O
.	O

These	O
patients	O
'	O
clinical	O
manifestations	O
were	O
vastly	O
different	O
from	O
each	O
other	O
,	O
as	O
were	O
their	O
treatment	O
responses	O
to	O
androstanazol	O
and	O
prednisone	O
.	O

This	O
finding	O
suggests	O
that	O
heterozygous	O
mutation(s	O
)	O
in	O
FA	O
genes	O
could	O
also	O
have	O
diverse	O
biological	O
and/or	O
pathophysiological	O
effects	O
on	O
FA	O
patients	O
or	O
FA	O
gene	O
carriers	O
.	O

Interestingly	O
,	O
we	O
were	O
not	O
able	O
to	O
identify	O
de	O
novo	O
mutations	O
in	O
the	O
genes	O
implicated	O
in	O
DNA	O
repair	O
pathways	O
when	O
the	O
sequencing	O
data	O
of	O
patients	O
were	O
compared	O
with	O
those	O
of	O
their	O
parents	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
indicate	O
that	O
Chinese	O
FA	O
patients	O
and	O
carriers	O
might	O
have	O
higher	O
and	O
more	O
complex	O
mutation	O
rates	O
in	O
FANC	O
genes	O
than	O
have	O
been	O
conventionally	O
recognized	O
.	O

Testing	O
of	O
the	O
fifteen	O
FANC	O
genes	O
in	O
FA	O
patients	O
and	O
their	O
family	O
members	O
should	O
be	O
a	O
regular	O
clinical	O
practice	O
to	O
determine	O
the	O
optimal	O
care	O
for	O
the	O
individual	O
patient	O
,	O
to	O
counsel	O
the	O
family	O
and	O
to	O
obtain	O
a	O
better	O
understanding	O
of	O
FA	O
pathophysiology	O
.	O

Mutations	B-Var
in	O
SMARCAD1	B-Gene
cause	B-Reg
autosomal	B-Disease
dominant	I-Disease
adermatoglyphia	I-Disease
and	O
perturb	B-Reg
the	O
expression	B-MPA
of	O
epidermal	O
differentiation	O
-	O
associated	O
genes	O
.	O

BACKGROUND	O
:	O
Autosomal	O
dominant	O
adermatoglyphia	O
(	O
ADG	O
)	O
is	O
characterized	O
by	O
lack	O
of	O
palmoplantar	O
epidermal	O
ridges	O
.	O

Recently	O
,	O
ADG	O
was	O
found	O
to	O
be	O
caused	O
in	O
one	O
family	O
by	O
a	O
mutation	O
in	O
SMARCAD1	O
,	O
a	O
member	O
of	O
the	O
SNF	O
subfamily	O
of	O
the	O
helicase	O
protein	O
superfamily	O
.	O

OBJECTIVES	O
:	O
To	O
investigate	O
the	O
genetic	O
basis	O
of	O
ADG	O
.	O

METHODS	O
:	O
We	O
used	O
direct	O
sequencing	O
and	O
global	O
gene	O
expression	O
analysis	O
.	O

RESULTS	O
:	O
We	O
identified	O
three	O
novel	O
heterozygous	O
mutations	O
in	O
SMARCAD1	O
(	O
c.378	O
+	O
2	O
T	O
>	O
C	O
,	O
c.378	O
+	O
5	O
G	O
>	O
C	O
and	O
c.378	O
+	O
1	O
G	O
>	O
A	O
)	O
in	O
a	O
total	O
of	O
six	O
patients	O
.	O

Surprisingly	O
,	O
all	O
four	O
ADG	O
-	O
causing	O
mutations	B-Var
identified	O
to	O
date	O
disrupt	B-NegReg
a	O
single	B-MPA
conserved	I-MPA
donor	I-MPA
splice	I-MPA
site	I-MPA
adjacent	O
to	O
the	O
3	O
'	O
end	O
of	O
a	O
noncoding	O
exon	O
and	O
are	O
predicted	O
to	O
result	O
in	O
haploinsufficiency	B-NegReg
for	O
a	O
skin	B-MPA
-	I-MPA
specific	I-MPA
isoform	I-MPA
of	O
SMARCAD1	B-Gene
.	O

These	O
data	O
indicate	O
a	O
pivotal	O
role	O
for	O
the	O
SMARCAD1-skin	O
specific	O
isoform	O
in	O
dermatoglyph	O
formation	O
.	O

In	O
order	O
to	O
better	O
understand	O
the	O
consequences	O
of	O
ADG	O
-	O
associated	O
mutations	O
,	O
we	O
ascertained	O
the	O
global	O
transcription	O
profiles	O
of	O
primary	O
keratinocytes	O
downregulated	O
for	O
SMARCAD1	O
and	O
of	O
patient	O
-	O
derived	O
keratinocytes	O
.	O

A	O
total	O
of	O
eight	O
genes	O
were	O
found	O
to	O
be	O
differentially	O
expressed	O
in	O
both	O
patient	O
-	O
derived	O
and	O
knocked	O
down	O
keratinocytes	O
.	O

Of	O
interest	O
,	O
these	O
differentially	O
expressed	O
genes	O
have	O
been	O
implicated	O
in	O
epidermal	O
ontogenesis	O
and	O
differentiation	O
,	O
and	O
in	O
psoriasis	O
,	O
which	O
is	O
characterized	O
by	O
abnormal	O
finger	O
ridge	O
patterns	O
.	O

CONCLUSIONS	O
:	O
The	O
present	O
data	O
suggest	O
that	O
ADG	O
is	O
genetically	O
homogeneous	O
and	O
result	O
from	O
perturbed	O
expression	O
of	O
epidermal	O
differentiation	O
-	O
associated	O
genes	O
.	O

Genetics	O
and	O
pathophysiology	O
of	O
primary	O
dystonia	O
with	O
special	O
emphasis	O
on	O
DYT1	O
and	O
DYT5	O
.	O

DYT1	O
and	O
DYT5	O
are	O
early	O
-	O
onset	O
dominant	O
inherited	O
dystonias	O
.	O

DYT1	B-Disease
is	O
caused	B-Reg
by	I-Reg
mutations	B-Var
of	O
the	O
TOR1A	B-Gene
gene	O
,	O
located	O
on	O
9q34	O
,	O
which	O
causes	O
dysfunction	B-NegReg
of	O
the	O
D1	B-Pathway
direct	I-Pathway
pathway	I-Pathway
or	O
the	O
indirect	B-Pathway
pathway	I-Pathway
.	O

Dysfunction	O
of	O
the	O
former	O
causes	O
postural	B-Disease
-	I-Disease
type	I-Disease
and	I-Disease
segmental	I-Disease
dystonia	I-Disease
;	I-Disease
the	O
latter	O
causes	O
action	B-Disease
-	I-Disease
type	I-Disease
dystonia	I-Disease
.	O

In	O
families	O
with	O
action	O
-	O
type	O
dystonia	O
,	O
there	O
are	O
cases	O
with	O
focal	O
and	O
segmental	O
dystonia	O
.	O

Ages	O
of	O
onset	O
of	O
postural	O
-	O
type	O
dystonia	O
are	O
around	O
6	O
years	O
,	O
and	O
8	O
to	O
10	O
years	O
in	O
cases	O
of	O
action	O
-	O
type	O
dystonia	O
.	O

Focal	O
and	O
segmental	O
dystonia	O
develops	O
in	O
the	O
teens	O
.	O

Mental	O
and	O
psychological	O
functions	O
are	O
preserved	O
.	O

DYT5	B-Disease
is	O
caused	B-Reg
by	I-Reg
heterozygous	O
mutations	B-Var
of	O
the	O
GCH1	B-Gene
gene	O
,	O
located	O
on	O
14q22.1-q22.2	O
.	O

Again	O
,	O
mental	O
and	O
psychological	O
functions	O
are	O
preserved	O
.	O

Clinically	O
,	O
there	O
are	O
two	O
types	O
:	O
postural	O
and	O
action	O
.	O

Postural	O
-	O
type	O
dystonia	O
occurs	O
around	O
6	O
years	O
of	O
age	O
,	O
with	O
postural	O
dystonia	O
of	O
one	O
leg	O
,	O
and	O
all	O
extremities	O
and	O
trunk	O
muscles	O
are	O
involved	O
by	O
the	O
late	O
teens	O
.	O

Action	O
-	O
type	O
dystonia	O
shows	O
dystonic	O
movements	O
from	O
around	O
8	O
to	O
10	O
years	O
of	O
age	O
.	O

In	O
both	O
types	O
,	O
all	O
symptoms	O
show	O
diurnal	O
fluctuations	O
that	O
diminish	O
with	O
age	O
and	O
are	O
no	O
longer	O
apparent	O
in	O
the	O
late	O
teens	O
.	O

L	O
-	O
dopa	O
produces	O
dramatic	O
effects	O
,	O
which	O
continue	O
throughout	O
the	O
course	O
of	O
the	O
illness	O
.	O

In	O
both	O
postural	O
and	O
action	O
types	O
,	O
each	O
family	O
or	O
sporadic	O
case	O
has	O
a	O
particular	O
mutation	O
.	O

It	O
remains	O
unclear	O
why	O
specific	O
mutations	O
cause	O
certain	O
age-	O
and	O
gender	O
-	O
specific	O
symptoms	O
.	O

First	O
report	O
of	O
a	O
deletion	O
encompassing	O
an	O
entire	O
exon	O
in	O
the	O
homogentisate	O
1,2-dioxygenase	O
gene	O
causing	O
alkaptonuria	O
.	O

Alkaptonuria	B-Disease
is	O
often	O
diagnosed	O
clinically	O
with	O
episodes	O
of	O
dark	O
urine	O
,	O
biochemically	O
by	O
the	O
accumulation	O
of	O
peripheral	O
homogentisic	O
acid	O
and	O
molecularly	O
by	B-Reg
the	I-Reg
presence	I-Reg
of	I-Reg
mutations	B-Var
in	O
the	O
homogentisate	O
1,2-dioxygenase	O
gene	O
(	B-Gene
HGD	I-Gene
)	I-Gene
.	O

Alkaptonuria	B-Disease
is	O
invariably	O
associated	B-Reg
with	I-Reg
HGD	B-Gene
mutations	B-Var
,	O
which	O
consist	O
of	O
single	B-Var
nucleotide	I-Var
variants	I-Var
and	O
small	B-Var
insertions	I-Var
/	I-Var
deletions	I-Var
.	O

Surprisingly	O
,	O
the	O
presence	O
of	O
deletions	O
beyond	O
a	O
few	O
nucleotides	O
among	O
over	O
150	O
reported	O
deleterious	O
mutations	O
has	O
not	O
been	O
described	O
,	O
raising	O
the	O
suspicion	O
that	O
this	O
gene	O
might	O
be	O
protected	O
against	O
the	O
detrimental	O
mechanisms	O
of	O
gene	O
rearrangements	O
.	O

The	O
quest	O
for	O
an	O
HGD	O
mutation	O
in	O
a	O
proband	O
with	O
AKU	O
revealed	O
with	O
a	O
SNP	O
array	O
five	O
large	O
regions	O
of	O
homozygosity	O
(	O
5	O
-	O
16	O
Mb	O
)	O
,	O
one	O
of	O
which	O
includes	O
the	O
HGD	O
gene	O
.	O

A	O
homozygous	O
deletion	O
of	O
649	O
bp	O
deletion	O
that	O
encompasses	O
the	O
72	O
nucleotides	O
of	O
exon	O
2	O
and	O
surrounding	O
DNA	O
sequences	O
in	O
flanking	O
introns	O
of	O
the	O
HGD	O
gene	O
was	O
unveiled	O
in	O
a	O
proband	O
with	O
AKU	O
.	O

The	O
nature	O
of	O
this	O
deletion	O
suggests	O
that	O
this	O
in	O
-	O
frame	O
deletion	O
could	O
generate	O
a	O
protein	O
without	O
exon	O
2	O
.	O

Thus	O
,	O
we	O
modeled	O
the	O
tertiary	O
structure	O
of	O
the	O
mutant	O
protein	O
structure	O
to	O
determine	O
the	O
effect	O
of	O
exon	O
2	O
deletion	O
.	O

While	O
the	O
two	O
β	O
-	O
pleated	O
sheets	O
encoded	O
by	O
exon	O
2	O
were	O
missing	O
in	O
the	O
mutant	O
structure	O
,	O
other	O
β	O
-	O
pleated	O
sheets	O
are	O
largely	O
unaffected	O
by	O
the	O
deletion	O
.	O

However	O
,	O
nine	O
novel	O
α	O
-	O
helical	O
coils	O
substituted	O
the	O
eight	O
coils	O
present	O
in	O
the	O
native	O
HGD	O
crystal	O
structure	O
.	O

Thus	O
,	O
this	O
deletion	B-Var
results	B-Reg
in	I-Reg
a	O
deleterious	O
enzyme	B-Enzyme
,	O
which	O
is	O
consistent	O
with	O
the	O
proband	O
's	O
phenotype	O
.	O

Screening	O
for	O
mutations	O
in	O
the	O
HGD	O
gene	O
,	O
particularly	O
in	O
the	O
Middle	O
East	O
,	O
ought	O
to	O
include	O
this	O
exon	O
2	O
deletion	O
in	O
order	O
to	O
determine	O
its	O
frequency	O
and	O
uncover	O
its	O
origin	O
.	O

Identification	O
of	O
two	O
novel	O
mutations	O
in	O
patients	O
with	O
X	O
-	O
linked	O
primary	O
immunodeficiencies	O
.	O

Primary	B-Disease
immunodeficiency	I-Disease
diseases	I-Disease
(	O
PID	O
)	O
are	O
a	O
heterogeneous	O
group	O
of	O
inherited	O
disorders	O
with	O
defects	O
in	O
one	O
or	O
more	O
component	O
of	O
the	O
immune	O
system	O
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
gene	O
mutations	O
in	O
four	O
X	O
-	O
linked	O
PID	O
pedigrees	O
,	O
which	O
include	O
one	O
X-	O
linked	O
agammaglobulinemia	O
(	O
XLA	O
)	O
pedigree	O
,	O
one	O
X	O
-	O
linked	O
chronic	O
granulomatous	O
disease	O
(	O
XCGD	O
)	O
pedigree	O
,	O
and	O
two	O
X	O
-	O
linked	O
Hyper	O
IgM	O
syndrome	O
(	O
XHIGM	O
)	O
pedigrees	O
.	O

Sequence	O
analysis	O
of	O
the	O
BTK	B-Gene
gene	O
revealed	O
a	O
novel	O
mutation	O
(	B-Var
c.1802_1803delinsGCC	I-Var
,	O
p	O
.	O
Phe601CysfsX3	O
)	O
which	O
results	B-Reg
in	O
the	O
developmental	B-CPA
arrest	I-CPA
of	I-CPA
B	I-CPA
cells	I-CPA
in	O
the	O
bone	O
marrow	O
.	O

Sequence	O
analysis	O
of	O
the	O
CYBB	B-Gene
gene	O
revealed	O
a	O
recurrent	O
frameshift	O
mutation	O
(	B-Var
c.1313_1314delinsT	I-Var
)	I-Var
in	O
exon	O
10	O
,	O
which	O
generates	B-Reg
a	O
premature	B-MPA
stop	I-MPA
codon	O
(	O
p	O
.	O
Lys438IlefsX63	O
)	O
.	O

One	O
novel	O
frameshift	O
mutation	O
(	B-Var
c.114delG	I-Var
,	O
p	O
.	O
Ser39GlnfsX14	O
)	O
and	O
one	O
recurrent	O
missense	O
mutation	O
(	B-Var
c.499G	I-Var
>	I-Var
C	I-Var
,	O
p	O
.	O
Gly167Arg	O
)	O
were	O
found	O
in	O
the	O
CD40LG	B-Gene
gene	O
and	O
cause	O
defective	B-NegReg
T	B-CPA
cell	I-CPA
functioning	I-CPA
.	O

In	O
conclusion	O
,	O
our	O
study	O
identified	O
two	O
novel	O
mutations	O
on	O
the	O
BTK	O
and	O
CD40LG	O
genes	O
in	O
Chinese	O
patients	O
and	O
established	O
accurate	O
and	O
simple	O
genetic	O
diagnostic	O
methods	O
for	O
three	O
X	O
-	O
linked	O
PID	O
.	O

Novel	O
COL9A3	B-Gene
mutation	B-Var
in	O
a	O
family	O
diagnosed	O
with	B-Reg
multiple	B-Disease
epiphyseal	I-Disease
dysplasia	I-Disease
:	I-Disease
a	O
case	O
report	O
.	O

BACKGROUND	O
:	O
Multiple	O
epiphyseal	O
dysplasia	O
is	O
a	O
common	O
skeletal	O
dysplasia	O
characterized	O
by	O
mild	O
short	O
stature	O
,	O
early	O
-	O
onset	O
osteoarthritis	O
mainly	O
involving	O
the	O
hip	O
and	O
knee	O
joints	O
,	O
and	O
abnormally	O
small	O
and/or	O
irregular	O
epiphyses	O
.	O

Multiple	O
epiphyseal	O
dysplasia	O
is	O
clinically	O
and	O
genetically	O
heterogeneous	O
and	O
six	O
genes	O
are	O
associated	O
with	O
the	O
phenotype	O
of	O
multiple	O
epiphyseal	O
dysplasia	O
.	O

CASE	O
PRESENTATION	O
:	O
A	O
12-year	O
-	O
old	O
Korean	O
boy	O
presented	O
with	O
intermittent	O
knee	O
pain	O
.	O

His	O
height	O
was	O
144.6	O
cm	O
(	O
20th	O
percentile	O
)	O
and	O
family	O
history	O
was	O
notable	O
for	O
early	O
-	O
onset	O
osteoarthritis	O
in	O
his	O
father	O
.	O

The	O
proband	O
's	O
x	O
-	O
rays	O
revealed	O
epiphyseal	O
changes	O
characteristic	O
of	O
multiple	O
epiphyseal	O
dysplasia	O
associated	O
with	O
a	O
collagen	O
IX	O
defect	O
,	O
with	O
manifestations	O
primarily	O
restricted	O
to	O
the	O
knees	O
.	O

Mutational	O
analysis	O
identified	O
a	O
novel	O
c.104G	B-Var
>	I-Var
A	I-Var
substitution	O
in	O
exon	O
2	O
of	O
COL9A3	B-Gene
,	O
resulting	B-Reg
in	I-Reg
p	B-Var
.	I-Var
Gly35Asp	I-Var
in	O
the	O
proband	O
and	O
his	O
father	O
.	O

In	O
silico	O
analyses	O
predicted	O
the	O
p	O
.	O
Gly35Asp	O
amino	O
acid	O
change	O
to	O
be	O
detelerious	O
,	O
and	O
molecular	O
dynamics	O
simulation	O
demonstrated	O
a	O
major	O
structural	O
change	O
in	O
the	O
heterotrimeric	O
collagen	O
IX	O
.	O

CONCLUSION	O
:	O
So	O
far	O
,	O
three	O
COL9A3	O
mutations	O
,	O
have	O
been	O
reported	O
.	O

These	O
three	O
mutations	B-Var
are	O
located	O
at	O
the	O
splice	O
donor	O
or	O
acceptor	O
site	O
of	O
COL9A3	B-Gene
and	O
cause	B-Reg
skipping	B-MPA
of	I-MPA
exon	I-MPA
3	I-MPA
,	O
resulting	B-Reg
in	I-Reg
the	O
deletion	B-Var
of	O
12	O
aminoacids	O
in	O
the	O
COL3	O
domain	O
of	O
COL9A3	B-Gene
.	O

In	O
contrast	O
,	O
the	O
novel	O
missense	O
mutation	O
identified	O
in	O
this	O
two	O
-	O
generation	O
family	O
with	O
multiple	O
epiphyseal	O
dysplasia	O
is	O
a	O
missense	O
mutation	B-Var
affecting	B-Reg
the	O
Gly	B-MPA
residue	I-MPA
of	O
the	O
Pro	O
-	O
Pro	O
-	O
Gly	O
repeat	O
sequence	O
in	O
the	O
COL3	O
domain	O
of	O
collage	O
IX	O
,	O
with	O
accompanying	O
major	O
structural	B-MPA
change	O
of	O
the	O
collagen	B-Protein
peptide	O
.	O

Rett	O
-	O
like	O
onset	O
in	O
late	B-Disease
-	I-Disease
infantile	I-Disease
neuronal	I-Disease
ceroid	I-Disease
lipofuscinosis	I-Disease
(	O
CLN7	O
)	O
caused	B-Reg
by	I-Reg
compound	O
heterozygous	O
mutation	B-Var
in	O
the	O
MFSD8	B-Gene
gene	O
and	O
review	O
of	O
the	O
literature	O
data	O
on	O
clinical	O
onset	O
signs	O
.	O

BACKGROUND	O
:	O
We	O
present	O
clinical	O
and	O
molecular	O
findings	O
of	O
a	O
patient	O
with	O
ceroid	O
-	O
lipofuscinosis	O
CLN7	B-Disease
,	O
with	B-Reg
a	O
compound	O
heterozygous	O
mutation	B-Var
of	O
the	O
MFSD8	B-Gene
gene	O
,	O
with	O
Rett	O
syndrome	O
clinical	O
signs	O
onset	O
and	O
a	O
later	O
development	O
of	O
full	O
picture	O
of	O
vLINCL	O
.	O

CASE	O
PRESENTATION	O
:	O
A	O
7	O
years	O
-	O
old	O
female	O
patient	O
with	O
normal	O
development	O
until	O
the	O
age	O
12	O
months	O
,	O
developed	O
Rett	O
like	O
clinical	O
picture	O
(	O
psychomotor	O
regression	O
,	O
microcephaly	O
,	O
stereotypic	O
hands	O
movements	O
in	O
the	O
midline	O
,	O
hyperventilation	O
episodes	O
)	O
present	O
at	O
the	O
onset	O
of	O
her	O
condition	O
(	O
age	O
18	O
months	O
)	O
,	O
features	O
still	O
present	O
at	O
the	O
initial	O
evaluation	O
in	O
our	O
clinic	O
at	O
age	O
5	O
years	O
.	O

RESULTS	O
:	O
MECP2	O
(	O
methyl	O
CpG	O
binding	O
protein	O
2	O
)	O
gene	O
mutation	O
was	O
negative	O
.	O

At	O
age	O
6	O
years	O
she	O
was	O
readmitted	O
for	O
severe	O
ataxia	O
and	O
blindness	O
,	O
seizures	O
,	O
and	O
severe	O
developmental	O
regression	O
leading	O
to	O
NCL	O
(	O
neuronal	O
ceroid	O
lipofuscinosis	O
)	O
suspicion	O
.	O

EEG	O
showed	O
slow	O
background	O
with	O
IRDA	O
(	O
intermittent	O
rhythmic	O
delta	O
activity	O
)	O
.	O

A	O
conjunctive	O
biopsy	O
showed	O
abnormal	O
curvilinear	O
and	O
fingerprint	O
lysosomal	O
deposits	O
,	O
and	O
genetic	O
analysis	O
revealed	O
two	O
heterozygous	O
mutations	O
of	O
MFSD8	O
gene	O
(	O
c.881C	O
>	O
A	O
p	O
.	O
Thr294Lys	O
and	O
c.754	O
+	O
2	O
T	O
>	O
A	O
)	O
each	O
inherited	O
from	O
carrier	O
parents	O
and	O
a	O
heterozygous	O
variant	O
(	O
c.470A	O
>	O
C	O
p	O
.	O
Asp157Ala	O
)	O
of	O
CLN5	O
gene	O
.	O

CONCLUSION	O
:	O
NCL	O
should	O
be	O
suspected	O
and	O
MFSD8	O
genetic	O
testing	O
should	O
also	O
be	O
considered	O
in	O
patients	O
with	O
Rett	O
like	O
phenotype	O
at	O
onset	O
and	O
negative	O
MECP2	O
mutation	O
.	O

Such	O
cases	O
should	O
be	O
carefully	O
and	O
frequently	O
re	O
-	O
evaluated	O
in	O
order	O
to	O
avoid	O
delayed	O
diagnosis	O
and	O
offer	O
proper	O
genetic	O
advice	O
to	O
the	O
family	O
.	O

In	O
our	O
knowledge	O
,	O
this	O
might	O
be	O
the	O
first	O
case	O
of	O
CLN7	O
disease	O
with	O
Rett	O
like	O
onset	O
described	O
in	O
the	O
literature	O
,	O
which	O
developed	O
typical	O
vLINCL	O
clinical	O
phenotype	O
after	O
age	O
5.5	O
years	O
.	O

A	O
short	O
review	O
of	O
the	O
literature	O
showing	O
NCL	O
onset	O
modalities	O
is	O
presented	O
.	O

Novel	O
homozygous	B-Var
deletion	I-Var
of	O
segmental	O
KAL1	B-Gene
and	O
entire	O
STS	B-Gene
cause	B-Reg
Kallmann	B-Disease
syndrome	I-Disease
and	O
X	B-Disease
-	I-Disease
linked	I-Disease
ichthyosis	I-Disease
in	O
a	O
Chinese	O
family	O
.	O

Kallmann	O
syndrome	O
(	O
KS	O
)	O
is	O
a	O
genetically	O
heterogeneous	O
disease	O
characterised	O
by	O
hypogonadotrophic	O
hypogonadism	O
in	O
association	O
with	O
anosmia	O
or	O
hyposmia	O
.	O

This	O
condition	O
affects	O
1	O
in	O
10	O
000	O
men	O
and	O
1	O
in	O
50	O
000	O
women	O
.	O

Defects	O
in	O
seventeen	O
genes	O
including	O
KAL1	O
gene	O
contribute	O
to	O
the	O
molecular	O
basis	O
of	O
KS	O
.	O

We	O
report	O
the	O
clinical	O
characteristics	O
,	O
molecular	O
causes	O
and	O
treatment	O
outcome	O
of	O
two	O
Chinese	O
brothers	O
with	O
KS	O
and	O
X	O
-	O
linked	O
ichthyosis	O
.	O

The	O
phenotypes	O
of	O
the	O
patients	O
were	O
characterised	O
by	O
bilateral	O
cryptorchidism	O
,	O
unilateral	O
renal	O
agenesis	O
in	O
one	O
patient	O
but	O
normal	O
kidney	O
development	O
in	O
another	O
.	O

The	O
patients	O
had	O
low	O
serum	O
testosterone	O
,	O
follicle	O
-	O
stimulating	O
hormone	O
and	O
luteinising	O
hormone	O
levels	O
and	O
a	O
blunt	O
response	O
to	O
the	O
gonadotrophin	O
-	O
releasing	O
hormone	O
stimulation	O
test	O
.	O

After	O
human	O
chorionic	O
gonadotrophin	O
treatment	O
,	O
the	O
serum	O
testosterone	O
levels	O
were	O
normalized	O
,	O
and	O
the	O
pubic	O
hair	O
,	O
penis	O
length	O
and	O
testicular	O
volumes	O
were	O
greatly	O
improved	O
in	O
both	O
of	O
the	O
patients	O
.	O

The	O
two	O
affected	O
siblings	O
had	O
the	O
same	O
novel	O
deletion	O
at	O
Xp22.3	O
including	O
exons	O
9	O
-	O
14	O
of	O
KAL1	O
gene	O
and	O
entire	O
STS	O
gene	O
.	O

Our	O
study	O
broadens	O
the	O
mutation	B-Var
spectrum	O
in	O
the	O
KAL1	B-Gene
gene	O
associated	B-Reg
with	I-Reg
KS	B-Disease
and	O
facilitates	O
the	O
genetic	O
diagnosis	O
and	O
counselling	O
for	O
KS	O
.	O

[	O
Heterozygote	O
forms	O
of	O
familial	O
Mediterranean	O
fever	O
can	O
be	O
manifested	O
in	O
adults	O
as	O
myofacial	O
pain	O
syndrome	O
]	O
.	O

Heterozygote	O
Formen	O
des	O
familiären	O
Mittelmeerfiebers	O
können	O
beim	O
Erwachsenen	O
als	O
myofasziales	O
Schmerzsyndrom	O
imponieren	O
.	O

BACKGROUND	O
:	O
Familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
(	O
FMF	O
)	O
is	O
a	O
disease	O
characterized	O
by	O
recurrent	O
fever	O
,	O
serositis	O
,	O
arthritis	O
and	O
unspecific	O
myalgia	O
.	O

It	O
is	O
prevalent	O
among	O
Mediterranean	O
people	O
and	O
has	O
been	O
shown	O
to	O
be	O
associated	B-Reg
with	O
mutations	B-Var
in	O
the	O
Mediterranean	O
fever	O
(	B-Gene
MEFV	I-Gene
)	I-Gene
gene	O
which	O
,	O
encodes	O
pyrin	O
a	O
regulatory	O
protein	O
of	O
the	O
inflammasome	O
.	O

As	O
heterozygous	B-Var
mutations	I-Var
in	O
MEFV	B-Gene
can	O
be	O
associated	B-Reg
with	O
only	O
mild	O
inflammatory	O
symptoms	O
,	O
such	O
as	O
arthralgia	B-CPA
or	O
chronic	B-CPA
fibromyalgic	I-CPA
pain	I-CPA
,	O
FMF	O
may	O
be	O
underdiagnosed	O
in	O
the	O
current	O
diagnostic	O
work	O
-	O
up	O
of	O
musculoskeletal	O
diseases	O
.	O

METHODS	O
:	O
The	O
selection	O
of	O
patients	O
was	O
carried	O
out	O
according	O
to	O
the	O
following	O
criteria	O
:	O
myofacial	O
pain	O
syndrome	O
,	O
seronegative	O
oligoarthralgia	O
,	O
a	O
slight	O
inflammatory	O
constellation	O
and	O
ethnic	O
origin	O
from	O
the	O
Mediterranean	O
area	O
.	O

When	O
these	O
criteria	O
were	O
fulfilled	O
a	O
molecular	O
genetic	O
investigation	O
was	O
carried	O
out	O
RESULTS	O
:	O
This	O
article	O
presents	O
evidence	O
that	O
9	O
out	O
of	O
12	O
Mediterranean	O
patients	O
with	O
recurrent	O
myofascial	B-Disease
pain	I-Disease
syndrome	I-Disease
and	O
mild	B-CPA
inflammation	I-CPA
revealed	B-Reg
heterozygote	B-Var
mutations	I-Var
in	O
the	O
MEFV	B-Gene
gene	O
and	O
7	O
of	O
these	O
patients	O
benefitted	O
from	O
treatment	O
with	O
colchicine	O
.	O

DISCUSSION	O
:	O
As	O
colchicine	O
treatment	O
not	O
only	O
improved	O
the	O
myofascial	O
pain	O
but	O
also	O
prevented	O
FMF	O
-	O
associated	O
amyloidosis	O
and	O
nephropathy	O
,	O
differential	O
diagnosis	O
of	O
fibromyalgia	O
in	O
patients	O
of	O
Mediterranean	O
origin	O
should	O
include	O
FMF	O
and	O
a	O
genetic	O
screening	O
of	O
the	O
MEFV	O
locus	O
.	O

In	O
silico	O
analyses	O
of	O
missense	O
mutations	O
in	O
coagulation	O
factor	O
VIII	O
:	O
identification	O
of	O
severity	O
determinants	O
of	O
haemophilia	O
A.	O
Factor	O
VIII	O
(	B-Gene
FVIII	I-Gene
)	I-Gene
mutations	B-Var
cause	B-Reg
haemophilia	B-Disease
A	I-Disease
(	O
HA	O
)	O
,	O
an	O
X	O
-	O
linked	O
recessive	O
coagulation	O
disorder	O
.	O

Over	O
1000	O
missense	O
mutations	O
in	O
FVIII	O
are	O
known	O
and	O
they	O
lead	O
to	O
variable	O
clinical	O
phenotypes	O
(	O
severe	O
,	O
moderate	O
and	O
mild	O
)	O
.	O

The	O
exact	O
molecular	O
basis	O
of	O
this	O
phenotypic	O
heterogeneity	O
by	O
FVIII	O
missense	O
mutations	O
is	O
elusive	O
to	O
date	O
.	O

In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
identify	O
the	O
severity	O
determinants	O
that	O
cause	O
phenotypic	O
heterogeneity	O
of	O
HA	O
.	O

We	O
compiled	O
and	O
curated	O
a	O
data	O
set	O
of	O
766	O
missense	O
mutations	O
from	O
the	O
repertoire	O
of	O
missense	O
mutations	O
in	O
FVIII	O
.	O

We	O
analysed	O
these	O
mutations	O
by	O
computational	O
programs	O
(	O
e.g.	O
Swiss	O
-	O
PdbViewer	O
)	O
and	O
different	O
mutation	O
analysis	O
servers	O
(	O
e.g.	O
SIFT	O
,	O
PROVEAN	O
,	O
CUPSAT	O
,	O
PolyPhen2	O
,	O
MutPred	O
)	O
;	O
and	O
various	O
sequence-	O
and	O
structure	O
-	O
based	O
parameters	O
were	O
assessed	O
for	O
any	O
significant	O
distribution	O
bias	O
among	O
different	O
HA	O
phenotypes	O
.	O

Our	O
analyses	O
suggest	O
that	O
'	O
mutations	O
in	O
evolutionary	O
conserved	O
residues	O
'	O
,	O
'	O
mutations	O
in	O
buried	O
residues	O
'	O
,	O
mutation	B-Reg
-	I-Reg
induced	I-Reg
'	O
steric	O
clash	O
'	O
and	O
'	B-MPA
surface	I-MPA
electrostatic	I-MPA
potential	I-MPA
alteration	I-MPA
'	I-MPA
act	O
as	O
risk	O
factors	B-Reg
towards	O
severe	O
HA	B-Disease
.	O

We	O
have	O
developed	O
a	O
grading	O
system	O
for	O
FVIII	O
mutations	O
combining	O
the	O
severity	O
determinants	O
,	O
and	O
the	O
grading	O
pattern	O
correlates	O
with	O
HA	O
phenotype	O
.	O

This	O
study	O
will	O
help	O
to	O
correctly	O
associate	O
the	O
HA	O
phenotype	O
with	O
a	O
mutation	O
and	O
aid	O
early	O
characterization	O
of	O
novel	O
variants	O
.	O

X	B-Disease
-	I-Disease
linked	I-Disease
adrenal	I-Disease
hypoplasia	I-Disease
congenita	I-Disease
:	I-Disease
clinical	O
and	O
follow	O
-	O
up	O
findings	O
of	O
two	O
kindreds	O
,	O
one	O
with	B-Reg
a	O
novel	O
NR0B1	B-Gene
mutation	B-Var
.	O

X	B-Disease
-	I-Disease
linked	I-Disease
adrenal	I-Disease
hypoplasia	I-Disease
congenita	I-Disease
typically	O
manifests	O
as	O
primary	O
adrenal	B-Disease
insufficiency	I-Disease
in	O
the	O
newborn	O
age	O
and	O
hypogonadotropic	B-Disease
hypogonadism	I-Disease
in	O
males	O
,	O
being	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
NR0B1	B-Gene
gene	O
.	O

We	O
present	O
the	O
clinical	O
and	O
follow	O
-	O
up	O
findings	O
of	O
two	O
kindreds	O
with	O
NR0B1	O
mutations	O
.	O

The	O
proband	O
of	O
kindred	O
A	O
had	O
a	O
diagnosis	O
of	O
primary	O
adrenal	O
insufficiency	O
when	O
he	O
was	O
a	O
newborn	O
.	O

Family	O
history	O
was	O
relevant	O
for	O
a	O
maternal	O
uncle	O
death	O
at	O
the	O
newborn	O
age	O
.	O

Beyond	O
2	O
year	O
-	O
old	O
steroid	O
measurements	O
rendered	O
undetectable	O
and	O
delayed	O
bone	O
age	O
was	O
noticed	O
.	O

Molecular	O
analysis	O
of	O
NR0B1	B-Gene
gene	O
revealed	O
a	O
previously	O
unreported	O
mutation	O
(	B-Var
c.1084A	I-Var
>	I-Var
T	I-Var
)	I-Var
,	O
leading	B-Reg
to	I-Reg
a	O
premature	O
stop	O
codon	O
,	O
p	B-MPA
.	I-MPA
Lys362	I-MPA
*	I-MPA
,	O
in	O
exon	O
1	O
.	O

His	O
mother	O
and	O
sister	O
were	O
asymptomatic	O
carriers	O
.	O

At	O
14	O
year	O
-	O
old	O
he	O
had	O
3	O
mL	O
of	O
testicular	O
volume	O
and	O
biochemical	O
surveys	O
(	O
LH	O
<	O
0.1	O
UI	O
/	O
L	O
,	O
total	O
testosterone	O
<	O
10	O
ng	O
/	O
dL	O
)	O
concordant	O
with	O
hypogonadotrophic	O
hypogonadism	O
.	O

Kindred	O
B	O
had	O
two	O
males	O
diagnosed	O
with	O
adrenal	O
insufficiency	O
at	O
the	O
newborn	O
age	O
.	O

By	O
3	O
year	O
-	O
old	O
both	O
siblings	O
had	O
undetectable	O
androgen	O
levels	O
and	O
delayed	O
bone	O
age	O
.	O

NR0B1	O
molecular	O
analysis	O
identified	O
a	O
nonsense	O
mutation	O
in	O
both	O
cases	O
,	O
c.243C	O
>	O
G	O
;	O
p	O
.	O
Tyr81	O
*	O
,	O
in	O
exon	O
1	O
.	O

Their	O
mother	O
and	O
sister	O
were	O
asymptomatic	O
carriers	O
.	O

At	O
14	O
year	O
-	O
old	O
(	O
Tanner	O
stage	O
1	O
)	O
hypothalamic	O
-	O
pituitary	O
-	O
gonadal	O
axis	O
evaluation	O
in	O
both	O
males	O
(	O
LH	O
<	O
0.1UI	O
/	O
L	O
,	O
total	O
testosterone	O
<	O
10	O
ng	O
/	O
dL	O
)	O
confirmed	O
hypogonadotropic	O
hypogonadism	O
.	O

In	O
conclusion	O
,	O
biochemical	O
profiles	O
,	O
bone	O
age	O
and	O
an	O
X	O
-	O
linked	O
inheritance	O
led	O
to	O
suspicion	O
of	O
NR0B1	O
mutations	O
.	O

Two	O
nonsense	O
mutations	O
were	O
detected	O
in	O
both	O
kindreds	O
,	O
one	O
previously	O
unreported	O
(	O
c.1084A	O
>	O
T	O
;	O
p	O
.	O
Lys362	O
*	O
)	O
.	O

Mutation	O
identification	O
allowed	O
the	O
timely	O
institution	O
of	O
testosterone	O
in	O
patients	O
at	O
puberty	O
and	O
an	O
appropriate	O
genetic	O
counselling	O
for	O
relatives	O
.	O

Phenotypic	O
Variability	O
and	O
Newly	O
Identified	O
Mutations	B-Var
of	O
the	O
IVD	B-Gene
Gene	O
in	O
Japanese	O
Patients	O
with	B-Reg
Isovaleric	B-Disease
Acidemia	I-Disease
.	O

Isovaleric	O
acidemia	O
(	O
IVA	O
)	O
is	O
an	O
autosomal	O
recessive	O
inborn	O
error	O
affecting	O
leucine	O
metabolism	O
.	O

It	O
is	O
caused	O
by	O
a	O
deficiency	O
in	O
isovaleryl	O
-	O
CoA	O
dehydrogenase	O
(	O
IVD	O
)	O
,	O
a	O
mitochondrial	O
matrix	O
enzyme	O
that	O
catalyzes	O
the	O
oxidation	O
of	O
isovaleryl	O
-	O
CoA	O
to	O
3-methylcrotonyl	O
-	O
CoA.	O
IVD	O
is	O
a	O
FAD	O
-	O
containing	O
enzyme	O
,	O
consisting	O
of	O
four	O
identical	O
subunits	O
.	O

Clinical	O
features	O
of	O
IVA	O
include	O
poor	O
feeding	O
,	O
vomiting	O
,	O
lethargy	O
,	O
developmental	O
delay	O
,	O
metabolic	O
acidosis	O
,	O
and	O
a	O
characteristic	O
"	O
sweaty	O
foot	O
"	O
odor	O
.	O

IVA	O
is	O
one	O
of	O
the	O
target	O
disorders	O
for	O
newborn	O
screening	O
by	O
tandem	O
mass	O
spectrometry	O
(	O
MS	O
/	O
MS	O
)	O
.	O

The	O
human	O
IVD	O
gene	O
is	O
located	O
on	O
chromosome	O
15q	O
.	O

To	O
date	O
,	O
over	O
50	O
disease	O
-	O
causing	O
mutations	O
have	O
been	O
reported	O
worldwide	O
.	O

In	O
this	O
study	O
,	O
we	O
searched	O
for	O
IVD	O
mutations	O
in	O
five	O
Japanese	O
patients	O
with	O
IVA	O
(	O
neonatal	O
type	O
,	O
two	O
patients	O
;	O
chronic	O
intermittent	O
type	O
,	O
two	O
patients	O
;	O
and	O
mild	O
biochemical	O
type	O
,	O
one	O
patient	O
)	O
.	O

The	O
diagnosis	O
of	O
IVA	O
was	O
confirmed	O
by	O
urinary	O
organic	O
acid	O
analysis	O
using	O
gas	O
chromatography	O
and	O
mass	O
spectrometry	O
.	O

All	O
coding	O
exons	O
and	O
the	O
flanking	O
introns	O
in	O
the	O
IVD	O
gene	O
were	O
amplified	O
by	O
PCR	O
and	O
were	O
directly	O
sequenced	O
.	O

We	O
thus	O
identified	O
six	O
hitherto	O
unknown	O
mutations	O
(	O
p	O
.	O
G94D	O
,	O
p	O
.	O
E116	O
K	O
,	O
p	O
.	O
M167	O
T	O
,	O
p	O
.	O
L243P	O
,	O
p	O
.	O
L246P	O
,	O
and	O
c.696	O
+	O
1G	O
>	O
T	O
)	O
and	O
four	O
previously	O
reported	O
(	O
p	O
.	O
R53P	O
,	O
p	O
.	O
R395C	O
,	O
p	O
.	O
Y403C	O
,	O
and	O
p	O
.	O
E411	O
K	O
)	O
pathogenic	O
mutations	O
.	O

All	O
patients	O
were	O
compound	O
heterozygotes	O
,	O
and	O
each	O
mutation	O
was	O
identified	O
in	O
a	O
single	O
patient	O
.	O

Pathogenicity	O
of	O
newly	O
identified	O
mutations	O
was	O
validated	O
using	O
computational	O
programs	O
.	O

Among	O
them	O
,	O
the	O
p	B-Var
.	I-Var
M167	I-Var
T	I-Var
is	O
believed	O
to	O
influence	B-Reg
FAD	B-Interaction
binding	I-Interaction
,	O
as	O
the	O
position	O
167	O
is	O
present	O
in	O
one	O
of	O
the	O
FAD	O
-	O
binding	O
sites	O
.	O

Our	O
results	O
have	O
illustrated	O
the	O
heterogeneous	O
mutation	O
spectrum	O
and	O
clinical	O
presentation	O
of	O
IVA	O
in	O
the	O
Japanese	O
patients	O
.	O

Molecular	O
and	O
clinical	O
features	O
of	O
inherited	O
neuropathies	O
due	O
to	O
PMP22	O
duplication	O
.	O

PMP22	O
is	O
a	O
transmembrane	O
glycoprotein	O
component	O
of	O
myelin	O
,	O
important	O
for	O
myelin	O
functioning	O
.	O

Mutation	B-Var
of	O
PMP22	B-Gene
gene	O
which	O
encodes	O
for	O
the	O
production	O
of	O
PMP22	O
glycoprotein	O
is	O
associated	B-Reg
with	I-Reg
a	O
variety	O
of	O
inherited	O
neuropathies	B-Disease
.	O

This	O
literature	O
review	O
sought	O
to	O
review	O
the	O
molecular	O
mechanism	O
and	O
clinical	O
features	O
of	O
inherited	O
neuropathies	O
caused	O
by	O
PMP22	O
duplication	O
.	O

PMP22	O
duplication	O
causes	O
CMT1A	O
which	O
accounts	O
for	O
more	O
than	O
half	O
of	O
all	O
CMT	O
cases	O
and	O
about	O
70	O
%	O
of	O
CMT1	O
cases	O
.	O

It	O
manifests	O
with	O
muscle	O
weakness	O
,	O
depressed	O
reflexes	O
,	O
impaired	O
distal	O
sensation	O
,	O
hand	O
and	O
foot	O
deformities	O
,	O
slowing	O
of	O
NCV	O
and	O
onion	O
bulbs	O
.	O

With	O
no	O
specific	O
treatment	O
available	O
,	O
it	O
is	O
managed	O
conservatively	O
.	O

Future	O
treatment	O
may	O
be	O
based	O
on	O
the	O
molecular	O
genetics	O
of	O
the	O
disease	O
.	O

A	O
novel	O
gene	O
insertion	B-Var
combined	O
with	O
a	O
missense	O
mutation	O
causing	B-Reg
factor	B-Disease
VII	I-Disease
deficiency	I-Disease
in	O
two	O
unrelated	O
Chinese	O
families	O
.	O

Hereditary	O
coagulation	O
factor	O
VII	O
(	O
FVII	O
)	O
deficiency	O
is	O
a	O
rare	O
bleeding	O
disorder	O
characterized	O
by	O
reduced	O
FVII	O
activity	O
(	O
FVII	O
:	O
C	O
)	O
and	O
inconsistent	O
FVII	O
antigen	O
(	O
FVII	O
:	O
Ag	O
)	O
.	O

In	O
our	O
study	O
,	O
two	O
pregnant	O
probands	O
were	O
diagnosed	O
with	O
FVII	O
deficiency	O
,	O
based	O
on	O
the	O
tests	O
that	O
FVII	O
:	O
C	O
were	O
both	O
3	O
%	O
and	O
FVII	O
:	O
Ag	O
were	O
less	O
than	O
7.5	O
%	O
.	O

Gene	O
sequencing	O
revealed	O
the	O
same	O
compound	O
mutations	O
,	O
a	O
recurrent	O
missense	O
mutation	O
p	O
.	O
Arg277Cys	O
and	O
a	O
novel	O
insertion	O
mutation	O
g.11520	O
-	O
11521insT.	O
What	O
is	O
more	O
,	O
haplotype	O
analysis	O
of	O
SNPs	O
excluded	O
the	O
possibility	O
of	O
consanguinity	O
between	O
the	O
two	O
families	O
.	O

According	O
to	O
the	O
model	O
,	O
we	O
speculated	O
that	O
although	O
the	O
insertion	B-Var
mutation	O
was	O
close	O
to	O
the	O
carboxy	O
-	O
terminal	O
,	O
it	O
induced	B-PosReg
the	O
protein	B-MPA
extension	I-MPA
and	O
affected	B-Reg
the	B-MPA
3	I-MPA
'	I-MPA
untranslated	I-MPA
region	I-MPA
of	O
F7	B-Gene
gene	O
,	O
which	O
is	O
significant	O
to	O
posttranscriptional	O
regulation	O
.	O

Hypothetically	O
,	O
the	O
stability	O
or	O
translational	O
efficiency	O
of	O
mRNA	O
may	O
be	O
influenced	O
,	O
resulting	O
in	O
reducing	O
FVII	O
:	O
C.	O
Hereditary	O
spastic	O
paraplegia	O
SPG4	O
:	O
what	O
is	O
known	O
and	O
not	O
known	O
about	O
the	O
disease	O
.	O

Mutations	O
in	O
more	O
than	O
70	O
distinct	O
loci	O
and	O
more	O
than	O
50	O
mutated	O
gene	O
products	O
have	O
been	O
identified	O
in	O
patients	O
with	O
hereditary	B-Disease
spastic	I-Disease
paraplegias	I-Disease
,	O
a	O
diverse	O
group	O
of	O
neurological	O
disorders	O
characterized	O
predominantly	O
,	O
but	O
not	O
exclusively	O
,	O
by	O
progressive	O
lower	O
limb	O
spasticity	O
and	O
weakness	O
resulting	O
from	O
distal	O
degeneration	O
of	O
corticospinal	O
tract	O
axons	O
.	O

Mutations	B-Var
in	O
the	O
SPAST	B-Gene
(	O
previously	O
known	O
as	O
SPG4	B-Gene
)	I-Gene
gene	O
that	O
encodes	O
the	O
microtubule	O
-	O
severing	O
protein	O
called	O
spastin	O
,	O
are	O
the	O
most	O
common	O
cause	B-Reg
of	O
the	O
disease	B-Disease
.	O

The	O
aetiology	O
of	O
the	O
disease	O
is	O
poorly	O
understood	O
,	O
but	O
partial	O
loss	B-NegReg
of	O
microtubule	B-CPA
-	I-CPA
severing	I-CPA
activity	I-CPA
resulting	O
from	O
inactivating	B-Var
mutations	I-Var
in	O
one	O
SPAST	B-Gene
allele	O
is	O
the	O
most	O
postulated	O
explanation	O
.	O

Microtubule	O
severing	O
is	O
important	O
for	O
regulating	O
various	O
aspects	O
of	O
the	O
microtubule	O
array	O
,	O
including	O
microtubule	O
number	O
,	O
length	O
,	O
and	O
mobility	O
.	O

In	O
addition	O
,	O
higher	O
numbers	O
of	O
dynamic	O
plus	O
-	O
ends	O
of	O
microtubules	O
,	O
resulting	O
from	O
microtubule	O
-	O
severing	O
events	O
,	O
may	O
play	O
a	O
role	O
in	O
endosomal	O
tubulation	O
and	O
fission	O
.	O

Even	O
so	O
,	O
there	O
is	O
growing	O
evidence	O
that	O
decreased	O
severing	O
of	O
microtubules	O
does	O
not	O
fully	O
explain	O
HSP	O
-	O
SPG4	O
.	O

The	O
presence	O
of	O
two	O
translation	O
initiation	O
codons	O
in	O
SPAST	O
allows	O
synthesis	O
of	O
two	O
spastin	O
isoforms	O
:	O
a	O
full	O
-	O
length	O
isoform	O
called	O
M1	O
and	O
a	O
slightly	O
shorter	O
isoform	O
called	O
M87	O
.	O

M87	O
is	O
more	O
abundant	O
in	O
both	O
neuronal	O
and	O
non	O
-	O
neuronal	O
tissues	O
.	O

Studies	O
on	O
rodents	O
suggest	O
that	O
M1	O
is	O
only	O
readily	O
detected	O
in	O
adult	O
spinal	O
cord	O
,	O
which	O
is	O
where	O
nerve	O
degeneration	O
mainly	O
occurs	O
in	O
humans	O
with	O
HSP	O
-	O
SPG4	O
.	O

M1	O
,	O
due	O
to	O
its	O
hydrophobic	O
N	O
-	O
terminal	O
domain	O
not	O
shared	O
by	O
M87	O
,	O
may	O
insert	O
into	O
endoplasmic	O
reticulum	O
membrane	O
,	O
and	O
together	O
with	O
reticulons	O
,	O
atlastin	O
and	O
REEP1	O
,	O
may	O
play	O
a	O
role	O
in	O
the	O
morphogenesis	O
of	O
this	O
organelle	O
.	O

Some	B-Var
mutated	I-Var
spastins	B-Protein
may	O
act	O
in	O
dominant	O
-	O
negative	O
fashion	O
to	O
lower	B-NegReg
microtubule	B-CPA
-	I-CPA
severing	I-CPA
activity	I-CPA
,	O
but	O
others	B-Var
have	O
detrimental	B-NegReg
effects	I-NegReg
on	O
neurons	B-CPA
without	O
further	O
lowering	O
microtubule	O
severing	O
.	O

The	O
observed	O
adverse	B-NegReg
effects	I-NegReg
on	O
microtubule	B-CPA
dynamics	I-CPA
,	O
axonal	B-CPA
transport	I-CPA
,	O
endoplasmic	B-CPA
reticulum	I-CPA
,	O
and	O
endosomal	B-CPA
trafficking	I-CPA
are	O
likely	O
caused	O
not	O
only	O
by	O
diminished	B-NegReg
severing	B-CPA
of	I-CPA
microtubules	I-CPA
,	O
but	O
also	O
by	O
neurotoxicity	B-CPA
of	B-Reg
mutant	B-Var
spastin	B-Protein
proteins	I-Protein
,	O
chiefly	O
M1	B-Protein
.	O

Some	O
large	O
deletions	O
in	O
SPAST	O
might	O
also	O
affect	O
the	O
function	O
of	O
adjacent	O
genes	O
,	O
further	O
complicating	O
the	O
aetiology	O
of	O
the	O
disease	O
.	O

Clinical	O
phenotype	O
in	O
genetically	O
confirmed	O
von	O
Willebrand	O
disease	O
type	O
2N	O
patients	O
reflects	O
a	O
haemophilia	O
A	O
phenotype	O
.	O

INTRODUCTION	O
:	O
Von	B-Disease
Willebrand	I-Disease
disease	I-Disease
(	I-Disease
VWD	I-Disease
)	I-Disease
type	I-Disease
2N	I-Disease
is	O
characterized	O
by	O
a	O
defective	B-NegReg
binding	B-Interaction
of	O
factor	B-Protein
VIII	I-Protein
(	O
FVIII	O
)	O
to	O
von	B-Protein
Willebrand	I-Protein
factor	I-Protein
(	O
VWF	O
)	O
resulting	O
in	O
diminished	B-NegReg
plasma	B-CPA
FVIII	I-CPA
levels	I-CPA
and	O
a	O
clinical	O
phenotype	O
mimicking	O
mild	O
haemophilia	O
A.	O
Several	O
mutations	B-Var
in	O
the	O
FVIII	O
binding	O
site	O
of	O
VWF	B-Gene
have	O
been	O
reported	O
.	O

AIM	O
:	O
This	O
study	O
aims	O
to	O
examine	O
the	O
effect	O
of	O
genotype	O
on	O
clinical	O
phenotype	O
in	O
a	O
cohort	O
of	O
VWD	O
2N	O
patients	O
.	O

METHODS	O
:	O
Patients	O
with	O
at	O
least	O
one	O
genetically	O
confirmed	O
2N	O
mutation	O
were	O
selected	O
retrospectively	O
from	O
a	O
cohort	O
of	O
patients	O
with	O
suspected	O
VWD	O
.	O

Clinical	O
and	O
laboratory	O
phenotypes	O
including	O
bleeding	O
scores	O
(	O
BS	O
)	O
were	O
obtained	O
and	O
analysed	O
.	O

RESULTS	O
:	O
Forty	O
-	O
two	O
VWD	O
2N	O
patients	O
with	O
a	O
mean	O
age	O
of	O
44	O
years	O
were	O
included	O
.	O

Eleven	O
patients	O
were	O
homozygous	O
or	O
compound	O
heterozygous	O
(	O
genetically	O
confirmed	O
group	O
)	O
and	O
31	O
patients	O
were	O
heterozygously	O
affected	O
(	O
carriers	O
group	O
)	O
.	O

Statistically	O
significant	O
differences	O
between	O
genetically	O
confirmed	O
VWD	O
2N	O
patients	O
and	O
carriers	O
were	O
found	O
in	O
FVIII	O
activity	O
,	O
VWF	O
antigen	O
levels	O
,	O
VWF	O
-	O
FVIII	O
binding	O
capacity	O
,	O
FVIII	O
/	O
VWF	O
antigen	O
ratio	O
(	O
all	O
P<0.001	O
)	O
,	O
VWF	O
-	O
ristocetin	O
activity	O
(	O
p=0.001	O
)	O
and	O
VWF	O
collagen	O
binding	O
(	O
P	O
=	O
0.002	O
)	O
.	O

Median	O
BS	O
was	O
6	O
in	O
genetically	O
confirmed	O
VWD	O
2N	O
patients	O
compared	O
with	O
3	O
in	O
carriers	O
(	O
P	O
=	O
0.047	O
)	O
.	O

Haemarthrosis	O
,	O
muscle	O
haematomas	O
and	O
postpartum	O
haemorrhage	O
were	O
only	O
reported	O
in	O
genetically	O
confirmed	O
2N	O
patients	O
.	O

CONCLUSION	O
:	O
Phenotypic	O
analysis	O
showed	O
that	O
all	O
laboratory	O
parameters	O
are	O
lower	O
in	O
genetically	O
confirmed	O
VWD	O
2N	O
patients	O
compared	O
with	O
heterozygous	O
2N	O
carriers	O
.	O

The	O
clinical	O
phenotype	O
in	O
genetically	O
confirmed	O
VWD	O
2N	O
patients	O
is	O
comparable	O
to	O
mild	O
haemophilia	O
A	O
patients	O
and	O
more	O
severe	O
than	O
heterozygous	O
2N	O
carriers	O
.	O

A	O
novel	O
SLC12A3	B-Gene
gene	O
homozygous	O
mutation	B-Var
of	B-Reg
Gitelman	B-Disease
syndrome	I-Disease
in	O
an	O
Asian	O
pedigree	O
and	O
literature	O
review	O
.	O

OBJECTIVES	O
:	O
Gitelman	B-Disease
syndrome	I-Disease
(	O
GS	O
)	O
is	O
an	O
autosomal	O
recessive	O
disease	O
characterized	O
by	O
hypokalemic	O
metabolic	O
alkalosis	O
in	O
combination	O
with	O
significant	O
hypomagnesemia	O
and	O
hypocalciuria	O
which	O
is	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
SLC12A3	B-Gene
gene	O
.	O

In	O
this	O
study	O
,	O
we	O
reported	O
a	O
case	O
of	O
GS	O
pedigree	O
and	O
reviewed	O
pertinent	O
literature	O
so	O
as	O
to	O
explore	O
the	O
relationship	O
between	O
clinical	O
characteristics	O
and	O
genotype	O
meanwhile	O
provide	O
recommendations	O
for	O
the	O
diagnosis	O
and	O
treatment	O
of	O
GS	O
.	O

DESIGN	O
AND	O
METHODS	O
:	O
This	O
is	O
a	O
pedigree	O
-	O
based	O
genetic	O
study	O
of	O
GS	O
and	O
11	O
members	O
from	O
one	O
family	O
were	O
included	O
.	O

We	O
summarized	O
their	O
clinical	O
features	O
,	O
analyzed	O
laboratory	O
parameters	O
related	O
to	O
GS	O
and	O
SLC12A3	O
gene	O
.	O

RESULTS	O
:	O
The	O
proband	O
experienced	O
intermittent	O
severe	O
symptoms	O
of	O
weakness	O
accompanied	O
by	O
significant	O
hypokalemia	O
,	O
hypomagnesemia	O
and	O
hypocalciuria	O
in	O
laboratory	O
test	O
with	O
poor	O
treatments	O
.	O

His	O
mother	O
had	O
more	O
slight	O
symptoms	O
of	O
weakness	O
than	O
him	O
with	O
mild	O
hypokalemia	O
and	O
hypocalciuria	O
.	O

Mild	O
hypomagnesemia	O
was	O
also	O
observed	O
in	O
his	O
sister	O
with	O
occasional	O
weakness	O
.	O

All	O
other	O
pedigree	O
members	O
had	O
normal	O
laboratory	O
test	O
with	O
no	O
GS	O
-	O
related	O
symptoms	O
.	O

A	O
homozygous	O
mutation	O
of	O
SLC12A3	O
gene	O
(	O
c.488C	O
>	O
T	O
)	O
was	O
detected	O
by	O
genetic	O
testing	O
in	O
three	O
members	O
,	O
and	O
six	O
were	O
carriers	O
of	O
this	O
mutation	O
.	O

CONCLUSIONS	O
:	O
Genotype	O
and	O
phenotype	O
vary	O
significantly	O
among	O
GS	O
patients	O
.	O

Male	O
patients	O
tend	O
to	O
experience	O
more	O
severe	O
symptoms	O
and	O
poor	O
treatment	O
effect	O
.	O

Further	O
large	O
-	O
scale	O
population	O
,	O
animal	O
,	O
and	O
molecular	O
biology	O
experiments	O
are	O
required	O
to	O
investigate	O
the	O
complexity	O
of	O
GS	O
and	O
to	O
find	O
a	O
better	O
treatment	O
regimen	O
for	O
this	O
disease	O
.	O

Darier	O
disease	O
in	O
israel	O
:	O
combined	O
evaluation	O
of	O
genetic	O
and	O
neuropsychiatric	O
aspects	O
.	O

BACKGROUND	O
:	O
Darier	B-Disease
disease	I-Disease
(	O
DD	O
)	O
is	O
a	O
rare	O
genodermatose	O
caused	B-Reg
by	I-Reg
heterozygous	O
mutations	B-Var
in	O
the	O
ATP2A2	B-Gene
gene	O
and	O
has	O
been	O
associated	O
with	O
neuropsychiatric	O
manifestations	O
.	O

OBJECTIVES	O
:	O
To	O
investigate	O
the	O
genetic	O
basis	O
of	O
Israeli	O
patients	O
with	O
DD	O
,	O
and	O
its	O
association	O
with	O
neuropsychiatric	O
phenotype	O
.	O

METHODS	O
:	O
A	O
cohort	O
of	O
32	O
families	O
comprising	O
74	O
affected	O
individuals	O
and	O
13	O
unaffected	O
family	O
members	O
recruited	O
from	O
the	O
Haemek	O
Dermatology	O
Department	O
and	O
other	O
dermatology	O
clinics	O
in	O
Israel	O
were	O
evaluated	O
by	O
detailed	O
questionnaires	O
,	O
physical	O
examination	O
,	O
and	O
genetic	O
analysis	O
.	O

Main	O
outcome	O
measures	O
were	O
genetic	O
mutations	O
,	O
psychiatric	O
profile	O
,	O
and	O
their	O
association	O
.	O

RESULTS	O
:	O
23	O
mutations	O
in	O
ATP2A2	O
gene	O
were	O
scattered	O
over	O
the	O
entire	O
gene	O
,	O
14	O
of	O
them	O
novel	O
.	O

Two	O
families	O
shared	O
the	O
same	O
mutation	O
.	O

Twenty	O
-	O
one	O
patients	O
(	O
28.3	O
%	O
)	O
had	O
a	O
history	O
of	O
psychiatric	O
disorder	O
,	O
most	O
of	O
them	O
mood	O
disorders	O
;	O
another	O
7	O
(	O
9.4	O
%	O
)	O
patients	O
were	O
highly	O
suspected	O
of	O
having	O
a	O
psychiatric	O
disorder	O
;	O
21	O
(	O
27.6	O
%	O
)	O
reported	O
suicidal	O
thoughts	O
;	O
and	O
5	O
(	O
6.6	O
%	O
)	O
had	O
attempted	O
suicide	O
.	O

Psychiatric	O
phenotype	O
demonstrated	O
inter-	O
and	O
intra	O
-	O
familial	O
variability	O
,	O
and	O
was	O
not	O
associated	O
with	O
disease	O
severity	O
,	O
family	O
history	O
of	O
psychiatric	O
disease	O
,	O
or	O
mutation	O
location	O
.	O

CONCLUSIONS	O
:	O
The	O
cohort	O
demonstrated	O
genetic	O
heterogeneity	O
with	O
no	O
mutation	O
cluster	O
along	O
the	O
gene	O
,	O
and	O
high	O
prevalence	O
of	O
psychiatric	O
disorders	O
.	O

Although	O
no	O
clear	O
genotype	O
-	O
phenotype	O
correlation	O
was	O
found	O
,	O
the	O
results	O
point	O
to	O
a	O
major	O
effect	O
of	O
genetic	O
background	O
on	O
psychiatric	O
phenotype	O
,	O
together	O
with	O
other	O
modifiers	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

A	O
recurrent	B-Var
germline	I-Var
mutation	I-Var
in	O
the	O
PIGA	B-Gene
gene	O
causes	B-Reg
Simpson	B-Disease
-	I-Disease
Golabi	I-Disease
-	I-Disease
Behmel	I-Disease
syndrome	I-Disease
type	I-Disease
2	I-Disease
.	O

Hypomorphic	O
germline	O
mutations	O
in	O
the	O
PIGA	O
(	O
phosphatidylinositol	O
glycan	O
class	O
A	O
)	O
gene	O
recently	O
were	O
recognized	O
as	O
the	O
cause	O
of	O
a	O
clinically	O
heterogeneous	O
spectrum	O
of	O
X	O
-	O
linked	O
disorders	O
including	O
(	O
i	O
)	O
early	O
onset	O
epileptic	O
encephalopathy	O
with	O
severe	O
muscular	O
hypotonia	O
,	O
dysmorphism	O
,	O
multiple	O
congenital	O
anomalies	O
,	O
and	O
early	O
death	O
(	O
"	O
MCAHS2	O
"	O
)	O
,	O
(	O
ii	O
)	O
neurodegenerative	O
encephalopathy	O
with	O
systemic	O
iron	O
overload	O
(	O
ferro	O
-	O
cerebro	O
-	O
cutaneous	O
syndrome	O
,	O
"	O
FCCS	O
"	O
)	O
,	O
and	O
(	O
iii	O
)	O
intellectual	O
disability	O
and	O
seizures	O
without	O
dysmorphism	O
.	O

Previous	O
studies	O
showed	O
that	O
the	O
recurrent	O
PIGA	O
germline	O
mutation	O
c.1234C	O
>	O
T	O
(	O
p	O
.	O
Arg412	O
*	O
)	O
leads	O
to	O
a	O
clinical	O
phenotype	O
at	O
the	O
most	O
severe	O
end	O
of	O
the	O
spectrum	O
associated	O
with	O
early	O
infantile	O
lethality	O
.	O

We	O
identified	O
three	O
additional	O
individuals	O
from	O
two	O
unrelated	O
families	O
with	O
the	O
same	O
PIGA	O
mutation	O
.	O

Major	O
clinical	O
findings	O
include	O
early	O
onset	O
intractable	O
epileptic	O
encephalopathy	O
with	O
a	O
burst	O
-	O
suppression	O
pattern	O
on	O
EEG	O
,	O
generalized	O
muscular	O
hypotonia	O
,	O
structural	O
brain	O
abnormalities	O
,	O
macrocephaly	O
and	O
increased	O
birth	O
weight	O
,	O
joint	O
contractures	O
,	O
coarse	O
facial	O
features	O
,	O
widely	O
spaced	O
eyes	O
,	O
a	O
short	O
nose	O
with	O
anteverted	O
nares	O
,	O
gingival	O
overgrowth	O
,	O
a	O
wide	O
mouth	O
,	O
short	O
limbs	O
with	O
short	O
distal	O
phalanges	O
,	O
and	O
a	O
small	O
penis	O
.	O

Based	O
on	O
the	O
phenotypic	O
overlap	O
with	O
Simpson	O
-	O
Golabi	O
-	O
Behmel	O
syndrome	O
type	O
2	O
(	O
SGBS2	O
)	O
,	O
we	O
hypothesized	O
that	O
both	O
disorders	O
might	O
have	O
the	O
same	O
underlying	O
cause	O
.	O

We	O
were	O
able	O
to	O
confirm	O
the	O
same	O
c.1234C	O
>	O
T	O
(	O
p	O
.	O
Arg412	O
*	O
)	O
mutation	O
in	O
the	O
DNA	O
sample	O
from	O
an	O
affected	O
fetus	O
of	O
the	O
original	O
family	O
affected	O
with	O
SGBS2	O
.	O

We	O
conclude	O
that	O
the	O
recurrent	O
PIGA	B-Gene
germline	O
mutation	O
c.1234C	B-Var
>	I-Var
T	I-Var
leads	B-Reg
to	I-Reg
a	O
recognizable	B-CPA
clinical	I-CPA
phenotype	I-CPA
with	O
a	O
poor	O
prognosis	O
and	O
is	O
the	O
cause	B-Reg
of	O
SGBS2	B-Disease
.	O

©	O
2015	O
Wiley	O
Periodicals	O
,	O
Inc.	O
Incontinentia	O
pigmenti	O
(	O
Bloch	O
-	O
Sulzberger	O
syndrome	O
)	O
.	O

Incontinentia	B-Disease
pigmenti	I-Disease
(	O
IP	O
;	O
Bloch	O
-	O
Sulzberger	O
syndrome	O
;	O
OMIM	O
#	O
308300	O
)	O
is	O
an	O
X	O
-	O
linked	O
dominant	O
neurocutaneous	O
disorder	O
with	O
presumed	O
male	O
lethality	O
.	O

It	O
is	O
usually	O
diagnosed	O
in	O
female	O
newborns	O
based	O
on	O
skin	O
features	O
(	O
erythematous	O
,	O
vesicular	O
,	O
or	O
bullous	O
eruption	O
in	O
linear	O
streaks	O
)	O
.	O

The	O
skin	O
lesions	O
evolve	O
into	O
a	O
verrucous	O
stage	O
,	O
followed	O
by	O
atrophy	O
and	O
scarring	O
,	O
leaving	O
linear	O
areas	O
of	O
hypopigmentation	O
and	O
hyperpigmented	O
macules	O
in	O
bizarre	O
patterns	O
following	O
Blaschko	O
's	O
lines	O
.	O

Systemic	O
and	O
neurologic	O
complications	O
include	O
focal	O
seizures	O
and	O
hemorrhagic	O
cerebral	O
infarction	O
in	O
infants	O
,	O
and	O
retinal	O
vasculopathy	O
leading	O
to	O
blindness	O
.	O

Hypodontia	O
,	O
conical	O
or	O
pegged	O
teeth	O
,	O
and	O
linear	O
areas	O
of	O
alopecia	O
persist	O
into	O
adulthood	O
.	O

IP	B-Disease
is	O
caused	B-Reg
by	I-Reg
mutation	B-Var
of	O
the	O
IKBKG	B-Gene
/	I-Gene
NEMO	I-Gene
gene	O
on	O
Xq28	O
.	O

Deletion	O
of	O
exons	O
4	O
to	O
10	O
(	O
NEMOΔ4	O
-	O
10	O
)	O
accounts	O
for	O
about	O
80	O
%	O
of	O
cases	O
(	O
familial	O
and	O
sporadic	O
)	O
.	O

NEMO	B-Gene
mutation	B-Var
leads	O
to	O
loss	B-NegReg
of	I-NegReg
function	I-NegReg
of	O
NF	B-MPA
-	I-MPA
κB	I-MPA
,	O
a	O
critical	O
protein	O
that	O
modulates	O
cellular	O
proliferation	O
,	O
apoptosis	O
,	O
and	O
response	O
to	O
proinflammatory	O
factors	O
,	O
leading	B-Reg
to	I-Reg
the	O
characteristic	O
features	O
of	O
IP	B-Disease
.	O

In	O
female	O
carriers	O
,	O
selective	O
loss	O
of	O
cells	O
expressing	O
the	O
mutant	O
X	O
-	O
chromosome	O
results	O
in	O
completely	O
skewed	O
X	O
-	O
inactivation	O
in	O
the	O
majority	O
of	O
cases	O
.	O

Study	O
of	O
mouse	O
models	O
in	O
which	O
various	O
components	O
of	O
the	O
NF	O
-	O
κB	O
pathway	O
(	O
including	O
NEMO	O
)	O
have	O
been	O
knocked	O
out	O
has	O
contributed	O
significantly	O
to	O
our	O
understanding	O
of	O
disease	O
pathogenesis	O
.	O

Lipoid	O
proteinosis	O
.	O

Lipoid	B-Disease
proteinosis	I-Disease
is	O
a	O
rare	O
autosomal	O
recessive	O
disorder	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
ECM1	B-Gene
,	O
encoding	O
extracellular	O
matrix	O
protein	O
1	O
,	O
a	O
glycoprotein	O
expressed	O
in	O
many	O
organs	O
and	O
which	O
has	O
important	O
protein	O
-	O
protein	O
interactions	O
in	O
tissue	O
homeostasis	O
.	O

Although	O
the	O
disease	O
usually	O
presents	O
clinically	O
with	O
warty	O
infiltration	O
of	O
the	O
skin	O
and	O
mucous	O
membranes	O
and	O
a	O
hoarse	O
voice	O
,	O
neuropsychological	O
and	O
neuropsychiatric	O
abnormalities	O
are	O
often	O
prominent	O
features	O
.	O

There	O
may	O
be	O
bean-	O
or	O
comma	O
-	O
shaped	O
intracranial	O
calcifications	O
,	O
often	O
selectively	O
affecting	O
the	O
amygdala	O
.	O

Patients	O
with	O
lipoid	O
proteinosis	O
therefore	O
have	O
been	O
used	O
as	O
models	O
for	O
demonstrating	O
physiologic	O
and	O
pathologic	O
abnormalities	O
of	O
the	O
amygdala	O
with	O
respect	O
to	O
fear	O
processing	O
,	O
affect	O
and	O
cognition	O
,	O
anxiety	O
and	O
memory	O
.	O

Clinically	O
,	O
patients	O
may	O
also	O
have	O
epilepsy	O
,	O
especially	O
involving	O
the	O
temporal	O
lobes	O
.	O

Less	O
common	O
or	O
rare	O
disease	O
associations	O
are	O
headache	O
(	O
including	O
migraine	O
)	O
,	O
ataxia	O
,	O
dizziness	O
,	O
schizophrenia	O
,	O
generalized	O
dystonia	O
,	O
transient	O
brachiofacial	O
paralysis	O
,	O
and	O
intracerebral	O
hemorrhage	O
.	O

Beyond	O
the	O
foci	O
of	O
calcification	O
,	O
the	O
cause	O
of	O
the	O
neurologic	O
abnormalities	O
in	O
lipoid	O
proteinosis	O
is	O
unknown	O
,	O
although	O
the	O
ECM1	O
protein	O
can	O
normally	O
bind	O
to	O
various	O
extracellular	O
matrix	O
proteins	O
and	O
glycosaminoglycans	O
as	O
well	O
as	O
certain	O
enzymes	O
,	O
including	O
matrix	O
metalloproteinase	O
9	O
.	O

Loss	O
of	O
key	O
protein	O
-	O
protein	O
interactions	O
may	O
underscore	O
some	O
of	O
the	O
disease	O
pathophysiology	O
.	O

There	O
is	O
currently	O
no	O
effective	O
treatment	O
for	O
lipoid	O
proteinosis	O
and	O
clinical	O
care	O
is	O
largely	O
supportive	O
.	O

Paternal	O
uniparental	O
disomy	O
11p15.5	O
in	O
the	O
pancreatic	O
nodule	O
of	O
an	O
infant	O
with	O
Costello	O
syndrome	O
:	O
Shared	O
mechanism	O
for	O
hyperinsulinemic	O
hypoglycemia	O
in	O
neonates	O
with	O
Costello	O
and	O
Beckwith	O
-	O
Wiedemann	O
syndrome	O
and	O
somatic	O
loss	O
of	O
heterozygosity	O
in	O
Costello	O
syndrome	O
driving	O
clonal	O
expansion	O
.	O

Costello	B-Disease
syndrome	I-Disease
(	O
CS	O
)	O
entails	O
a	O
cancer	O
predisposition	O
and	O
is	O
caused	O
by	O
activating	B-PosReg
HRAS	B-Gene
mutations	B-Var
,	O
typically	O
arising	O
de	O
novo	O
in	O
the	O
paternal	O
germline	O
.	O

Hypoglycemia	O
is	O
common	O
in	O
CS	O
neonates	O
.	O

A	O
previously	O
reported	O
individual	O
with	O
the	O
rare	O
HRAS	O
p	O
.	O
Gln22Lys	O
had	O
hyperinsulinemic	O
hypoglycemia	O
.	O

Autopsy	O
showed	O
a	O
discrete	O
pancreatic	O
nodule	O
.	O

The	O
morphologic	O
and	O
immunohistochemistry	O
findings	O
,	O
including	O
loss	O
of	O
p57(Kip2	O
)	O
protein	O
,	O
were	O
identical	O
to	O
a	O
focal	O
lesion	O
of	O
congenital	O
hyperinsulinism	O
,	O
however	O
,	O
no	O
KCNJ11	O
or	O
ABCC8	O
mutation	O
was	O
identified	O
and	O
germline	O
derived	O
DNA	O
showed	O
no	O
alternation	O
of	O
the	O
maternal	O
or	O
paternal	O
11p15	O
alleles	O
.	O

Here	O
we	O
report	O
paternal	O
uniparental	O
disomy	O
(	O
pUPD	O
)	O
within	O
the	O
lesion	O
,	O
similar	O
to	O
the	O
pUPD11p15.5	O
in	O
Beckwith	O
-	O
Wiedemann	O
syndrome	O
(	O
BWS	O
)	O
.	O

The	O
similar	O
extent	O
of	O
the	O
pUPD	O
suggests	O
a	O
similar	O
mechanism	O
driving	O
hyperinsulinemia	O
in	O
both	O
conditions	O
.	O

After	O
coincidental	O
somatic	O
LOH	O
and	O
pUPD	O
,	O
the	O
growth	O
promoting	O
effects	O
of	O
the	O
paternally	O
derived	O
HRAS	O
mutation	O
,	O
in	O
combination	O
with	O
the	O
increased	O
function	O
of	O
the	O
adjacent	O
paternally	O
expressed	O
IGF2	O
,	O
may	O
together	O
result	O
in	O
clonal	O
expansion	O
.	O

Although	O
this	O
somatic	O
LOH	O
within	O
pancreatic	O
tissue	O
resulted	O
in	O
hyperinsulinism	O
,	O
similar	O
LOH	O
in	O
mesenchymal	O
cells	O
may	O
drive	O
embryonal	O
rhabdomyosarcoma	O
(	O
ERMS	O
)	O
.	O

Interestingly	O
,	O
biallelic	O
IGF2	O
expression	O
has	O
been	O
linked	O
to	O
rhabdomyosarcoma	O
tumorigenesis	O
and	O
pUPD11	O
occurred	O
in	O
all	O
8	O
ERMS	O
samples	O
from	O
CS	O
individuals	O
.	O

Somatic	O
KRAS	O
and	O
HRAS	O
mutations	O
occur	O
with	O
comparable	O
frequency	O
in	O
isolated	O
malignancies	O
.	O

Yet	O
,	O
the	O
malignancy	O
risk	O
in	O
CS	O
is	O
notably	O
higher	O
than	O
in	O
Noonan	O
syndrome	O
with	O
a	O
KRAS	O
mutation	O
.	O

It	O
is	O
conceivable	O
that	O
HRAS	O
co	O
-	O
localization	O
with	O
IGF2	O
and	O
the	O
combined	O
effect	O
of	O
pUPD	O
11p15.5	O
on	O
both	O
genes	O
contributes	O
to	O
the	O
oncogenic	O
potential	O
.	O

©	O
2015	O
Wiley	O
Periodicals	O
,	O
Inc.	O
Progranulin	O
deficiency	O
induces	O
overactivation	O
of	O
WNT5A	O
expression	O
via	O
TNF	O
-	O
α	O
/	O
NF	O
-	O
κB	O
pathway	O
in	O
peripheral	O
cells	O
from	O
frontotemporal	O
dementia	O
-	O
linked	O
granulin	O
mutation	O
carriers	O
.	O

BACKGROUND	O
:	O
Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
progranulin	O
gene	O
(	B-Gene
GRN	I-Gene
)	I-Gene
mutations	B-Var
have	O
been	O
identified	O
as	O
the	O
major	O
cause	O
of	O
frontotemporal	B-Disease
lobar	I-Disease
degeneration	I-Disease
with	O
transactive	O
response	O
(	O
TAR	O
)	O
DNA	O
-	O
binding	O
protein	O
43	O
(	O
TDP-43	O
)	O
pathology	O
(	O
frontotemporal	O
lobar	O
degeneration	O
[	O
FTLD]-TDP	O
)	O
;	O
however	O
,	O
little	O
is	O
known	O
about	O
the	O
association	O
between	O
progranulin	O
(	O
PGRN	O
)	O
deficiency	O
and	O
neuronal	O
loss	O
in	O
individuals	O
with	O
FTLD	O
-	O
TDP	O
.	O

Previously	O
we	O
reported	O
enhanced	O
proliferative	O
activity	O
associated	O
with	O
the	O
activation	O
of	O
WNT5A	O
/	O
CDK6	O
/	O
pRb	O
signalling	O
in	O
PGRN	O
-	O
deficient	O
cells	O
.	O

The	O
objective	O
of	O
this	O
work	O
was	O
to	O
elucidate	O
the	O
association	O
between	O
PGRN	O
deficiency	O
,	O
WNT5A	O
signalling	O
and	O
cell	O
proliferation	O
in	O
immortalized	O
lymphoblasts	O
from	O
carriers	O
of	O
the	O
c.709	O
-	O
1	O
G	O
>	O
A	O
GRN	O
mutation	O
(	O
asymptomatic	O
and	O
FTLD	O
-	O
TDP	O
)	O
.	O

METHODS	O
:	O
We	O
assessed	O
cell	O
proliferation	O
in	O
carriers	O
of	O
the	O
c.709	O
-	O
1	O
G	O
>	O
A	O
GRN	O
gene	O
mutation	O
and	O
controls	O
without	O
GRN	O
mutation	O
and	O
without	O
sign	O
of	O
neurologic	O
degeneration	O
by	O
cell	O
counting	O
or	O
using	O
an	O
MTT	O
assay	O
.	O

We	O
used	O
a	O
luciferase	O
assay	O
to	O
measure	O
the	O
nuclear	O
factor	O
-	O
κ	O
(	O
NF	O
-	O
κ	O
)	O
activity	O
.	O

We	O
evaluated	O
messenger	O
RNA	O
levels	O
using	O
quantitative	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
and	O
protein	O
levels	O
by	O
immunoblotting	O
.	O

Co	O
-	O
immunoprecipitation	O
was	O
used	O
to	O
analyze	O
the	O
interaction	O
between	O
PGRN	O
and	O
its	O
receptors	O
.	O

RESULTS	O
:	O
We	O
enrolled	O
19	O
carriers	O
of	O
the	O
GRN	O
gene	O
mutation	O
and	O
10	O
controls	O
in	O
this	O
study	O
.	O

The	O
PGRN	B-Var
-	I-Var
deficient	I-Var
cells	O
showed	O
increased	B-PosReg
expression	B-MPA
of	O
WNT5A	B-Gene
due	O
to	O
NF	B-Pathway
-	I-Pathway
κB	I-Pathway
signalling	I-Pathway
overactivation	B-PosReg
.	O

We	O
observed	O
a	O
competition	O
between	O
PGRN	O
and	O
tumour	O
necrosis	O
factor	O
-	O
α	O
(	O
TNF	O
-	O
α	O
)	O
for	O
binding	O
both	O
TNF	O
receptors	O
(	O
TNFR	O
)	O
I	O
and	O
II	O
.	O

Blocking	O
NF	O
-	O
κB	O
signalling	O
using	O
wedelolactone	O
or	O
specific	O
antibodies	O
against	O
TNFRs	O
inhibited	O
WNT5A	O
overexpression	O
and	O
proliferation	O
of	O
PGRN	O
-	O
deficient	O
cells	O
.	O

Conversely	O
,	O
the	O
activation	O
of	O
NF	O
-	O
κB	O
signalling	O
by	O
TNF	O
-	O
α	O
increased	O
WNT5A	O
-	O
dependent	O
proliferation	O
of	O
control	O
cells	O
.	O

LIMITATIONS	O
:	O
All	O
cell	O
lines	O
were	O
derived	O
from	O
individuals	O
harboring	O
the	O
same	O
splicing	O
GRN	O
mutation	O
.	O

Nevertheless	O
,	O
most	O
of	O
the	O
known	O
GRN	B-Gene
mutations	B-Var
lead	B-Reg
to	I-Reg
haploinsufficiency	B-Var
of	O
the	O
protein	B-Protein
.	O

CONCLUSION	O
:	O
Our	O
results	O
revealed	O
an	O
important	O
role	O
of	O
NF	O
-	O
κB	O
signalling	O
in	O
PGRN	O
-	O
associated	O
FTLD	O
-	O
TDP	O
and	O
confirm	O
that	O
PGRN	O
can	O
bind	O
to	O
TNF	O
-	O
a	O
receptors	O
regulating	O
the	O
expression	O
of	O
WNT5A	O
,	O
suggesting	O
novel	O
targets	O
for	O
treatment	O
of	O
FTLD	O
-	O
TDP	O
linked	O
to	O
GRN	O
mutations	O
.	O

ADIPOR1	B-Gene
is	O
Mutated	B-Var
in	B-Reg
Syndromic	O
Retinitis	B-Disease
Pigmentosa	I-Disease
.	O

Retinitis	O
pigmentosa	O
(	O
RP	O
)	O
is	O
a	O
genetically	O
heterogeneous	O
retinal	O
disorder	O
.	O

Despite	O
the	O
numerous	O
genes	O
associated	O
with	O
RP	O
already	O
identified	O
,	O
the	O
genetic	O
basis	O
remains	O
unknown	O
in	O
a	O
substantial	O
number	O
of	O
patients	O
and	O
families	O
.	O

In	O
this	O
study	O
,	O
we	O
performed	O
whole	O
exome	O
sequencing	O
to	O
investigate	O
the	O
molecular	O
basis	O
of	O
a	O
syndromic	O
RP	O
case	O
which	O
can	O
not	O
be	O
solved	O
by	O
mutations	O
in	O
known	O
disease	O
-	O
causing	O
genes	O
.	O

After	O
applying	O
a	O
series	O
of	O
variant	O
filtering	O
strategies	O
,	O
we	O
identified	O
an	O
apparently	O
homozygous	O
frameshift	O
mutation	O
,	O
c.31delC	O
(	O
p	O
.	O
Q11Rfs*24	O
)	O
in	O
the	O
ADIPOR1	O
gene	O
.	O

The	O
reported	O
phenotypes	O
of	O
Adipor1-null	O
mice	O
contain	O
retinal	O
dystrophy	O
,	O
obesity	O
and	O
behavioral	O
abnormalities	O
,	O
which	O
highly	O
mimic	O
those	O
in	O
the	O
syndromic	O
RP	O
patient	O
.	O

We	O
further	O
confirmed	O
ADIPOR1	O
retina	O
expression	O
by	O
immunohistochemistry	O
.	O

Our	O
results	O
established	O
ADIPOR1	O
as	O
a	O
novel	O
disease	O
-	O
causing	O
gene	O
for	O
syndromic	O
RP	O
and	O
highlight	O
the	O
importance	O
of	O
fatty	O
acid	O
transport	O
in	O
the	O
retina	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Dysferlinopathy	O
in	O
Iran	O
:	O
Clinical	O
and	O
genetic	O
report	O
.	O

BACKGROUND	O
:	O
Dysferlinopathy	B-Disease
is	O
caused	B-Reg
by	I-Reg
a	O
very	O
wide	O
range	O
of	O
autosomal	O
recessively	O
inherited	O
mutations	B-Var
of	O
the	O
Dysferlin	B-Gene
gene	I-Gene
.	O

It	O
causes	B-Reg
a	O
spectrum	O
of	O
muscle	O
diseases	O
including	O
limb	B-Disease
-	I-Disease
girdle	I-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
LGMD	O
)	O
2B	O
and	O
Miyoshi	B-Disease
myopathy	I-Disease
(	O
MM	O
)	O
.	O

We	O
describe	O
the	O
clinical	O
course	O
and	O
mutational	O
analyses	O
of	O
15	O
Iranian	O
patients	O
with	O
dysferlinopathy	O
from	O
9	O
different	O
families	O
.	O

METHODS	O
:	O
Genomic	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
and	O
55	O
exons	O
and	O
flanking	O
intronic	O
boundaries	O
of	O
the	O
dysferlin	O
gene	O
(	O
DYSF	O
;	O
NM_003494.2	O
)	O
were	O
screened	O
for	O
mutations	O
and	O
analyzed	O
.	O

RESULTS	O
:	O
From	O
15	O
studied	O
patients	O
in	O
9	O
families	O
,	O
5	O
patients	O
were	O
male	O
.	O

Seven	O
families	O
had	O
consanguineous	O
marriage	O
.	O

Median	O
age	O
of	O
onset	O
was	O
16.8	O
;	O
and	O
the	O
median	O
age	O
of	O
diagnosis	O
was	O
26.6	O
.	O

The	O
onset	O
was	O
clearly	O
distal	O
in	O
7	O
patients	O
,	O
and	O
proximal	O
in	O
6	O
patients	O
.	O

Three	O
patients	O
had	O
partial	O
biceps	O
atrophy	O
and	O
13	O
showed	O
prominent	O
calf	O
muscle	O
wasting	O
.	O

Foot	O
plantar	O
flexors	O
,	O
deep	O
finger	O
flexors	O
and	O
hip	O
adductors	O
were	O
predominantly	O
involved	O
.	O

Genetic	O
testing	O
showed	O
homozygous	O
mutation	O
of	O
dysferlin	O
gene	O
in	O
9	O
probands	O
,	O
5	O
of	O
which	O
were	O
not	O
previously	O
reported	O
.	O

CONCLUSION	O
:	O
This	O
work	O
,	O
in	O
fact	O
,	O
may	O
help	O
shed	O
some	O
light	O
on	O
the	O
pattern	O
of	O
this	O
morbidity	O
in	O
Iran	O
,	O
an	O
effort	O
that	O
may	O
have	O
not	O
been	O
attempted	O
so	O
far	O
.	O

Limb	O
-	O
girdle	O
muscular	O
dystrophy	O
type	O
2A	O
in	O
Brazilian	O
children	O
.	O

Calpainopathy	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
limb	I-Disease
girdle	I-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
LGMD2A	O
)	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
CAPN3	B-Gene
gene	O
.	O

Objective	O
To	O
present	O
clinical	O
and	O
histological	O
findings	O
in	O
six	O
children	O
with	O
a	O
molecular	O
diagnosis	O
of	O
LGMD2A	O
and	O
additionally	O
the	O
MRI	O
findings	O
in	O
two	O
of	O
them	O
.	O

Method	O
We	O
retrospectively	O
assessed	O
medical	O
records	O
of	O
6	O
patients	O
with	O
mutation	O
on	O
CAPN3	O
gene	O
.	O

Results	O
All	O
patients	O
were	O
female	O
(	O
three	O
to	O
12	O
years	O
)	O
.	O

The	O
mean	O
of	O
age	O
of	O
disease	O
onset	O
was	O
9	O
years	O
.	O

All	O
of	O
them	O
showed	O
progressive	O
weakness	O
with	O
predominance	O
in	O
lower	O
limbs	O
.	O

Other	O
findings	O
were	O
scapular	O
winging	O
,	O
joint	O
contractures	O
and	O
calf	O
hypertrophy	O
.	O

One	O
female	O
had	O
a	O
more	O
severe	O
phenotype	O
than	O
her	O
dizygotic	O
twin	O
sister	O
that	O
was	O
confirmed	O
by	O
muscle	O
MRI	O
.	O

Muscle	O
biopsies	O
showed	O
a	O
dystrophic	O
pattern	O
in	O
all	O
patients	O
.	O

Conclusion	O
In	O
this	O
cohort	O
of	O
children	O
with	O
LGMD2A	O
,	O
the	O
clinical	O
aspects	O
were	O
similar	O
to	O
adults	O
with	O
the	O
same	O
disorder	O
.	O

Frequency	O
of	O
mutations	O
in	O
Mediterranean	O
fever	O
gene	O
,	O
with	O
gender	O
and	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
a	O
Turkish	O
population	O
.	O

Familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
(	O
FMF	O
)	O
is	O
the	O
most	O
common	O
hereditary	O
inflammatory	O
periodic	O
disease	O
,	O
characterized	O
by	O
recurrent	O
episodes	O
of	O
fever	O
,	O
abdominal	O
pain	O
,	O
synovitis	O
and	O
pleurisy	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
frequency	O
and	O
distribution	O
of	O
Mediterranean	O
fever	O
(	B-Gene
MEFV	I-Gene
)	I-Gene
gene	O
mutations	B-Var
and	O
to	O
investigate	O
the	O
clinical	O
characteristics	O
and	O
genotype	O
-	O
phenotype	O
correlation	O
in	B-Reg
patients	O
with	O
FMF	B-Disease
in	O
Aydin	O
,	O
a	O
province	O
in	O
western	O
Anatolia	O
,	O
Turkey	O
.	O

Therefore	O
,	O
we	O
retrospectively	O
analysed	O
MEFV	O
gene	O
mutations	O
in	O
383	O
patients	O
with	O
suspected	O
FMF	O
and	O
the	O
clinical	O
features	O
of	O
327	O
among	O
them	O
.	O

The	O
MEFV	O
gene	O
mutations	O
were	O
investigated	O
using	O
the	O
reverse	O
dot	O
-	O
blot	O
hybridization	O
technique	O
.	O

We	O
detected	O
26	O
different	O
genotypes	O
and	O
11	O
different	O
mutations	O
.	O

The	O
most	O
common	O
mutations	O
in	O
our	O
cohort	O
were	O
p	O
.	O
M694V	O
(	O
41.15	O
%	O
)	O
,	O
p	O
.	O
E148Q	O
(	O
20.35	O
%	O
)	O
,	O
p	O
.	O
M680I(G	O
/	O
C	O
)	O
(	O
12.39	O
%	O
)	O
and	O
p	O
.	O
R761H	O
(	O
9.73	O
%	O
)	O
.	O

Abdominal	O
pain	O
(	O
86.2	O
%	O
)	O
,	O
fever	O
(	O
80.7	O
%	O
)	O
,	O
arthralgia	O
(	O
57.2	O
%	O
)	O
,	O
vomiting	O
(	O
36.1	O
%	O
)	O
,	O
arthritis	O
(	O
34.6	O
%	O
)	O
,	O
fatigue	O
(	O
31.5	O
%	O
)	O
,	O
anorexia	O
(	O
22.9	O
%	O
)	O
and	O
chest	O
pain	O
(	O
19.0	O
%	O
)	O
were	O
the	O
most	O
prevalent	O
clinical	O
features	O
in	O
our	O
patients	O
.	O

This	O
is	O
the	O
first	O
study	O
from	O
Aydin	O
in	O
which	O
the	O
distribution	O
of	O
MEFV	B-Gene
gene	O
mutations	B-Var
and	O
clinical	O
features	O
were	O
evaluated	O
in	B-Reg
patients	O
with	O
FMF	B-Disease
.	O

We	O
found	O
that	O
the	O
most	O
common	O
mutation	O
was	O
p	O
.	O
M694V	O
in	O
our	O
region	O
,	O
while	O
the	O
frequency	O
of	O
the	O
p	O
.	O
R761H	O
mutation	O
was	O
higher	O
compared	O
to	O
other	O
regions	O
of	O
Turkey	O
with	O
respect	O
to	O
extracted	O
data	O
from	O
previous	O
similar	O
studies	O
.	O

Presented	O
results	O
supported	O
the	O
clinical	O
findings	O
in	O
the	O
literature	O
that	O
the	O
homozygous	O
p	O
.	O
M694V	O
and	O
compound	O
heterozygous	O
genotype	O
were	O
associated	O
with	O
more	O
severe	O
courses	O
in	O
FMF	O
patients	O
.	O

Delayed	O
hemoglobin	O
switching	O
and	O
perinatal	O
neocytolysis	O
in	O
mice	O
with	O
gain	O
-	O
of	O
-	O
function	O
erythropoietin	O
receptor	O
.	O

Mutations	B-Var
of	O
the	O
truncated	O
cytoplasmic	O
domain	O
of	O
human	O
erythropoietin	O
receptor	O
(	B-Gene
EPOR	I-Gene
)	I-Gene
result	B-Reg
in	I-Reg
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
of	O
erythropoietin	B-Pathway
(	I-Pathway
EPO	I-Pathway
)	I-Pathway
signaling	I-Pathway
and	O
a	O
dominantly	B-Disease
inherited	I-Disease
polycythemia	I-Disease
,	O
primary	B-Disease
familial	I-Disease
and	I-Disease
congenital	I-Disease
polycythemia	I-Disease
(	O
PFCP	O
)	O
.	O

We	O
interrogated	O
the	O
unexplained	O
transient	O
absence	O
of	O
perinatal	O
polycythemia	O
observed	O
in	O
PFCP	O
patients	O
using	O
an	O
animal	O
model	O
of	O
PFCP	O
to	O
examine	O
its	O
erythropoiesis	O
during	O
embryonic	O
,	O
perinatal	O
,	O
and	O
early	O
postnatal	O
periods	O
.	O

In	O
this	O
model	O
,	O
we	O
replaced	O
the	O
murine	O
EpoR	O
gene	O
(	O
mEpoR	O
)	O
with	O
the	O
wild	O
-	O
type	O
human	O
EPOR	O
(	O
wtHEPOR	O
)	O
or	O
mutant	O
human	O
EPOR	O
gene	O
(	O
mtHEPOR	O
)	O
and	O
previously	O
reported	O
that	O
the	O
gain	O
-	O
of	O
-	O
function	O
mtHEPOR	O
mice	O
become	O
polycythemic	O
at	O
3~6	O
weeks	O
of	O
age	O
,	O
but	O
not	O
at	O
birth	O
,	O
similar	O
to	O
the	O
phenotype	O
of	O
PFCP	O
patients	O
.	O

In	O
contrast	O
,	O
wtHEPOR	O
mice	O
had	O
sustained	O
anemia	O
.	O

We	O
report	O
that	O
the	O
mtHEPOR	O
fetuses	O
are	O
polycythemic	O
,	O
but	O
their	O
polycythemia	O
is	O
abrogated	O
in	O
the	O
perinatal	O
period	O
and	O
reappears	O
again	O
at	O
3	O
weeks	O
after	O
birth	O
.	O

mtHEPOR	O
fetuses	O
have	O
a	O
delayed	O
switch	O
from	O
primitive	O
to	O
definitive	O
erythropoiesis	O
,	O
augmented	O
erythropoietin	O
signaling	O
,	O
and	O
prolonged	O
Stat5	O
phosphorylation	O
while	O
the	O
wtHEPOR	O
fetuses	O
are	O
anemic	O
.	O

Our	O
study	O
demonstrates	O
the	O
in	O
vivo	O
effect	O
of	O
excessive	O
EPO	O
/	O
EPOR	O
signaling	O
on	O
developmental	O
erythropoiesis	O
switch	O
and	O
describes	O
that	O
fetal	O
polycythemia	O
in	O
this	O
PFCP	O
model	O
is	O
followed	O
by	O
transient	O
correction	O
of	O
polycythemia	O
in	O
perinatal	O
life	O
associated	O
with	O
low	O
Epo	O
levels	O
and	O
increased	O
exposure	O
of	O
erythrocytes	O
'	O
phosphatidylserine	O
.	O

We	O
suggest	O
that	O
neocytolysis	O
contributes	O
to	O
the	O
observed	O
perinatal	O
correction	O
of	O
polycythemia	O
in	O
mtHEPOR	O
newborns	O
as	O
embryos	O
leaving	O
the	O
hypoxic	O
uterus	O
are	O
exposed	O
to	O
normoxia	O
at	O
birth	O
.	O

KEY	O
MESSAGE	O
:	O
Human	O
gain	O
-	O
of	O
-	O
function	O
EPOR	B-Gene
(	O
mtHEPOR	O
)	O
causes	B-Reg
fetal	B-Disease
polycythemia	I-Disease
in	O
knock	B-Var
-	I-Var
in	I-Var
mice	O
.	O

Wild	O
-	O
type	O
human	O
EPOR	O
causes	O
fetal	O
anemia	O
in	O
knock	O
-	O
in	O
mouse	O
model	O
.	O

mtHEPOR	O
mice	O
have	O
delayed	O
switch	O
from	O
primitive	O
to	O
definitive	O
erythropoiesis	O
.	O

Polycythemia	O
of	O
mtHEPOR	O
mice	O
is	O
transiently	O
corrected	O
in	O
perinatal	O
life	O
.	O

mtHEPOR	O
newborns	O
have	O
low	O
Epo	O
and	O
increased	O
exposure	O
of	O
erythrocytes	O
'	O
phosphatidylserine	O
.	O

Renal	O
Cell	O
Carcinoma	O
Programmed	O
Death	O
-	O
ligand	O
1	O
,	O
a	O
New	O
Direct	O
Target	O
of	O
Hypoxia	O
-	O
inducible	O
Factor-2	O
Alpha	O
,	O
is	O
Regulated	O
by	O
von	O
Hippel	O
-	O
Lindau	O
Gene	O
Mutation	O
Status	O
.	O

BACKGROUND	O
:	O
Clear	O
cell	O
renal	O
cell	O
carcinomas	O
(	O
ccRCC	O
)	O
frequently	O
display	O
a	O
loss	O
of	O
function	O
of	O
the	O
von	O
Hippel	O
-	O
Lindau	O
(	O
VHL	O
)	O
gene	O
.	O

OBJECTIVE	O
:	O
To	O
elucidate	O
the	O
putative	O
relationship	O
between	O
VHL	O
mutation	O
status	O
and	O
immune	O
checkpoint	O
ligand	O
programmed	O
death	O
-	O
ligand	O
1	O
(	O
PD	O
-	O
L1	O
)	O
expression	O
.	O

DESIGN	O
,	O
SETTING	O
,	O
AND	O
PARTICIPANTS	O
:	O
A	O
series	O
of	O
32	O
renal	O
tumors	O
composed	O
of	O
11	O
VHL	O
tumor	O
-	O
associated	O
and	O
21	O
sporadic	O
RCCs	O
were	O
used	O
to	O
evaluate	O
PD	O
-	O
L1	O
expression	O
levels	O
after	O
sequencing	O
of	O
the	O
three	O
exons	O
and	O
exon	O
-	O
intron	O
junctions	O
of	O
the	O
VHL	O
gene	O
.	O

The	O
786-O	O
,	O
A498	O
,	O
and	O
RCC4	O
cell	O
lines	O
were	O
used	O
to	O
investigate	O
the	O
mechanisms	O
of	O
PD	O
-	O
L1	O
regulation	O
.	O

OUTCOME	O
MEASUREMENTS	O
AND	O
STATISTICAL	O
ANALYSIS	O
:	O
Fisher	O
's	O
exact	O
test	O
was	O
used	O
for	O
VHL	O
mutation	O
and	O
Kruskal	O
-	O
Wallis	O
test	O
for	O
PD	O
-	O
L1	O
expression	O
.	O

If	O
no	O
covariate	O
accounted	O
for	O
the	O
association	O
of	O
VHL	O
and	O
PD	O
-	O
L1	O
,	O
then	O
a	O
Kruskal	O
-	O
Wallis	O
test	O
was	O
used	O
;	O
otherwise	O
Cochran	O
-	O
Mantel	O
-	O
Haenzsel	O
test	O
was	O
used	O
.	O

We	O
also	O
used	O
the	O
Fligner	O
-	O
Policello	O
test	O
to	O
compare	O
two	O
medians	O
when	O
the	O
distributions	O
had	O
different	O
dispersions	O
.	O

RESULTS	O
AND	O
LIMITATIONS	O
:	O
We	O
demonstrated	O
that	O
tumors	O
from	O
ccRCC	O
patients	O
with	O
VHL	B-Gene
biallelic	O
inactivation	B-Var
(	O
ie	O
,	O
loss	O
of	O
function	O
)	O
display	O
a	O
significant	O
increase	B-PosReg
in	O
PD	B-Protein
-	I-Protein
L1	I-Protein
expression	B-MPA
compared	O
with	O
ccRCC	O
tumors	O
carrying	O
one	O
VHL	O
wild	O
-	O
type	O
allele	O
.	O

Using	O
the	O
inducible	O
VHL	O
786-O	O
-	O
derived	O
cell	O
lines	O
with	O
varying	O
hypoxia	O
-	O
inducible	O
factor-2	O
alpha	O
(	O
HIF-2α	O
)	O
stabilization	O
levels	O
,	O
we	O
showed	O
that	O
PD	B-Protein
-	I-Protein
L1	I-Protein
expression	B-MPA
levels	I-MPA
positively	O
correlate	B-Reg
with	O
VHL	B-Gene
mutation	B-Var
and	O
HIF-2α	O
expression	O
.	O

Targeting	O
HIF-2α	O
decreased	O
PD	O
-	O
L1	O
,	O
while	O
HIF-2α	O
overexpression	O
increased	O
PD	O
-	O
L1	O
mRNA	O
and	O
protein	O
levels	O
in	O
ccRCC	O
cells	O
.	O

Interestingly	O
,	O
chromatin	O
immunoprecipitation	O
and	O
luciferase	O
assays	O
revealed	O
a	O
direct	O
binding	O
of	O
HIF-2α	O
to	O
a	O
transcriptionally	O
active	O
hypoxia	O
-	O
response	O
element	O
in	O
the	O
human	O
PD	O
-	O
L1	O
proximal	O
promoter	O
in	O
786-O	O
cells	O
.	O

CONCLUSIONS	O
:	O
Our	O
work	O
provides	O
the	O
first	O
evidence	O
that	O
VHL	B-Gene
mutations	B-Var
positively	O
correlate	B-Reg
with	O
PD	B-Protein
-	I-Protein
L1	I-Protein
expression	B-MPA
in	O
ccRCC	O
and	O
may	O
influence	B-Reg
the	O
response	B-MPA
to	I-MPA
ccRCC	I-MPA
anti	I-MPA
-	I-MPA
PD	I-MPA
-	I-MPA
L1	I-MPA
/	I-MPA
PD-1	I-MPA
immunotherapy	I-MPA
.	O

PATIENT	O
SUMMARY	O
:	O
We	O
investigated	O
the	O
relationship	O
between	O
von	O
Hippel	O
-	O
Lindau	O
mutations	O
and	O
programmed	O
death	O
-	O
ligand	O
1	O
expression	O
.	O

We	O
demonstrated	O
that	O
von	B-Gene
Hippel	I-Gene
-	I-Gene
Lindau	I-Gene
mutation	B-Var
status	O
significantly	O
correlated	B-Reg
with	O
programmed	B-MPA
death	I-MPA
-	I-MPA
ligand	I-MPA
1	I-MPA
expression	I-MPA
in	O
clear	O
cell	O
renal	O
cell	O
carcinomas	O
.	O

Huntington	O
's	O
Disease	O
:	O
Relationship	O
Between	O
Phenotype	O
and	O
Genotype	O
.	O

Huntington	B-Disease
's	I-Disease
disease	I-Disease
(	O
HD	O
)	O
is	O
an	O
autosomal	O
dominant	O
inherited	O
neurodegenerative	O
disease	O
with	O
the	O
typical	O
manifestations	O
of	O
involuntary	O
movements	O
,	O
psychiatric	O
and	O
behavior	O
disorders	O
,	O
and	O
cognitive	O
impairment	O
.	O

It	O
is	O
caused	B-Reg
by	I-Reg
the	O
dynamic	B-Var
mutation	I-Var
in	I-Var
CAG	I-Var
triplet	I-Var
repeat	I-Var
number	I-Var
in	I-Var
exon	I-Var
1	I-Var
of	O
huntingtin	O
(	B-Gene
HTT	I-Gene
)	I-Gene
gene	O
.	O

The	O
symptoms	O
of	O
HD	O
especially	O
the	O
age	O
at	O
onset	O
are	O
related	O
to	O
the	O
genetic	O
characteristics	O
,	O
both	O
the	O
CAG	O
triplet	O
repeat	O
and	O
the	O
modified	O
factors	O
.	O

Here	O
,	O
we	O
reviewed	O
the	O
recent	O
advancement	O
on	O
the	O
genotype	O
-	O
phenotype	O
relationship	O
of	O
HD	O
,	O
mainly	O
focus	O
on	O
the	O
characteristics	O
of	O
different	O
expanded	O
CAG	O
repeat	O
number	O
,	O
genetic	O
modifiers	O
,	O
and	O
CCG	O
repeat	O
number	O
in	O
the	O
3	O
'	O
end	O
of	O
CAG	O
triplet	O
repeat	O
and	O
their	O
effects	O
on	O
the	O
phenotype	O
.	O

We	O
also	O
reviewed	O
the	O
special	O
forms	O
of	O
HD	O
(	O
juvenile	O
HD	O
,	O
atypical	O
onset	O
HD	O
,	O
and	O
homozygous	O
HD	O
)	O
and	O
their	O
phenotype	O
-	O
genotype	O
correlations	O
.	O

The	O
review	O
will	O
aid	O
clinicians	O
to	O
predict	O
the	O
onset	O
age	O
and	O
disease	O
course	O
of	O
HD	O
,	O
give	O
the	O
genetic	O
counseling	O
,	O
and	O
accelerate	O
research	O
into	O
the	O
HD	O
mechanism	O
.	O

Polyamine	B-Enzyme
oxidase	I-Enzyme
5	I-Enzyme
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
Arabidopsis	O
thaliana	O
trigger	B-Reg
metabolic	B-MPA
and	I-MPA
transcriptional	I-MPA
reprogramming	I-MPA
and	O
promote	B-PosReg
salt	B-MPA
stress	I-MPA
tolerance	I-MPA
.	O

The	O
family	O
of	O
polyamine	O
oxidases	O
(	O
PAO	O
)	O
in	O
Arabidopsis	O
(	O
AtPAO1	O
-	O
5	O
)	O
mediates	O
polyamine	O
(	O
PA	O
)	O
back	O
-	O
conversion	O
,	O
which	O
reverses	O
the	O
PA	O
biosynthetic	O
pathway	O
from	O
spermine	O
and	O
its	O
structural	O
isomer	O
thermospermine	O
(	O
tSpm	O
)	O
into	O
spermidine	O
and	O
then	O
putrescine	O
.	O

Here	O
,	O
we	O
have	O
studied	O
the	O
involvement	O
of	O
PA	O
back	O
-	O
conversion	O
in	O
Arabidopsis	O
salinity	O
tolerance	O
.	O

AtPAO5	O
is	O
the	O
Arabidopsis	O
PAO	O
gene	O
member	O
most	O
transcriptionally	O
induced	O
by	O
salt	O
stress	O
.	O

Two	O
independent	O
loss	O
-	O
of	O
-	O
function	O
mutants	B-Var
(	O
atpao5	O
-	O
2	O
and	O
atpao5	O
-	O
3	O
)	O
were	O
found	O
to	O
exhibit	O
constitutively	O
higher	B-PosReg
tSpm	B-MPA
levels	I-MPA
,	O
with	O
associated	O
increased	O
salt	O
tolerance	O
.	O

Using	O
global	O
transcriptional	O
and	O
metabolomic	O
analyses	O
,	O
the	O
underlying	O
mechanisms	O
were	O
studied	O
.	O

Stimulation	B-PosReg
of	O
abscisic	B-MPA
acid	I-MPA
and	I-MPA
jasmonate	I-MPA
(	I-MPA
JA	I-MPA
)	I-MPA
biosynthesis	I-MPA
and	O
accumulation	B-MPA
of	I-MPA
important	I-MPA
compatible	I-MPA
solutes	I-MPA
,	O
such	O
as	O
sugars	O
,	O
polyols	O
and	O
proline	O
,	O
as	O
well	O
as	O
TCA	B-MPA
cycle	I-MPA
intermediates	I-MPA
were	O
observed	O
in	O
atpao5	O
mutants	B-Var
under	O
salt	O
stress	O
.	O

Expression	O
analyses	O
indicate	O
that	O
tSpm	O
modulates	O
the	O
transcript	O
levels	O
of	O
several	O
target	O
genes	O
,	O
including	O
many	O
involved	O
in	O
the	O
biosynthesis	O
and	O
signalling	O
of	O
JA	O
,	O
some	O
of	O
which	O
are	O
already	O
known	O
to	O
promote	O
salinity	O
tolerance	O
.	O

Transcriptional	O
modulation	O
by	O
tSpm	O
is	O
isomer	O
-	O
dependent	O
,	O
thus	O
demonstrating	O
the	O
specificity	O
of	O
this	O
response	O
.	O

Overall	O
,	O
we	O
conclude	O
that	O
tSpm	O
triggers	O
metabolic	O
and	O
transcriptional	O
reprogramming	O
that	O
promotes	O
salt	O
stress	O
tolerance	O
in	O
Arabidopsis	O
.	O

Recessive	B-Disease
dystrophic	I-Disease
epidermolysis	I-Disease
bullosa	I-Disease
caused	B-Reg
by	I-Reg
a	O
de	B-CPA
novo	I-CPA
interstitial	I-CPA
deletion	B-NegReg
spanning	O
COL7A1	B-Gene
and	O
a	O
hemizygous	O
splicing	B-Var
mutation	I-Var
in	I-Var
trans	I-Var
.	O

BACKGROUND	O
:	O
Recessive	B-Disease
dystrophic	I-Disease
epidermolysis	I-Disease
bullosa	I-Disease
(	O
RDEB	O
)	O
is	O
a	O
rare	O
heritable	O
blistering	O
skin	O
condition	O
caused	O
by	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
the	O
COL7A1	B-Gene
gene	O
.	O

Incongruent	O
gene	O
transmission	O
is	O
occasionally	O
reported	O
in	O
recessive	O
diseases	O
,	O
and	O
its	O
underlying	O
mechanism	O
is	O
often	O
uniparental	O
disomy	O
(	O
UPD	O
)	O
.	O

AIM	O
:	O
To	O
understand	O
the	O
genetic	O
basis	O
of	O
incongruent	O
gene	O
transmission	O
in	O
a	O
Chinese	O
family	O
with	O
RDEB	O
,	O
in	O
which	O
a	O
discrepancy	O
of	O
COL7A1	O
genotyping	O
was	O
encountered	O
during	O
our	O
mutation	O
analysis	O
.	O

METHODS	O
:	O
We	O
used	O
a	O
pCAS2	O
minigene	O
-	O
based	O
in	O
vitro	O
splicing	O
assay	O
to	O
confirm	O
the	O
pathogenicity	O
of	O
the	O
splicing	O
variant	O
we	O
identified	O
in	O
the	O
proband	O
.	O

Next	O
,	O
a	O
combination	O
of	O
genetic	O
tools	O
,	O
including	O
whole	O
-	O
genome	O
SNP	O
array	O
analysis	O
and	O
multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
copy	O
number	O
analysis	O
,	O
was	O
used	O
to	O
unravel	O
the	O
cause	O
of	O
the	O
discrepancy	O
in	O
the	O
COL7A1	O
genotyping	O
.	O

RESULTS	O
:	O
Sanger	O
sequencing	O
identified	O
a	O
novel	O
,	O
single	O
-	O
peak	O
mutation	O
,	O
c.4980	O
+	O
5G	O
>	O
C	O
,	O
in	O
COL7A1	O
in	O
the	O
proband	O
,	O
which	O
was	O
heterozygous	O
in	O
his	O
father	O
and	O
wild	O
type	O
in	O
his	O
mother	O
.	O

In	O
vitro	O
splicing	O
assay	O
showed	O
that	O
c.4980	O
+	O
5G	O
>	O
C	O
was	O
pathogenic	O
and	O
led	O
to	O
skipping	O
of	O
COL7A1	O
exon	O
53	O
.	O

SNP	O
array	O
analysis	O
and	O
multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
of	O
the	O
proband	O
's	O
DNA	O
revealed	O
a	O
maternally	O
derived	O
,	O
de	O
novo	O
,	O
interstitial	O
deletion	O
on	O
chromosome	O
3p21.31	O
,	O
which	O
removed	O
COL7A1	O
and	O
15	O
flanking	O
genes	O
,	O
excluding	O
the	O
possibility	O
of	O
UPD	O
.	O

CONCLUSION	O
:	O
Our	O
findings	O
favour	O
an	O
exceptionally	O
rare	O
event	O
,	O
namely	O
a	O
de	O
novo	O
COL7A1	O
microdeletion	O
in	O
concurrence	O
with	O
an	O
inherited	O
mutation	O
in	O
trans	O
.	O

This	O
study	O
should	O
aid	O
molecular	O
diagnosis	O
and	O
genetic	O
counselling	O
of	O
RDEB	O
and	O
possibly	O
other	O
recessive	O
diseases	O
in	O
which	O
genotyping	O
discrepancy	O
is	O
encountered	O
.	O

A	O
novel	O
frameshift	O
mutation	O
leading	O
to	O
inherited	O
type	O
I	O
antithrombin	O
deficiency	O
.	O

Inherited	B-Disease
antithrombin	I-Disease
(	I-Disease
AT	I-Disease
)	I-Disease
deficiency	I-Disease
is	O
an	O
autosomal	O
dominant	O
thrombotic	O
disorder	O
.	O

We	O
encountered	O
a	O
case	O
of	O
inherited	O
type	O
I	O
AT	B-Disease
deficiency	I-Disease
and	O
identified	B-Reg
the	O
mutation	O
responsible	O
;	O
a	O
novel	O
5406delA	B-Var
mutation	I-Var
in	O
the	O
SERPINC1	B-Gene
gene	O
appeared	O
to	O
have	O
caused	B-Reg
a	O
frameshift	B-MPA
with	I-MPA
premature	I-MPA
termination	I-MPA
at	I-MPA
amino	I-MPA
acid	I-MPA
+283	I-MPA
.	O

The	O
recombinant	O
AT	O
protein	O
including	O
5406delA	O
was	O
not	O
detected	O
in	O
cell	O
lysates	O
or	O
culture	O
supernatants	O
.	O

These	O
results	O
will	O
contribute	O
to	O
the	O
creation	O
of	O
an	O
accurate	O
database	O
and	O
define	O
the	O
molecular	O
basis	O
for	O
AT	O
deficiency	O
.	O

Increase	O
in	O
NRAS	O
mutant	O
allele	O
percentage	O
during	O
metastatic	O
melanoma	O
progression	O
.	O

One	O
-	O
fifth	O
of	O
cutaneous	B-Disease
melanomas	I-Disease
have	O
dominant	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutations	B-Var
of	O
the	O
NRAS	B-Gene
oncogene	O
.	O

We	O
report	O
the	O
first	O
two	O
cases	O
of	O
increasing	O
NRAS	O
mutant	O
allele	O
frequency	O
in	O
melanoma	O
metastases	O
and	O
show	O
that	O
the	O
chromosomal	O
mechanism	O
of	O
this	O
homozygosity	O
is	O
an	O
increased	O
polysomy	O
of	O
chromosome	O
1	O
.	O

We	O
observed	O
an	O
increase	O
in	O
NRAS	O
mutant	O
allele	O
percentage	O
(	O
NRAS	O
-	O
MA%	O
)	O
in	O
the	O
metastatic	O
melanoma	O
progression	O
from	O
2	O
patients	O
with	O
melanomas	O
harbouring	O
a	O
NRAS	O
mutation	O
(	O
p	O
.	O
Q61	O
K	O
in	O
case	O
1	O
and	O
p	O
.	O
Q61R	O
in	O
case	O
2	O
)	O
.	O

In	O
case	O
1	O
,	O
we	O
observed	O
a	O
NRAS	O
-	O
MA%	O
increase	O
from	O
18	O
%	O
within	O
the	O
first	O
metastatic	O
node	O
to	O
81	O
%	O
,	O
92	O
%	O
and	O
85	O
%	O
respectively	O
in	O
the	O
three	O
subsequent	O
metastases	O
:	O
lymph	O
node	O
,	O
brain	O
and	O
subcutaneous	O
metastases	O
biopsied	O
1	O
,	O
6	O
and	O
17	O
months	O
,	O
respectively	O
,	O
after	O
the	O
initial	O
lymph	O
node	O
biopsy	O
.	O

In	O
case	O
2	O
,	O
we	O
observed	O
an	O
increase	O
in	O
NRAS	O
-	O
MA%	O
from	O
40	O
%	O
within	O
the	O
primary	O
melanoma	O
to	O
63	O
%	O
within	O
the	O
metastatic	O
lymph	O
node	O
.	O

FISH	O
analysis	O
showed	O
the	O
same	O
results	O
in	O
both	O
cases	O
:	O
a	O
frequent	O
polysomy	O
of	O
chromosome	O
1	O
in	O
metastasis	O
samples	O
with	O
NRAS	O
mutant	O
allele	O
percentage	O
>	O
60	O
%	O
,	O
while	O
most	O
cells	O
were	O
disomic	O
in	O
the	O
samples	O
with	O
well	O
-	O
balanced	O
heterozygous	O
mutations	O
.	O

The	O
percentage	O
of	O
NRAS	O
mutant	O
allele	O
may	O
increase	O
during	O
metastatic	O
progression	O
and	O
may	O
be	O
associated	O
with	O
chromosomal	O
instability	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
evaluate	O
the	O
prognostic	O
impact	O
of	O
the	O
NRAS	O
homozygous	O
status	O
and/or	O
polyploidy	O
in	O
metastatic	O
cutaneous	O
melanomas	O
.	O

A	O
Comprehensive	O
Analysis	O
of	O
Choroideremia	O
:	O
From	O
Genetic	O
Characterization	O
to	O
Clinical	O
Practice	O
.	O

Choroideremia	B-Disease
(	O
CHM	O
)	O
is	O
a	O
rare	O
X	O
-	O
linked	O
disease	O
leading	O
to	O
progressive	O
retinal	O
degeneration	O
resulting	O
in	O
blindness	O
.	O

The	O
disorder	O
is	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
CHM	B-Gene
gene	O
encoding	O
REP-1	O
protein	O
,	O
an	O
essential	O
component	O
of	O
the	O
Rab	O
geranylgeranyltransferase	O
(	O
GGTase	O
)	O
complex	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
evaluated	O
a	O
multi	O
-	O
technique	O
analysis	O
algorithm	O
to	O
describe	O
the	O
mutational	O
spectrum	O
identified	O
in	O
a	O
large	O
cohort	O
of	O
cases	O
and	O
further	O
correlate	O
CHM	O
variants	O
with	O
phenotypic	O
characteristics	O
and	O
biochemical	O
defects	O
of	O
choroideremia	O
patients	O
.	O

Molecular	O
genetic	O
testing	O
led	O
to	O
the	O
characterization	O
of	O
36	O
out	O
of	O
45	O
unrelated	O
CHM	O
families	O
(	O
80	O
%	O
)	O
,	O
allowing	O
the	O
clinical	O
reclassification	O
of	O
four	O
CHM	O
families	O
.	O

Haplotype	O
reconstruction	O
showed	O
independent	O
origins	O
for	O
the	O
recurrent	O
p	O
.	O
Arg293	O
*	O
and	O
p	O
.	O
Lys178Argfs*5	O
mutations	O
,	O
suggesting	O
the	O
presence	O
of	O
hotspots	O
in	O
CHM	O
,	O
as	O
well	O
as	O
the	O
identification	O
of	O
two	O
different	O
unrelated	O
events	O
involving	O
exon	O
9	O
deletion	O
.	O

No	O
certain	O
genotype	O
-	O
phenotype	O
correlation	O
could	O
be	O
established	O
.	O

Furthermore	O
,	O
all	O
the	O
patients	O
´	O
fibroblasts	O
analyzed	O
presented	O
significantly	O
increased	O
levels	O
of	O
unprenylated	O
Rabs	O
proteins	O
compared	O
to	O
control	O
cells	O
;	O
however	O
,	O
this	O
was	O
not	O
related	O
to	O
the	O
genotype	O
.	O

This	O
research	O
demonstrates	O
the	O
major	O
potential	O
of	O
the	O
algorithm	O
proposed	O
for	O
diagnosis	O
.	O

Our	O
data	O
enhance	O
the	O
importance	O
of	O
establish	O
a	O
differential	O
diagnosis	O
with	O
other	O
retinal	O
dystrophies	O
,	O
supporting	O
the	O
idea	O
of	O
an	O
underestimated	O
prevalence	O
of	O
choroideremia	O
.	O

Moreover	O
,	O
they	O
suggested	O
that	O
the	O
severity	O
of	O
the	O
disorder	O
can	O
not	O
be	O
exclusively	O
explained	O
by	O
the	O
genotype	O
.	O

Four	O
novel	O
ATP2C1	B-Gene
mutations	B-Var
in	O
Chinese	O
patients	O
with	B-Reg
Hailey	B-Disease
-	I-Disease
Hailey	I-Disease
disease	I-Disease
.	O

Hailey	O
-	O
Hailey	O
disease	O
(	O
HHD	O
)	O
is	O
a	O
kind	O
of	O
autosomal	O
dominant	O
dermatosis	O
.	O

The	O
ATP2C1	O
gene	O
has	O
been	O
identified	O
as	O
the	O
pathogenic	O
gene	O
of	O
HHD	O
since	O
2000	O
.	O

In	O
this	O
study	O
,	O
direct	O
DNA	O
sequencing	O
was	O
used	O
to	O
identify	O
ATP2C1	O
gene	O
mutations	O
in	O
four	O
Chinese	O
families	O
and	O
two	O
sporadic	O
cases	O
with	O
HHD	O
.	O

The	O
entire	O
coding	O
and	O
flanking	O
intronic	O
sequences	O
of	O
ATP2C1	O
were	O
screened	O
for	O
mutations	O
and	O
five	O
heterozygous	O
mutations	O
of	O
the	O
ATP2C1	O
gene	O
were	O
detected	O
in	O
the	O
four	O
pedigrees	O
and	O
two	O
sporadic	O
cases	O
with	O
HHD	O
.	O

Four	O
of	O
them	O
were	O
novel	O
,	O
including	O
three	O
frame	O
-	O
shift	O
mutations	O
(	O
c.1330delC	O
,	O
c.888_889insT	O
,	O
c.478_479insA	O
)	O
and	O
one	O
nonsense	O
mutation	O
(	O
c.1720C	O
>	O
T	O
)	O
.	O

These	O
data	O
added	O
new	O
variants	O
to	O
the	O
database	O
of	O
ATP2C1	B-Gene
mutations	B-Var
associated	B-Reg
with	I-Reg
HHD	B-Disease
.	O

Glycogen	O
storage	O
disease	O
type	O
III	O
:	O
diagnosis	O
,	O
genotype	O
,	O
management	O
,	O
clinical	O
course	O
and	O
outcome	O
.	O

Glycogen	B-Disease
storage	I-Disease
disease	I-Disease
type	I-Disease
III	I-Disease
(	O
GSDIII	O
)	O
is	O
a	O
rare	O
disorder	O
of	O
glycogenolysis	O
due	B-Reg
to	I-Reg
AGL	B-Gene
gene	O
mutations	B-Var
,	O
causing	O
glycogen	O
debranching	O
enzyme	O
deficiency	O
and	O
storage	O
of	O
limited	O
dextrin	O
.	O

Patients	O
with	O
GSDIIIa	O
show	O
involvement	O
of	O
liver	O
and	O
cardiac	O
/	O
skeletal	O
muscle	O
,	O
whereas	O
GSDIIIb	O
patients	O
display	O
only	O
liver	O
symptoms	O
and	O
signs	O
.	O

The	O
International	O
Study	O
on	O
Glycogen	O
Storage	O
Disease	O
(	O
ISGSDIII	O
)	O
is	O
a	O
descriptive	O
retrospective	O
,	O
international	O
,	O
multi	O
-	O
centre	O
cohort	O
study	O
of	O
diagnosis	O
,	O
genotype	O
,	O
management	O
,	O
clinical	O
course	O
and	O
outcome	O
of	O
175	O
patients	O
from	O
147	O
families	O
(	O
86	O
%	O
GSDIIIa	O
;	O
14	O
%	O
GSDIIIb	O
)	O
,	O
with	O
follow	O
-	O
up	O
into	O
adulthood	O
in	O
91	O
patients	O
.	O

In	O
total	O
58	O
AGL	O
mutations	O
(	O
non	O
-	O
missense	O
mutations	O
were	O
overrepresented	O
and	O
21	O
novel	O
mutations	O
were	O
observed	O
)	O
were	O
identified	O
in	O
76	O
families	O
.	O

GSDIII	O
patients	O
first	O
presented	O
before	O
the	O
age	O
of	O
1.5	O
years	O
,	O
hepatomegaly	O
was	O
the	O
most	O
common	O
presenting	O
clinical	O
sign	O
.	O

Dietary	O
management	O
was	O
very	O
diverse	O
and	O
included	O
frequent	O
meals	O
,	O
uncooked	O
cornstarch	O
and	O
continuous	O
gastric	O
drip	O
feeding	O
.	O

Chronic	O
complications	O
involved	O
the	O
liver	O
(	O
hepatic	O
cirrhosis	O
,	O
adenoma(s	O
)	O
,	O
and/or	O
hepatocellular	O
carcinoma	O
in	O
11	O
%	O
)	O
,	O
heart	O
(	O
cardiac	O
involvement	O
and	O
cardiomyopathy	O
,	O
in	O
58	O
%	O
and	O
15	O
%	O
,	O
respectively	O
,	O
generally	O
presenting	O
in	O
early	O
childhood	O
)	O
,	O
and	O
muscle	O
(	O
pain	O
in	O
34	O
%	O
)	O
.	O

Type	O
2	O
diabetes	O
mellitus	O
was	O
diagnosed	O
in	O
eight	O
out	O
of	O
91	O
adult	O
patients	O
(	O
9	O
%	O
)	O
.	O

In	O
adult	O
patients	O
no	O
significant	O
correlation	O
was	O
detected	O
between	O
(	O
non-	O
)	O
missense	O
AGL	O
genotypes	O
and	O
hepatic	O
,	O
cardiac	O
or	O
muscular	O
complications	O
.	O

This	O
study	O
demonstrates	O
heterogeneity	O
in	O
a	O
large	O
cohort	O
of	O
ageing	O
GSDIII	O
patients	O
.	O

An	O
international	O
GSD	O
patient	O
registry	O
is	O
warranted	O
to	O
prospectively	O
define	O
the	O
clinical	O
course	O
,	O
heterogeneity	O
and	O
the	O
effect	O
of	O
different	O
dietary	O
interventions	O
in	O
patients	O
with	O
GSDIII	O
.	O

Gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
Function	I-PosReg
Mutations	B-Var
in	O
RARB	B-Gene
Cause	B-Reg
Intellectual	B-MPA
Disability	I-MPA
with	O
Progressive	B-MPA
Motor	I-MPA
Impairment	I-MPA
.	O

Retinoic	O
acid	O
(	O
RA	O
)	O
signaling	O
plays	O
a	O
key	O
role	O
in	O
the	O
development	O
and	O
function	O
of	O
several	O
systems	O
in	O
mammals	O
.	O

We	O
previously	O
discovered	O
that	O
the	O
de	O
novo	O
mutations	O
c.1159C	B-Var
>	I-Var
T	I-Var
(	O
p	O
.	O
Arg387Cys	O
)	O
and	O
c.1159C	B-Var
>	I-Var
A	I-Var
(	O
p	O
.	O
Arg387Ser	O
)	O
in	O
the	O
RA	O
Receptor	O
Beta	O
(	B-Gene
RARB	I-Gene
)	I-Gene
gene	O
cause	B-Reg
microphthalmia	B-Disease
and	O
diaphragmatic	B-Disease
hernia	I-Disease
.	O

However	O
,	O
the	O
natural	O
history	O
of	O
affected	O
subjects	O
beyond	O
the	O
prenatal	O
or	O
neonatal	O
period	O
was	O
unknown	O
.	O

Here	O
,	O
we	O
describe	O
nine	O
additional	O
subjects	O
with	O
microphthalmia	O
who	O
have	O
de	O
novo	O
mutations	O
in	O
RARB	O
,	O
including	O
the	O
previously	O
described	O
p	O
.	O
Arg387Cys	O
as	O
well	O
as	O
the	O
novel	O
c.887G	O
>	O
C	O
(	O
p	O
.	O
Gly296Ala	O
)	O
and	O
c.638T	O
>	O
C	O
(	O
p	O
.	O
Leu213Pro	O
)	O
.	O

Moreover	O
,	O
we	O
review	O
the	O
information	O
on	O
four	O
previously	O
reported	O
cases	O
.	O

All	O
subjects	O
who	O
survived	O
the	O
neonatal	O
period	O
(	O
n	O
=	O
10	O
)	O
displayed	O
severe	O
global	O
developmental	O
delay	O
with	O
progressive	O
motor	O
impairment	O
due	O
to	O
spasticity	O
and/or	O
dystonia	O
(	O
with	O
or	O
without	O
chorea	O
)	O
.	O

The	O
majority	O
of	O
subjects	O
also	O
showed	O
Chiari	O
type	O
I	O
malformation	O
and	O
severe	O
feeding	O
difficulties	O
.	O

We	O
previously	O
found	O
that	O
p	O
.	O
Arg387Cys	O
and	O
p	O
.	O
Arg387Ser	O
induce	O
a	O
gain	O
-	O
of	O
-	O
function	O
.	O

We	O
show	O
here	O
that	O
the	O
p	B-Var
.	I-Var
Gly296Ala	I-Var
and	O
p	B-Var
.	I-Var
Leu213Pro	I-Var
RARB	B-Gene
mutations	O
further	O
promote	B-PosReg
the	O
RA	B-MPA
ligand	I-MPA
-	I-MPA
induced	I-MPA
transcriptional	I-MPA
activity	I-MPA
by	O
twofold	O
to	O
threefold	O
over	O
the	O
wild	O
-	O
type	O
receptor	O
,	O
also	O
indicating	O
a	O
gain	O
-	O
of	O
-	O
function	O
mechanism	O
.	O

These	O
observations	O
suggest	O
that	O
precise	O
regulation	O
of	O
RA	O
signaling	O
is	O
required	O
for	O
brain	O
development	O
and/or	O
function	O
in	O
humans	O
.	O

Long	O
-	O
term	O
vemurafenib	O
treatment	O
drives	B-Reg
inhibitor	B-MPA
resistance	I-MPA
through	O
a	O
spontaneous	O
KRAS	B-Gene
G12D	B-Var
mutation	O
in	O
a	O
BRAF	O
V600E	O
papillary	O
thyroid	O
carcinoma	O
model	O
.	O

The	O
BRAF	O
V600E	O
mutation	O
is	O
commonly	O
observed	O
in	O
papillary	O
thyroid	O
cancer	O
(	O
PTC	O
)	O
and	O
predominantly	O
activates	O
the	O
MAPK	O
pathway	O
.	O

Presence	O
of	O
BRAF	O
V600E	O
predicts	O
increasing	O
risk	O
of	O
recurrence	O
and	O
higher	O
mortality	O
rate	O
,	O
and	O
treatment	O
options	O
for	O
such	O
patients	O
are	O
limited	O
.	O

Vemurafenib	O
,	O
a	O
BRAF	O
V600E	O
inhibitor	O
,	O
is	O
initially	O
effective	O
,	O
but	O
cells	O
inevitably	O
develop	O
alternative	O
mechanisms	O
of	O
pathway	O
activation	O
.	O

Mechanisms	O
of	O
primary	O
resistance	O
have	O
been	O
described	O
in	O
short	O
-	O
term	O
cultures	O
of	O
PTC	O
cells	O
;	O
however	O
,	O
mechanisms	O
of	O
acquired	O
resistance	O
have	O
not	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
possible	O
adaptive	O
mechanisms	O
of	O
BRAF	O
V600E	O
inhibitor	O
resistance	O
in	O
KTC1	O
thyroid	O
cancer	O
cells	O
following	O
long	O
-	O
term	O
vemurafenib	O
exposure	O
.	O

We	O
found	O
that	O
a	O
subpopulation	O
of	O
KTC1	O
cells	O
acquired	O
resistance	O
to	O
vemurafenib	O
following	O
5	O
months	O
of	O
treatment	O
with	O
the	O
inhibitor	O
.	O

Resistance	O
coincided	O
with	O
the	O
spontaneous	O
acquisition	O
of	O
a	O
KRAS	O
G12D	O
activating	O
mutation	O
.	O

Increases	O
in	O
activated	O
AKT	O
,	O
ERK1/2	O
,	O
and	O
EGFR	O
were	O
observed	O
in	O
these	O
cells	O
.	O

In	O
addition	O
,	O
the	O
resistant	O
cells	O
were	O
less	O
sensitive	O
to	O
combinations	O
of	O
vemurafenib	O
and	O
MEK1	O
inhibitor	O
or	O
AKT	O
inhibitor	O
.	O

These	O
results	O
support	O
the	O
KRAS	B-Gene
G12D	B-Var
mutation	O
as	O
a	O
genetic	O
mechanism	O
of	O
spontaneously	O
acquired	B-Reg
secondary	B-MPA
BRAF	I-MPA
inhibitor	I-MPA
resistance	I-MPA
in	O
BRAF	O
V600E	O
thyroid	O
cancer	O
cells	O
.	O

Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
the	O
APX1	B-Gene
gene	O
result	O
in	O
enhanced	B-PosReg
selenium	B-MPA
tolerance	I-MPA
in	O
Arabidopsis	O
thaliana	O
.	O

It	O
is	O
generally	O
recognized	O
that	O
excess	O
selenium	O
(	O
Se	O
)	O
has	O
a	O
negative	O
effect	O
on	O
the	O
growth	O
and	O
development	O
of	O
plants	O
.	O

Numerous	O
studies	O
have	O
identified	O
key	O
genes	O
involved	O
in	O
selenium	O
tolerance	O
in	O
plants	O
;	O
however	O
,	O
our	O
understanding	O
of	O
its	O
molecular	O
mechanisms	O
is	O
far	O
from	O
complete	O
.	O

In	O
this	O
study	O
,	O
we	O
isolated	O
an	O
Arabidopsis	O
selenium	O
-	O
resistant	O
mutant	B-Var
from	O
the	O
mutant	O
XVE	O
pool	O
lines	O
because	O
of	O
its	O
increased	B-PosReg
root	B-MPA
growth	I-MPA
and	O
fresh	B-MPA
weight	I-MPA
in	O
Se	O
stress	O
,	O
and	O
cloned	O
the	O
gene	O
,	O
which	O
encodes	O
the	O
cytosolic	O
ascorbate	O
peroxidase	O
(	O
APX1	O
)	O
.	O

Two	O
other	O
APX1	O
gene	O
knockout	O
allelic	O
lines	O
were	O
also	O
selenium	O
resistant	O
,	O
and	O
the	O
APX1-complementary	O
COM1	O
restored	O
the	O
growth	O
state	O
of	O
wild	O
type	O
under	O
Se	O
stress	O
.	O

In	O
addition	O
,	O
these	O
APX1	O
allelic	O
lines	O
accumulated	O
more	O
Se	O
than	O
did	O
wild	O
-	O
type	O
plants	O
when	O
subjected	O
to	O
Se	O
stress	O
.	O

Further	O
analysis	O
revealed	O
that	O
the	O
APX1-mediated	O
Se	O
tolerance	O
was	O
associated	O
,	O
at	O
least	O
in	O
part	O
,	O
with	O
the	O
enhanced	O
activities	O
of	O
antioxidant	O
enzymes	O
catalase	O
,	O
glutathione	O
peroxidase	O
and	O
glutathione	O
reductase	O
.	O

Moreover	O
,	O
enhanced	B-PosReg
Se	B-MPA
resistance	I-MPA
of	O
the	O
mutants	B-Var
was	O
associated	B-Reg
with	O
glutathione	B-MPA
(	O
GSH	O
)	O
,	O
which	O
had	O
the	O
higher	O
expression	O
level	O
of	O
GSH1	O
gene	O
involved	O
in	O
GSH	O
synthesis	O
and	O
consequently	O
increased	O
GSH	O
content	O
.	O

Our	O
results	O
provide	O
genetic	O
evidence	O
indicating	O
that	O
loss	O
-	O
of	O
-	O
function	O
of	O
APX1	O
results	O
in	O
tolerance	O
to	O
Se	O
stress	O
.	O

Coexistence	O
of	O
Mosaic	O
Uniparental	O
Isodisomy	O
and	O
a	O
KCNJ11	O
Mutation	O
Presenting	O
as	O
Diffuse	O
Congenital	O
Hyperinsulinism	O
and	O
Hemihypertrophy	O
.	O

BACKGROUND	O
:	O
Isolated	O
hyperinsulinaemic	B-Disease
hypoglycaemia	I-Disease
(	O
HH	O
)	O
commonly	O
results	B-Reg
from	I-Reg
recessively	B-Var
inherited	I-Var
mutations	I-Var
in	O
the	O
ABCC8	B-Gene
and	O
KCNJ11	B-Gene
genes	O
that	O
are	O
located	O
on	O
chromosome	O
11p15.1	O
.	O

More	O
rarely	O
,	O
HH	O
can	O
feature	O
in	O
patients	O
with	O
Beckwith	O
-	O
Wiedemann	O
syndrome	O
(	O
BWS	O
)	O
,	O
a	O
congenital	O
overgrowth	O
disorder	O
,	O
resulting	O
from	O
defects	O
at	O
a	O
differentially	O
methylated	O
region	O
telomeric	O
to	O
the	O
K	O
-	O
ATP	O
channel	O
genes	O
at	O
chromosome	O
11p15.5	O
.	O

SUBJECT	O
:	O
We	O
undertook	O
genetic	O
testing	O
in	O
a	O
patient	O
with	O
diazoxide	O
-	O
unresponsive	O
HH	O
diagnosed	O
at	O
birth	O
.	O

Physical	O
examination	O
later	O
revealed	O
hemihypertrophy	O
of	O
the	O
right	O
arm	O
,	O
a	O
feature	O
of	O
BWS	O
.	O

RESULTS	O
:	O
We	O
identified	O
a	O
novel	O
mosaic	O
,	O
paternally	O
-	O
inherited	O
KCNJ11	O
mutation(s	O
)	O
in	O
the	O
patient	O
.	O

Further	O
analysis	O
confirmed	O
uniparental	O
disomy	O
(	O
UPD	O
)	O
of	O
chromosome	O
11	O
,	O
which	O
extended	O
across	O
the	O
KCNJ11	O
gene	O
at	O
11p15.1	O
and	O
the	O
BWS	O
locus	O
at	O
11p15.5	O
.	O

CONCLUSION	O
:	O
These	O
results	O
highlight	O
the	O
importance	O
of	O
considering	O
UPD	O
as	O
a	O
mechanism	O
of	O
disease	O
in	O
patients	O
with	O
HH	O
and	O
a	O
paternally	O
inherited	O
K	O
-	O
ATP	O
channel	O
mutation	O
,	O
especially	O
when	O
additional	O
syndromic	O
features	O
are	O
present	O
.	O

Loss	O
of	O
T	O
-	O
cell	O
quiescence	O
by	O
targeting	O
Slfn2	O
prevents	O
the	O
development	O
and	O
progression	O
of	O
T	O
-	O
ALL	O
.	O

T	O
-	O
cell	O
acute	O
lymphoblastic	O
leukemia	O
(	O
T	O
-	O
ALL	O
)	O
is	O
an	O
aggressive	O
malignancy	O
of	O
thymocytes	O
.	O

Despite	O
significant	O
improvement	O
in	O
the	O
treatment	O
of	O
T	O
-	O
ALL	O
,	O
approximately	O
20	O
%	O
of	O
children	O
and	O
most	O
adults	O
undergo	O
relapse	O
.	O

Previous	O
findings	O
demonstrated	O
that	O
loss	B-NegReg
of	O
T	B-CPA
-	I-CPA
cell	I-CPA
quiescence	I-CPA
due	O
to	O
a	O
mutation	B-Var
in	O
the	O
Slfn2	B-Gene
gene	O
(	O
elektra	O
)	O
leads	B-Reg
to	I-Reg
acquisition	O
of	O
an	O
aberrant	B-CPA
developmental	I-CPA
program	I-CPA
by	O
which	O
T	O
-	O
cells	O
lose	B-NegReg
their	O
renewal	B-CPA
capabilities	I-CPA
and	O
undergo	B-CPA
apoptosis	I-CPA
.	O

Here	O
we	O
show	O
that	O
the	O
elektra	O
mutation	O
in	O
Slfn2	O
completely	O
prevents	O
a	O
severe	O
lymphoproliferative	O
disease	O
caused	O
by	O
overexpression	O
of	O
BCL2	O
in	O
combination	O
with	O
Fas	O
deficiency	O
in	O
mice	O
.	O

Moreover	O
,	O
Slfn2	O
impaired	O
-	O
function	O
protects	O
mice	O
from	O
experimental	O
disease	O
similar	O
to	O
human	O
T	O
-	O
ALL	O
by	O
severely	O
impairing	O
the	O
proliferation	O
potential	O
and	O
survival	O
of	O
leukemic	O
T	O
-	O
cells	O
,	O
partially	O
by	O
activation	O
of	O
the	O
p53	O
tumor	O
suppressor	O
protein	O
.	O

Our	O
study	O
suggest	O
that	O
in	O
certain	O
malignancies	O
,	O
such	O
as	O
T	O
-	O
ALL	O
,	O
a	O
novel	O
therapeutic	O
strategy	O
may	O
be	O
applied	O
by	O
imposing	O
aberrant	O
development	O
of	O
leukemic	O
cells	O
.	O

Furthermore	O
,	O
as	O
the	O
elektra	O
mutation	B-Var
in	O
Slfn2	B-Gene
seems	O
to	O
impair	B-Reg
only	O
T	B-CPA
-	I-CPA
cells	I-CPA
and	O
monocytes	B-CPA
,	O
targeting	O
Slfn2	O
is	O
expected	O
to	O
be	O
harmless	O
to	O
other	O
cell	O
types	O
,	O
and	O
thereby	O
could	O
be	O
a	O
promising	O
target	O
for	O
treating	O
malignancies	O
.	O

Together	O
our	O
results	O
demonstrate	O
the	O
potential	O
of	O
targeting	O
Slfn2	O
and	O
its	O
human	O
paralog	O
for	O
T	O
-	O
ALL	O
treatment	O
.	O

Mutational	B-Var
Spectrum	O
of	O
the	O
MEFV	B-Gene
Gene	O
in	O
AA	O
Amyloidosis	O
Associated	B-Reg
With	I-Reg
Familial	B-Disease
Mediterranean	I-Disease
Fever	I-Disease
.	O

INTRODUCTION	O
:	O
Familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
(	O
FMF	O
)	O
is	O
a	O
recessively	O
inherited	O
disease	O
which	O
is	O
characterized	O
by	O
recurrent	O
episodic	O
fever	O
,	O
abdominal	O
pain	O
,	O
and	O
polyserositis	O
.	O

It	O
is	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
MEFV	B-Gene
gene	O
,	O
encoding	O
the	O
pyrin	O
protein	O
.	O

The	O
most	O
important	O
complication	O
of	O
FMF	O
is	O
secondary	O
(	O
AA	O
)	O
amyloidosis	O
that	O
leads	O
to	O
kidney	O
failure	O
.	O

This	O
study	O
aimed	O
to	O
identify	O
the	O
frequency	O
and	O
distribution	O
of	O
MEFV	O
mutations	O
in	O
Turkish	O
patients	O
with	O
FMF	O
-	O
associated	O
AA	O
amyloidosis	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
A	O
total	O
of	O
57	O
patients	O
with	O
FMF	O
-	O
associated	O
AA	O
amyloidosis	O
and	O
60	O
healthy	O
controls	O
were	O
included	O
in	O
this	O
study	O
.	O

We	O
analyzed	O
the	O
MEFV	O
gene	O
for	O
E148Q	O
,	O
M694V	O
,	O
M680I	O
,	O
and	O
V726A	O
mutations	O
and	O
R202Q	O
variant	O
by	O
polymerase	O
chain	O
reaction	O
and	O
restriction	O
fragment	O
length	O
polymorphism	O
methods	O
.	O

Results	O
.	O

The	O
male	O
-	O
female	O
ratio	O
was	O
0.72	O
.	O

The	O
mean	O
age	O
of	O
the	O
patients	O
was	O
29.8	O
±	O
12.8	O
years	O
.	O

Among	O
the	O
patients	O
,	O
the	O
rate	O
of	O
the	O
MEFV	O
mutations	O
was	O
found	O
to	O
be	O
77.2	O
%	O
.	O

The	O
most	O
frequently	O
observed	O
genotype	O
was	O
homozygous	O
M694V	O
mutation	O
,	O
which	O
was	O
present	O
in	O
17	O
patients	O
(	O
29.8	O
%	O
,	O
P	O
<	O
.001	O
)	O
,	O
followed	O
by	O
compound	O
heterozygous	O
M680I	O
/	O
M694V	O
(	O
14.3	O
%	O
,	O
P	O
=	O
.01	O
)	O
.	O

The	O
R202Q	O
allele	O
frequencies	O
were	O
significantly	O
different	O
between	O
patients	O
and	O
control	O
group	O
(	O
P	O
=	O
.02	O
;	O
odds	O
ratio	O
,	O
0.53	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0.30	O
to	O
0.94	O
)	O
.	O

CONCLUSIONS	O
:	O
In	O
this	O
study	O
,	O
mutation	O
analysis	O
of	O
MEFV	O
gene	O
confirmed	O
that	O
the	O
most	O
frequent	O
mutation	O
was	O
homozygous	O
M694V	O
genotype	O
.	O

R202Q	O
may	O
be	O
important	O
in	O
patients	O
with	O
FMF	O
-	O
associated	O
AA	O
amyloidosis	O
.	O

Thus	O
,	O
it	O
is	O
suggested	O
that	O
investigation	O
of	O
R202Q	O
should	O
be	O
considered	O
as	O
a	O
genetic	O
test	O
for	O
Turkish	O
FMF	O
patients	O
.	O

Oncogenic	O
Mutant	O
p53	O
Gain	O
of	O
Function	O
Nourishes	O
the	O
Vicious	O
Cycle	O
of	O
Tumor	O
Development	O
and	O
Cancer	O
Stem	O
-	O
Cell	O
Formation	O
.	O

More	O
than	O
half	O
of	O
human	O
tumors	O
harbor	O
an	O
inactivated	O
p53	O
tumor	O
-	O
suppressor	O
gene	O
.	O

It	O
is	O
well	O
accepted	O
that	O
mutant	B-Var
p53	B-Gene
shows	O
an	O
oncogenic	O
gain	O
-	O
of	O
-	O
function	O
(	O
GOF	O
)	O
activity	O
that	O
facilitates	B-PosReg
the	O
transformed	B-MPA
phenotype	I-MPA
of	I-MPA
cancer	I-MPA
cells	I-MPA
.	O

In	O
addition	O
,	O
a	O
growing	O
body	O
of	O
evidence	O
supports	O
the	O
notion	O
that	O
cancer	O
stem	O
cells	O
comprise	O
a	O
seminal	O
constituent	O
in	O
the	O
initiation	O
and	O
progression	O
of	O
cancer	O
development	O
.	O

Here	O
,	O
we	O
elaborate	O
on	O
the	O
mutant	B-Var
p53	B-Gene
oncogenic	O
GOF	B-PosReg
leading	O
toward	O
the	B-MPA
acquisition	I-MPA
of	I-MPA
a	I-MPA
transformed	I-MPA
phenotype	I-MPA
,	O
as	O
well	O
as	O
placing	O
mutant	O
p53	O
as	O
a	O
major	O
component	O
in	O
the	O
establishment	O
of	O
cancer	O
stem	O
cell	O
entity	O
.	O

Therefore	O
,	O
therapy	O
targeted	O
toward	O
cancer	O
stem	O
cells	O
harboring	O
mutant	O
p53	O
is	O
expected	O
to	O
pave	O
the	O
way	O
to	O
eradicate	O
tumor	O
growth	O
and	O
recurrence	O
.	O

N	O
-	O
glycan	O
containing	O
a	O
core	O
α1,3-fucose	O
residue	O
is	O
required	O
for	O
basipetal	O
auxin	O
transport	O
and	O
gravitropic	O
response	O
in	O
rice	O
(	O
Oryza	O
sativa	O
)	O
.	O

In	O
plants	O
,	O
α1,3-fucosyltransferase	O
(	O
FucT	O
)	O
catalyzes	O
the	O
transfer	O
of	O
fucose	O
from	O
GDP	O
-	O
fucose	O
to	O
asparagine	O
-	O
linked	O
GlcNAc	O
of	O
the	O
N	O
-	O
glycan	O
core	O
in	O
the	O
medial	O
Golgi	O
.	O

To	O
explore	O
the	O
physiological	O
significance	O
of	O
this	O
processing	O
,	O
we	O
isolated	O
two	O
Oryza	O
sativa	O
(	O
rice	O
)	O
mutants	O
(	O
fuct-1	O
and	O
fuct-2	O
)	O
with	O
loss	O
of	O
FucT	O
function	O
.	O

Biochemical	O
analyses	O
of	O
the	O
N	O
-	O
glycan	O
structure	O
confirmed	O
that	O
α1,3-fucose	O
is	O
missing	B-Var
from	O
the	O
N	O
-	O
glycans	O
of	O
allelic	O
fuct-1	B-Gene
and	O
fuct-2	B-Gene
.	O

Compared	O
with	O
the	O
wild	O
-	O
type	O
cv	O
Kitaake	O
,	O
fuct-1	O
displayed	O
a	O
larger	B-PosReg
tiller	B-MPA
angle	I-MPA
,	O
shorter	B-NegReg
internode	B-MPA
and	O
panicle	B-MPA
lengths	O
,	O
and	O
decreased	B-NegReg
grain	B-MPA
filling	I-MPA
as	O
well	O
as	O
an	O
increase	B-PosReg
in	O
chalky	B-MPA
grains	I-MPA
with	I-MPA
abnormal	I-MPA
shape	I-MPA
.	O

The	O
mutant	O
allele	O
fuct-2	O
gave	O
rise	O
to	O
similar	O
developmental	O
abnormalities	O
,	O
although	O
they	O
were	O
milder	O
than	O
those	O
of	O
fuct-1	O
.	O

Restoration	O
of	O
a	O
normal	O
tiller	O
angle	O
in	O
fuct-1	O
by	O
complementation	O
demonstrated	O
that	O
the	O
phenotype	O
is	O
caused	O
by	O
the	O
loss	O
of	O
FucT	O
function	O
.	O

Both	O
fuct-1	O
and	O
fuct-2	O
plants	O
exhibited	O
reduced	O
gravitropic	O
responses	O
.	O

Expression	O
of	O
the	O
genes	O
involved	O
in	O
tiller	O
and	O
leaf	O
angle	O
control	O
was	O
also	O
affected	O
in	O
the	O
mutants	O
.	O

We	O
demonstrate	O
that	O
reduced	O
basipetal	O
auxin	O
transport	O
and	O
low	O
auxin	O
accumulation	O
at	O
the	O
base	O
of	O
the	O
shoot	O
in	O
fuct-1	O
account	O
for	O
both	O
the	O
reduced	O
gravitropic	O
response	O
and	O
the	O
increased	O
tiller	O
angle	O
.	O

Hajdu	O
-	O
Cheney	O
Syndrome	O
,	O
a	O
Disease	O
Associated	O
with	O
NOTCH2	O
Mutations	O
.	O

Notch	O
plays	O
an	O
important	O
function	O
in	O
skeletal	O
homeostasis	O
,	O
osteoblastogenesis	O
,	O
and	O
osteoclastogenesis	O
.	O

Hajdu	B-Disease
-	I-Disease
Cheney	I-Disease
syndrome	I-Disease
(	O
HCS	O
)	O
is	O
a	O
rare	O
disease	O
associated	O
with	O
mutations	B-Var
in	O
NOTCH2	B-Gene
leading	B-Reg
to	I-Reg
the	O
translation	B-MPA
of	I-MPA
a	I-MPA
truncated	I-MPA
NOTCH2	B-Gene
stable	O
protein	B-Protein
.	O

As	O
a	O
consequence	O
,	O
a	O
gain	O
-	O
of	O
-	O
NOTCH2	O
function	O
is	O
manifested	O
.	O

HCS	O
is	O
inherited	O
as	O
an	O
autosomal	O
dominant	O
disease	O
although	O
sporadic	O
cases	O
exist	O
.	O

HCS	O
is	O
characterized	O
by	O
craniofacial	O
developmental	O
defects	O
,	O
including	O
platybasia	O
and	O
wormian	O
bones	O
,	O
osteoporosis	O
with	O
fractures	O
,	O
and	O
acro	O
-	O
osteolysis	O
.	O

Subjects	O
may	O
suffer	O
severe	O
neurological	O
complications	O
,	O
and	O
HCS	O
presents	O
with	O
cardiovascular	O
defects	O
and	O
polycystic	O
kidneys	O
.	O

An	O
experimental	O
mouse	O
model	O
harboring	O
a	O
HCSNotch2	O
mutation	O
exhibits	O
osteopenia	O
secondary	O
to	O
enhanced	O
bone	O
resorption	O
suggesting	O
this	O
as	O
a	O
possible	O
mechanism	O
for	O
the	O
skeletal	O
disease	O
.	O

If	O
the	O
same	O
mechanisms	O
were	O
operational	O
in	O
humans	O
,	O
anti	O
-	O
resorptive	O
therapy	O
could	O
correct	O
the	O
bone	O
loss	O
,	O
but	O
not	O
necessarily	O
the	O
acro	O
-	O
osteolysis	O
.	O

In	O
conclusion	O
,	O
HCS	O
is	O
a	O
devastating	O
disease	O
associated	O
with	O
a	O
gain	O
-	O
of	O
-	O
NOTCH2	O
function	O
resulting	O
in	O
diverse	O
clinical	O
manifestations	O
.	O

Phenotypes	O
and	O
Genotypes	O
in	O
Five	O
Children	O
with	O
Congenital	O
Insensitivity	O
to	O
Pain	O
with	O
Anhidrosis	O
.	O

BACKGROUND	O
:	O
Congenital	B-Disease
insensitivity	I-Disease
to	I-Disease
pain	I-Disease
with	I-Disease
anhidrosis	I-Disease
is	O
an	O
extremely	O
rare	O
hereditary	O
disorder	O
linked	B-Reg
to	I-Reg
variants	B-Var
in	O
NTRK1	B-Gene
.	O

Our	O
goal	O
was	O
to	O
characterize	O
the	O
clinical	O
features	O
and	O
the	O
genetic	O
basis	O
of	O
the	O
disorder	O
in	O
Chinese	O
patients	O
.	O

METHODS	O
:	O
Patients	O
were	O
enrolled	O
via	O
social	O
networking	O
.	O

Clinical	O
features	O
were	O
investigated	O
by	O
interview	O
,	O
chart	O
review	O
,	O
and	O
physical	O
examination	O
.	O

DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
to	O
genotype	O
NTRK1	O
in	O
patients	O
and	O
their	O
parents	O
.	O

Variants	O
identified	O
were	O
checked	O
against	O
a	O
control	O
cohort	O
by	O
high	O
-	O
throughput	O
sequencing	O
,	O
and	O
the	O
effects	O
of	O
these	O
variants	O
were	O
assessed	O
in	O
silico	O
.	O

RESULTS	O
:	O
Clinical	O
features	O
in	O
five	O
patients	O
were	O
cataloged	O
,	O
and	O
six	O
loss	O
-	O
of	O
-	O
function	O
NTRK1	O
variants	O
were	O
identified	O
,	O
including	O
a	O
frameshift	O
variant	O
c.963delG	O
,	O
a	O
nonsense	O
variant	O
c.1804C	O
>	O
T	O
,	O
an	O
intron	O
variant	O
c.851	O
-	O
33T	O
>	O
A	O
,	O
and	O
three	O
missense	O
variants	O
c.1802T	O
>	O
G	O
,	O
c.2074C	O
>	O
T	O
,	O
and	O
c.2311C	O
>	O
T.	O
CONCLUSIONS	O
:	O
The	O
results	O
expand	O
the	O
spectrum	O
of	O
clinical	O
and	O
genetic	O
features	O
of	O
congenital	O
insensitivity	O
to	O
pain	O
with	O
anhidrosis	O
and	O
will	O
help	O
facilitate	O
analysis	O
of	O
genotype	O
-	O
phenotype	O
association	O
in	O
the	O
future	O
.	O

The	O
impact	O
of	O
intermittent	O
versus	O
continuous	O
exposure	O
to	O
EGFR	O
tyrosine	O
kinase	O
inhibitor	O
on	O
selection	O
of	O
EGFR	O
T790M	O
-	O
mutant	O
drug	O
-	O
resistant	O
clones	O
in	O
a	O
lung	O
cancer	O
cell	O
line	O
carrying	O
activating	O
EGFR	O
mutation	O
.	O

Drug	O
-	O
resistant	O
cell	O
lines	O
are	O
essential	O
tools	O
for	O
investigating	O
the	O
mechanisms	O
of	O
resistance	O
to	O
molecular	O
-	O
targeted	O
anti	O
-	O
cancer	O
drugs	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
how	O
to	O
establish	O
clinically	O
relevant	O
drug	O
-	O
resistant	O
cell	O
lines	O
.	O

Our	O
study	O
examined	O
the	O
impact	O
of	O
a	O
drug	O
-	O
free	O
period	O
on	O
the	O
establishment	O
of	O
a	O
cell	O
line	O
with	O
clinically	O
relevant	O
resistance	O
to	O
molecular	O
-	O
targeted	O
drugs	O
.	O

We	O
used	O
PC9	O
cells	O
,	O
a	O
lung	O
cancer	O
cell	O
line	O
carrying	O
EGFR	O
mutation	O
,	O
because	O
this	O
is	O
a	O
validated	O
target	O
for	O
EGFR	O
tyrosine	O
kinase	O
inhibitors	O
(	O
TKI	O
)	O
.	O

PC9	O
cells	O
were	O
intermittently	O
or	O
continuously	O
exposed	O
to	O
increasing	O
concentrations	O
of	O
gefitinib	O
(	O
0.01	O
μM	O
to	O
1.0	O
μM	O
)	O
and	O
the	O
emergence	O
of	O
the	O
most	O
common	O
acquired	O
resistance	O
mutation	O
in	O
EGFR	O
,	O
T790	O
M	O
,	O
was	O
determined	O
.	O

T790	O
M	O
was	O
detected	O
at	O
a	O
25-fold	O
lower	O
drug	O
concentration	O
in	O
cells	O
continuously	O
exposed	O
to	O
gefitinib	O
(	O
PC9	O
/	O
GRc	O
)	O
than	O
in	O
cells	O
intermittently	O
exposed	O
to	O
gefitinib	O
(	O
PC9	O
/	O
GRi	O
)	O
(	O
0.04	O
μM	O
vs	O
1.0	O
μM	O
,	O
respectively	O
)	O
.	O

The	O
mutation	B-Var
frequencies	O
at	O
those	O
drug	O
concentrations	O
were	O
19.8	O
%	O
and	O
8.0	O
%	O
in	O
PC9	O
/	O
GRc	O
and	O
PC9	O
/	O
GRi	O
cells	O
,	O
respectively	O
.	O

After	O
drug	O
-	O
free	O
culture	O
for	O
8	O
weeks	O
,	O
resistance	B-MPA
to	I-MPA
gefitinib	I-MPA
decreased	B-NegReg
in	O
the	O
PC9	O
/	O
GRi	O
cells	O
but	O
not	O
in	O
the	O
PC9	O
/	O
GRc	O
cells	O
.	O

In	O
the	O
PC9	O
/	O
GRc	O
cells	O
,	O
the	O
frequency	O
of	O
the	O
T790	O
M	O
mutation	O
was	O
consistently	O
about	O
20	O
%	O
from	O
0.04	O
μM	O
to	O
1.0	O
μM	O
of	O
gefitinib	O
.	O

In	O
the	O
PC9	O
/	O
GRc	O
cells	O
,	O
the	O
T790	O
M	O
mutation	O
was	O
detected	O
in	O
all	O
single	O
-	O
cell	O
clones	O
,	O
at	O
frequencies	O
ranging	O
from	O
7.0	O
%	O
to	O
37.0	O
%	O
,	O
with	O
a	O
median	O
of	O
19.5	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
17.3%-20.9	O
%	O
)	O
.	O

In	O
conclusion	O
,	O
compared	O
with	O
intermittent	O
drug	O
exposure	O
,	O
continuous	O
exposure	O
might	O
select	O
better	O
minor	O
drug	O
-	O
resistant	O
clones	O
when	O
creating	O
cell	O
lines	O
resistant	O
to	O
molecular	O
-	O
targeted	O
drugs	O
.	O

Identification	O
of	O
mutations	B-Var
in	O
the	O
F8	B-Gene
and	O
F9	B-Gene
gene	O
in	O
families	O
with	B-Reg
haemophilia	B-Disease
using	O
targeted	O
high	O
-	O
throughput	O
sequencing	O
.	O

INTRODUCTION	O
:	O
At	O
present	O
,	O
many	O
methods	O
are	O
available	O
for	O
the	O
genetic	O
diagnosis	O
of	O
haemophilia	O
,	O
including	O
indirect	O
linkage	O
analysis	O
,	O
direct	O
sequencing	O
.	O

However	O
,	O
these	O
methods	O
are	O
time	O
-	O
consuming	O
,	O
labourious	O
,	O
and	O
limited	O
in	O
their	O
application	O
.	O

Therefore	O
,	O
the	O
development	O
of	O
new	O
,	O
more	O
effective	O
techniques	O
is	O
necessary	O
.	O

AIM	O
:	O
To	O
detect	O
the	O
F8	B-Gene
and	O
F9	B-Gene
gene	O
mutations	B-Var
in	O
patients	O
with	B-Reg
haemophilia	B-Disease
and	O
their	O
female	O
relatives	O
in	O
29	O
haemophilia	O
A	O
(	O
HA	O
)	O
and	O
11	O
haemophilia	O
B	O
(	O
HB	O
)	O
families	O
.	O

METHODS	O
:	O
*	O
FVIII	O
:	O
C	O
and	O
FIX	O
:	O
C	O
were	O
analyzed	O
using	O
one	O
-	O
stage	O
method	O
,	O
and	O
factor	O
VIII	O
and	O
factor	O
IX	O
inhibitors	O
were	O
tested	O
using	O
the	O
Bethesda	O
method	O
.	O

Intron	O
22	O
and	O
one	O
inversions	O
were	O
identified	O
using	O
long	O
-	O
distance	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
standard	O
PCR	O
.	O

Non	O
-	O
inversion	O
mutations	O
of	O
the	O
F8	O
and	O
F9	O
gene	O
were	O
identified	O
by	O
targeted	O
high	O
-	O
throughput	O
sequencing	O
.	O

All	O
mutations	O
were	O
verified	O
by	O
Sanger	O
sequencing	O
.	O

RESULTS	O
:	O
Intron	O
22	O
inversion	O
was	O
detected	O
in	O
eight	O
HA	O
families	O
and	O
intron	O
one	O
inversion	O
was	O
detected	O
in	O
one	O
HA	O
family	O
.	O

Apart	O
from	O
the	O
inversion	O
mutations	O
,	O
20	O
mutations	O
were	O
identified	O
in	O
HA	O
families	O
,	O
including	O
17	O
previously	O
reported	O
and	O
three	O
novel	O
mutations	O
:	O
c.5724G	O
>	O
A	O
(	O
p	O
.	O
Trp1908	O
*	O
)	O
,	O
c.6116	O
-	O
1_6120delGAGTGTinsTCC	O
(	O
p	O
.	O
Lys2039Ilefs*13	O
)	O
,	O
and	O
c.5220	O
-	O
2A	O
>	O
C.	O
We	O
found	O
a	O
complex	O
rearrangement	O
in	O
HA	O
:	O
intron	O
one	O
inversion	O
concomitant	O
with	O
exon	O
one	O
deletion	O
.	O

In	O
HB	O
,	O
eight	O
recurrent	O
mutations	O
were	O
detected	O
,	O
including	O
six	O
missense	O
mutations	O
and	O
two	O
nonsense	O
mutations	O
.	O

CONCLUSION	O
:	O
Targeted	O
high	O
-	O
throughput	O
sequencing	O
is	O
an	O
effective	O
technique	O
to	O
detect	O
the	O
F8	O
and	O
F9	O
gene	O
mutations	O
,	O
especially	O
for	O
the	O
discovery	O
of	O
novel	O
mutations	O
.	O

The	O
method	O
is	O
highly	O
accurate	O
,	O
time	O
-	O
saving	O
and	O
shows	O
great	O
advantage	O
in	O
uncovering	O
large	O
deletion	O
mutations	O
and	O
also	O
in	O
distinguishing	O
the	O
wild	O
-	O
type	O
genotype	O
and	O
heterozygous	O
large	O
deletions	O
.	O

Loss	B-NegReg
of	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
RP1	B-Gene
are	O
responsible	O
for	O
retinitis	B-Disease
pigmentosa	I-Disease
in	O
consanguineous	O
familial	O
cases	O
.	O

PURPOSE	O
:	O
This	O
study	O
was	O
undertaken	O
to	O
identify	O
causal	O
mutations	O
responsible	O
for	O
autosomal	O
recessive	O
retinitis	O
pigmentosa	O
(	O
arRP	O
)	O
in	O
consanguineous	O
families	O
.	O

METHODS	O
:	O
Large	O
consanguineous	O
families	O
were	O
ascertained	O
from	O
the	O
Punjab	O
province	O
of	O
Pakistan	O
.	O

An	O
ophthalmic	O
examination	O
consisting	O
of	O
a	O
fundus	O
evaluation	O
and	O
electroretinography	O
(	O
ERG	O
)	O
was	O
completed	O
,	O
and	O
small	O
aliquots	O
of	O
blood	O
were	O
collected	O
from	O
all	O
participating	O
individuals	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
white	O
blood	O
cells	O
,	O
and	O
a	O
genome	O
-	O
wide	O
linkage	O
or	O
a	O
locus	O
-	O
specific	O
exclusion	O
analysis	O
was	O
completed	O
with	O
polymorphic	O
short	O
tandem	O
repeats	O
(	O
STRs	O
)	O
.	O

Two	O
-	O
point	O
logarithm	O
of	O
odds	O
(	O
LOD	O
)	O
scores	O
were	O
calculated	O
,	O
and	O
all	O
coding	O
exons	O
and	O
exon	O
-	O
intron	O
boundaries	O
of	O
RP1	O
were	O
sequenced	O
to	O
identify	O
the	O
causal	O
mutation	O
.	O

RESULTS	O
:	O
The	O
ophthalmic	O
examination	O
showed	O
that	O
affected	O
individuals	O
in	O
all	O
families	O
manifest	O
cardinal	O
symptoms	O
of	O
RP	O
.	O

Genome	O
-	O
wide	O
scans	O
localized	O
the	O
disease	O
phenotype	O
to	O
chromosome	O
8q	O
,	O
a	O
region	O
harboring	O
RP1	O
,	O
a	O
gene	O
previously	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
RP	O
.	O

Sanger	O
sequencing	O
identified	O
a	O
homozygous	O
single	O
base	O
deletion	O
in	O
exon	O
4	O
:	O
c.3697delT	O
(	O
p	O
.	O
S1233Pfs22	O
*	O
)	O
,	O
a	O
single	O
base	O
substitution	O
in	O
intron	O
3	O
:	O
c.787	O
+	O
1G	O
>	O
A	O
(	O
p	O
.	O
I263Nfs8	O
*	O
)	O
,	O
a	O
2	O
bp	O
duplication	O
in	O
exon	O
2	O
:	O
c.551_552dupTA	O
(	O
p	O
.	O
Q185Yfs4	O
*	O
)	O
and	O
an	O
11,117	O
bp	O
deletion	O
that	O
removes	O
all	O
three	O
coding	O
exons	O
of	O
RP1	O
.	O

These	O
variations	O
segregated	O
with	O
the	O
disease	O
phenotype	O
within	O
the	O
respective	O
families	O
and	O
were	O
not	O
present	O
in	O
ethnically	O
matched	O
control	O
samples	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
strongly	O
suggest	O
that	O
these	O
mutations	O
in	O
RP1	O
are	O
responsible	O
for	O
the	O
retinal	O
phenotype	O
in	O
affected	O
individuals	O
of	O
all	O
four	O
consanguineous	O
families	O
.	O

Ectrodactyly	B-Disease
and	I-Disease
Lethal	I-Disease
Pulmonary	I-Disease
Acinar	I-Disease
Dysplasia	I-Disease
Associated	B-Reg
with	O
Homozygous	O
FGFR2	B-Gene
Mutations	B-Var
Identified	O
by	O
Exome	O
Sequencing	O
.	O

Ectrodactyly	O
/	O
split	O
hand	O
-	O
foot	O
malformation	O
is	O
genetically	O
heterogeneous	O
with	O
more	O
than	O
100	O
syndromic	O
associations	O
.	O

Acinar	O
dysplasia	O
is	O
a	O
rare	O
congenital	O
lung	O
lesion	O
of	O
unknown	O
etiology	O
,	O
which	O
is	O
frequently	O
lethal	O
postnatally	O
.	O

To	O
date	O
,	O
there	O
have	O
been	O
no	O
reports	O
of	O
combinations	O
of	O
these	O
two	O
phenotypes	O
.	O

Here	O
,	O
we	O
present	O
an	O
infant	O
from	O
a	O
consanguineous	O
union	O
with	O
both	O
ectrodactyly	O
and	O
autopsy	O
confirmed	O
acinar	O
dysplasia	O
.	O

SNP	O
array	O
and	O
whole	O
-	O
exome	O
sequencing	O
analyses	O
of	O
the	O
affected	O
infant	O
identified	O
a	O
novel	O
homozygous	O
Fibroblast	O
Growth	O
Factor	O
Receptor	O
2	O
(	O
FGFR2	O
)	O
missense	O
mutation	O
(	O
p	O
.	O
R255Q	O
)	O
in	O
the	O
IgIII	O
domain	O
(	O
D3	O
)	O
.	O

Expression	O
studies	O
of	O
Fgfr2	O
in	O
development	O
show	O
localization	O
to	O
the	O
affected	O
limbs	O
and	O
organs	O
.	O

Molecular	O
modeling	O
and	O
genetic	O
and	O
functional	O
assays	O
support	O
that	O
this	O
mutation	O
is	O
at	O
least	O
a	O
partial	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutation	B-Var
,	O
and	O
contributes	O
to	O
ectrodactyly	B-Disease
and	I-Disease
acinar	I-Disease
dysplasia	I-Disease
only	O
in	O
homozygosity	O
,	O
unlike	O
previously	O
reported	O
heterozygous	O
activating	O
FGFR2	B-Gene
mutations	B-Var
that	O
cause	B-Reg
Crouzon	B-Disease
,	O
Apert	B-Disease
,	O
and	O
Pfeiffer	B-Disease
syndromes	I-Disease
.	O

This	O
is	O
the	O
first	O
report	O
of	O
mutations	O
in	O
a	O
human	O
disease	O
with	O
ectrodactyly	O
with	O
pulmonary	O
acinar	O
dysplasia	O
and	O
,	O
as	O
such	O
,	O
homozygous	O
loss	O
-	O
of	O
-	O
function	O
FGFR2	O
mutations	O
represent	O
a	O
unique	O
syndrome	O
.	O

X	B-Disease
-	I-Disease
linked	I-Disease
Congenital	I-Disease
Adrenal	I-Disease
Hypoplasia	I-Disease
with	B-Reg
a	O
Novel	O
NR0B1	B-Gene
/	I-Gene
DAX	I-Gene
Gene	O
Mutation	B-Var
.	O

BACKGROUND	O
:	O
The	O
etiology	O
of	O
primary	O
adrenal	O
insufficiency	O
has	O
implications	O
for	O
further	O
management	O
of	O
the	O
condition	O
.	O

CASE	O
CHARACTERISTICS	O
:	O
A	O
5-year	O
-	O
old	O
boy	O
presented	O
in	O
adrenal	O
crisis	O
with	O
glucocorticoid	O
and	O
mineralocorticoid	O
deficiency	O
.	O

OBSERVATION	O
:	O
Investigations	O
confirmed	O
primary	O
adrenal	B-CPA
insufficiency	B-NegReg
and	O
ruled	O
out	O
the	O
common	O
etiologies	O
.	O

Genetic	O
testing	O
identified	O
a	O
novel	O
NR0B1	B-Gene
/	I-Gene
DAX	I-Gene
gene	O
mutation	B-Var
.	O

MESSAGE	O
:	O
A	O
genetic	O
diagnosis	O
in	O
children	O
with	O
primary	O
adrenal	O
insufficiency	O
is	O
useful	O
to	O
provide	O
genetic	O
counselling	O
.	O

Severe	O
Early	B-Disease
-	I-Disease
Onset	I-Disease
Combined	I-Disease
Immunodeficiency	I-Disease
due	O
to	O
Heterozygous	O
Gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
Function	I-PosReg
Mutations	B-Var
in	O
STAT1	B-Gene
.	O

PURPOSE	O
:	O
Loss	O
and	O
gain	O
-	O
of	O
-	O
function	O
(	O
GOF	O
)	O
mutations	O
in	O
human	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
1	O
(	O
STAT1	O
)	O
lead	O
to	O
distinct	O
phenotypes	O
.	O

Although	O
recurrent	O
infections	O
are	O
common	O
to	O
both	O
types	O
of	O
STAT1	O
mutations	O
,	O
GOF	B-PosReg
mutations	B-Var
are	O
distinguished	O
by	O
chronic	B-Disease
mucocutaneous	I-Disease
candidiasis	I-Disease
and	O
autoimmunity	B-Disease
.	O

However	O
,	O
the	O
clinical	O
spectra	O
of	O
STAT1	O
GOF	O
mutations	O
continue	O
to	O
expand	O
.	O

We	O
here	O
describe	O
two	O
patients	O
with	O
STAT1	B-Gene
GOF	B-PosReg
mutations	B-Var
presenting	O
early	O
in	O
life	O
with	O
combined	B-Disease
immunodeficiency	I-Disease
(	O
CID	O
)	O
.	O

METHODS	O
:	O
Clinical	O
data	O
and	O
laboratory	O
findings	O
including	O
immunophenotyping	O
,	O
level	O
of	O
interferon	O
(	O
IFN)-γ	O
/	O
IL-17(+	O
)	O
T	O
cells	O
,	O
interferon	O
-	O
induced	O
STAT1	O
phosphorylation	O
,	O
and	O
JAK	O
inhibitor	O
assays	O
were	O
evaluated	O
.	O

Sequencing	O
of	O
STAT1	O
gene	O
was	O
performed	O
by	O
Sanger	O
sequencer	O
.	O

RESULTS	O
:	O
Patient	O
1	O
(	O
P1	O
)	O
had	O
persistent	O
oral	O
candidiasis	O
and	O
cytomegalovirus	O
(	O
CMV	O
)	O
infection	O
since	O
2	O
months	O
of	O
age	O
and	O
later	O
developed	O
cavitary	O
lung	O
lesions	O
due	O
to	O
Mycobacterium	O
tuberculosis	O
.	O

Patient	O
2	O
(	O
P2	O
)	O
presented	O
with	O
oral	O
candidiasis	O
and	O
recurrent	O
pneumonia	O
at	O
4	O
months	O
of	O
age	O
and	O
subsequently	O
developed	O
CMV	O
pneumonitis	O
.	O

Both	O
patients	O
suffered	O
heterozygous	O
missense	B-Var
mutations	I-Var
in	O
STAT1	B-Gene
,	O
leading	B-Reg
to	I-Reg
deleterious	O
amino	O
acid	O
substitutions	B-Var
in	O
the	O
DNA	O
binding	O
domain	O
(	O
P1	O
:	O
c.1154C	B-Var
>	I-Var
T	I-Var
;	I-Var
p	B-Var
.	I-Var
T385	I-Var
M	I-Var
;	I-Var
P2	O
.	O

c.971	B-Var
G	I-Var
>	I-Var
T	I-Var
;	I-Var
p	B-Var
.	I-Var
C324F	I-Var
)	I-Var
.	O

Circulating	O
CD4(+	O
)	O
T	O
cells	O
of	O
both	O
patients	O
exhibited	O
increased	B-PosReg
interferon	B-MPA
-	I-MPA
γ	I-MPA
and	O
decreased	B-NegReg
IL-17	B-MPA
expression	I-MPA
as	O
compared	O
to	O
controls	O
.	O

They	O
also	O
exhibited	O
increased	B-PosReg
IFN	B-MPA
-	I-MPA
β	I-MPA
and	O
-γ	B-MPA
-	I-MPA
induced	I-MPA
STAT1	I-MPA
phosphorylation	I-MPA
that	O
was	O
reversed	O
upon	O
treatment	O
with	O
the	O
JAK	O
kinase	O
inhibitor	O
ruxolitinib	O
.	O

CONCLUSION	O
:	O
STAT1	O
GOF	O
mutations	O
may	O
present	O
early	O
in	O
life	O
with	O
CID	O
,	O
consistent	O
with	O
the	O
clinical	O
heterogeneity	O
of	O
the	O
disease	O
.	O

JAK	O
kinase	O
inhibitors	O
may	O
potentially	O
be	O
useful	O
in	O
some	O
patients	O
as	O
adjunct	O
therapy	O
pending	O
definitive	O
treatment	O
with	O
bone	O
marrow	O
transplantation	O
.	O

Directed	O
evolution	O
of	O
a	O
sphingomyelin	O
flippase	O
reveals	O
mechanism	O
of	O
substrate	O
backbone	O
discrimination	O
by	O
a	O
P4-ATPase	O
.	O

Phospholipid	O
flippases	O
in	O
the	O
type	O
IV	O
P	O
-	O
type	O
ATPase	O
(	O
P4-ATPases	O
)	O
family	O
establish	O
membrane	O
asymmetry	O
and	O
play	O
critical	O
roles	O
in	O
vesicular	O
transport	O
,	O
cell	O
polarity	O
,	O
signal	O
transduction	O
,	O
and	O
neurologic	O
development	O
.	O

All	O
characterized	O
P4-ATPases	O
flip	O
glycerophospholipids	O
across	O
the	O
bilayer	O
to	O
the	O
cytosolic	O
leaflet	O
of	O
the	O
membrane	O
,	O
but	O
how	O
these	O
enzymes	O
distinguish	O
glycerophospholipids	O
from	O
sphingolipids	O
is	O
not	O
known	O
.	O

We	O
used	O
a	O
directed	O
evolution	O
approach	O
to	O
examine	O
the	O
molecular	O
mechanisms	O
through	O
which	O
P4-ATPases	O
discriminate	O
substrate	O
backbone	O
.	O

A	O
mutagenesis	O
screen	O
in	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
has	O
identified	O
several	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutations	B-Var
in	O
the	O
P4-ATPase	B-Enzyme
Dnf1	O
that	O
facilitate	B-PosReg
the	O
transport	B-MPA
of	O
a	O
novel	O
lipid	O
substrate	O
,	O
sphingomyelin	O
.	O

We	O
found	O
that	O
a	O
highly	O
conserved	O
asparagine	O
(	O
N220	O
)	O
in	O
the	O
first	O
transmembrane	O
segment	O
is	O
a	O
key	O
enforcer	O
of	O
glycerophospholipid	O
selection	O
,	O
and	O
specific	O
substitutions	O
at	O
this	O
site	O
allow	O
transport	O
of	O
sphingomyelin	O
.	O

Loss	B-NegReg
of	I-NegReg
function	I-NegReg
mutation	B-Var
in	O
LOX	B-Gene
causes	O
thoracic	B-Disease
aortic	I-Disease
aneurysm	I-Disease
and	I-Disease
dissection	I-Disease
in	O
humans	O
.	O

Thoracic	O
aortic	O
aneurysms	O
and	O
dissections	O
(	O
TAAD	O
)	O
represent	O
a	O
substantial	O
cause	O
of	O
morbidity	O
and	O
mortality	O
worldwide	O
.	O

Many	O
individuals	O
presenting	O
with	O
an	O
inherited	O
form	O
of	O
TAAD	O
do	O
not	O
have	O
causal	O
mutations	O
in	O
the	O
set	O
of	O
genes	O
known	O
to	O
underlie	O
disease	O
.	O

Using	O
whole	O
-	O
genome	O
sequencing	O
in	O
two	O
first	O
cousins	O
with	O
TAAD	O
,	O
we	O
identified	O
a	O
missense	O
mutation	O
in	O
the	O
lysyl	O
oxidase	O
(	B-Gene
LOX	I-Gene
)	I-Gene
gene	O
(	B-Var
c.893	I-Var
T	I-Var
>	I-Var
G	I-Var
encoding	O
p	B-Var
.	I-Var
Met298Arg	I-Var
)	I-Var
that	O
cosegregated	O
with	O
disease	O
in	O
the	O
family	O
.	O

Using	O
clustered	O
regularly	O
interspaced	O
short	O
palindromic	O
repeats	O
(	O
CRISPR)/clustered	O
regularly	O
interspaced	O
short	O
palindromic	O
repeats	O
-	O
associated	O
protein-9	O
nuclease	O
(	O
Cas9	O
)	O
genome	O
engineering	O
tools	O
,	O
we	O
introduced	O
the	O
human	O
mutation	O
into	O
the	O
homologous	O
position	O
in	O
the	O
mouse	O
genome	O
,	O
creating	O
mice	O
that	O
were	O
heterozygous	O
and	O
homozygous	O
for	O
the	O
human	O
allele	O
.	O

Mutant	O
mice	O
that	O
were	O
heterozygous	O
for	O
the	O
human	O
allele	O
displayed	O
disorganized	O
ultrastructural	O
properties	O
of	O
the	O
aortic	O
wall	O
characterized	O
by	O
fragmented	O
elastic	O
lamellae	O
,	O
whereas	O
mice	O
homozygous	O
for	O
the	O
human	O
allele	O
died	O
shortly	O
after	O
parturition	O
from	O
ascending	O
aortic	O
aneurysm	O
and	O
spontaneous	O
hemorrhage	O
.	O

These	O
data	O
suggest	O
that	O
a	O
missense	B-Var
mutation	I-Var
in	O
LOX	B-Gene
is	O
associated	B-Reg
with	O
aortic	B-Disease
disease	I-Disease
in	O
humans	O
,	O
likely	O
through	O
insufficient	B-NegReg
cross	B-Interaction
-	I-Interaction
linking	I-Interaction
of	O
elastin	B-Protein
and	O
collagen	B-MPA
in	O
the	O
aortic	O
wall	O
.	O

Mutation	B-Var
carriers	O
may	O
be	O
predisposed	B-Reg
to	O
vascular	B-Disease
diseases	I-Disease
because	O
of	O
weakened	B-NegReg
vessel	B-CPA
walls	I-CPA
under	O
stress	O
conditions	O
.	O

LOX	O
sequencing	O
for	O
clinical	O
TAAD	O
may	O
identify	O
additional	O
mutation	O
carriers	O
in	O
the	O
future	O
.	O

Additional	O
studies	O
using	O
our	O
mouse	O
model	O
of	O
LOX	O
-	O
associated	O
TAAD	O
have	O
the	O
potential	O
to	O
clarify	O
the	O
mechanism	O
of	O
disease	O
and	O
identify	O
novel	O
therapeutics	O
specific	O
to	O
this	O
genetic	O
cause	O
.	O

Fanconi	O
-	O
Bickel	O
syndrome	O
in	O
two	O
Palestinian	O
children	O
:	O
marked	O
phenotypic	O
variability	O
with	O
identical	O
mutation	O
.	O

BACKGROUND	O
:	O
Fanconi	B-Disease
-	I-Disease
Bickel	I-Disease
syndrome	I-Disease
(	O
FBS	O
,	O
OMIM	O
227810	O
)	O
is	O
a	O
rare	O
autosomal	O
recessive	O
disease	O
caused	B-Reg
by	I-Reg
a	O
deficiency	B-Var
of	O
glucose	O
transporter	O
2	O
(	B-Gene
GLUT2	I-Gene
)	I-Gene
,	O
a	O
member	O
of	O
the	O
facilitative	O
glucose	O
transporter	O
family	O
(	O
Santer	O
et	O
al	O
.	O

J	O
Inherit	O
Metab	O
Dis	O
21:191	O
-	O
194	O
,	O
1998	O
)	O
.	O

The	O
typical	O
clinical	O
picture	O
is	O
characterized	O
by	O
hepatorenal	O
glycogen	O
accumulation	O
resulting	O
in	O
hepato-	O
and	O
nephromegaly	O
,	O
impaired	O
utilization	O
of	O
glucose	O
and	O
galactose	O
,	O
proximal	O
renal	O
tubular	O
dysfunction	O
,	O
rickets	O
and	O
severe	O
short	O
stature	O
.	O

CASE	O
PRESENTATION	O
:	O
We	O
report	O
2	O
Palestinian	O
patients	O
from	O
2	O
families	O
who	O
were	O
homozygous	O
for	O
the	O
mutation	O
p	O
.	O
R301X	O
(	O
C	O
>	O
T	O
)	O
in	O
exon	O
7of	O
GLUT2	O
gene	O
.	O

Patient	O
1	O
showed	O
clinical	O
and	O
laboratory	O
improvement	O
with	O
age	O
characterized	O
by	O
normal	O
growth	O
and	O
resolution	O
of	O
rickets	O
.	O

Patient	O
2	O
had	O
severe	O
phenotype	O
characterized	O
by	O
progressive	O
weight	O
loss	O
,	O
persistent	O
metabolic	O
acidosis	O
,	O
marked	O
polyuria	O
and	O
clinical	O
and	O
laboratory	O
findings	O
of	O
rickets	O
progressing	O
to	O
death	O
at	O
age	O
10	O
months	O
.	O

CONCLUSION	O
:	O
This	O
report	O
further	O
expands	O
the	O
clinical	O
spectrum	O
of	O
FBS	O
even	O
with	O
identical	O
mutations	O
.	O

Other	O
yet	O
unknown	O
genetic	O
,	O
environmental	O
or	O
stochastic	O
factors	O
may	O
be	O
responsible	O
for	O
phenotypic	O
variability	O
.	O

Gli2	O
gene	O
-	O
environment	O
interactions	O
contribute	O
to	O
the	O
etiological	O
complexity	O
of	O
holoprosencephaly	O
:	O
evidence	O
from	O
a	O
mouse	O
model	O
.	O

Holoprosencephaly	B-Disease
(	O
HPE	O
)	O
is	O
a	O
common	O
and	O
severe	O
human	O
developmental	O
abnormality	O
marked	O
by	O
malformations	O
of	O
the	O
forebrain	O
and	O
face	O
.	O

Although	O
several	O
genetic	O
mutations	O
have	O
been	O
linked	O
to	O
HPE	O
,	O
phenotypic	O
outcomes	O
range	O
dramatically	O
,	O
and	O
most	O
cases	O
can	O
not	O
be	O
attributed	O
to	O
a	O
specific	O
cause	O
.	O

Gene	O
-	O
environment	O
interaction	O
has	O
been	O
invoked	O
as	O
a	O
premise	O
to	O
explain	O
the	O
etiological	O
complexity	O
of	O
HPE	O
,	O
but	O
identification	O
of	O
interacting	O
factors	O
has	O
been	O
extremely	O
limited	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
mutations	B-Var
in	O
Gli2	B-Gene
,	O
which	O
encodes	O
a	O
Hedgehog	O
pathway	O
transcription	O
factor	O
,	O
can	O
cause	B-Reg
or	O
predispose	O
to	O
HPE	B-Disease
depending	O
upon	O
gene	O
dosage	O
.	O

On	O
the	O
C57BL/6J	O
background	O
,	O
homozygous	B-Var
GLI2	B-Gene
loss	B-NegReg
of	I-NegReg
function	I-NegReg
results	O
in	O
the	O
characteristic	O
brain	O
and	O
facial	O
features	O
seen	O
in	O
severe	O
human	O
HPE	B-Disease
,	O
including	O
midfacial	O
hypoplasia	O
,	O
hypotelorism	O
and	O
medial	O
forebrain	O
deficiency	O
with	O
loss	O
of	O
ventral	O
neurospecification	O
.	O

Although	O
normally	O
indistinguishable	O
from	O
wild	O
-	O
type	O
littermates	O
,	O
we	O
demonstrate	O
that	O
mice	O
with	O
single	O
-	O
allele	O
Gli2	O
mutations	O
exhibit	O
increased	O
penetrance	O
and	O
severity	O
of	O
HPE	O
in	O
response	O
to	O
low	O
-	O
dose	O
teratogen	O
exposure	O
.	O

This	O
genetic	O
predisposition	O
is	O
associated	O
with	O
a	O
Gli2	O
dosage	O
-	O
dependent	O
attenuation	O
of	O
Hedgehog	O
ligand	O
responsiveness	O
at	O
the	O
cellular	O
level	O
.	O

In	O
addition	O
to	O
revealing	O
a	O
causative	O
role	O
for	O
GLI2	O
in	O
HPE	O
genesis	O
,	O
these	O
studies	O
demonstrate	O
a	O
mechanism	O
by	O
which	O
normally	O
silent	O
genetic	O
and	O
environmental	O
factors	O
can	O
interact	O
to	O
produce	O
severe	O
outcomes	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
provide	O
a	O
framework	O
for	O
the	O
understanding	O
of	O
the	O
extreme	O
phenotypic	O
variability	O
observed	O
in	O
humans	O
carrying	O
GLI2	O
mutations	O
and	O
a	O
paradigm	O
for	O
reducing	O
the	O
incidence	O
of	O
this	O
morbid	O
birth	O
defect	O
.	O

Identification	O
of	O
15	O
novel	O
partial	O
SHOX	O
deletions	O
and	O
13	O
partial	O
duplications	O
,	O
and	O
a	O
review	O
of	O
the	O
literature	O
reveals	O
intron	O
3	O
to	O
be	O
a	O
hotspot	O
region	O
.	O

Short	O
stature	O
homeobox	O
gene	O
(	O
SHOX	O
)	O
is	O
located	O
in	O
the	O
pseudoautosomal	O
region	O
1	O
of	O
the	O
sex	O
chromosomes	O
.	O

It	O
encodes	O
a	O
transcription	O
factor	O
implicated	O
in	O
the	O
skeletal	O
growth	O
.	O

Point	B-Var
mutations	I-Var
,	O
deletions	B-Var
or	O
duplications	B-Var
of	O
SHOX	B-Gene
or	O
its	O
transcriptional	O
regulatory	O
elements	O
are	O
associated	B-Reg
with	O
two	O
skeletal	O
dysplasias	O
,	O
Léri	B-Disease
-	I-Disease
Weill	I-Disease
dyschondrosteosis	I-Disease
(	O
LWD	O
)	O
and	O
Langer	B-Disease
mesomelic	I-Disease
dysplasia	I-Disease
(	O
LMD	O
)	O
,	O
as	O
well	O
as	O
in	O
a	O
small	O
proportion	O
of	O
idiopathic	B-Disease
short	I-Disease
stature	I-Disease
(	O
ISS	O
)	O
individuals	O
.	O

We	O
have	O
identified	O
a	O
total	O
of	O
15	O
partial	O
SHOX	O
deletions	O
and	O
13	O
partial	O
SHOX	O
duplications	O
in	O
LWD	O
,	O
LMD	O
and	O
ISS	O
patients	O
referred	O
for	O
routine	O
SHOX	O
diagnostics	O
during	O
a	O
10	O
year	O
period	O
(	O
2004	O
-	O
2014	O
)	O
.	O

Subsequently	O
,	O
we	O
characterized	O
these	O
alterations	O
using	O
MLPA	O
(	O
multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
assay	O
)	O
,	O
fine	O
-	O
tiling	O
array	O
CGH	O
(	O
comparative	O
genomic	O
hybridation	O
)	O
and	O
breakpoint	O
PCR	O
.	O

Nearly	O
half	O
of	O
the	O
alterations	O
have	O
a	O
distal	O
or	O
proximal	O
breakpoint	O
in	O
intron	O
3	O
.	O

Evaluation	O
of	O
our	O
data	O
and	O
that	O
in	O
the	O
literature	O
reveals	O
that	O
although	O
partial	O
deletions	O
and	O
duplications	O
only	O
account	O
for	O
a	O
small	O
fraction	O
of	O
SHOX	O
alterations	O
,	O
intron	O
3	O
appears	O
to	O
be	O
a	O
breakpoint	O
hotspot	O
,	O
with	O
alterations	O
arising	O
by	O
non	O
-	O
allelic	O
homologous	O
recombination	O
,	O
non	O
-	O
homologous	O
end	O
joining	O
or	O
other	O
complex	O
mechanisms	O
.	O

VHL	O
Germline	O
Mutations	O
in	O
Argentinian	O
Patients	O
with	O
Clinical	O
Diagnoses	O
or	O
Single	O
Typical	O
Manifestations	O
of	O
Type	O
1	O
von	O
Hippel	O
-	O
Lindau	O
Disease	O
.	O

AIMS	O
:	O
von	B-Disease
Hippel	I-Disease
-	I-Disease
Lindau	I-Disease
(	O
VHL	O
)	O
disease	O
is	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
VHL	B-Gene
tumor	O
suppressor	O
gene	O
.	O

As	O
tumors	O
that	O
develop	O
in	O
the	O
context	O
of	O
VHL	O
also	O
occur	O
in	O
a	O
sporadic	O
context	O
,	O
the	O
frequency	O
of	O
this	O
syndrome	O
may	O
be	O
underestimated	O
.	O

Our	O
aim	O
was	O
to	O
identify	O
VHL	O
gene	O
mutations	O
in	O
Argentinian	O
patients	O
who	O
fulfilled	O
the	O
clinical	O
criteria	O
for	O
type	O
1	O
VHL	O
disease	O
and	O
in	O
patients	O
with	O
VHL	O
-	O
associated	O
manifestations	O
that	O
did	O
not	O
meet	O
these	O
criteria	O
.	O

METHODS	O
:	O
We	O
performed	O
a	O
retrospective	O
cohort	O
study	O
,	O
including	O
patients	O
who	O
met	O
current	O
diagnostic	O
criteria	O
for	O
type	O
1	O
VHL	O
(	O
Group	O
1	O
,	O
n	O
=	O
19	O
)	O
and	O
patients	O
with	O
VHL	O
-	O
associated	O
manifestations	O
that	O
did	O
not	O
meet	O
these	O
criteria	O
(	O
Group	O
2	O
,	O
n	O
=	O
21	O
)	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
leukocytes	O
.	O

Mutation	O
analysis	O
involved	O
DNA	O
sequencing	O
,	O
while	O
large	O
deletions	O
were	O
determined	O
by	O
universal	O
primer	O
quantitative	O
fluorescent	O
multiplex	O
polymerase	O
chain	O
reaction	O
(	O
UPQFM	O
-	O
PCR	O
)	O
and	O
multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
(	O
MLPA	O
)	O
analysis	O
.	O

RESULTS	O
:	O
VHL	O
mutations	O
were	O
detected	O
in	O
16/19	O
(	O
84.2	O
%	O
)	O
patients	O
in	O
Group	O
1	O
and	O
included	O
:	O
gross	O
deletions	O
(	O
4/16	O
)	O
;	O
nonsense	O
mutations	O
(	O
6/16	O
)	O
;	O
frameshift	O
mutations	O
(	O
4/16	O
)	O
;	O
missense	O
mutations	O
(	O
1/16	O
)	O
;	O
and	O
splicing	O
mutations	O
(	O
1/16	O
)	O
.	O

Three	O
of	O
these	O
mutations	O
were	O
novel	O
.	O

No	O
alterations	O
were	O
found	O
in	O
3	O
of	O
19	O
VHL	O
patients	O
.	O

In	O
Group	O
2	O
,	O
one	O
nonsense	O
VHL	O
mutation	O
was	O
detected	O
in	O
a	O
young	O
patient	O
with	O
a	O
solitary	O
central	O
nervous	O
system	O
hemangioblastoma	O
without	O
familial	O
history	O
.	O

A	O
study	O
of	O
30	O
first	O
-	O
degree	O
relatives	O
revealed	O
four	O
carriers	O
with	O
VHL	O
mutations	O
.	O

CONCLUSIONS	O
:	O
We	O
found	O
three	O
novel	O
mutations	O
in	O
the	O
VHL	O
gene	O
in	O
our	O
population	O
.	O

Our	O
results	O
emphasize	O
the	O
importance	O
of	O
a	O
complete	O
genetic	O
study	O
of	O
VHL	O
to	O
confirm	O
type	O
1	O
VHL	O
disease	O
,	O
not	O
only	O
in	O
patients	O
with	O
clinical	O
diagnostic	O
criteria	O
but	O
also	O
in	O
those	O
presenting	O
a	O
single	O
typical	O
manifestation	O
.	O

Dysferlin	O
Gene	O
Mutation	O
Spectrum	O
in	O
a	O
Large	O
Cohort	O
of	O
Chinese	O
Patients	O
with	O
Dysferlinopathy	O
.	O

BACKGROUND	O
:	O
Dysferlinopathy	B-Disease
is	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
dysferlin	O
(	B-Gene
DYSF	I-Gene
)	I-Gene
gene	O
.	O

Here	O
,	O
we	O
described	O
the	O
genetic	O
features	O
of	O
a	O
large	O
cohort	O
of	O
Chinese	O
patients	O
with	O
this	O
disease	O
.	O

METHODS	O
:	O
Eighty	O
-	O
nine	O
index	O
patients	O
were	O
included	O
in	O
the	O
study	O
.	O

DYSF	O
gene	O
analysis	O
was	O
performed	O
by	O
Sanger	O
sequencing	O
in	O
41	O
patients	O
and	O
targeted	O
next	O
generation	O
sequencing	O
(	O
NGS	O
)	O
in	O
48	O
patients	O
.	O

Multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
(	O
MLPA	O
)	O
was	O
performed	O
to	O
detect	O
exon	O
duplication	O
/	O
deletion	O
in	O
patients	O
with	O
only	O
one	O
pathogenic	O
mutation	O
.	O

RESULTS	O
:	O
Among	O
the	O
89	O
index	O
patients	O
,	O
79	O
patients	O
were	O
demonstrated	O
to	O
carry	O
two	O
disease	O
-	O
causing	O
(	O
73	O
cases	O
)	O
or	O
possibly	O
disease	O
-	O
causing	O
mutations	O
(	O
6	O
cases	O
)	O
,	O
including	O
26	O
patients	O
with	O
homozygous	O
mutations	O
.	O

We	O
identified	O
105	O
different	O
mutations	O
,	O
including	O
59	O
novel	O
ones	O
.	O

Notably	O
,	O
in	O
13	O
patients	O
in	O
whom	O
only	O
one	O
pathogenic	O
mutation	O
was	O
initially	O
found	O
by	O
Sanger	O
sequencing	O
or	O
NGS	O
,	O
3	O
were	O
further	O
identified	O
to	O
carry	O
exon	O
deletions	O
by	O
MLPA	O
.	O

The	O
mutations	O
identified	O
in	O
this	O
study	O
appeared	O
to	O
cluster	O
in	O
the	O
N	O
-	O
terminal	O
region	O
.	O

Mutation	O
types	O
included	O
missense	O
mutations	O
(	O
30.06	O
%	O
)	O
,	O
nonsense	O
mutations	O
(	O
17.18	O
%	O
)	O
,	O
frameshift	O
mutations	O
(	O
30.67	O
%	O
)	O
,	O
in	O
-	O
frame	O
deletions	O
(	O
2.45	O
%	O
)	O
,	O
intronic	O
mutations	O
(	O
17.79	O
%	O
)	O
,	O
and	O
exonic	O
rearrangement	O
(	O
1.84	O
%	O
)	O
.	O

No	O
genotype	O
-	O
phenotype	O
correlation	O
was	O
identified	O
.	O

CONCLUSIONS	O
:	O
DYSF	O
mutations	O
in	O
Chinese	O
patients	O
clustered	O
in	O
the	O
N	O
-	O
terminal	O
region	O
of	O
the	O
gene	O
.	O

Exonic	O
rearrangements	O
were	O
found	O
in	O
23	O
%	O
of	O
patients	O
with	O
only	O
one	O
pathogenic	O
mutation	O
identified	O
by	O
Sanger	O
sequencing	O
or	O
NGS	O
.	O

The	O
novel	O
mutations	O
found	O
in	O
this	O
study	O
greatly	O
expanded	O
the	O
mutational	O
spectrum	O
of	O
dysferlinopathy	O
.	O

Whole	O
-	O
exome	O
sequencing	O
identifies	O
multiple	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
of	O
NF	O
-	O
κB	O
pathway	O
regulators	O
in	O
nasopharyngeal	O
carcinoma	O
.	O

Nasopharyngeal	O
carcinoma	O
(	O
NPC	O
)	O
is	O
an	O
epithelial	O
malignancy	O
with	O
a	O
unique	O
geographical	O
distribution	O
.	O

The	O
genomic	O
abnormalities	O
leading	O
to	O
NPC	O
pathogenesis	O
remain	O
unclear	O
.	O

In	O
total	O
,	O
135	O
NPC	O
tumors	O
were	O
examined	O
to	O
characterize	O
the	O
mutational	O
landscape	O
using	O
whole	O
-	O
exome	O
sequencing	O
and	O
targeted	O
resequencing	O
.	O

An	O
APOBEC	O
cytidine	O
deaminase	O
mutagenesis	O
signature	O
was	O
revealed	O
in	O
the	O
somatic	O
mutations	O
.	O

Noticeably	O
,	O
multiple	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
were	O
identified	O
in	O
several	O
NF	O
-	O
κB	O
signaling	O
negative	O
regulators	O
NFKBIA	O
,	O
CYLD	O
,	O
and	O
TNFAIP3	O
Functional	O
studies	O
confirmed	O
that	O
inhibition	O
of	O
NFKBIA	O
had	O
a	O
significant	O
impact	O
on	O
NF	O
-	O
κB	O
activity	O
and	O
NPC	O
cell	O
growth	O
.	O

The	O
identified	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
NFKBIA	B-Gene
leading	O
to	O
protein	B-MPA
truncation	I-MPA
contributed	O
to	O
the	O
altered	B-Reg
NF	B-Pathway
-	I-Pathway
κB	I-Pathway
activity	B-MPA
,	O
which	O
is	O
critical	O
for	O
NPC	O
tumorigenesis	O
.	O

In	O
addition	O
,	O
somatic	O
mutations	O
were	O
found	O
in	O
several	O
cancer	O
-	O
relevant	O
pathways	O
,	O
including	O
cell	O
cycle	O
-	O
phase	O
transition	O
,	O
cell	O
death	O
,	O
EBV	O
infection	O
,	O
and	O
viral	O
carcinogenesis	O
.	O

These	O
data	O
provide	O
an	O
enhanced	O
road	O
map	O
for	O
understanding	O
the	O
molecular	O
basis	O
underlying	O
NPC	O
.	O

ACOX2	O
deficiency	O
:	O
A	O
disorder	O
of	O
bile	O
acid	O
synthesis	O
with	O
transaminase	O
elevation	O
,	O
liver	O
fibrosis	O
,	O
ataxia	O
,	O
and	O
cognitive	O
impairment	O
.	O

Acyl	O
CoA	O
Oxidase	O
2	O
(	O
ACOX2	O
)	O
encodes	O
branched	O
-	O
chain	O
acyl	O
-	O
CoA	O
oxidase	O
,	O
a	O
peroxisomal	O
enzyme	O
believed	O
to	O
be	O
involved	O
in	O
the	O
metabolism	O
of	O
branched	O
-	O
chain	O
fatty	O
acids	O
and	O
bile	O
acid	O
intermediates	O
.	O

Deficiency	O
of	O
this	O
enzyme	O
has	O
not	O
been	O
described	O
previously	O
.	O

We	O
report	O
an	O
8-y	O
-	O
old	O
male	O
with	O
intermittently	O
elevated	O
transaminase	O
levels	O
,	O
liver	O
fibrosis	O
,	O
mild	O
ataxia	O
,	O
and	O
cognitive	O
impairment	O
.	O

Exome	O
sequencing	O
revealed	O
a	O
previously	O
unidentified	O
homozygous	O
premature	O
termination	O
mutation	O
(	B-Var
p	I-Var
.	I-Var
Y69	I-Var
*	I-Var
)	I-Var
in	O
ACOX2	B-Gene
Immunohistochemistry	O
confirmed	O
the	O
absence	B-NegReg
of	O
ACOX2	B-Gene
expression	B-MPA
in	O
the	O
patient	O
's	O
liver	O
,	O
and	O
biochemical	O
analysis	O
showed	O
marked	O
elevation	B-PosReg
of	O
intermediate	B-MPA
bile	I-MPA
acids	I-MPA
upstream	O
of	O
ACOX2	O
.	O

These	O
findings	O
define	O
a	O
potentially	O
treatable	O
inborn	O
error	O
of	O
bile	O
acid	O
biosynthesis	O
caused	O
by	O
ACOX2	O
deficiency	O
.	O

Prevalence	O
and	O
phenotypic	O
characterization	O
of	O
MC4R	O
variants	O
in	O
a	O
large	O
pediatric	O
cohort	O
.	O

OBJECTIVE	O
:	O
We	O
aimed	O
to	O
determine	O
the	O
prevalence	O
of	O
melanocortin-4	O
receptor	O
(	O
MC4R	O
)	O
variants	O
in	O
a	O
large	O
German	O
cohort	O
of	O
children	O
with	O
obesity	O
in	O
a	O
pediatric	O
outpatient	O
clinic	O
and	O
to	O
ascertain	O
whether	O
there	O
is	O
a	O
specific	O
phenotype	O
associated	O
with	O
loss	O
-	O
of	O
-	O
function	O
variants	O
as	O
previously	O
reported	O
.	O

STUDY	O
DESIGN	O
:	O
Eight	O
hundred	O
and	O
ninety	O
-	O
nine	O
patients	O
from	O
our	O
pediatric	O
obesity	O
clinic	O
were	O
screened	O
for	O
MC4R	O
variants	O
by	O
DNA	O
sequencing	O
after	O
PCR	O
amplification	O
.	O

Retrospective	O
statistical	O
analysis	O
of	O
anthropometric	O
and	O
metabolic	O
characteristics	O
was	O
performed	O
,	O
comparing	O
patients	O
with	O
and	O
without	O
MC4R	O
variants	O
across	O
the	O
entire	O
cohort	O
(	O
n=586	O
)	O
as	O
well	O
as	O
in	O
case	O
-	O
control	O
analysis	O
using	O
patients	O
with	O
common	O
sequence	O
MC4R	O
individually	O
matched	O
for	O
age	O
,	O
sex	O
and	O
body	O
mass	O
index	O
standard	O
deviation	O
score	O
(	O
SDS	O
)	O
(	O
n=11	O
case	O
-	O
control	O
pairs	O
)	O
.	O

RESULTS	O
:	O
We	O
identified	O
heterozygous	O
variants	O
within	O
the	O
coding	O
region	O
of	O
the	O
MC4R	B-Gene
gene	O
in	O
n=22	O
(	O
2.45	O
%	O
)	O
patients	O
.	O

Fourteen	O
(	O
1.56	O
%	O
)	O
had	O
a	O
variant	B-Var
that	O
impaired	B-NegReg
receptor	B-CPA
function	I-CPA
.	O

One	O
new	O
frameshift	O
(	O
p	O
.	O
F152Sfs	O
)	O
,	O
an	O
yet	O
unpublished	O
nonsense	O
mutation	O
(	O
p	O
.	O
Q156X	O
)	O
and	O
one	O
nonsynonymous	O
variation	O
(	O
p	O
.	O
V65E	O
)	O
described	O
in	O
the	O
Mouse	O
Genome	O
Database	O
were	O
detected	O
.	O

Across	O
the	O
whole	O
cohort	O
,	O
at	O
all	O
ages	O
,	O
mean	O
height	O
SDS	O
in	O
subjects	O
with	O
impaired	O
receptor	O
function	O
was	O
higher	O
than	O
in	O
patients	O
with	O
common	O
sequence	O
MC4R.	O
In	O
matched	O
individuals	O
,	O
this	O
trend	O
persisted	O
(	O
8	O
of	O
the	O
11	O
pairs	O
)	O
within	O
the	O
case	O
-	O
control	O
setting	O
.	O

No	O
differences	O
were	O
found	O
regarding	O
metabolic	O
characteristics	O
.	O

CONCLUSIONS	O
:	O
The	O
observed	O
prevalence	O
of	O
mutations	O
causing	O
impaired	O
receptor	O
function	O
in	O
this	O
large	O
cohort	O
is	O
comparable	O
to	O
other	O
pediatric	O
cohorts	O
.	O

MC4R	O
deficiency	O
tends	O
to	O
lead	O
to	O
a	O
taller	O
stature	O
,	O
confirming	O
previous	O
clinical	O
reports	O
.	O

The	O
association	O
of	O
MC4R	O
mutations	O
with	O
a	O
distinct	O
phenotype	O
concerning	O
metabolic	O
characteristics	O
remains	O
questionable	O
.	O

Novel	O
MBTPS2	B-Gene
missense	B-Var
mutation	I-Var
causes	B-Reg
a	O
keratosis	B-Disease
follicularis	I-Disease
spinulosa	I-Disease
decalvans	I-Disease
phenotype	O
:	O
mutation	O
update	O
and	O
review	O
of	O
the	O
literature	O
.	O

Keratosis	B-Disease
follicularis	I-Disease
spinulosa	I-Disease
decalvans	I-Disease
(	O
KFSD	O
)	O
is	O
an	O
X	O
-	O
linked	O
condition	O
characterized	O
by	O
keratotic	O
follicular	O
papules	O
and	O
progressive	O
alopecia	O
,	O
which	O
is	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
MBTPS2	B-Gene
gene	O
.	O

We	O
carried	O
out	O
a	O
genetic	O
study	O
on	O
a	O
child	O
who	O
was	O
suspected	O
clinically	O
to	O
have	O
KFSD	O
.	O

Sanger	O
sequencing	O
was	O
performed	O
to	O
detect	O
mutations	O
in	O
the	O
entire	O
coding	O
region	O
of	O
MBTPS2	O
.	O

A	O
novel	O
missense	O
mutation	O
(	B-Var
c.599C	I-Var
>	I-Var
T	I-Var
)	I-Var
was	O
identified	O
in	O
the	O
patient	O
,	O
confirming	B-Reg
a	O
diagnosis	O
of	O
KFSD	B-Disease
.	O

We	O
reviewed	O
related	O
cases	O
with	O
MBTPS2	O
mutations	O
for	O
evidence	O
of	O
genotype	O
-	O
phenotype	O
correlations	O
.	O

Temperature	O
-	O
dependent	O
autoimmunity	O
mediated	O
by	O
chs1	O
requires	O
its	O
neighboring	O
TNL	O
gene	O
SOC3	O
.	O

Toll	O
/	O
interleukin	O
receptor	O
(	O
TIR)-nucleotide	O
binding	O
site	O
(	O
NB)-type	O
(	O
TN	O
)	O
proteins	O
are	O
encoded	O
by	O
a	O
family	O
of	O
21	O
genes	O
in	O
the	O
Arabidopsis	O
genome	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
a	O
mutation	O
in	O
the	O
TN	O
gene	O
CHS1	O
activates	O
the	O
activation	O
of	O
defense	O
responses	O
at	O
low	O
temperatures	O
.	O

However	O
,	O
the	O
underlying	O
molecular	O
mechanism	O
remains	O
unknown	O
.	O

To	O
genetically	O
dissect	O
chs1-mediated	O
signaling	O
,	O
we	O
isolated	O
genetic	O
suppressors	O
of	O
chs1	O
-	O
2	O
(	O
soc	O
)	O
.	O

Several	O
independent	O
soc	O
mutants	O
carried	O
mutations	O
in	O
the	O
same	O
TIR	O
-	O
NB	O
-	O
leucine	O
-	O
rich	O
repeat	O
(	O
LRR	O
)	O
(	O
TNL)-encoding	O
gene	O
SOC3	O
,	O
which	O
is	O
adjacent	O
to	O
CHS1	O
on	O
chromosome	O
1	O
.	O

Expression	B-MPA
of	O
SOC3	B-Gene
was	O
upregulated	B-PosReg
in	O
the	O
chs1	B-Gene
-	I-Gene
2	I-Gene
mutant	B-Var
.	O

Mutations	O
in	O
six	O
soc3	O
alleles	O
and	O
downregulation	O
of	O
SOC3	O
by	O
an	O
artificial	O
microRNA	O
construct	O
fully	O
rescued	O
the	O
chilling	O
sensitivity	O
and	O
defense	O
defects	O
of	O
chs1	O
-	O
2	O
.	O

Biochemical	O
studies	O
showed	O
that	O
CHS1	O
interacted	O
with	O
the	O
NB	O
and	O
LRR	O
domains	O
of	O
SOC3	O
;	O
however	O
,	O
mutated	O
chs1	O
interacted	O
with	O
the	O
TIR	O
,	O
NB	O
and	O
LRR	O
domains	O
of	O
SOC3	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

This	O
study	O
reveals	O
that	O
the	O
TN	O
protein	O
CHS1	O
interacts	O
with	O
the	O
TNL	O
protein	O
SOC3	O
to	O
modulate	O
temperature	O
-	O
dependent	O
autoimmunity	O
.	O

INPPL1	B-Gene
gene	O
mutations	B-Var
in	B-Reg
opsismodysplasia	B-Disease
.	O

The	O
INPPL1	O
(	O
inositol	O
polyphosphate	O
phosphatase	O
-	O
like	O
1	O
)	O
gene	O
encodes	O
the	O
inositol	O
phosphatase	O
,	O
SHIP2	O
(	O
for	O
src	O
homology	O
2	O
domain	O
-	O
containing	O
inositol	O
phosphatase	O
2	O
)	O
.	O

SHIP2	O
functions	O
to	O
dephosphorylate	O
,	O
and	O
negatively	O
regulate	O
,	O
the	O
lipid	O
second	O
messenger	O
phosphatidylinositol	O
(	O
3,4,5)P3	O
.	O

SHIP2	O
has	O
been	O
well	O
studied	O
in	O
the	O
area	O
of	O
insulin	O
resistance	O
and	O
obesity	O
but	O
has	O
roles	O
in	O
cancer	O
and	O
other	O
disorders	O
.	O

Recently	O
,	O
it	O
was	O
reported	O
that	O
mutations	B-Var
in	O
INPPL1	B-Gene
cause	B-Reg
opsismodysplasia	B-Disease
,	O
a	O
rare	O
,	O
autosomal	O
recessive	O
severe	O
skeletal	O
dysplasia	O
.	O

This	O
review	O
focuses	O
on	O
the	O
mutations	O
associated	O
with	O
opsismodysplasia	O
and	O
explores	O
the	O
role	O
of	O
I	O
SHIP2	O
in	O
skeletal	O
development	O
.	O

Genetic	O
screening	O
of	O
the	O
FLCN	O
gene	O
identify	O
six	O
novel	O
variants	O
and	O
a	O
Danish	O
founder	O
mutation	O
.	O

Pathogenic	O
germline	O
mutations	B-Var
in	O
the	O
folliculin	O
(	B-Gene
FLCN	I-Gene
)	I-Gene
tumor	O
suppressor	O
gene	O
predispose	O
to	B-Reg
Birt	B-Disease
-	I-Disease
Hogg	I-Disease
-	I-Disease
Dubé	I-Disease
(	O
BHD	O
)	O
syndrome	O
,	O
a	O
rare	O
disease	O
characterized	O
by	O
the	O
development	O
of	O
cutaneous	O
hamartomas	O
(	O
fibrofolliculomas	O
)	O
,	O
multiple	O
lung	O
cysts	O
,	O
spontaneous	O
pneumothoraces	O
and	O
renal	O
cell	O
cancer	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
the	O
identification	O
of	O
13	O
variants	O
and	O
three	O
polymorphisms	O
in	O
the	O
FLCN	O
gene	O
in	O
143	O
Danish	O
patients	O
or	O
families	O
with	O
suspected	O
BHD	O
syndrome	O
.	O

Functional	O
mini	O
-	O
gene	O
splicing	O
analysis	O
revealed	O
that	O
two	O
intronic	O
variants	O
(	O
c.1062	O
+	O
2T	O
>	O
G	O
and	O
c.1177	O
-	O
5_1177	O
-	O
3del	O
)	O
introduced	O
splicing	O
aberrations	O
.	O

Eleven	O
families	O
exhibited	O
the	O
c.1062	O
+	O
2T	O
>	O
G	O
mutation	O
.	O

Combined	O
single	O
nucleotide	O
polymorphism	O
array	O
-	O
haplotype	O
analysis	O
showed	O
that	O
these	O
families	O
share	O
a	O
3-Mb	O
genomic	O
fragment	O
containing	O
the	O
FLCN	O
gene	O
,	O
revealing	O
that	O
the	O
c.1062	O
+	O
2T	O
>	O
G	O
mutation	O
is	O
a	O
Danish	O
founder	O
mutation	O
.	O

On	O
the	O
basis	O
of	O
in	O
silico	O
prediction	O
and	O
functional	O
splicing	O
assays	O
,	O
we	O
classify	O
the	O
16	O
identified	O
variants	O
in	O
the	O
FLCN	O
gene	O
as	O
follows	O
:	O
nine	O
as	O
pathogenic	O
,	O
one	O
as	O
likely	O
pathogenic	O
,	O
three	O
as	O
likely	O
benign	O
and	O
three	O
as	O
polymorphisms	O
.	O

In	O
conclusion	O
,	O
the	O
study	O
describes	O
the	O
FLCN	O
mutation	O
spectrum	O
in	O
Danish	O
BHD	O
patients	O
,	O
and	O
contributes	O
to	O
a	O
better	O
understanding	O
of	O
BHD	O
syndrome	O
and	O
management	O
of	O
BHD	O
patients	O
.	O

Structural	O
brain	O
abnormalities	O
in	O
a	O
single	O
gene	O
disorder	O
associated	O
with	O
epilepsy	O
,	O
language	O
impairment	O
and	O
intellectual	O
disability	O
.	O

Childhood	O
speech	O
and	O
language	O
deficits	O
are	O
highly	O
prevalent	O
and	O
are	O
a	O
common	O
feature	O
of	O
neurodevelopmental	O
disorders	O
.	O

However	O
,	O
it	O
is	O
difficult	O
to	O
investigate	O
the	O
underlying	O
causal	O
pathways	O
because	O
many	O
diagnostic	O
groups	O
have	O
a	O
heterogeneous	O
aetiology	O
.	O

Studying	O
disorders	O
with	O
a	O
shared	O
genetic	O
cause	O
and	O
shared	O
cognitive	O
deficits	O
can	O
provide	O
crucial	O
insight	O
into	O
the	O
cellular	O
mechanisms	O
and	O
neural	O
systems	O
that	O
give	O
rise	O
to	O
those	O
impairments	O
.	O

The	O
current	O
study	O
investigated	O
structural	O
brain	O
differences	O
of	O
individuals	O
with	O
mutations	B-Var
in	O
ZDHHC9	B-Gene
,	O
which	O
is	O
associated	B-Reg
with	I-Reg
a	O
specific	O
neurodevelopmental	O
phenotype	O
including	O
prominent	O
speech	B-Disease
and	I-Disease
language	I-Disease
impairments	I-Disease
and	O
intellectual	B-Disease
disability	I-Disease
.	O

We	O
used	O
multiple	O
structural	O
neuroimaging	O
methods	O
to	O
characterise	O
neuroanatomy	O
in	O
this	O
group	O
,	O
and	O
observed	O
bilateral	O
reductions	O
in	O
cortical	O
thickness	O
in	O
areas	O
surrounding	O
the	O
temporo	O
-	O
parietal	O
junction	O
,	O
parietal	O
lobule	O
,	O
and	O
inferior	O
frontal	O
lobe	O
,	O
and	O
decreased	O
microstructural	O
integrity	O
of	O
cortical	O
,	O
subcortical	O
-	O
cortical	O
,	O
and	O
interhemispheric	O
white	O
matter	O
projections	O
.	O

These	O
findings	O
are	O
compared	O
to	O
reports	O
for	O
other	O
genetic	O
groups	O
and	O
genetically	O
heterogeneous	O
disorders	O
with	O
a	O
similar	O
presentation	O
.	O

Overlap	O
in	O
the	O
neuroanatomical	O
phenotype	O
suggests	O
a	O
common	O
pathway	O
that	O
particularly	O
affects	O
the	O
development	O
of	O
temporo	O
-	O
parietal	O
and	O
inferior	O
frontal	O
areas	O
,	O
and	O
their	O
connections	O
.	O

Pharmacological	O
Chaperoning	O
:	O
A	O
Potential	O
Treatment	O
for	O
PMM2-CDG	O
.	O

The	O
congenital	B-Disease
disorder	I-Disease
of	I-Disease
glycosylation	I-Disease
(	I-Disease
CDG	I-Disease
)	I-Disease
due	I-Disease
to	I-Disease
phosphomannomutase	I-Disease
2	I-Disease
deficiency	I-Disease
(	O
PMM2-CDG	O
)	O
,	O
the	O
most	O
common	O
N	O
-	O
glycosylation	O
disorder	O
,	O
is	O
a	O
multisystem	O
disease	O
for	O
which	O
no	O
effective	O
treatment	O
is	O
available	O
.	O

The	O
recent	O
functional	O
characterization	O
of	O
disease	O
-	O
causing	O
mutations	O
described	O
in	O
patients	O
with	O
PMM2-CDG	B-Disease
led	O
to	O
the	O
idea	O
of	O
a	O
therapeutic	O
strategy	O
involving	O
pharmacological	O
chaperones	O
(	O
PC	O
)	O
to	O
rescue	O
PMM2	B-Gene
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
.	O

The	O
present	O
work	O
describes	O
the	O
high	O
-	O
throughput	O
screening	O
,	O
by	O
differential	O
scanning	O
fluorimetry	O
,	O
of	O
10,000	O
low	O
-	O
molecular	O
-	O
weight	O
compounds	O
from	O
a	O
commercial	O
library	O
,	O
to	O
search	O
for	O
possible	O
PCs	O
for	O
the	O
enzyme	O
PMM2	O
.	O

This	O
exercise	O
identified	O
eight	O
compounds	O
that	O
increased	O
the	O
thermal	O
stability	O
of	O
PMM2	O
.	O

Of	O
these	O
,	O
four	O
compounds	O
functioned	O
as	O
potential	O
PCs	O
that	O
significantly	O
increased	O
the	O
stability	O
of	O
several	O
destabilizing	O
and	O
oligomerization	O
mutants	O
and	O
also	O
increased	O
PMM	O
activity	O
in	O
a	O
disease	O
model	O
of	O
cells	O
overexpressing	O
PMM2	O
mutations	O
.	O

Structural	O
analysis	O
revealed	O
one	O
of	O
these	O
compounds	O
to	O
provide	O
an	O
excellent	O
starting	O
point	O
for	O
chemical	O
optimization	O
since	O
it	O
passed	O
tests	O
based	O
on	O
a	O
number	O
of	O
pharmacochemical	O
quality	O
filters	O
.	O

The	O
present	O
results	O
provide	O
the	O
first	O
proof	O
-	O
of	O
-	O
concept	O
of	O
a	O
possible	O
treatment	O
for	O
PMM2-CDG	O
and	O
describe	O
a	O
promising	O
chemical	O
structure	O
as	O
a	O
starting	O
point	O
for	O
the	O
development	O
of	O
new	O
therapeutic	O
agents	O
for	O
this	O
severe	O
orphan	O
disease	O
.	O

Subtypes	O
of	O
SERPINC1	O
mutations	O
and	O
the	O
thrombotic	O
phenotype	O
of	O
inherited	O
antithrombin	O
deficient	O
individuals	O
in	O
Chinese	O
Han	O
population	O
.	O

Inherited	B-Disease
antithrombin	I-Disease
(	I-Disease
AT	I-Disease
)	I-Disease
deficiency	I-Disease
is	O
a	O
rare	O
autosomal	O
disease	O
that	O
could	O
increase	O
the	O
risk	O
of	O
venous	O
thromboembolism	O
(	O
VTE	O
)	O
and	O
usually	O
caused	B-Reg
by	I-Reg
mutations	B-Var
of	O
SERPINC1	B-Gene
.	O

Although	O
a	O
number	O
of	O
mutations	O
of	O
SERPINC1	O
have	O
been	O
reported	O
in	O
Chinese	O
Han	O
population	O
,	O
the	O
impact	O
of	O
different	O
subtypes	O
of	O
these	O
mutations	O
on	O
the	O
thrombotic	O
phenotype	O
is	O
still	O
unknown	O
.	O

Here	O
,	O
we	O
performed	O
a	O
retrospective	O
cohort	O
study	O
including	O
169	O
AT	O
patients	O
from	O
63	O
families	O
to	O
compare	O
the	O
clinical	O
features	O
between	O
null	O
mutation	O
carriers	O
and	O
missense	O
mutation	O
carriers	O
.	O

We	O
found	O
that	O
patients	O
carrying	O
null	O
mutations	O
have	O
a	O
higher	O
risk	O
of	O
VTE	O
(	O
HR	O
2.29	O
,	O
95	O
%	O
CI	O
1.16	O
-	O
4.69	O
,	O
P=0.02	O
adjusted	O
for	O
sex	O
and	O
VTE	O
family	O
history	O
)	O
and	O
earlier	O
median	O
onset	O
age	O
of	O
VTE	O
(	O
27	O
vs.	O
32years	O
,	O
P=0.045	O
)	O
as	O
well	O
as	O
lower	O
AT	O
activities	O
(	O
47.6±1.0	O
%	O
vs.	O
59.1±2.3	O
%	O
,	O
P<0.001	O
)	O
than	O
those	O
with	O
missense	O
mutations	O
.	O

We	O
also	O
observed	O
that	O
thrombus	O
location	O
sites	O
showed	O
no	O
difference	O
between	O
null	O
mutation	O
carriers	O
and	O
missense	O
mutation	O
carriers	O
,	O
gene	O
locations	O
of	O
the	O
mutations	O
did	O
not	O
relate	O
with	O
the	O
incidence	O
rate	O
of	O
VTE	O
.	O

This	O
study	O
demonstrated	O
that	O
different	O
types	O
of	O
SERPINC1	O
mutations	O
may	O
play	O
different	O
roles	O
in	O
the	O
development	O
of	O
VTE	O
and	O
should	O
be	O
considered	O
in	O
the	O
prevention	O
of	O
VTE	O
.	O

Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
of	O
an	O
Arabidopsis	O
NADPH	B-Enzyme
pyrophosphohydrolase	I-Enzyme
,	O
AtNUDX19	O
,	O
impacts	B-Reg
on	O
the	O
pyridine	B-MPA
nucleotides	I-MPA
status	I-MPA
and	O
confers	B-PosReg
photooxidative	B-CPA
stress	I-CPA
tolerance	I-CPA
.	O

The	O
levels	O
and	O
redox	O
states	O
of	O
pyridine	O
nucleotides	O
,	O
such	O
as	O
NADP(H	O
)	O
,	O
regulate	O
the	O
cellular	O
redox	O
homeostasis	O
,	O
which	O
is	O
crucial	O
for	O
photooxidative	O
stress	O
response	O
in	O
plants	O
.	O

However	O
,	O
how	O
they	O
are	O
controlled	O
is	O
poorly	O
understood	O
.	O

An	O
Arabidopsis	O
Nudix	O
hydrolase	O
,	O
AtNUDX19	O
,	O
was	O
previously	O
identified	O
to	O
have	O
NADPH	O
hydrolytic	O
activity	O
in	O
vitro	O
,	O
suggesting	O
this	O
enzyme	O
to	O
be	O
a	O
regulator	O
of	O
the	O
NADPH	O
status	O
.	O

We	O
herein	O
examined	O
the	O
physiological	O
role	O
of	O
AtNUDX19	B-Gene
using	O
its	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutants	B-Var
.	O

NADPH	B-CPA
levels	I-CPA
were	O
increased	B-PosReg
in	O
nudx19	B-Gene
mutants	B-Var
under	O
both	O
normal	O
and	O
high	O
light	O
conditions	O
,	O
while	O
NADP(+	B-MPA
)	I-MPA
and	O
NAD(+	B-MPA
)	I-MPA
levels	I-MPA
were	O
decreased	B-PosReg
.	O

Despite	O
the	O
high	O
redox	O
states	O
of	O
NADP(H	O
)	O
,	O
nudx19	O
mutants	O
exhibited	O
high	O
tolerance	O
to	O
moderate	O
light-	O
or	O
methylviologen	O
-	O
induced	O
photooxidative	O
stresses	O
.	O

This	O
tolerance	O
might	O
be	O
partially	O
attributed	O
to	O
the	O
activation	O
of	O
either	O
or	O
both	O
photosynthesis	O
and	O
the	O
antioxidant	O
system	O
.	O

Furthermore	O
,	O
a	O
microarray	O
analysis	O
suggested	O
the	O
role	O
of	O
ANUDX19	O
in	O
regulation	O
of	O
the	O
salicylic	O
acid	O
(	O
SA	O
)	O
response	O
in	O
a	O
negative	O
manner	O
.	O

Indeed	O
,	O
nudx19	O
mutants	O
accumulated	O
SA	O
and	O
showed	O
high	O
sensitivity	O
to	O
the	O
hormone	O
.	O

Our	O
findings	O
demonstrate	O
that	O
ANUDX19	O
acts	O
as	O
an	O
NADPH	O
pyrophosphohydrolase	O
to	O
modulate	O
cellular	O
levels	O
and	O
redox	O
states	O
of	O
pyridine	O
nucleotides	O
and	O
fine	O
-	O
tunes	O
photooxidative	O
stress	O
response	O
through	O
the	O
regulation	O
of	O
photosynthesis	O
,	O
antioxidant	O
system	O
,	O
and	O
possibly	O
hormonal	O
signaling	O
.	O

Compound	O
heterozygous	O
LDLR	O
variant	O
in	O
severely	O
affected	O
familial	O
hypercholesterolemia	O
patient	O
.	O

Familial	B-Disease
hypercholesterolemia	I-Disease
(	O
FH	O
)	O
is	O
most	O
commonly	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
LDL	O
receptor	O
(	B-Gene
LDLR	I-Gene
)	I-Gene
,	O
which	O
is	O
responsible	O
for	O
hepatic	O
clearance	O
of	O
LDL	O
from	O
the	O
blood	O
circulation	O
.	O

We	O
described	O
a	O
severely	O
affected	O
FH	O
proband	O
and	O
their	O
first	O
-	O
degree	O
blood	O
relatives	O
;	O
the	O
proband	O
was	O
resistant	O
to	O
statin	O
therapy	O
and	O
was	O
managed	O
on	O
an	O
LDL	O
apheresis	O
program	O
.	O

In	O
order	O
to	O
find	O
the	O
causative	O
genetic	O
variant	O
in	O
this	O
family	O
,	O
direct	O
exon	O
sequencing	O
of	O
the	O
LDLR	O
,	O
APOB	O
and	O
PCSK9	O
genes	O
was	O
performed	O
.	O

We	O
identified	O
a	O
compound	O
heterozygous	O
mutation	O
in	O
the	O
proband	O
with	O
missense	O
p.(W577C	O
)	O
and	O
frameshift	O
p.(G676Afs33	O
)	O
variants	O
at	O
exons	O
12	O
and	O
14	O
of	O
the	O
LDLR	O
gene	O
respectively	O
.	O

DNA	O
sequencing	O
of	O
LDLR	O
gene	O
from	O
the	O
parents	O
demonstrated	O
that	O
the	O
missense	O
variant	O
was	O
inherited	O
from	O
the	O
mother	O
and	O
frameshift	O
variant	O
was	O
inherited	O
from	O
the	O
father	O
.	O

The	O
frameshift	B-Var
variant	I-Var
resulted	O
in	O
a	O
stop	B-MPA
signal	I-MPA
33	I-MPA
codons	I-MPA
downstream	I-MPA
of	O
the	O
deletion	B-NegReg
,	O
which	O
most	O
likely	O
led	O
to	O
a	O
truncated	B-Protein
protein	I-Protein
that	O
lacks	B-NegReg
important	B-MPA
functional	I-MPA
domains	I-MPA
,	O
including	O
the	O
trans	O
-	O
membrane	O
domain	O
and	O
the	O
cytoplasmic	O
tail	O
domain	O
.	O

The	O
missense	O
variant	O
is	O
also	O
predicted	O
to	O
be	O
likely	O
pathogenic	O
and	O
affect	O
EGF	O
-	O
precursor	O
homology	O
domain	O
of	O
the	O
LDLR	O
protein	O
.	O

The	O
segregation	O
pattern	O
of	O
the	O
variants	O
was	O
consistent	O
with	O
the	O
lipid	O
profile	O
,	O
suggesting	O
a	O
more	O
severe	O
FH	O
phenotype	O
when	O
the	O
variants	O
are	O
in	O
the	O
compound	O
heterozygous	O
state	O
.	O

The	O
finding	O
of	O
a	O
compound	O
heterozygous	O
mutation	O
causing	O
severe	O
FH	O
phenotype	O
is	O
important	O
for	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
and	O
also	O
enlarges	O
the	O
spectrum	O
of	O
FH	O
-	O
causative	O
LDLR	O
variants	O
in	O
the	O
Arab	O
population	O
,	O
including	O
the	O
Saudi	O
population	O
.	O

Activity	O
of	O
NaV1.2	O
promotes	O
neurodegeneration	O
in	O
an	O
animal	O
model	O
of	O
multiple	O
sclerosis	O
.	O

Counteracting	O
the	O
progressive	O
neurological	O
disability	O
caused	O
by	O
neuronal	O
and	O
axonal	O
loss	O
is	O
the	O
major	O
unmet	O
clinical	O
need	O
in	O
multiple	O
sclerosis	O
therapy	O
.	O

However	O
,	O
the	O
mechanisms	O
underlying	O
irreversible	O
neuroaxonal	O
degeneration	O
in	O
multiple	O
sclerosis	O
and	O
its	O
animal	O
model	O
experimental	O
autoimmune	O
encephalomyelitis	O
(	O
EAE	O
)	O
are	O
not	O
well	O
understood	O
.	O

A	O
long	O
-	O
standing	O
hypothesis	O
holds	O
that	O
the	O
distribution	O
of	O
voltage	O
-	O
gated	O
sodium	O
channels	O
along	O
demyelinated	O
axons	O
contributes	O
to	O
neurodegeneration	O
by	O
increasing	O
neuroaxonal	O
sodium	O
influx	O
and	O
energy	O
demand	O
during	O
CNS	O
inflammation	O
.	O

Here	O
,	O
we	O
tested	O
this	O
hypothesis	O
in	O
vivo	O
by	O
inserting	O
a	O
human	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutation	B-Var
in	O
the	O
mouse	O
NaV1.2-encoding	O
gene	O
Scn2a	B-Gene
that	O
is	O
known	O
to	O
increase	O
NaV1.2-mediated	O
persistent	O
sodium	O
currents	O
.	O

In	O
mutant	O
mice	O
,	O
CNS	B-CPA
inflammation	I-CPA
during	I-CPA
EAE	I-CPA
leads	O
to	O
elevated	B-PosReg
neuroaxonal	B-CPA
degeneration	I-CPA
and	O
increased	B-PosReg
disability	B-CPA
and	O
lethality	B-CPA
compared	O
with	O
wild	O
-	O
type	O
littermate	O
controls	O
.	O

Importantly	O
,	O
immune	O
cell	O
infiltrates	O
were	O
not	O
different	O
between	O
mutant	O
EAE	O
mice	O
and	O
wild	O
-	O
type	O
EAE	O
mice	O
.	O

Thus	O
,	O
this	O
study	O
shows	O
that	O
increased	O
neuronal	O
NaV1.2	O
activity	O
exacerbates	O
inflammation	O
-	O
induced	O
neurodegeneration	O
irrespective	O
of	O
immune	O
cell	O
alterations	O
and	O
identifies	O
NaV1.2	O
as	O
a	O
promising	O
neuroprotective	O
drug	O
target	O
in	O
multiple	O
sclerosis	O
.	O

Exome	O
sequencing	O
reveals	O
germline	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
EGFR	B-Gene
mutation	B-Var
in	O
an	O
adult	O
with	O
Lhermitte	B-Disease
-	I-Disease
Duclos	I-Disease
disease	I-Disease
.	O

Lhermitte	B-Disease
-	I-Disease
Duclos	I-Disease
disease	I-Disease
(	O
LDD	O
)	O
is	O
a	O
rare	O
cerebellar	O
disorder	O
believed	O
to	O
be	O
pathognomonic	O
for	O
Cowden	O
syndrome	O
.	O

Presently	O
,	O
the	O
only	O
known	O
etiology	B-Reg
is	O
germline	O
PTEN	B-Gene
mutation	B-Var
.	O

We	O
report	O
a	O
41-yr	O
-	O
old	O
white	O
female	O
diagnosed	O
with	O
LDD	O
and	O
wild	O
-	O
type	O
for	O
PTEN	O
.	O

Exome	O
sequencing	O
revealed	O
a	O
germline	O
heterozygous	O
EGFR	B-Gene
mutation	B-Var
that	O
breaks	B-NegReg
a	O
disulfide	B-MPA
bond	I-MPA
in	I-MPA
the	I-MPA
receptor	I-MPA
's	I-MPA
extracellular	I-MPA
domain	I-MPA
,	O
resulting	O
in	O
constitutive	B-MPA
activation	B-PosReg
.	O

Functional	O
studies	O
demonstrate	O
activation	B-PosReg
of	O
ERK	B-Pathway
/	I-Pathway
AKT	I-Pathway
signaling	I-Pathway
pathways	I-Pathway
,	O
mimicking	O
PTEN	B-Gene
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
downstream	O
effects	O
.	O

The	O
identification	O
of	O
EGFR	O
as	O
a	O
candidate	O
LDD	O
susceptibility	O
gene	O
contributes	O
to	O
advancement	O
of	O
molecular	O
diagnosis	O
and	O
targeted	O
therapy	O
for	O
this	O
rare	O
condition	O
with	O
limited	O
treatment	O
options	O
.	O

GBA2	B-Gene
Mutations	B-Var
Cause	B-Reg
a	O
Marinesco	B-Disease
-	I-Disease
Sjögren	I-Disease
-	I-Disease
Like	I-Disease
Syndrome	I-Disease
:	I-Disease
Genetic	O
and	O
Biochemical	O
Studies	O
.	O

BACKGROUND	O
:	O
With	O
the	O
advent	O
new	O
sequencing	O
technologies	O
,	O
we	O
now	O
have	O
the	O
tools	O
to	O
understand	O
the	O
phenotypic	O
diversity	O
and	O
the	O
common	O
occurrence	O
of	O
phenocopies	O
.	O

We	O
used	O
these	O
techniques	O
to	O
investigate	O
two	O
Norwegian	O
families	O
with	O
an	O
autosomal	O
recessive	O
cerebellar	O
ataxia	O
with	O
cataracts	O
and	O
mental	O
retardation	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
chip	O
analysis	O
followed	O
by	O
Exome	O
sequencing	O
identified	O
a	O
2	O
bp	O
homozygous	O
deletion	O
in	O
GBA2	O
in	O
both	O
families	O
,	O
c.1528_1529del	B-Var
[	O
p	O
.	O
Met510Valfs*17	O
]	O
.	O

Furthermore	O
,	O
we	O
report	O
the	O
biochemical	O
characterization	O
of	O
GBA2	O
in	O
these	O
patients	O
.	O

Our	O
studies	O
show	O
that	O
a	O
reduced	B-NegReg
activity	B-MPA
of	O
GBA2	B-Gene
is	O
sufficient	O
to	O
elevate	B-PosReg
the	O
levels	B-MPA
of	O
glucosylceramide	B-MPA
to	O
similar	O
levels	O
as	O
seen	O
in	O
Gaucher	O
disease	O
.	O

Furthermore	O
,	O
leucocytes	O
seem	O
to	O
be	O
the	O
proper	O
enzyme	O
source	O
for	O
in	O
vitro	O
analysis	O
of	O
GBA2	O
activity	O
.	O

CONCLUSIONS	O
:	O
We	O
report	O
GBA2	B-Gene
mutations	B-Var
causing	B-Reg
a	O
Marinesco	B-Disease
-	I-Disease
Sjögren	I-Disease
-	I-Disease
like	I-Disease
syndrome	I-Disease
in	O
two	O
Norwegian	O
families	O
.	O

One	O
of	O
the	O
families	O
was	O
originally	O
diagnosed	O
with	O
Marinesco	O
-	O
Sjögren	O
syndrome	O
based	O
on	O
an	O
autosomal	O
recessive	O
cerebellar	O
ataxia	O
with	O
cataracts	O
and	O
mental	O
retardation	O
.	O

Our	O
findings	O
highlight	O
the	O
phenotypic	O
variability	O
associated	O
with	O
GBA2	O
mutations	O
,	O
and	O
suggest	O
that	O
patients	O
with	O
Marinesco	O
-	O
Sjögren	O
-	O
like	O
syndromes	O
should	O
be	O
tested	O
for	O
mutations	O
in	O
this	O
gene	O
.	O

Compound	O
Heterozygosity	O
for	O
Null	B-Var
Mutations	I-Var
and	O
a	O
Common	O
Hypomorphic	O
Risk	O
Haplotype	O
in	O
TBX6	B-Gene
Causes	B-Reg
Congenital	B-Disease
Scoliosis	I-Disease
.	O

Congenital	O
scoliosis	O
(	O
CS	O
)	O
occurs	O
as	O
a	O
result	O
of	O
vertebral	O
malformations	O
and	O
has	O
an	O
incidence	O
of	O
0.5	O
-	O
1/1,000	O
births	O
.	O

Recently	O
,	O
TBX6	O
on	O
chromosome	O
16p11.2	O
was	O
reported	O
as	O
a	O
disease	O
gene	O
for	O
CS	O
;	O
about	O
10	O
%	O
of	O
Chinese	O
CS	O
patients	O
were	O
compound	O
heterozygotes	O
for	O
rare	O
null	O
mutations	O
and	O
a	O
common	O
haplotype	O
defined	O
by	O
three	O
SNPs	O
in	O
TBX6	O
.	O

All	O
patients	O
had	O
hemivertebrae	O
.	O

We	O
recruited	O
94	O
Japanese	O
CS	O
patients	O
,	O
investigated	O
the	O
TBX6	O
locus	O
for	O
both	O
mutations	O
and	O
the	O
risk	O
haplotype	O
,	O
examined	O
transcriptional	O
activities	O
of	O
mutant	O
TBX6	O
in	O
vitro	O
,	O
and	O
evaluated	O
clinical	O
and	O
radiographic	O
features	O
.	O

We	O
identified	O
TBX6	O
null	O
mutations	O
in	O
nine	O
patients	O
,	O
including	O
a	O
missense	O
mutation	O
that	O
had	O
a	O
loss	O
of	O
function	O
in	O
vitro	O
.	O

All	O
had	O
the	O
risk	O
haplotype	O
in	O
the	O
opposite	O
allele	O
.	O

One	O
of	O
the	O
mutations	O
showed	O
dominant	O
negative	O
effect	O
.	O

Although	O
all	O
Chinese	O
patients	O
had	O
one	O
or	O
more	O
hemivertebrae	O
,	O
two	O
Japanese	O
patients	O
did	O
not	O
have	O
hemivertebra	O
.	O

The	O
compound	O
heterozygosity	O
of	O
null	O
mutations	O
and	O
the	O
common	O
risk	O
haplotype	O
in	O
TBX6	O
also	O
causes	O
CS	O
in	O
Japanese	O
patients	O
with	O
similar	O
incidence	O
.	O

Hemivertebra	O
was	O
not	O
a	O
specific	O
type	O
of	O
spinal	O
malformation	O
in	O
TBX6-associated	O
CS	O
(	O
TACS	O
)	O
.	O

A	O
heterozygous	O
TBX6	B-Gene
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutation	B-Var
has	O
been	O
reported	O
in	O
a	O
family	O
with	O
autosomal	B-Disease
-	I-Disease
dominant	I-Disease
spondylocostal	I-Disease
dysostosis	I-Disease
,	O
but	O
it	O
may	O
represent	O
a	O
spectrum	O
of	O
the	O
same	O
disease	O
with	O
TACS	O
.	O

Aspartylglucosaminuria	B-Disease
caused	B-Reg
by	I-Reg
a	O
novel	O
homozygous	O
mutation	B-Var
in	O
the	O
AGA	B-Gene
gene	O
was	O
identified	O
by	O
an	O
exome	O
-	O
first	O
approach	O
in	O
a	O
patient	O
from	O
Japan	O
.	O

BACKGROUND	O
:	O
Aspartylglucosaminuria	O
(	O
AGU	O
)	O
is	O
an	O
autosomal	O
recessive	O
lysosomal	O
storage	O
disorder	O
caused	O
by	O
a	O
deficiency	O
of	O
the	O
lysosomal	O
enzyme	O
,	O
aspartylglucosaminidase	O
(	O
AGA	O
)	O
.	O

This	O
disorder	O
is	O
rare	O
in	O
the	O
general	O
population	O
except	O
in	O
Finland	O
.	O

Since	O
the	O
most	O
characteristic	O
feature	O
of	O
this	O
disorder	O
is	O
a	O
progressive	O
developmental	O
regression	O
,	O
patients	O
often	O
show	O
no	O
specific	O
symptoms	O
in	O
the	O
initial	O
stages	O
,	O
and	O
thus	O
early	O
diagnosis	O
is	O
often	O
challenging	O
.	O

CASE	O
REPORT	O
:	O
We	O
encountered	O
a	O
16-year	O
-	O
old	O
boy	O
who	O
began	O
to	O
show	O
difficulties	O
in	O
his	O
speech	O
at	O
the	O
age	O
of	O
6years	O
.	O

Due	O
to	O
a	O
mild	O
regression	O
in	O
his	O
development	O
,	O
he	O
gradually	O
lost	O
common	O
daily	O
abilities	O
.	O

His	O
diagnosis	O
was	O
first	O
obtained	O
through	O
exome	O
sequencing	O
that	O
identified	O
a	O
novel	O
homozygous	O
mutation	O
in	O
the	O
AGA	O
gene	O
.	O

This	O
result	O
was	O
reasonable	O
because	O
of	O
parental	O
consanguinity	O
.	O

Reduced	O
enzymatic	O
activity	O
of	O
AGA	O
was	O
then	O
confirmed	O
.	O

His	O
urine	O
was	O
retrospectively	O
screened	O
by	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
/	O
ionization	O
time	O
-	O
of	O
-	O
flight	O
mass	O
spectrometry	O
(	O
MALDI	O
-	O
TOF	O
-	O
MS	O
)	O
and	O
a	O
specific	O
pattern	O
of	O
abnormal	O
metabolites	O
was	O
identified	O
.	O

CONCLUSIONS	O
:	O
Because	O
both	O
exome	O
sequencing	O
and	O
MALDI	O
-	O
TOF	O
-	O
MS	O
screening	O
are	O
adaptable	O
and	O
comprehensive	O
,	O
future	O
combinatory	O
use	O
of	O
these	O
methods	O
would	O
be	O
useful	O
for	O
diagnosis	O
of	O
rare	O
inborn	O
errors	O
of	O
metabolism	O
such	O
as	O
AGU	O
.	O

WT1	O
Haploinsufficiency	O
Supports	O
Milder	O
Renal	O
Manifestation	O
in	O
Two	O
Patients	O
with	O
Denys	O
-	O
Drash	O
Syndrome	O
.	O

Denys	B-Disease
-	I-Disease
Drash	I-Disease
syndrome	I-Disease
(	O
DDS	O
)	O
is	O
characterized	O
by	O
nephropathy	O
,	O
genital	O
abnormalities	O
,	O
and	O
predisposition	O
to	O
Wilms	O
'	O
tumor	O
.	O

DDS	O
patients	O
usually	O
present	B-Reg
heterozygous	O
de	O
novo	O
germline	O
WT1	B-Gene
mutations	B-Var
.	O

The	O
WT1	O
gene	O
comprises	O
10	O
exons	O
encoding	O
the	O
N	O
-	O
terminal	O
transactivation	O
and	O
the	O
C	O
-	O
terminal	O
DNA	O
-	O
binding	O
regions	O
.	O

Two	O
unrelated	O
patients	O
with	O
genital	O
ambiguity	O
and	O
Wilms	O
'	O
tumor	O
were	O
analyzed	O
by	O
sequencing	O
of	O
the	O
WT1	O
gene	O
,	O
and	O
3	O
mutations	O
in	O
exon	O
1	O
were	O
identified	O
of	O
which	O
2	O
are	O
novel	O
.	O

Patient	O
1	O
carried	O
a	O
c.555delC	B-Var
mutation	O
that	O
causes	B-Reg
a	O
frameshift	B-Var
and	O
a	O
premature	B-MPA
stop	I-MPA
codon	O
.	O

Patient	O
2	O
carried	O
both	O
c.421A	B-Var
>	I-Var
C	I-Var
and	O
c.424C	B-Var
>	I-Var
T	I-Var
aberrations	O
that	O
lead	B-Reg
to	I-Reg
the	O
missense	O
p	B-Var
.	I-Var
Lys141Gln	I-Var
and	O
the	O
nonsense	O
p	B-Var
.	I-Var
Lys142	I-Var
*	I-Var
mutation	O
,	O
respectively	O
.	O

As	O
both	O
patients	O
were	O
heterozygous	O
for	O
the	O
mutations	O
,	O
we	O
tested	O
their	O
parents	O
who	O
did	O
not	O
carry	O
any	O
mutation	O
.	O

Therefore	O
,	O
the	O
3	O
WT1	O
mutations	O
occurred	O
de	O
novo	O
in	O
both	O
patients	O
.	O

Heterozygous	O
mutations	B-Var
result	O
in	O
WT1	B-Gene
haploinsufficiency	O
as	O
they	O
impair	B-NegReg
protein	B-Protein
production	B-MPA
.	O

They	O
are	O
associated	O
with	O
a	O
milder	O
DDS	O
phenotype	O
as	O
observed	O
in	O
the	O
patients	O
studied	O
here	O
.	O

Delineating	O
the	O
phenotypic	O
spectrum	O
of	O
Bainbridge	B-Disease
-	I-Disease
Ropers	I-Disease
syndrome	I-Disease
:	I-Disease
12	O
new	O
patients	O
with	O
de	O
novo	O
,	O
heterozygous	O
,	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
ASXL3	B-Gene
and	O
review	O
of	O
published	O
literature	O
.	O

BACKGROUND	O
:	O
Bainbridge	B-Disease
-	I-Disease
Ropers	I-Disease
syndrome	I-Disease
(	O
BRPS	O
)	O
is	O
a	O
recently	O
described	O
developmental	O
disorder	O
caused	B-Reg
by	I-Reg
de	O
novo	O
truncating	B-Var
mutations	I-Var
in	O
the	O
additional	O
sex	O
combs	O
like	O
3	O
(	B-Gene
ASXL3	I-Gene
)	I-Gene
gene	O
.	O

To	O
date	O
,	O
there	O
have	O
been	O
fewer	O
than	O
10	O
reported	O
patients	O
.	O

OBJECTIVES	O
:	O
Here	O
,	O
we	O
delineate	O
the	O
BRPS	O
phenotype	O
further	O
by	O
describing	O
a	O
series	O
of	O
12	O
previously	O
unreported	O
patients	O
identified	O
by	O
the	O
Deciphering	O
Developmental	O
Disorders	O
study	O
.	O

METHODS	O
:	O
Trio	O
-	O
based	O
exome	O
sequencing	O
was	O
performed	O
on	O
all	O
12	O
patients	O
included	O
in	O
this	O
study	O
,	O
which	O
found	O
a	O
de	O
novo	O
truncating	O
mutation	O
in	O
ASXL3	O
.	O

Detailed	O
phenotypic	O
information	O
and	O
patient	O
images	O
were	O
collected	O
and	O
summarised	O
as	O
part	O
of	O
this	O
study	O
.	O

RESULTS	O
:	O
By	O
obtaining	O
genotype	O
:	O
phenotype	O
data	O
,	O
we	O
have	O
been	O
able	O
to	O
demonstrate	O
a	O
second	O
mutation	O
cluster	O
region	O
within	O
ASXL3	O
.	O

This	O
report	O
expands	O
the	O
phenotype	O
of	O
older	O
patients	O
with	O
BRPS	O
;	O
common	O
emerging	O
features	O
include	O
severe	O
intellectual	O
disability	O
(	O
11/12	O
)	O
,	O
p	O
absent	O
speech	O
(	O
12/12	O
)	O
,	O
autistic	O
traits	O
(	O
9/12	O
)	O
,	O
distinct	O
face	O
(	O
arched	O
eyebrows	O
,	O
prominent	O
forehead	O
,	O
high	O
-	O
arched	O
palate	O
,	O
hypertelorism	O
and	O
downslanting	O
palpebral	O
fissures	O
)	O
,	O
(	O
9/12	O
)	O
,	O
hypotonia	O
(	O
11/12	O
)	O
and	O
significant	O
feeding	O
difficulties	O
(	O
9/12	O
)	O
when	O
young	O
.	O

DISCUSSION	O
:	O
Similarities	O
in	O
the	O
patients	O
reported	O
previously	O
in	O
comparison	O
with	O
this	O
cohort	O
included	O
their	O
distinctive	O
craniofacial	O
features	O
,	O
feeding	O
problems	O
,	O
absent	O
/	O
limited	O
speech	O
and	O
intellectual	O
disability	O
.	O

Shared	O
behavioural	O
phenotypes	O
include	O
autistic	O
traits	O
,	O
hand	O
-	O
flapping	O
,	O
rocking	O
,	O
aggressive	O
behaviour	O
and	O
sleep	O
disturbance	O
.	O

CONCLUSIONS	O
:	O
This	O
series	O
expands	O
the	O
phenotypic	O
spectrum	O
of	O
this	O
severe	O
disorder	O
and	O
highlights	O
its	O
surprisingly	O
high	O
frequency	O
.	O

With	O
the	O
advent	O
of	O
advanced	O
genomic	O
screening	O
,	O
we	O
are	O
likely	O
to	O
identify	O
more	O
variants	O
in	O
this	O
gene	O
presenting	O
with	O
a	O
variable	O
phenotype	O
,	O
which	O
this	O
study	O
will	O
explore	O
.	O

Rhomboid	O
family	O
member	O
2	O
regulates	O
cytoskeletal	O
stress	O
-	O
associated	O
Keratin	O
16	O
.	O

Keratin	O
16	O
(	O
K16	O
)	O
is	O
a	O
cytoskeletal	O
scaffolding	O
protein	O
highly	O
expressed	O
at	O
pressure	O
-	O
bearing	O
sites	O
of	O
the	O
mammalian	O
footpad	O
.	O

It	O
can	O
be	O
induced	O
in	O
hyperproliferative	O
states	O
such	O
as	O
wound	O
healing	O
,	O
inflammation	O
and	O
cancer	O
.	O

Here	O
we	O
show	O
that	O
the	O
inactive	O
rhomboid	O
protease	O
RHBDF2	O
(	O
iRHOM2	O
)	O
regulates	O
thickening	O
of	O
the	O
footpad	O
epidermis	O
through	O
its	O
interaction	O
with	O
K16	O
.	O

K16	O
expression	O
is	O
absent	O
in	O
the	O
thinned	O
footpads	O
of	O
irhom2(-/-	O
)	O
mice	O
compared	O
with	O
irhom2(+/+)mice	O
,	O
due	O
to	O
reduced	O
keratinocyte	O
proliferation	O
.	O

Gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutations	B-Var
in	O
iRHOM2	B-Gene
underlie	O
Tylosis	B-Disease
with	I-Disease
oesophageal	I-Disease
cancer	I-Disease
(	O
TOC	O
)	O
,	O
characterized	O
by	O
palmoplantar	O
thickening	O
,	O
upregulate	B-PosReg
K16	B-MPA
with	O
robust	O
downregulation	B-NegReg
of	O
its	O
type	B-MPA
II	I-MPA
keratin	I-MPA
binding	I-MPA
partner	I-MPA
,	O
K6	I-MPA
.	O

By	O
orchestrating	O
the	O
remodelling	O
and	O
turnover	O
of	O
K16	O
,	O
and	O
uncoupling	O
it	O
from	O
K6	O
,	O
iRHOM2	O
regulates	O
the	O
epithelial	O
response	O
to	O
physical	O
stress	O
.	O

These	O
findings	O
contribute	O
to	O
our	O
understanding	O
of	O
the	O
molecular	O
mechanisms	O
underlying	O
hyperproliferation	O
of	O
the	O
palmoplantar	O
epidermis	O
in	O
both	O
physiological	O
and	O
disease	O
states	O
,	O
and	O
how	O
this	O
'	O
stress	O
'	O
keratin	O
is	O
regulated	O
.	O

Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutation	B-Var
of	O
the	O
calcium	B-Protein
sensor	I-Protein
CBL1	I-Protein
increases	B-PosReg
aluminum	B-MPA
sensitivity	I-MPA
in	O
Arabidopsis	O
.	O

Despite	O
the	O
physiological	O
importance	O
of	O
aluminum	O
(	O
Al	O
)	O
phytotoxicity	O
for	O
plants	O
,	O
it	O
remained	O
unknown	O
if	O
,	O
and	O
how	O
,	O
calcineurin	O
B	O
-	O
like	O
calcium	O
sensors	O
(	O
CBLs	O
)	O
and	O
CBL	O
-	O
interacting	O
protein	O
kinases	O
(	O
CIPKs	O
)	O
are	O
involved	O
in	O
Al	O
resistance	O
.	O

We	O
performed	O
a	O
comparative	O
physiological	O
and	O
whole	O
transcriptome	O
investigation	O
of	O
an	O
Arabidopsis	O
CBL1	B-Gene
mutant	B-Var
(	O
cbl1	O
)	O
and	O
the	O
wild	O
-	O
type	O
(	O
WT	O
)	O
.	O

cbl1	O
plants	O
exudated	O
less	B-NegReg
Al	B-MPA
-	I-MPA
chelating	I-MPA
malate	I-MPA
,	O
accumulated	O
more	B-PosReg
Al	B-MPA
,	O
and	O
displayed	O
a	O
severe	B-CPA
root	I-CPA
growth	I-CPA
reduction	B-NegReg
in	O
response	O
to	O
Al	O
.	O

Genes	O
involved	O
in	O
metabolism	O
,	O
transport	O
,	O
cell	O
wall	O
modification	O
,	O
transcription	O
and	O
oxidative	O
stress	O
were	O
differentially	O
regulated	O
between	O
the	O
two	O
lines	O
,	O
under	O
both	O
control	O
and	O
Al	O
stress	O
treatments	O
.	O

Exposure	O
to	O
Al	O
resulted	O
in	O
up	O
-	O
regulation	O
of	O
a	O
large	O
set	O
of	O
genes	O
only	O
in	O
WT	O
and	O
not	O
cbl1	O
shoots	O
,	O
while	O
a	O
different	O
set	O
of	O
genes	O
were	O
down	O
-	O
regulated	O
in	O
cbl1	O
but	O
not	O
in	O
WT	O
roots	O
.	O

These	O
differences	O
allowed	O
us	O
,	O
for	O
the	O
first	O
time	O
,	O
to	O
define	O
a	O
calcium	O
-	O
regulated	O
/	O
dependent	O
transcriptomic	O
network	O
for	O
Al	O
stress	O
responses	O
.	O

Our	O
analyses	O
reveal	O
not	O
only	O
the	O
fundamental	O
role	O
of	O
CBL1	O
in	O
the	O
adjustment	O
of	O
central	O
transcriptomic	O
networks	O
involved	O
in	O
maintaining	O
adequate	O
physiological	O
homeostasis	O
processes	O
,	O
but	O
also	O
that	O
a	O
high	O
shoot	O
-	O
root	O
dynamics	O
is	O
required	O
for	O
the	O
proper	O
deployment	O
of	O
Al	O
resistance	O
responses	O
in	O
the	O
root	O
.	O

Clinical	O
and	O
molecular	O
consequences	O
of	O
disease	O
-	O
associated	O
de	O
novo	O
mutations	O
in	O
SATB2	O
.	O

PURPOSE	O
:	O
To	O
characterize	O
features	O
associated	O
with	O
de	O
novo	O
mutations	O
affecting	O
SATB2	O
function	O
in	O
individuals	O
ascertained	O
on	O
the	O
basis	O
of	O
intellectual	O
disability	O
.	O

METHODS	O
:	O
Twenty	O
previously	O
unreported	O
individuals	O
with	O
19	O
different	O
SATB2	O
mutations	O
(	O
11	O
loss	O
-	O
of	O
-	O
function	O
and	O
8	O
missense	O
variants	O
)	O
were	O
studied	O
.	O

Fibroblasts	O
were	O
used	O
to	O
measure	O
mutant	O
protein	O
production	O
.	O

Subcellular	O
localization	O
and	O
mobility	O
of	O
wild	O
-	O
type	O
and	O
mutant	O
SATB2	O
were	O
assessed	O
using	O
fluorescently	O
tagged	O
protein	O
.	O

RESULTS	O
:	O
Recurrent	O
clinical	O
features	O
included	O
neurodevelopmental	O
impairment	O
(	O
19/19	O
)	O
,	O
absent	O
/	O
near	O
absent	O
speech	O
(	O
16/19	O
)	O
,	O
normal	O
somatic	O
growth	O
(	O
17/19	O
)	O
,	O
cleft	O
palate	O
(	O
9/19	O
)	O
,	O
drooling	O
(	O
12/19	O
)	O
,	O
and	O
dental	O
anomalies	O
(	O
8/19	O
)	O
.	O

Six	O
of	O
eight	O
missense	O
variants	O
clustered	O
in	O
the	O
first	O
CUT	O
domain	O
.	O

Sibling	O
recurrence	O
due	O
to	O
gonadal	O
mosaicism	O
was	O
seen	O
in	O
one	O
family	O
.	O

A	O
nonsense	B-Var
mutation	I-Var
in	I-Var
the	I-Var
last	I-Var
exon	I-Var
resulted	B-Reg
in	I-Reg
production	O
of	O
a	O
truncated	B-MPA
protein	B-Protein
retaining	O
all	O
three	O
DNA	O
-	O
binding	O
domains	O
.	O

SATB2	B-Gene
nuclear	O
mobility	O
was	O
mutation	O
-	O
dependent	O
;	O
p	B-Var
.	I-Var
Arg389Cys	I-Var
in	I-Var
CUT1	I-Var
increased	B-PosReg
mobility	B-MPA
and	O
both	O
p	B-Var
.	I-Var
Gly515Ser	I-Var
in	I-Var
CUT2	I-Var
and	O
p	B-Var
.	I-Var
Gln566Lys	I-Var
between	I-Var
CUT2	I-Var
and	I-Var
HOX	I-Var
reduced	B-NegReg
mobility	B-MPA
.	O

The	O
clinical	O
features	O
in	O
individuals	O
with	O
missense	O
variants	O
were	O
indistinguishable	O
from	O
those	O
with	O
loss	O
of	O
function	O
.	O

CONCLUSION	O
:	O
SATB2	B-Gene
haploinsufficiency	B-Var
is	O
a	O
common	O
cause	B-Reg
of	O
syndromic	B-Disease
intellectual	I-Disease
disability	I-Disease
.	O

When	O
mutant	B-Var
SATB2	B-Gene
protein	O
is	O
produced	O
,	O
the	O
protein	B-Protein
appears	O
functionally	B-MPA
inactive	B-NegReg
with	O
a	O
disrupted	O
pattern	O
of	O
chromatin	O
or	O
matrix	O
association	O
.	O

Genet	O
Med	O
advance	O
online	O
publication	O
02	O
February	O
2017	O
.	O

Loss	B-Var
of	O
Ssq1	B-Gene
leads	B-Reg
to	O
mitochondrial	B-CPA
dysfunction	I-CPA
,	O
activation	B-CPA
of	I-CPA
autophagy	I-CPA
and	O
cell	B-CPA
cycle	I-CPA
arrest	I-CPA
due	O
to	O
iron	B-MPA
overload	B-PosReg
triggered	O
by	O
mitochondrial	B-MPA
iron	I-MPA
-	I-MPA
sulfur	I-MPA
cluster	I-MPA
assembly	I-MPA
defects	B-NegReg
in	O
Candida	O
albicans	O
.	O

Iron	O
-	O
sulfur	O
clusters	O
perform	O
essential	O
functions	O
in	O
enzymatic	O
catalysis	O
and	O
homeostatic	O
regulation	O
.	O

Here	O
we	O
for	O
the	O
first	O
time	O
identified	O
Ssq1	O
as	O
an	O
essential	O
component	O
for	O
iron	O
-	O
sulfur	O
cluster	O
assembly	O
in	O
Candida	O
albicans	O
.	O

Ssq1	O
played	O
an	O
important	O
role	O
in	O
cell	O
growth	O
.	O

Shutting	O
off	O
SSQ1	O
led	O
to	O
accumulation	O
of	O
intracellular	O
iron	O
,	O
especially	O
in	O
mitochondria	O
,	O
and	O
disorder	O
of	O
intracellular	O
iron	O
regulation	O
.	O

In	O
tetO	O
-	O
SSQ1	O
,	O
iron	O
overloading	O
triggered	O
the	O
oxidative	O
damage	O
of	O
mitochondrial	O
function	O
.	O

Surprisingly	O
,	O
disruption	O
of	O
SSQ1	O
activated	O
autophagic	O
pathway	O
.	O

The	O
mitochondrial	B-CPA
dysfunction	I-CPA
was	O
further	O
aggravated	B-NegReg
when	O
CCZ1	B-Gene
(	O
which	O
is	O
essential	O
for	O
autophagy	O
)	O
and	O
SSQ1	B-Gene
was	O
simultaneously	O
deleted	B-Var
,	O
suggesting	O
that	O
autophagy	O
played	O
a	O
critical	O
role	O
in	O
maintenance	O
of	O
mitochondrial	O
function	O
in	O
tetO	O
-	O
SSQ1	O
.	O

In	O
addition	O
,	O
double	O
deletion	B-Var
of	O
SSQ1	B-Gene
and	O
CCZ1	B-Gene
further	O
elevated	B-PosReg
cellular	B-MPA
iron	I-MPA
levels	I-MPA
in	O
comparison	O
with	O
tetO	O
-	O
SSQ1	O
,	O
indicating	O
that	O
autophagy	O
participated	O
in	O
maintenance	O
of	O
iron	O
homeostasis	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
loss	B-Var
of	O
SSQ1	B-Gene
led	O
to	O
increasing	B-PosReg
protein	B-Protein
expression	B-MPA
of	O
Rnr1	B-Gene
and	O
redistribution	B-MPA
of	O
Rnr2	B-Gene
from	O
the	O
nucleus	O
to	O
cytoplasm	O
,	O
and	O
further	O
resulted	B-Reg
in	O
cell	B-CPA
cycle	I-CPA
arrest	I-CPA
.	O

The	O
results	O
implied	O
that	O
cell	O
cycle	O
arrest	O
was	O
caused	O
by	O
activating	O
the	O
checkpoint	O
pathway	O
because	O
of	O
impairing	O
the	O
iron	O
-	O
sulfur	O
cluster	O
assembly	O
in	O
tetO	O
-	O
SSQ1	O
.	O

Shutting	O
off	O
SSQ1	O
led	O
to	O
a	O
significant	O
defect	O
in	O
filamentous	O
development	O
.	O

Interestingly	O
,	O
the	O
tetO	O
-	O
SSQ1ccz1Δ	O
/	O
Δ	O
growth	O
was	O
inhibited	O
on	O
hyphae	O
-	O
inducing	O
solid	O
media	O
.	O

Both	O
tetO	O
-	O
SSQ1	O
and	O
tetO	O
-	O
SSQ1ccz1Δ	O
/	O
Δ	O
exhibited	O
extremely	O
attenuated	O
virulence	O
,	O
indicating	O
that	O
Ssq1	O
might	O
provide	O
a	O
promising	O
target	O
for	O
antifungal	O
drugs	O
development	O
.	O

In	O
summary	O
,	O
our	O
findings	O
provide	O
new	O
insights	O
into	O
the	O
understanding	O
of	O
iron	O
-	O
sulfur	O
cluster	O
assembly	O
-	O
related	O
gene	O
in	O
C.	O
albicans	O
.	O

Identification	O
of	O
TAZ	B-Gene
mutations	B-Var
in	O
pediatric	O
patients	O
with	B-Reg
cardiomyopathy	B-Disease
by	O
targeted	O
next	O
-	O
generation	O
sequencing	O
in	O
a	O
Chinese	O
cohort	O
.	O

BACKGROUND	O
:	O
Barth	O
syndrome	O
(	O
BTHS	O
)	O
is	O
a	O
rare	O
X	O
-	O
linked	O
recessive	O
disease	O
characterized	O
by	O
cardiomyopathy	O
,	O
neutropenia	O
,	O
skeletal	O
myopathy	O
and	O
growth	O
delay	O
.	O

Early	O
diagnosis	O
and	O
appropriate	O
treatment	O
may	O
improve	O
the	O
prognosis	O
of	O
this	O
disease	O
.	O

The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
determine	O
the	O
role	O
of	O
targeted	O
next	O
-	O
generation	O
sequencing	O
(	O
NGS	O
)	O
in	O
the	O
early	O
diagnosis	O
of	O
BTHS	O
in	O
children	O
with	O
cardiomyopathy	O
.	O

METHODS	O
:	O
During	O
the	O
period	O
between	O
2012	O
and	O
2015	O
,	O
a	O
gene	O
panel	O
-	O
based	O
NGS	O
approach	O
was	O
used	O
to	O
search	O
for	O
potentially	O
disease	O
-	O
causing	O
genetic	O
variants	O
in	O
all	O
patients	O
referred	O
to	O
our	O
institution	O
with	O
a	O
clinical	O
diagnosis	O
of	O
primary	O
cardiomyopathy	O
.	O

NGS	O
was	O
performed	O
using	O
the	O
Illumina	O
sequencing	O
system	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
180	O
Chinese	O
pediatric	O
patients	O
(	O
114	O
males	O
and	O
66	O
females	O
)	O
diagnosed	O
with	O
primary	O
cardiomyopathy	O
were	O
enrolled	O
in	O
this	O
study	O
.	O

TAZ	O
mutations	O
were	O
identified	O
in	O
four	O
of	O
the	O
male	O
index	O
patients	O
,	O
including	O
two	O
novel	O
mutations	O
(	O
c.527A	O
>	O
G	O
,	O
p	O
.	O
H176R	O
and	O
c.134_136delinsCC	O
,	O
p	O
.	O
H45PfsX38	O
)	O
.	O

All	O
four	O
probands	O
and	O
two	O
additional	O
affected	O
male	O
family	O
members	O
were	O
born	O
at	O
full	O
term	O
with	O
a	O
median	O
birth	O
weight	O
of	O
2350	O
g	O
(	O
range	O
,	O
2000	O
-	O
2850	O
g	O
)	O
.	O

The	O
median	O
age	O
at	O
diagnosis	O
of	O
cardiomyopathy	O
was	O
3.0	O
months	O
(	O
range	O
,	O
1.0	O
-	O
20.0	O
months	O
)	O
.	O

The	O
baseline	O
echocardiography	O
revealed	O
prominent	O
dilation	O
and	O
trabeculations	O
of	O
the	O
left	O
ventricle	O
with	O
impaired	O
systolic	O
function	O
in	O
the	O
six	O
patients	O
,	O
four	O
of	O
which	O
fulfilled	O
the	O
diagnostic	O
criteria	O
of	O
left	O
ventricular	O
noncompaction	O
.	O

Other	O
aspects	O
of	O
their	O
clinical	O
presentations	O
included	O
hypotonia	O
(	O
6/6	O
)	O
,	O
growth	O
delay	O
(	O
6/6	O
)	O
,	O
neutropenia	O
(	O
3/6	O
)	O
and	O
3-methylglutaconic	O
aciduria	O
(	O
4/5	O
)	O
.	O

Five	O
patients	O
died	O
at	O
a	O
median	O
age	O
of	O
7.5	O
months	O
(	O
range	O
,	O
7.0	O
-	O
12.0	O
months	O
)	O
.	O

The	O
cause	O
of	O
death	O
was	O
heart	O
failure	O
associated	O
with	O
infection	O
in	O
three	O
patients	O
and	O
cardiac	O
arrhythmia	O
in	O
two	O
patients	O
.	O

The	O
remaining	O
one	O
patient	O
survived	O
beyond	O
infancy	O
but	O
had	O
fallen	O
into	O
a	O
persistent	O
vegetative	O
state	O
after	O
suffering	O
from	O
cardiac	O
arrest	O
.	O

CONCLUSIONS	O
:	O
This	O
is	O
the	O
first	O
report	O
of	O
systematic	O
mutation	O
screening	O
of	O
TAZ	O
in	O
a	O
large	O
cohort	O
of	O
pediatric	O
patients	O
with	O
primary	O
cardiomyopathy	O
using	O
the	O
NGS	O
approach	O
.	O

TAZ	O
mutations	O
were	O
found	O
in	O
4/114	O
(	O
3.5	O
%	O
)	O
male	O
patients	O
with	O
primary	O
cardiomyopathy	O
.	O

Our	O
findings	O
indicate	O
that	O
the	O
inclusion	O
of	O
TAZ	O
gene	O
testing	O
in	O
cardiomyopathy	O
genetic	O
testing	O
panels	O
may	O
contribute	O
to	O
the	O
early	O
diagnosis	O
of	O
BTHS	O
.	O

Mutations	B-Var
in	O
DONSON	B-Gene
disrupt	B-NegReg
replication	B-MPA
fork	I-MPA
stability	I-MPA
and	O
cause	B-Reg
microcephalic	B-Disease
dwarfism	I-Disease
.	O

To	O
ensure	O
efficient	O
genome	O
duplication	O
,	O
cells	O
have	O
evolved	O
numerous	O
factors	O
that	O
promote	O
unperturbed	O
DNA	O
replication	O
and	O
protect	O
,	O
repair	O
and	O
restart	O
damaged	O
forks	O
.	O

Here	O
we	O
identify	O
downstream	O
neighbor	O
of	O
SON	O
(	O
DONSON	O
)	O
as	O
a	O
novel	O
fork	O
protection	O
factor	O
and	O
report	O
biallelic	O
DONSON	O
mutations	O
in	O
29	O
individuals	O
with	O
microcephalic	O
dwarfism	O
.	O

We	O
demonstrate	O
that	O
DONSON	O
is	O
a	O
replisome	O
component	O
that	O
stabilizes	O
forks	O
during	O
genome	O
replication	O
.	O

Loss	B-Var
of	O
DONSON	B-Gene
leads	B-Reg
to	I-Reg
severe	O
replication	B-MPA
-	I-MPA
associated	I-MPA
DNA	I-MPA
damage	I-MPA
arising	O
from	O
nucleolytic	O
cleavage	O
of	O
stalled	O
replication	O
forks	O
.	O

Furthermore	O
,	O
ATM-	B-MPA
and	I-MPA
Rad3-related	I-MPA
(	I-MPA
ATR)-dependent	I-MPA
signaling	I-MPA
in	O
response	O
to	O
replication	O
stress	O
is	O
impaired	B-NegReg
in	O
DONSON	B-Var
-	I-Var
deficient	I-Var
cells	O
,	O
resulting	O
in	O
decreased	B-NegReg
checkpoint	B-MPA
activity	I-MPA
and	O
the	O
potentiation	B-PosReg
of	O
chromosomal	B-MPA
instability	I-MPA
.	O

Hypomorphic	B-Var
mutations	I-Var
in	O
DONSON	B-Gene
substantially	O
reduce	B-NegReg
DONSON	B-Gene
protein	B-Protein
levels	B-MPA
and	O
impair	B-NegReg
fork	B-MPA
stability	I-MPA
in	O
cells	O
from	O
patients	O
,	O
consistent	O
with	O
defective	O
DNA	O
replication	O
underlying	O
the	O
disease	O
phenotype	O
.	O

In	O
summary	O
,	O
we	O
have	O
identified	O
mutations	B-Var
in	O
DONSON	B-Gene
as	O
a	O
common	O
cause	B-Reg
of	O
microcephalic	B-Disease
dwarfism	I-Disease
and	O
established	O
DONSON	O
as	O
a	O
critical	O
replication	O
fork	O
protein	O
required	O
for	O
mammalian	O
DNA	O
replication	O
and	O
genome	O
stability	O
.	O

Phenotypic	O
spectrum	O
of	O
Charcot	B-Disease
-	I-Disease
Marie	I-Disease
-	I-Disease
Tooth	I-Disease
disease	O
due	B-Reg
to	I-Reg
LITAF	B-Gene
/	I-Gene
SIMPLE	I-Gene
mutations	B-Var
:	I-Var
a	O
study	O
of	O
18	O
patients	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
Charcot	B-Disease
-	I-Disease
Marie	I-Disease
-	I-Disease
Tooth	I-Disease
(	O
CMT	O
)	O
1C	O
due	B-Reg
to	I-Reg
mutations	B-Var
in	O
LITAF	B-Gene
/	I-Gene
SIMPLE	I-Gene
is	O
a	O
rare	O
subtype	O
amongst	O
the	O
autosomal	O
dominant	O
demyelinating	O
forms	O
of	O
CMT	O
.	O

Our	O
objective	O
was	O
to	O
report	O
the	O
clinical	O
and	O
electrophysiological	O
characteristics	O
of	O
18	O
CMT1C	O
patients	O
and	O
compare	O
them	O
to	O
20	O
patients	O
with	O
PMP22	O
mutations	O
:	O
10	O
CMT1A	O
patients	O
and	O
10	O
patients	O
with	O
hereditary	O
neuropathy	O
with	O
liability	O
to	O
pressure	O
palsies	O
(	O
HNPP	O
)	O
.	O

METHODS	O
:	O
Charcot	O
-	O
Marie	O
-	O
Tooth	O
1C	O
patients	O
were	O
followed	O
-	O
up	O
in	O
referral	O
centres	O
for	O
neuromuscular	O
diseases	O
or	O
were	O
identified	O
by	O
familial	O
survey	O
.	O

All	O
CMT1A	O
and	O
HNPP	O
patients	O
were	O
recruited	O
at	O
the	O
referral	O
centre	O
for	O
neuromuscular	O
diseases	O
of	O
Pitié	O
-	O
Salpêtrière	O
Hospital	O
.	O

RESULTS	O
:	O
Two	O
phenotypes	O
were	O
identified	O
amongst	O
18	O
CMT1C	O
patients	O
:	O
the	O
classical	O
CMT	O
form	O
(	O
'	O
CMT	O
-	O
like	O
'	O
,	O
11	O
cases	O
)	O
and	O
a	O
predominantly	O
sensory	O
form	O
(	O
'	O
sensory	O
form	O
'	O
,	O
seven	O
cases	O
)	O
.	O

The	O
mean	O
CMT	O
neuropathy	O
score	O
was	O
4.45	O
in	O
CMT1C	O
patients	O
.	O

Motor	O
nerve	O
conduction	O
velocities	O
in	O
the	O
upper	O
limbs	O
were	O
significantly	O
more	O
reduced	O
in	O
CMT1A	O
than	O
in	O
CMT1C	O
patients	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
motor	O
nerve	O
conduction	O
velocity	O
of	O
the	O
median	O
nerve	O
was	O
significantly	O
lower	O
in	O
CMT1C	O
compared	O
to	O
the	O
HNPP	O
group	O
.	O

Distal	O
motor	O
latency	O
was	O
significantly	O
more	O
prolonged	O
in	O
CMT1A	O
patients	O
compared	O
to	O
the	O
CMT1C	O
and	O
HNPP	O
groups	O
,	O
the	O
latter	O
two	O
groups	O
having	O
similar	O
distal	O
motor	O
latency	O
values	O
.	O

Molecular	O
analysis	O
revealed	O
five	O
new	O
LITAF	O
/	O
SIMPLE	O
mutations	O
(	O
Ala111Thr	O
,	O
Gly112Ala	O
,	O
Trp116Arg	O
,	O
Pro135Leu	O
,	O
Arg160Cys	O
)	O
.	O

CONCLUSIONS	O
:	O
Our	O
study	O
delineates	O
CMT1C	O
as	O
mostly	O
a	O
mild	O
form	O
of	O
neuropathy	O
,	O
and	O
gives	O
clinical	O
and	O
electrophysiological	O
clues	O
differentiating	O
CMT1C	O
from	O
CMT1A	O
and	O
HNPP	O
.	O

Delineating	O
phenotypes	O
in	O
CMT	O
subtypes	O
is	O
important	O
to	O
orient	O
molecular	O
diagnosis	O
and	O
to	O
help	O
to	O
interpret	O
complex	O
molecular	O
findings	O
.	O

A	O
Novel	O
Homozygous	O
Missense	O
Mutation	B-Var
in	O
HOXC13	B-Gene
Leads	B-Reg
to	I-Reg
Autosomal	O
Recessive	O
Pure	B-Disease
Hair	I-Disease
and	I-Disease
Nail	I-Disease
Ectodermal	I-Disease
Dysplasia	I-Disease
.	O

Pure	O
hair	O
and	O
nail	O
ectodermal	O
dysplasia	O
(	O
PHNED	O
)	O
is	O
a	O
rare	O
disorder	O
that	O
presents	O
with	O
hypotrichosis	O
and	O
nail	O
dystrophy	O
while	O
sparing	O
other	O
ectodermal	O
structures	O
such	O
as	O
teeth	O
and	O
sweat	O
glands	O
.	O

We	O
describe	O
a	O
homozygous	O
novel	O
missense	O
mutation	B-Var
in	O
the	O
HOXC13	B-Gene
gene	O
that	O
resulted	B-Reg
in	I-Reg
autosomal	O
recessive	O
PHNED	B-Disease
in	O
a	O
Hispanic	O
child	O
.	O

The	O
mutation	O
c.812A	O
>	O
G	O
(	O
p	O
.	O
Gln271Arg	O
)	O
is	O
located	O
within	O
the	O
DNA	O
-	O
binding	O
domain	O
of	O
the	O
HOXC13	O
gene	O
,	O
cosegregates	O
within	O
the	O
family	O
,	O
and	O
is	O
predicted	O
to	O
be	O
maximally	O
damaging	O
.	O

This	O
is	O
the	O
first	O
reported	O
case	O
of	O
a	O
missense	O
HOXC13	B-Gene
mutation	B-Var
resulting	B-Reg
in	I-Reg
PHNED	B-Disease
and	O
the	O
first	O
reported	O
case	O
of	O
PHNED	O
identified	O
in	O
a	O
North	O
American	O
family	O
.	O

Our	O
findings	O
illustrate	O
the	O
critical	O
role	O
of	O
HOXC13	O
in	O
human	O
hair	O
and	O
nail	O
development	O
.	O

SERPINC1	B-Gene
gene	O
mutations	B-Var
in	B-Reg
antithrombin	B-Disease
deficiency	I-Disease
.	O

Existing	O
evidence	O
suggests	O
that	O
in	O
most	O
cases	O
antithrombin	B-Disease
deficiency	I-Disease
can	O
be	O
explained	B-Reg
by	I-Reg
mutations	B-Var
in	O
its	O
gene	O
,	O
SERPINC1	B-Gene
.	O

We	O
investigated	O
the	O
molecular	O
background	O
of	O
antithrombin	O
deficiency	O
in	O
a	O
single	O
centre	O
family	O
cohort	O
study	O
.	O

We	O
included	O
a	O
total	O
of	O
21	O
families	O
comprising	O
15	O
original	O
probands	O
and	O
sixty	O
-	O
six	O
relatives	O
,	O
6	O
of	O
who	O
were	O
surrogate	O
probands	O
for	O
the	O
genetic	O
analysis	O
.	O

Antithrombin	O
activity	O
and	O
antigen	O
levels	O
were	O
measured	O
.	O

The	O
heparin	O
-	O
antithrombin	O
binding	O
ratio	O
assay	O
was	O
used	O
to	O
distinguish	O
between	O
the	O
different	O
subtypes	O
of	O
type	O
II	O
antithrombin	O
deficiency	O
.	O

SERPINC1	O
mutations	O
were	O
detected	O
by	O
direct	O
sequencing	O
of	O
all	O
7	O
exons	O
and	O
regulatory	O
regions	O
,	O
and	O
multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
.	O

Eighty	O
-	O
six	O
per	O
cent	O
of	O
the	O
families	O
had	O
a	O
detrimental	O
SERPINC1	O
gene	O
mutation	O
that	O
segregated	O
in	O
the	O
family	O
.	O

We	O
detected	O
13	O
different	O
SERPINC1	O
gene	O
mutations	O
of	O
which	O
5	O
were	O
novel	O
.	O

Among	O
all	O
these	O
mutations	O
,	O
44	O
%	O
was	O
associated	O
with	O
type	O
I	O
deficiency	O
,	O
whereas	O
the	O
remainder	O
was	O
associated	O
with	O
type	O
II	O
heparin	O
binding	O
site	O
(	O
11	O
%	O
)	O
,	O
type	O
II	O
pleiotropic	O
effect	O
(	O
33	O
%	O
)	O
,	O
type	O
II	O
reactive	O
site	O
(	O
6	O
%	O
)	O
or	O
had	O
the	O
antithrombin	O
Cambridge	O
II	O
mutation	O
(	O
6	O
%	O
)	O
.	O

The	O
current	O
study	O
reports	O
several	O
novel	O
SERPINC1	O
mutations	O
,	O
thereby	O
adding	O
to	O
our	O
knowledge	O
of	O
the	O
molecular	O
background	O
of	O
antithrombin	O
deficiency	O
.	O

Finally	O
,	O
our	O
results	O
point	O
out	O
the	O
importance	O
of	O
future	O
research	O
outside	O
the	O
conventional	O
SERPINC1	O
gene	O
approach	O
.	O

Control	O
of	O
Kir	O
channel	O
gating	O
by	O
cytoplasmic	O
domain	O
interface	O
interactions	O
.	O

Inward	O
rectifier	O
potassium	O
(	O
Kir	O
)	O
channels	O
are	O
expressed	O
in	O
almost	O
all	O
mammalian	O
tissues	O
and	O
play	O
critical	O
roles	O
in	O
the	O
control	O
of	O
excitability	O
.	O

Pancreatic	O
ATP	O
-	O
sensitive	O
K	O
(	O
KATP	O
)	O
channels	O
are	O
key	O
regulators	O
of	O
insulin	O
secretion	O
and	O
comprise	O
Kir6.2	O
subunits	O
coupled	O
to	O
sulfonylurea	O
receptors	O
.	O

Because	O
these	O
channels	O
are	O
reversibly	O
inhibited	O
by	O
cytoplasmic	O
ATP	O
,	O
they	O
link	O
cellular	O
metabolism	O
with	O
membrane	O
excitability	O
.	O

Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
the	O
pore	O
-	O
forming	O
Kir6.2	B-Gene
subunit	O
cause	O
congenital	B-Disease
hyperinsulinism	I-Disease
as	O
a	O
result	O
of	O
diminished	B-NegReg
channel	B-MPA
activity	I-MPA
.	O

Here	O
,	O
we	O
show	O
that	O
several	O
disease	O
mutations	B-Var
,	O
which	O
disrupt	B-NegReg
intersubunit	B-CPA
salt	I-CPA
bridges	I-CPA
at	O
the	O
interface	O
of	O
the	O
cytoplasmic	O
domains	O
(	O
CD	O
-	O
I	O
)	O
of	O
adjacent	O
subunits	O
,	O
induce	O
loss	B-NegReg
of	O
channel	B-MPA
activity	I-MPA
via	O
a	O
novel	O
channel	O
behavior	O
:	O
after	O
ATP	O
removal	O
,	O
channels	O
open	O
but	O
then	O
rapidly	O
inactivate	O
.	O

Re	O
-	O
exposure	O
to	O
inhibitory	O
ATP	O
causes	O
recovery	O
from	O
this	O
inactivation	O
.	O

Inactivation	O
can	O
be	O
abolished	O
by	O
application	O
of	O
phosphatidylinositol-4,5-bisphosphate	O
(	O
PIP2	O
)	O
to	O
the	O
cytoplasmic	O
face	O
of	O
the	O
membrane	O
,	O
an	O
effect	O
that	O
can	O
be	O
explained	O
by	O
a	O
simple	O
kinetic	O
model	O
in	O
which	O
PIP2	O
binding	O
competes	O
with	O
the	O
inactivation	O
process	O
.	O

Kir2.1	O
channels	O
contain	O
homologous	O
salt	O
bridges	O
,	O
and	O
we	O
find	O
that	O
mutations	O
that	O
disrupt	O
CD	O
-	O
I	O
interactions	O
in	O
Kir2.1	O
also	O
reduce	O
channel	O
activity	O
and	O
PIP2	O
sensitivity	O
.	O

Kir2.1	O
channels	O
also	O
contain	O
an	O
additional	O
CD	O
-	O
I	O
salt	O
bridge	O
that	O
is	O
not	O
present	O
in	O
Kir6.2	O
channels	O
.	O

Introduction	O
of	O
this	O
salt	O
bridge	O
into	O
Kir6.2	O
partially	O
rescues	O
inactivating	O
mutants	O
from	O
the	O
phenotype	O
.	O

These	O
results	O
indicate	O
that	O
the	O
stability	O
of	O
the	O
intersubunit	O
CD	O
-	O
I	O
is	O
a	O
major	O
determinant	O
of	O
the	O
inactivation	O
process	O
in	O
Kir6.2	O
and	O
may	O
control	O
gating	O
in	O
other	O
Kir	O
channels	O
.	O

Patient	O
-	O
specific	O
induced	O
pluripotent	O
stem	O
cells	O
to	O
evaluate	O
the	O
pathophysiology	O
of	O
TRNT1-associated	O
Retinitis	O
pigmentosa	O
.	O

Retinitis	B-Disease
pigmentosa	I-Disease
(	O
RP	O
)	O
is	O
a	O
heterogeneous	O
group	O
of	O
monogenic	O
disorders	O
characterized	O
by	O
progressive	O
death	O
of	O
the	O
light	O
-	O
sensing	O
photoreceptor	O
cells	O
of	O
the	O
outer	O
neural	O
retina	O
.	O

We	O
recently	O
identified	O
novel	O
hypomorphic	O
mutations	B-Var
in	O
the	O
tRNA	O
Nucleotidyl	O
Transferase	O
,	O
CCA	O
-	O
Adding	O
1	O
(	B-Gene
TRNT1	I-Gene
)	I-Gene
gene	O
that	O
cause	B-Reg
early	O
-	O
onset	O
RP	B-Disease
.	O

To	O
model	O
this	O
disease	O
in	O
vitro	O
,	O
we	O
generated	O
patient	O
-	O
specific	O
iPSCs	O
and	O
iPSC	O
-	O
derived	O
retinal	O
organoids	O
from	O
dermal	O
fibroblasts	O
of	O
patients	O
with	O
molecularly	O
confirmed	O
TRNT1-associated	O
RP	O
.	O

Pluripotency	O
was	O
confirmed	O
using	O
rt	O
-	O
PCR	O
,	O
immunocytochemistry	O
,	O
and	O
a	O
TaqMan	O
Scorecard	O
Assay	O
.	O

Mutations	B-Var
in	O
TRNT1	B-Gene
caused	O
reduced	B-NegReg
levels	B-MPA
of	I-MPA
full	I-MPA
-	I-MPA
length	I-MPA
TRNT1	B-Gene
protein	B-Protein
and	O
expression	B-MPA
of	I-MPA
a	I-MPA
truncated	I-MPA
smaller	I-MPA
protein	B-Protein
in	O
both	O
patient	O
-	O
specific	O
iPSCs	O
and	O
iPSC	O
-	O
derived	O
retinal	O
organoids	O
.	O

Patient	O
-	O
specific	O
iPSCs	O
and	O
iPSC	O
-	O
derived	O
retinal	O
organoids	O
exhibited	O
a	O
deficit	O
in	O
autophagy	O
,	O
as	O
evidenced	O
by	O
aberrant	O
accumulation	O
of	O
LC3-II	O
and	O
elevated	O
levels	O
of	O
oxidative	O
stress	O
.	O

Autologous	O
stem	O
cell	O
-	O
based	O
disease	O
modeling	O
will	O
provide	O
a	O
platform	O
for	O
testing	O
multiple	O
avenues	O
of	O
treatment	O
in	O
patients	O
suffering	O
from	O
TRNT1-associated	O
RP	O
.	O

Gain	B-Var
-	I-Var
of	I-Var
-	I-Var
function	I-Var
p53	B-Gene
activates	B-PosReg
multiple	O
signaling	B-Pathway
pathways	I-Pathway
to	O
induce	B-PosReg
oncogenicity	B-CPA
in	O
lung	B-Disease
cancer	I-Disease
cells	O
.	O

Gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
(	O
GOF	O
)	O
mutants	B-Var
of	O
p53	B-Gene
upregulate	B-PosReg
genes	B-Gene
implicated	B-Reg
in	O
cell	B-CPA
proliferation	I-CPA
and	O
oncogenesis	B-CPA
.	O

Here	O
,	O
we	O
report	O
that	O
GOF	B-Var
p53	B-Gene
induces	O
tumorigenicity	O
through	O
simultaneous	O
activation	B-PosReg
of	O
key	B-Pathway
oncogenic	I-Pathway
pathways	I-Pathway
including	O
those	O
controlling	O
putative	O
tumor	O
-	O
initiating	O
cell	O
functions	O
.	O

We	O
determined	O
that	O
in	O
cells	O
expressing	O
p53-R273H	B-Var
,	O
GOF	O
p53	O
simultaneously	O
upregulates	B-PosReg
genes	O
from	O
multiple	B-Pathway
signaling	I-Pathway
pathways	I-Pathway
by	O
recognizing	O
promoters	O
containing	O
distinct	O
transcription	O
factor	O
(	O
TF	O
)	O
binding	O
sites	O
.	O

Our	O
analytical	O
data	O
support	O
a	O
model	O
in	O
which	O
GOF	B-Var
p53	B-Gene
complexes	O
with	O
two	O
TFs	O
on	O
the	O
promoter	O
-	O
a	O
mediator	O
protein	O
,	O
Med17	O
,	O
and	O
a	O
histone	O
acetyl	O
transferase	O
,	O
activating	B-PosReg
histone	B-MPA
acetylation	I-MPA
-	I-MPA
and	I-MPA
enhances	B-PosReg
gene	B-MPA
expression	I-MPA
to	O
signal	O
cell	O
proliferation	O
and	O
oncogenesis	O
.	O

Thus	O
,	O
therapeutic	O
inhibition	O
of	O
one	O
GOF	O
p53-induced	O
pathway	O
would	O
be	O
insufficient	O
to	O
prevent	O
tumor	O
growth	O
as	O
the	O
oncoprotein	O
activates	O
a	O
multitude	O
of	O
parallel	O
pathways	O
.	O

This	O
discovery	O
suggests	O
enormous	O
selection	O
advantage	O
for	O
cancer	O
cells	O
with	O
GOF	O
p53	O
to	O
induce	O
oncogenic	O
growth	O
,	O
highlighting	O
the	O
problems	O
of	O
cancer	O
therapy	O
.	O

Hand	O
eczema	O
,	O
atopic	O
dermatitis	O
and	O
filaggrin	O
mutations	O
in	O
adult	O
Danes	O
:	O
a	O
registry	O
-	O
based	O
study	O
assessing	O
risk	O
of	O
disability	O
pension	O
.	O

BACKGROUND	O
:	O
Atopic	O
dermatitis	O
and	O
hand	O
eczema	O
often	O
impair	O
the	O
ability	O
of	O
people	O
to	O
work	O
.	O

Only	O
a	O
few	O
studies	O
have	O
investigated	O
whether	O
individuals	O
with	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
filaggrin	O
gene	O
(	B-Gene
FLG	I-Gene
)	I-Gene
mutations	B-Var
,	O
who	O
often	O
have	O
severe	O
and	O
early	O
onset	O
of	O
dermatitis	B-Disease
,	O
experience	O
occupational	O
consequences	O
.	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
personal	O
consequences	O
of	O
having	O
atopic	O
dermatitis	O
and/or	O
hand	O
eczema	O
and	O
FLG	O
mutations	O
.	O

METHOD	O
:	O
Adult	O
Danes	O
from	O
the	O
general	O
population	O
(	O
n	O
=	O
3247	O
)	O
and	O
patients	O
with	O
atopic	O
dermatitis	O
and/or	O
hand	O
eczema	O
(	O
n	O
=	O
496	O
)	O
were	O
genotyped	O
for	O
common	O
FLG	O
mutations	O
,	O
and	O
completed	O
a	O
questionnaire	O
about	O
skin	O
symptoms	O
and	O
hand	O
eczema	O
.	O

Socioeconomic	O
variables	O
,	O
including	O
disability	O
pension	O
,	O
and	O
information	O
on	O
work	O
in	O
risk	O
occupations	O
were	O
retrieved	O
from	O
national	O
registries	O
.	O

The	O
reasons	O
for	O
granting	O
disability	O
pension	O
were	O
unknown	O
.	O

RESULTS	O
:	O
Disability	O
pension	O
was	O
associated	O
with	O
hand	O
eczema	O
in	O
the	O
general	O
population	O
,	O
especially	O
among	O
individuals	O
with	O
a	O
history	O
of	O
atopic	O
dermatitis	O
.	O

Moreover	O
,	O
self	O
-	O
reported	O
hand	O
eczema	O
and	O
atopic	O
dermatitis	O
were	O
associated	O
with	O
particularly	O
high	O
risk	O
of	O
disability	O
pension	O
among	O
FLG	O
mutation	O
carriers	O
[	O
odds	O
ratio	O
(	O
OR	O
)	O
4.02	O
and	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
:	O
1.15	O
-	O
14.11	O
;	O
and	O
OR	O
6.01	O
and	O
95%CI	O
:	O
2.37	O
-	O
15.34	O
,	O
respectively	O
]	O
.	O

Furthermore	O
,	O
60	O
%	O
of	O
the	O
FLG	O
mutation	O
carriers	O
with	O
atopic	O
dermatitis	O
who	O
developed	O
hand	O
eczema	O
had	O
experienced	O
symptoms	O
before	O
adulthood	O
.	O

CONCLUSION	O
:	O
In	O
the	O
general	O
population	O
,	O
self	O
-	O
reported	O
hand	O
eczema	O
and	O
atopic	O
dermatitis	O
,	O
particularly	O
in	O
individuals	O
with	O
a	O
genetically	O
impaired	O
skin	O
barrier	O
,	O
were	O
associated	O
with	O
disability	O
pension	O
,	O
suggesting	O
that	O
FLG	B-Gene
mutations	B-Var
carriers	B-Reg
with	I-Reg
a	O
history	O
of	O
atopic	B-Disease
dermatitis	I-Disease
and	O
hand	B-Disease
eczema	I-Disease
could	O
benefit	O
from	O
early	O
attention	O
with	O
respect	O
to	O
choice	O
of	O
occupation	O
.	O

ATM	O
Gene	O
Mutation	O
Detection	O
Techniques	O
and	O
Functional	O
Analysis	O
.	O

Ataxia	B-Disease
Telangiectasia	I-Disease
(	O
A	O
-	O
T	O
)	O
is	O
caused	O
by	O
biallelic	O
inactivation	B-NegReg
of	O
the	O
Ataxia	O
Telangiectasia	O
Mutated	O
(	B-Gene
ATM	I-Gene
)	I-Gene
gene	O
,	O
due	O
to	O
nonsense	B-Var
or	I-Var
missense	I-Var
mutations	I-Var
,	O
small	O
insertions	O
/	O
deletions	O
(	B-Var
indels	I-Var
)	I-Var
,	O
splicing	B-Var
alterations	I-Var
,	O
and	O
large	B-Var
genomic	I-Var
rearrangements	I-Var
.	O

After	O
establishing	O
A	O
-	O
T	O
clinical	O
diagnosis	O
,	O
a	O
molecular	O
confirmation	O
is	O
needed	O
,	O
based	O
on	O
the	O
detection	O
of	O
one	O
of	O
these	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
at	O
least	O
one	O
allele	O
.	O

In	O
most	O
cases	O
,	O
the	O
pathogenicity	O
of	O
the	O
detected	O
mutations	O
is	O
sufficient	O
to	O
make	O
a	O
definitive	O
diagnosis	O
.	O

More	O
rarely	O
,	O
mutations	O
of	O
unknown	O
consequences	O
are	O
identified	O
and	O
direct	O
biological	O
analyses	O
are	O
required	O
to	O
establish	O
their	O
pathogenic	O
characters	O
.	O

In	O
such	O
cases	O
,	O
complementary	O
analyses	O
of	O
ATM	O
expression	O
,	O
localization	O
,	O
and	O
activity	O
allow	O
fine	O
characterization	O
of	O
these	O
mutations	O
and	O
facilitate	O
A	O
-	O
T	O
diagnosis	O
.	O

Here	O
,	O
we	O
present	O
genetic	O
and	O
biochemical	O
protocols	O
currently	O
used	O
in	O
the	O
laboratory	O
that	O
have	O
proven	O
to	O
be	O
highly	O
accurate	O
,	O
reproducible	O
,	O
and	O
quantitative	O
.	O

We	O
also	O
provide	O
additional	O
discussion	O
on	O
the	O
critical	O
points	O
of	O
the	O
techniques	O
presented	O
here	O
.	O

Truncating	O
mutations	O
in	O
SPAST	O
patients	O
are	O
associated	O
with	O
a	O
high	O
rate	O
of	O
psychiatric	O
comorbidities	O
in	O
hereditary	O
spastic	O
paraplegia	O
.	O

BACKGROUND	O
:	O
The	O
hereditary	B-Disease
spastic	I-Disease
paraplegias	I-Disease
(	O
HSPs	O
)	O
are	O
a	O
rare	O
and	O
heterogeneous	O
group	O
of	O
neurodegenerative	O
disorders	O
that	O
are	O
clinically	O
characterised	O
by	O
progressive	O
lower	O
limb	O
spasticity	O
.	O

They	O
are	O
classified	O
as	O
either	O
'	O
pure	O
'	O
or	O
'	O
complex	O
'	O
where	O
spastic	O
paraplegia	O
is	O
complicated	O
with	O
additional	O
neurological	O
features	O
.	O

Mutations	B-Var
in	O
the	O
spastin	O
gene	O
(	B-Gene
SPAST	I-Gene
)	I-Gene
are	O
the	O
most	O
common	O
cause	B-Reg
of	O
HSP	B-Disease
and	O
typically	O
present	O
with	O
a	O
pure	O
form	O
.	O

METHODS	O
:	O
We	O
assessed	O
in	O
detail	O
the	O
phenotypic	O
and	O
genetic	O
spectrum	O
of	O
SPAST	O
-	O
related	O
HSP	O
focused	O
on	O
118	O
patients	O
carrying	O
SPAST	O
mutations	O
.	O

RESULTS	O
:	O
This	O
study	O
,	O
one	O
of	O
the	O
largest	O
cohorts	O
of	O
genetically	O
confirmed	O
spastin	O
patients	O
to	O
date	O
,	O
contributes	O
with	O
the	O
discovery	O
of	O
a	O
significant	O
number	O
of	O
novel	O
SPAST	O
mutations	O
.	O

Our	O
data	O
reveal	O
a	O
high	O
rate	O
of	O
complex	O
cases	O
(	O
25	O
%	O
)	O
,	O
with	O
psychiatric	O
disorders	O
among	O
the	O
most	O
common	O
comorbidity	O
(	O
10	O
%	O
of	O
all	O
SPASTpatients	O
)	O
.	O

Further	O
,	O
we	O
identify	O
a	O
genotype	O
-	O
phenotype	O
correlation	O
between	O
patients	O
carrying	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
SPAST	B-Gene
and	O
the	O
presence	O
of	O
psychiatric	B-Disease
disorders	I-Disease
.	O

R202Q	B-Var
/	I-Var
M694V	I-Var
as	O
novel	O
MEFV	B-Gene
gene	O
mutations	O
in	B-Reg
chronic	B-Disease
periodontitis	I-Disease
and	O
familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
.	O

BACKGROUND	O
AND	O
OBJECTIVE	O
:	O
Familial	O
Mediterranean	O
fever	O
(	O
FMF	O
)	O
and	O
chronic	O
periodontitis	O
are	O
inflammatory	O
diseases	O
leading	O
to	O
an	O
increase	O
in	O
the	O
number	O
of	O
inflammasomes	O
.	O

To	O
date	O
,	O
no	O
published	O
studies	O
have	O
reported	O
on	O
mutations	O
in	O
the	O
Mediterranean	O
fever	O
(	O
MEFV	O
)	O
gene	O
in	O
patients	O
with	O
chronic	O
periodontitis	O
,	O
although	O
the	O
roles	B-Reg
of	O
MEFV	B-Gene
gene	O
mutations	B-Var
in	O
FMF	B-Disease
and	O
FMF	B-Disease
-	I-Disease
associated	I-Disease
amyloidosis	I-Disease
(	O
FMF	O
-	O
A	O
)	O
are	O
well	O
known	O
.	O

Therefore	O
,	O
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
frequencies	O
of	O
MEFV	O
gene	O
mutations	O
and	O
serum	O
amyloid	O
A	O
(	O
SAA	O
)	O
and	O
high	O
-	O
sensitivity	O
C	O
-	O
reactive	O
protein	O
(	O
hs	O
-	O
CRP	O
)	O
levels	O
in	O
patients	O
with	O
chronic	O
periodontitis	O
,	O
FMF	O
and	O
FMF	O
-	O
A.	O
MATERIAL	O
AND	O
METHODS	O
:	O
The	O
study	O
population	O
included	O
122	O
patients	O
with	O
FMF	O
and	O
128	O
subjects	O
who	O
were	O
systemically	O
healthy	O
.	O

Clinical	O
periodontal	O
parameters	O
,	O
including	O
the	O
plaque	O
index	O
,	O
gingival	O
index	O
,	O
probing	O
pocket	O
depth	O
,	O
clinical	O
attachment	O
level	O
and	O
percentage	O
of	O
bleeding	O
on	O
probing	O
were	O
recorded	O
.	O

Blood	O
samples	O
were	O
obtained	O
from	O
patients	O
with	O
FMF	O
and	O
systemically	O
healthy	O
controls	O
,	O
and	O
all	O
mutations	O
located	O
on	O
exons	O
2	O
and	O
10	O
of	O
the	O
MEFV	O
gene	O
were	O
analyzed	O
by	O
DNA	O
Sanger	O
Sequencing	O
,	O
which	O
is	O
the	O
gold	O
standard	O
.	O

SAA	O
and	O
high	O
-	O
sensitive	O
CRP	O
levels	O
were	O
also	O
assessed	O
.	O

RESULTS	O
:	O
Mean	O
gingival	O
index	O
,	O
percentage	O
of	O
bleeding	O
on	O
probing	O
,	O
probing	O
pocket	O
depth	O
and	O
clinical	O
attachment	O
level	O
,	O
and	O
the	O
levels	O
of	O
SAA	O
and	O
hs	O
-	O
CRP	O
were	O
higher	O
in	O
the	O
FMF	O
-	O
A	O
group	O
than	O
those	O
in	O
the	O
FMF	O
and	O
control	O
groups	O
.	O

The	O
two	O
most	O
relevant	O
mutations	O
in	O
patients	O
with	O
FMF	O
were	O
heterozygous	O
M694V	O
(	O
46.2	O
%	O
)	O
,	O
and	O
heterozygous	O
R202Q	O
(	O
32.7	O
%	O
)	O
.	O

The	O
frequencies	O
of	O
the	O
homozygous	O
M694V	O
and	O
R202Q	O
mutations	O
in	O
the	O
FMF	O
-	O
A	O
group	O
were	O
53.8	O
%	O
and	O
46.1	O
%	O
,	O
respectively	O
.	O

The	O
complex	O
R202Q	O
/	O
M694V	O
homozygous	O
state	O
led	O
to	O
an	O
increased	O
risk	O
of	O
chronic	O
periodontitis	O
(	O
odds	O
ratio	O
:	O
3.6	O
)	O
,	O
and	O
FMF	O
-	O
A	O
(	O
odds	O
ratio	O
:	O
7.6	O
)	O
.	O

CONCLUSION	O
:	O
This	O
is	O
the	O
first	O
study	O
to	O
report	O
the	O
R202Q	O
mutation	O
in	O
patients	O
with	O
periodontitis	O
.	O

Furthermore	O
,	O
the	O
MEFV	O
gene	O
-	O
mediated	O
inflammatory	O
pathway	O
increased	O
serum	O
acute	O
phase	O
reactants	O
,	O
and	O
the	O
changes	O
in	O
the	O
R202Q	B-Var
and	O
M694V	B-Var
could	O
play	B-Reg
a	I-Reg
role	I-Reg
in	O
inflammatory	B-Disease
-	I-Disease
genetic	I-Disease
diseases	I-Disease
,	O
such	O
as	O
FMF	O
,	O
FMF	O
-	O
associated	O
amyloidosis	O
and	O
chronic	O
periodontitis	O
.	O

Linking	O
the	O
degree	O
of	O
virilization	O
in	O
females	O
with	O
congenital	O
adrenal	O
hyperplasia	O
to	O
genotype	O
.	O

Mutations	B-Var
of	O
CYP21A2	B-Gene
variably	O
decrease	B-NegReg
21-hydroxylase	B-Enzyme
activity	B-MPA
and	O
result	B-Reg
in	I-Reg
a	O
spectrum	O
of	O
disease	O
expressions	O
in	O
patients	O
with	O
congenital	B-Disease
adrenal	I-Disease
hyperplasia	I-Disease
(	O
CAH	O
)	O
.	O

We	O
examined	O
the	O
association	O
between	O
CYP21A2	O
mutations	O
and	O
virilization	O
(	O
Prader	O
score	O
)	O
in	O
females	O
with	O
CAH	O
.	O

The	O
study	O
population	O
included	O
187	O
CAH	B-Disease
females	O
with	B-Reg
fully	O
characterized	O
CYP21A2	B-Gene
mutations	B-Var
.	O

One	O
hundred	O
fifty	O
-	O
eight	O
patients	O
were	O
sorted	O
into	O
groups	O
by	O
expected	O
enzyme	O
activity	O
(	O
percent	O
of	O
normal	O
activity	O
)	O
of	O
the	O
less	O
severely	O
affected	O
allele	O
:	O
(	O
A	O
)	O
null	O
,	O
0	O
%	O
;	O
(	O
B	O
)	O
I2	O
G	O
,	O
1	O
%	O
;	O
(	O
C	O
)	O
I172N	O
,	O
2	O
%	O
;	O
and	O
(	O
D	O
)	O
V281L	O
,	O
>	O
2	O
%	O
.	O

We	O
observed	O
an	O
inverse	O
relationship	O
between	O
virilization	O
and	O
residual	O
enzyme	O
activity	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Subjects	O
in	O
group	O
A	O
or	O
B	O
had	O
a	O
significantly	O
higher	O
likelihood	O
(	O
unadjusted	O
odds	O
ratio	O
:	O
16	O
;	O
P	O
<	O
0.001	O
)	O
of	O
developing	O
severe	O
virilization	O
compared	O
with	O
those	O
in	O
group	O
C.	O
Surprisingly	O
,	O
24	O
%	O
of	O
group	O
D	O
patients	O
,	O
whose	O
mutation	O
is	O
usually	O
associated	O
with	O
nonclassical	O
(	O
NC	O
)	O
CAH	O
,	O
had	O
severe	O
virilization	O
.	O

Among	O
subjects	O
with	O
the	O
NC	O
P30L	O
mutation	O
,	O
66	O
%	O
expressed	O
unexpected	O
virilization	O
.	O

Virilization	O
,	O
usually	O
leading	O
to	O
extensive	O
reconstructive	O
surgery	O
,	O
is	O
highly	O
likely	O
in	O
patients	O
with	O
null	O
or	O
I2	O
G	O
mutations	O
;	O
however	O
,	O
NC	O
mutations	O
(	O
P30L	O
/	O
V281L	O
)	O
may	O
also	O
lead	O
to	O
unexpected	O
virilization	O
.	O

These	O
findings	O
have	O
implications	O
for	O
prenatal	O
counseling	O
and	O
highlight	O
the	O
need	O
for	O
additional	O
investigations	O
into	O
other	O
factors	O
that	O
influence	O
virilization	O
in	O
CAH	O
.	O

A	O
Novel	O
Missense	B-Var
Mutation	I-Var
in	O
Peripheral	B-Protein
Myelin	I-Protein
Protein-22	I-Protein
Causes	B-Reg
Charcot	B-Disease
-	I-Disease
Marie	I-Disease
-	I-Disease
Tooth	I-Disease
Disease	I-Disease
.	O

BACKGROUND	O
:	O
Charcot	O
-	O
Marie	O
-	O
Tooth	O
disease	O
(	O
CMT	O
)	O
is	O
the	O
most	O
common	O
inherited	O
peripheral	O
neuropathy	O
.	O

A	O
great	O
number	O
of	O
causative	O
genes	O
have	O
been	O
described	O
in	O
CMT	O
,	O
and	O
among	O
them	O
,	O
the	O
heterozygous	O
duplication	O
of	O
peripheral	O
myelin	O
protein-22	O
(	O
PMP22	O
)	O
is	O
the	O
major	O
cause	O
.	O

Although	O
the	O
missense	B-Var
mutation	I-Var
in	O
PMP22	B-Gene
is	O
rarely	O
reported	O
,	O
it	O
has	O
been	O
demonstrated	O
to	O
be	O
associated	B-Reg
with	O
CMT	B-Disease
.	O

This	O
study	O
described	O
a	O
novel	O
missense	B-Var
mutation	I-Var
of	O
PMP22	B-Gene
in	B-Reg
a	O
Chinese	O
family	O
with	O
CMT	B-Disease
phenotype	O
.	O

METHODS	O
:	O
Targeted	O
next	O
-	O
generation	O
sequencing	O
(	O
NGS	O
)	O
was	O
used	O
to	O
screen	O
the	O
causative	O
genes	O
in	O
a	O
family	O
featured	O
with	O
an	O
autosomal	O
dominant	O
demyelinating	O
form	O
of	O
CMT	O
.	O

The	O
potential	O
variants	O
identified	O
by	O
targeted	O
NGS	O
were	O
verified	O
by	O
Sanger	O
sequencing	O
and	O
classified	O
according	O
to	O
the	O
American	O
College	O
of	O
Medical	O
Genetics	O
and	O
Genomics	O
standards	O
and	O
guidelines	O
.	O

Further	O
cell	O
transfection	O
studies	O
were	O
performed	O
to	O
characterize	O
the	O
function	O
of	O
the	O
novel	O
variant	O
.	O

RESULTS	O
:	O
Using	O
targeted	O
NGS	O
,	O
a	O
novel	O
heterozygous	O
missense	O
variant	O
in	O
PMP22	O
(	O
c.320G	O
>	O
A	O
,	O
p	O
.	O
G107D	O
)	O
was	O
identified	O
.	O

In	O
vitro	O
cell	O
functional	O
studies	O
revealed	O
that	O
mutant	O
PMP22	B-Gene
protein	B-Protein
carrying	O
p	B-Var
.	I-Var
G107D	I-Var
mutation	O
lost	B-NegReg
the	O
ability	B-CPA
to	I-CPA
reach	I-CPA
the	I-CPA
plasma	I-CPA
membrane	I-CPA
,	O
was	O
mainly	O
retained	O
in	O
the	O
endoplasmic	O
reticulum	O
,	O
and	O
induced	B-Reg
cell	B-CPA
apoptosis	I-CPA
.	O

CONCLUSIONS	O
:	O
This	O
study	O
supported	O
the	O
notion	O
that	O
missense	B-Var
mutations	I-Var
in	O
PMP22	B-Gene
give	O
rise	O
to	O
a	O
CMT	B-Disease
phenotype	O
,	O
possibly	O
through	O
a	O
toxic	B-PosReg
gain	I-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mechanism	O
.	O

[	O
Genetic	O
and	O
prenatal	O
diagnosis	O
for	O
a	O
haemophilia	B-Disease
A	I-Disease
family	O
with	B-Reg
two	O
novel	O
mutations	B-Var
of	O
F8	B-Gene
gene	O
]	O
.	O

OBJECTIVE	O
:	O
To	O
conduct	O
genetic	O
diagnosis	O
for	O
a	O
family	O
affected	O
with	O
hamophilia	O
A.	O
METHODS	O
:	O
Potential	O
mutations	O
of	O
the	O
F8	O
gene	O
were	O
analyzed	O
with	O
PCR	O
and	O
Sanger	O
sequencing	O
.	O

Carriers	O
of	O
the	O
mutation	O
were	O
identified	O
through	O
linkage	O
analysis	O
using	O
short	O
tandem	O
repeat	O
(	O
STR	O
)	O
markers	O
.	O

Suspected	O
mutations	O
were	O
verified	O
among	O
100	O
healthy	O
controls	O
to	O
rule	O
out	O
genetic	O
polymorphism	O
.	O

Prenatal	O
diagnosis	O
was	O
provided	O
based	O
on	O
the	O
above	O
results	O
.	O

RESULTS	O
:	O
Sequencing	O
analysis	O
has	O
identified	O
two	O
mutations	O
,	O
c.1	O
A	O
>	O
T	O
and	O
c.4	O
C	O
>	O
T	O
,	O
which	O
have	O
replaced	O
the	O
start	O
codon	O
(	O
ATG	O
)	O
with	O
leucine	O
(	O
TTG	O
)	O
and	O
glutamine	O
(	O
GAA	O
)	O
with	O
the	O
stop	O
codon	O
(	O
TAA	O
)	O
,	O
respectively	O
.	O

The	O
same	O
mutations	O
were	O
not	O
found	O
among	O
the	O
100	O
healthy	O
controls	O
.	O

The	O
patient	O
's	O
mother	O
and	O
sister	O
were	O
heterozygous	O
for	O
the	O
same	O
mutations	O
.	O

Upon	O
prenatal	O
diagnosis	O
,	O
the	O
fetus	O
was	O
determined	O
as	O
a	O
male	O
and	O
did	O
not	O
harbor	O
the	O
above	O
mutations	O
.	O

Linkage	O
analysis	O
also	O
confirmed	O
that	O
the	O
fetus	O
has	O
inherited	O
the	O
non	O
-	O
risk	O
X	O
chromosome	O
from	O
his	O
maternal	O
grandfather	O
.	O

CONCLUSION	O
:	O
Detection	O
of	O
pathogenic	O
mutations	O
can	O
enable	O
prenatal	O
diagnosis	O
for	O
the	O
disease	O
.	O

Comprehensive	O
analysis	O
for	O
genetic	O
diagnosis	O
of	O
Dystrophinopathies	O
in	O
Japan	O
.	O

BACKGROUND	O
:	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
DMD	O
)	O
is	O
the	O
most	O
common	O
disease	O
in	O
children	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
DMD	B-Gene
gene	O
,	O
and	O
DMD	O
and	O
Becker	O
muscular	O
dystrophy	O
(	O
BMD	O
)	O
are	O
collectively	O
called	O
dystrophinopathies	O
.	O

Dystrophinopathies	O
show	O
a	O
complex	O
mutation	O
spectrum	O
.	O

The	O
importance	O
of	O
mutation	O
databases	O
,	O
with	O
clinical	O
phenotypes	O
and	O
protein	O
studies	O
of	O
patients	O
,	O
is	O
increasingly	O
recognized	O
as	O
a	O
reference	O
for	O
genetic	O
diagnosis	O
and	O
for	O
the	O
development	O
of	O
gene	O
therapy	O
.	O

METHODS	O
:	O
We	O
used	O
the	O
data	O
from	O
the	O
Japanese	O
Registry	O
of	O
Muscular	O
Dystrophy	O
(	O
Remudy	O
)	O
compiled	O
during	O
from	O
July	O
2009	O
to	O
March	O
2017	O
,	O
and	O
reviewed	O
1497	O
patients	O
with	O
dystrophinopathies	O
.	O

RESULTS	O
:	O
The	O
spectrum	O
of	O
identified	O
mutations	O
contained	O
exon	O
deletions	O
(	O
61	O
%	O
)	O
,	O
exon	O
duplications	O
(	O
13	O
%	O
)	O
,	O
nonsense	O
mutations	O
(	O
13	O
%	O
)	O
,	O
small	O
deletions	O
(	O
5	O
%	O
)	O
,	O
small	O
insertions	O
(	O
3	O
%	O
)	O
,	O
splice	O
-	O
site	O
mutations	O
(	O
4	O
%	O
)	O
,	O
and	O
missense	O
mutations	O
(	O
1	O
%	O
)	O
.	O

Exon	O
deletions	O
were	O
found	O
most	O
frequently	O
in	O
the	O
central	O
hot	O
spot	O
region	O
between	O
exons	O
45	O
-	O
52	O
(	O
42	O
%	O
)	O
,	O
and	O
most	O
duplications	O
were	O
detected	O
in	O
the	O
proximal	O
hot	O
spot	O
region	O
between	O
exons	O
3	O
-	O
25	O
(	O
47	O
%	O
)	O
.	O

In	O
the	O
371	O
patients	O
harboring	O
a	O
small	O
mutation	O
,	O
194	O
mutations	O
were	O
reported	O
and	O
187	O
mutations	O
were	O
unreported	O
.	O

CONCLUSIONS	O
:	O
We	O
report	O
the	O
largest	O
dystrophinopathies	O
mutation	O
dataset	O
in	O
Japan	O
from	O
a	O
national	O
patient	O
registry	O
,	O
"	O
Remudy	O
"	O
.	O

This	O
dataset	O
provides	O
a	O
useful	O
reference	O
to	O
support	O
the	O
genetic	O
diagnosis	O
and	O
treatment	O
of	O
dystrophinopathy	O
.	O

A	O
Defective	O
mRNA	O
Cleavage	O
and	O
Polyadenylation	O
Complex	O
Facilitates	O
Expansions	O
of	O
Transcribed	O
(	O
GAA)n	O
Repeats	O
Associated	O
with	O
Friedreich	O
's	O
Ataxia	O
.	O

Expansions	O
of	O
microsatellite	O
repeats	O
are	O
responsible	O
for	O
numerous	O
hereditary	O
diseases	O
in	O
humans	O
,	O
including	O
myotonic	O
dystrophy	O
and	O
Friedreich	O
's	O
ataxia	O
.	O

Whereas	O
the	O
length	O
of	O
an	O
expandable	O
repeat	O
is	O
the	O
main	O
factor	O
determining	O
disease	O
inheritance	O
,	O
recent	O
data	O
point	O
to	O
genomic	O
trans	O
modifiers	O
that	O
can	O
impact	O
the	O
likelihood	O
of	O
expansions	O
and	O
disease	O
progression	O
.	O

Detection	O
of	O
these	O
modifiers	O
may	O
lead	O
to	O
understanding	O
and	O
treating	O
repeat	O
expansion	O
diseases	O
.	O

Here	O
,	O
we	O
describe	O
a	O
method	O
for	O
the	O
rapid	O
,	O
genome	O
-	O
wide	O
identification	O
of	O
trans	O
modifiers	O
for	O
repeat	O
expansion	O
in	O
a	O
yeast	O
experimental	O
system	O
.	O

Using	O
this	O
method	O
,	O
we	O
found	O
that	O
missense	B-Var
mutations	I-Var
in	O
the	O
endoribonuclease	O
subunit	O
(	B-Gene
Ysh1	I-Gene
)	I-Gene
of	O
the	O
mRNA	O
cleavage	O
and	O
polyadenylation	O
complex	O
dramatically	O
increase	B-PosReg
the	B-MPA
rate	I-MPA
of	I-MPA
(	I-MPA
GAA)n	I-MPA
repeat	I-MPA
expansions	I-MPA
but	O
only	O
when	O
they	O
are	O
actively	O
transcribed	O
.	O

These	O
expansions	O
correlate	O
with	O
slower	B-NegReg
transcription	B-MPA
elongation	I-MPA
caused	O
by	O
the	O
ysh1	B-Gene
mutation	B-Var
.	O

These	O
results	O
reveal	O
an	O
interplay	O
between	O
RNA	O
processing	O
and	O
repeat	O
-	O
mediated	O
genome	O
instability	O
,	O
confirming	O
the	O
validity	O
of	O
our	O
approach	O
.	O

Diverse	O
phenotype	O
of	O
hypokalaemic	O
periodic	O
paralysis	O
within	O
a	O
family	O
.	O

Hypokalaemic	O
periodic	O
paralysis	O
typically	O
presents	O
with	O
intermittent	O
mild	O
-	O
to	O
-	O
moderate	O
weakness	O
lasting	O
hours	O
to	O
days	O
.	O

We	O
report	O
a	O
case	O
with	O
an	O
uncommon	O
phenotype	O
of	O
late	O
-	O
onset	O
myopathy	O
without	O
episodic	O
paralytic	O
attacks	O
.	O

Initial	O
work	O
-	O
up	O
including	O
muscle	O
biopsy	O
was	O
inconclusive	O
.	O

A	O
subsequent	O
review	O
of	O
the	O
right	O
deltoid	O
biopsy	O
,	O
long	O
exercise	O
testing	O
and	O
repeated	O
family	O
history	O
was	O
helpful	O
,	O
followed	O
by	O
appropriate	O
genetic	O
testing	O
.	O

We	O
identified	O
a	O
heterozygous	O
pathogenic	O
mutation	O
in	O
calcium	O
ion	O
channel	O
(	B-Var
CACNA1S	I-Var
:	I-Var
c.1583G	I-Var
>	I-Var
A	I-Var
p	I-Var
.	I-Var
Arg528His	I-Var
)	I-Var
causing	B-Reg
hypokalaemic	B-Disease
periodic	I-Disease
paralysis	I-Disease
.	O

Myopathy	O
can	O
present	O
without	O
episodic	O
paralysis	O
and	O
the	O
frequency	O
of	O
paralytic	O
episodes	O
does	O
not	O
correlate	O
well	O
with	O
the	O
development	O
and	O
progression	O
of	O
a	O
fixed	O
myopathy	O
.	O

Our	O
report	O
also	O
highlights	O
the	O
intrafamilial	O
phenotypic	O
variation	O
of	O
hypokalaemic	B-Disease
periodic	I-Disease
paralysis	I-Disease
secondary	O
to	B-Reg
a	O
CACNA1S	B-Gene
gene	O
mutation	B-Var
.	O

Genetic	O
anticipation	O
in	O
Swedish	O
Lynch	O
syndrome	O
families	O
.	O

Among	O
hereditary	O
colorectal	O
cancer	O
predisposing	O
syndromes	O
,	O
Lynch	B-Disease
syndrome	I-Disease
(	O
LS	O
)	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
DNA	O
mismatch	O
repair	O
genes	O
MLH1	B-Gene
,	O
MSH2	B-Gene
,	O
MSH6	B-Gene
or	O
PMS2	B-Gene
is	O
the	O
most	O
common	O
.	O

Patients	O
with	O
LS	O
have	O
an	O
increased	O
risk	O
of	O
early	O
onset	O
colon	O
and	O
endometrial	O
cancer	O
,	O
but	O
also	O
other	O
tumors	O
that	O
generally	O
have	O
an	O
earlier	O
onset	O
compared	O
to	O
the	O
general	O
population	O
.	O

However	O
,	O
age	O
at	O
first	O
primary	O
cancer	O
varies	O
within	O
families	O
and	O
genetic	O
anticipation	O
,	O
i.e.	O
decreasing	O
age	O
at	O
onset	O
in	O
successive	O
generations	O
,	O
has	O
been	O
suggested	O
in	O
LS	O
.	O

Anticipation	O
is	O
a	O
well	O
-	O
known	O
phenomenon	O
in	O
e.g	O
neurodegenerative	O
diseases	O
and	O
several	O
reports	O
have	O
studied	O
anticipation	O
in	O
heritable	O
cancer	O
.	O

The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
determine	O
whether	O
anticipation	O
can	O
be	O
shown	O
in	O
a	O
nationwide	O
cohort	O
of	O
Swedish	O
LS	O
families	O
referred	O
to	O
the	O
regional	O
departments	O
of	O
clinical	O
genetics	O
in	O
Lund	O
,	O
Stockholm	O
,	O
Linköping	O
,	O
Uppsala	O
and	O
Umeå	O
between	O
the	O
years	O
1990	O
-	O
2013	O
.	O

We	O
analyzed	O
a	O
homogenous	O
group	O
of	O
mutation	O
carriers	O
,	O
utilizing	O
information	O
from	O
both	O
affected	O
and	O
non	O
-	O
affected	O
family	O
members	O
.	O

In	O
total	O
,	O
239	O
families	O
with	O
a	O
mismatch	O
repair	O
gene	O
mutation	O
(	O
96	O
MLH1	O
families	O
,	O
90	O
MSH2	O
families	O
including	O
one	O
family	O
with	O
an	O
EPCAM	O
-	O
MSH2	O
deletion	O
,	O
39	O
MSH6	O
families	O
,	O
12	O
PMS2	O
families	O
,	O
and	O
2	O
MLH1+PMS2	O
families	O
)	O
comprising	O
1028	O
at	O
-	O
risk	O
carriers	O
were	O
identified	O
among	O
the	O
Swedish	O
LS	O
families	O
,	O
of	O
which	O
1003	O
mutation	O
carriers	O
had	O
available	O
follow	O
-	O
up	O
information	O
and	O
could	O
be	O
included	O
in	O
the	O
study	O
.	O

Using	O
a	O
normal	O
random	O
effects	O
model	O
(	O
NREM	O
)	O
we	O
estimate	O
a	O
2.1	O
year	O
decrease	O
in	O
age	O
of	O
diagnosis	O
per	O
generation	O
.	O

An	O
alternative	O
analysis	O
using	O
a	O
mixed	O
-	O
effects	O
Cox	O
proportional	O
hazards	O
model	O
(	O
COX	O
-	O
R	O
)	O
estimates	O
a	O
hazard	O
ratio	O
of	O
exp(0.171	O
)	O
,	O
or	O
about	O
1.19	O
,	O
for	O
age	O
of	O
diagnosis	O
between	O
consecutive	O
generations	O
.	O

LS	O
-	O
associated	O
gene	O
-	O
specific	O
anticipation	O
effects	O
are	O
evident	O
for	O
MSH2	O
(	O
2.6	O
years	O
/	O
generation	O
for	O
NREM	O
and	O
hazard	O
ratio	O
of	O
1.33	O
for	O
COX	O
-	O
R	O
)	O
and	O
PMS2	O
(	O
7.3	O
years	O
/	O
generation	O
and	O
hazard	O
ratio	O
of	O
1.86	O
)	O
.	O

The	O
estimated	O
anticipation	O
effects	O
for	O
MLH1	O
and	O
MSH6	O
are	O
smaller	O
.	O

EYS	O
mutation	O
update	O
:	O
In	O
silico	O
assessment	O
of	O
271	O
reported	O
and	O
26	O
novel	O
variants	O
in	O
patients	O
with	O
retinitis	O
pigmentosa	O
.	O

Mutations	B-Var
in	O
Eyes	O
shut	O
homolog	O
(	B-Gene
EYS	I-Gene
)	I-Gene
are	O
one	O
of	O
the	O
most	O
common	O
causes	B-Reg
of	O
autosomal	B-Disease
recessive	I-Disease
(	I-Disease
ar	I-Disease
)	I-Disease
retinitis	I-Disease
pigmentosa	I-Disease
(	O
RP	O
)	O
,	O
a	O
progressive	O
blinding	O
disorder	O
.	O

The	O
exact	O
function	O
of	O
the	O
EYS	O
protein	O
and	O
the	O
pathogenic	O
mechanisms	O
underlying	O
EYS	O
-	O
associated	O
RP	O
are	O
still	O
poorly	O
understood	O
,	O
which	O
hampers	O
the	O
interpretation	O
of	O
the	O
causality	O
of	O
many	O
EYS	O
variants	O
discovered	O
to	O
date	O
.	O

We	O
collected	O
all	O
reported	O
EYS	O
variants	O
present	O
in	O
377	O
arRP	O
index	O
cases	O
published	O
before	O
June	O
2017	O
,	O
and	O
uploaded	O
them	O
in	O
the	O
Leiden	O
Open	O
Variation	O
Database	O
(	O
www.LOVD.nl/EYS	O
)	O
.	O

We	O
also	O
describe	O
36	O
additional	O
index	O
cases	O
,	O
carrying	O
26	O
novel	O
variants	O
.	O

Of	O
the	O
297	O
unique	O
EYS	O
variants	O
identified	O
,	O
almost	O
half	O
(	O
n	O
=	O
130	O
)	O
are	O
predicted	O
to	O
result	O
in	O
premature	O
truncation	O
of	O
the	O
EYS	O
protein	O
.	O

Classification	O
of	O
all	O
variants	O
using	O
the	O
American	O
College	O
of	O
Medical	O
Genetics	O
and	O
Genomics	O
guidelines	O
revealed	O
that	O
the	O
predicted	O
pathogenicity	O
of	O
these	O
variants	O
cover	O
the	O
complete	O
spectrum	O
ranging	O
from	O
likely	O
benign	O
to	O
pathogenic	O
,	O
although	O
especially	O
missense	O
variants	O
largely	O
fall	O
in	O
the	O
category	O
of	O
uncertain	O
significance	O
.	O

Besides	O
the	O
identification	O
of	O
likely	O
benign	O
alleles	O
previously	O
reported	O
as	O
being	O
probably	O
pathogenic	O
,	O
our	O
comprehensive	O
analysis	O
underscores	O
the	O
need	O
of	O
functional	O
assays	O
to	O
assess	O
the	O
causality	O
of	O
EYS	O
variants	O
,	O
in	O
order	O
to	O
improve	O
molecular	O
diagnostics	O
and	O
counseling	O
of	O
patients	O
with	O
EYS	O
-	O
associated	O
RP	O
.	O

Ciliopathy	O
-	O
associated	O
mutations	B-Var
of	O
IFT122	B-Gene
impair	B-NegReg
ciliary	B-Protein
protein	I-Protein
trafficking	B-MPA
but	O
not	O
ciliogenesis	O
.	O

The	O
intraflagellar	O
transport	O
(	O
IFT	O
)	O
machinery	O
containing	O
the	O
IFT	O
-	O
A	O
and	O
IFT	O
-	O
B	O
complexes	O
mediates	O
ciliary	O
protein	O
trafficking	O
.	O

Mutations	B-Var
in	O
the	O
genes	O
encoding	O
the	O
six	O
subunits	O
of	O
the	O
IFT	O
-	O
A	O
complex	O
(	B-Gene
IFT43	I-Gene
,	O
IFT121	B-Gene
,	O
IFT122	B-Gene
,	O
IFT139	B-Gene
,	O
IFT140	B-Gene
,	O
and	O
IFT144	B-Gene
)	I-Gene
are	O
known	O
to	O
cause	B-Reg
skeletal	O
ciliopathies	O
,	O
including	O
cranioectodermal	B-Disease
dysplasia	I-Disease
(	O
CED	O
)	O
.	O

As	O
the	O
IFT122	O
subunit	O
connects	O
the	O
core	O
and	O
peripheral	O
subcomplexes	O
of	O
the	O
IFT	O
-	O
A	O
complex	O
,	O
it	O
is	O
expected	O
to	O
play	O
a	O
pivotal	O
role	O
in	O
the	O
complex	O
.	O

Indeed	O
,	O
we	O
here	O
showed	O
that	O
knockout	O
(	O
KO	O
)	O
of	O
the	O
IFT122	O
gene	O
in	O
hTERT	O
-	O
RPE1	O
cells	O
using	O
the	O
CRISPR	O
/	O
Cas9	O
system	O
led	O
to	O
a	O
severe	O
ciliogenesis	O
defect	O
,	O
whereas	O
KO	O
of	O
other	O
IFT	O
-	O
A	O
genes	O
had	O
minor	O
effects	O
on	O
ciliogenesis	O
but	O
impaired	O
ciliary	O
protein	O
trafficking	O
.	O

Exogenous	O
expression	O
of	O
not	O
only	O
wild	O
-	O
type	O
IFT122	O
but	O
also	O
its	O
CED	O
-	O
associated	O
missense	O
mutants	O
,	O
which	O
fail	O
to	O
interact	O
with	O
other	O
IFT	O
-	O
A	O
subunits	O
,	O
rescued	O
the	O
ciliogenesis	O
defect	O
of	O
IFT122-KO	O
cells	O
.	O

However	O
,	O
IFT122-KO	O
cells	O
expressing	O
CED	O
-	O
type	O
IFT122	B-Gene
mutants	B-Var
showed	O
defects	B-NegReg
in	O
ciliary	B-Protein
protein	I-Protein
trafficking	B-MPA
,	O
such	O
as	O
ciliary	O
entry	O
of	O
Smoothened	O
in	O
response	O
to	O
Hedgehog	O
signaling	O
activation	O
.	O

The	O
trafficking	O
defects	O
partially	O
resembled	O
those	O
observed	O
in	O
IFT144-KO	O
cells	O
,	O
which	O
demonstrate	O
failed	O
assembly	O
of	O
the	O
functional	O
IFT	O
-	O
A	O
complex	O
at	O
the	O
base	O
of	O
cilia	O
.	O

These	O
observations	O
make	O
it	O
likely	O
that	O
,	O
although	O
IFT122	O
is	O
essential	O
for	O
ciliogenesis	O
,	O
CED	O
-	O
type	O
missense	O
mutations	O
underlie	O
a	O
skeletal	O
ciliopathy	O
phenotype	O
by	O
perturbing	O
ciliary	O
protein	O
trafficking	O
with	O
minor	O
effects	O
on	O
ciliogenesis	O
per	O
se	O
.	O

Association	O
of	O
the	O
AADAC	O
gene	O
and	O
Tourette	O
syndrome	O
in	O
a	O
Han	O
Chinese	O
cohort	O
.	O

Tourette	B-Disease
syndrome	I-Disease
(	O
TS	O
)	O
is	O
a	O
complex	O
neuropsychiatric	O
disorder	O
with	O
chronic	O
motor	O
and	O
vocal	O
tics	O
.	O

Though	O
the	O
etiology	O
is	O
elusive	O
,	O
strong	O
evidence	O
for	O
a	O
genetic	O
contribution	O
to	O
TS	O
has	O
been	O
established	O
.	O

To	O
date	O
,	O
various	O
chromosomal	O
or	O
genetic	O
alterations	O
have	O
been	O
implicated	O
in	O
its	O
pathogenesis	O
.	O

Recently	O
,	O
the	O
deletion	O
in	O
the	O
arylacetamide	O
deacetylase	O
gene	O
(	O
AADAC	O
)	O
was	O
reported	O
to	O
be	O
associated	O
with	O
TS	O
.	O

To	O
investigate	O
the	O
association	O
between	O
the	O
AADAC	O
gene	O
variants	O
and	O
TS	O
,	O
we	O
conducted	O
genetic	O
analysis	O
of	O
the	O
AADAC	O
gene	O
in	O
200	O
Han	O
Chinese	O
patients	O
and	O
300	O
ethnicity	O
-	O
matched	O
normal	O
controls	O
.	O

Two	O
variants	O
,	O
including	O
a	O
heterozygous	O
splice	O
-	O
site	O
variant	O
,	O
c.361	O
+	O
1	O
G	O
>	O
A	O
(	O
rs762169706	O
)	O
,	O
and	O
a	O
missense	O
variant	O
,	O
c.744A	O
>	O
T	O
(	O
p	O
.	O
R248S	O
,	O
rs186388618	O
)	O
,	O
were	O
identified	O
in	O
two	O
unrelated	O
patients	O
.	O

The	O
c.361	B-Var
+	I-Var
1	I-Var
G	I-Var
>	I-Var
A	I-Var
variant	O
,	O
absent	O
in	O
300	O
ethnicity	O
-	O
matched	O
controls	O
,	O
led	B-Reg
to	I-Reg
the	O
deletion	B-Var
of	O
exon	O
2	O
in	O
AADAC	O
mRNA	O
,	O
probably	O
associated	B-Reg
with	I-Reg
development	O
of	O
TS	B-Disease
.	O

The	O
c.744A	O
>	O
T	O
variant	O
,	O
predicted	O
to	O
be	O
damaging	O
,	O
was	O
identified	O
in	O
two	O
normal	O
controls	O
.	O

The	O
findings	O
indicate	O
that	O
the	O
AADAC	B-Gene
gene	O
c.361	B-Var
+	I-Var
1	I-Var
G	I-Var
>	I-Var
A	I-Var
variant	O
may	O
be	O
a	O
potential	O
candidate	B-Reg
factor	I-Reg
for	O
TS	B-Disease
development	O
,	O
though	O
further	O
investigations	O
are	O
warranted	O
.	O

MeCP2	O
as	O
an	O
Activator	O
of	O
Gene	O
Expression	O
.	O

Rett	B-Disease
syndrome	I-Disease
is	O
a	O
neurodevelopmental	O
disorder	O
that	O
primarily	O
affects	O
females	O
and	O
is	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
methyl	O
-	O
CpG	O
-	O
binding	O
-	O
protein	O
2	O
(	B-Gene
MECP2	I-Gene
)	I-Gene
gene	O
.	O

Initially	O
,	O
MeCP2	O
had	O
been	O
shown	O
to	O
be	O
a	O
repressor	O
of	O
gene	O
transcription	O
.	O

In	O
their	O
2008	O
paper	O
,	O
Chahrour	O
and	O
colleagues	O
(	O
DOI	O
:	O
10.1126	O
/	O
science.1153252	O
)	O
reported	O
that	O
MeCP2	O
could	O
also	O
function	O
as	O
a	O
transcriptional	O
activator	O
.	O

Molecular	O
Analysis	O
-	O
Based	O
Genetic	O
Characterization	O
of	O
a	O
Cohort	O
of	O
Patients	O
with	O
Duchenne	O
and	O
Becker	O
Muscular	O
Dystrophy	O
in	O
Eastern	O
China	O
.	O

Background	O
:	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
DMD	O
)	O
and	O
Becker	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
BMD	O
)	O
are	O
common	O
X	O
-	O
linked	O
recessive	O
neuromuscular	O
disorders	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
dystrophin	B-Gene
gene	I-Gene
.	O

Multiplex	O
polymerase	O
chain	O
reaction	O
(	O
multiplex	O
PCR	O
)	O
and	O
multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
(	O
MLPA	O
)	O
are	O
the	O
most	O
common	O
methods	O
for	O
detecting	O
dystrophin	O
gene	O
mutations	O
.	O

This	O
study	O
aimed	O
to	O
contrast	O
the	O
two	O
methods	O
and	O
discern	O
the	O
genetic	O
characterization	O
of	O
patients	O
with	O
DMD	O
/	O
BMD	O
in	O
Eastern	O
China	O
.	O

Methods	O
:	O
We	O
collected	O
121	O
probands	O
,	O
64	O
mothers	O
of	O
probands	O
,	O
and	O
15	O
fetuses	O
in	O
our	O
study	O
.	O

The	O
dystrophin	O
gene	O
was	O
detected	O
by	O
multiplex	O
PCR	O
primarily	O
in	O
28	O
probands	O
,	O
and	O
MLPA	O
was	O
used	O
in	O
multiplex	O
PCR	O
-	O
negative	O
cases	O
subsequently	O
.	O

The	O
dystrophin	O
gene	O
of	O
the	O
remaining	O
93	O
probands	O
and	O
62	O
female	O
potential	O
carriers	O
was	O
tested	O
by	O
MLPA	O
directly	O
.	O

In	O
fetuses	O
,	O
multiplex	O
PCR	O
and	O
MLPA	O
were	O
performed	O
on	O
4	O
fetuses	O
and	O
10	O
fetuses	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
sequencing	O
was	O
also	O
performed	O
in	O
4	O
probands	O
with	O
negative	O
MLPA	O
.	O

Results	O
:	O
We	O
found	O
that	O
61.98	O
%	O
of	O
the	O
subjects	O
had	O
genetic	O
mutations	O
including	O
deletions	O
(	O
50.41	O
%	O
)	O
and	O
duplications	O
(	O
11.57	O
%	O
)	O
.	O

There	O
were	O
43.75	O
%	O
of	O
mothers	O
as	O
carriers	O
of	O
the	O
mutation	O
.	O

In	O
15	O
fetuses	O
,	O
2	O
out	O
of	O
7	O
male	O
fetuses	O
were	O
found	O
to	O
be	O
unhealthy	O
and	O
2	O
out	O
of	O
8	O
female	O
fetuses	O
were	O
found	O
to	O
be	O
carriers	O
.	O

Exons	O
3	O
-	O
26	O
and	O
45	O
-	O
52	O
have	O
the	O
maximum	O
frequency	O
in	O
mutation	O
regions	O
.	O

In	O
the	O
frequency	O
of	O
exons	O
individually	O
,	O
exon	O
47	O
and	O
exon	O
50	O
were	O
the	O
most	O
common	O
in	O
deleted	O
regions	O
and	O
exons	O
5	O
,	O
6	O
,	O
and	O
7	O
were	O
found	O
most	O
frequently	O
in	O
duplicated	O
regions	O
.	O

Conclusions	O
:	O
MLPA	O
has	O
better	O
productivity	O
and	O
sensitivity	O
than	O
multiplex	O
PCR	O
.	O

Prenatal	O
diagnosis	O
should	O
be	O
applied	O
in	O
DMD	O
high	O
-	O
risk	O
fetuses	O
to	O
reduce	O
the	O
disease	O
incidence	O
.	O

Furthermore	O
,	O
it	O
is	O
the	O
responsibility	O
of	O
physicians	O
to	O
inform	O
female	O
carriers	O
the	O
importance	O
of	O
prenatal	O
diagnosis	O
.	O

A	O
novel	O
mutation	B-Var
in	O
RDH5	B-Gene
gene	O
causes	B-Reg
retinitis	B-Disease
pigmentosa	I-Disease
in	O
consanguineous	O
Pakistani	O
family	O
.	O

Retinitis	O
pigmentosa	O
(	O
RP	O
)	O
is	O
the	O
most	O
frequent	O
genetically	O
and	O
clinically	O
heterogeneous	O
inherited	O
retinal	O
degeneration	O
.	O

To	O
date	O
,	O
more	O
than	O
80	O
genes	O
have	O
been	O
identified	O
that	O
cause	O
autosomal	O
dominant	O
,	O
autosomal	O
recessive	O
and	O
X	O
linked	O
RP	O
.	O

However	O
,	O
locus	O
and	O
allelic	O
heterogeneity	O
of	O
RP	O
has	O
not	O
been	O
fully	O
captured	O
yet	O
.	O

This	O
heterogeneity	O
and	O
lack	O
of	O
an	O
accurate	O
genotype	O
phenotype	O
correlation	O
makes	O
molecular	O
dissection	O
of	O
the	O
disease	O
more	O
difficult	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
characterize	O
the	O
underlying	O
pathogenic	O
variants	O
of	O
RP	O
in	O
Pakistan	O
.	O

For	O
this	O
purpose	O
,	O
a	O
large	O
consanguineous	O
family	O
with	O
RP	O
phenotype	O
showing	O
autosomal	O
recessive	O
mode	O
of	O
inheritance	O
was	O
selected	O
after	O
a	O
complete	O
ophthalmological	O
examination	O
.	O

Next	O
generation	O
sequencing	O
was	O
used	O
for	O
the	O
identification	O
of	O
molecular	O
determinant	O
followed	O
by	O
Sanger	O
-	O
sequencing	O
for	O
confirmation	O
.	O

After	O
sequence	O
analysis	O
a	O
novel	O
homozygous	O
missense	O
mutation	O
,	O
(	B-Var
c.602	I-Var
C	I-Var
>	I-Var
T	I-Var
)	I-Var
in	O
exon	O
4	O
of	O
the	O
RDH5	B-Gene
gene	O
(	O
MIM	O
:	O
601617	O
)	O
was	O
identified	O
.	O

This	O
mutation	O
resulted	B-Reg
in	I-Reg
substitution	O
of	O
phenyl	O
alanine	O
for	O
serine	O
at	O
amino	O
acid	O
201	O
(	B-Var
p	I-Var
.	I-Var
Ser201Phe	I-Var
)	I-Var
of	O
the	O
RDH5	B-Gene
gene	O
.	O

The	O
same	O
mutation	O
was	O
not	O
detected	O
in	O
the	O
200	O
ethnically	O
-	O
matched	O
control	O
samples	O
by	O
Sanger	O
sequencing	O
.	O

The	O
identified	O
mutant	O
allele	O
segregated	O
in	O
homozygous	O
fashion	O
in	O
all	O
the	O
affected	O
individuals	O
of	O
pedigree	O
.	O

Identification	O
of	O
this	O
mutation	O
reveals	O
the	O
allelic	O
heterogeneity	O
of	O
RDH5	O
in	O
patients	O
with	O
RP	O
phenotype	O
.	O

The	O
findings	O
of	O
this	O
study	O
demonstrate	O
the	O
clinical	O
significance	O
of	O
next	O
generation	O
sequencing	O
to	O
understand	O
the	O
molecular	O
basis	O
of	O
diseases	O
and	O
would	O
help	O
to	O
reveal	O
new	O
proteins	O
and	O
their	O
function	O
in	O
visual	O
cycle	O
will	O
pave	O
the	O
way	O
for	O
early	O
diagnosis	O
,	O
genetic	O
counseling	O
and	O
better	O
therapeutic	O
inventions	O
.	O

Targeted	O
Next	O
Generation	O
Sequencing	O
Revealed	O
Novel	O
PRPF31	B-Gene
Mutations	B-Var
in	B-Reg
Autosomal	B-Disease
Dominant	I-Disease
Retinitis	I-Disease
Pigmentosa	I-Disease
.	O

BACKGROUND	O
:	O
Retinitis	O
pigmentosa	O
(	O
RP	O
)	O
is	O
a	O
rare	O
type	O
of	O
inherited	O
retinal	O
dystrophy	O
that	O
can	O
result	O
in	O
progressive	O
vision	O
loss	O
.	O

Molecular	O
diagnosis	O
of	O
RP	O
is	O
challenging	O
due	O
to	O
phenotypic	O
and	O
genotypic	O
heterogeneities	O
.	O

AIMS	O
:	O
This	O
study	O
aimed	O
to	O
identify	O
the	O
pathogenic	O
mutations	O
in	O
two	O
Chinese	O
families	O
with	O
autosomal	O
dominant	O
RP	O
(	O
adRP	O
)	O
and	O
in	O
a	O
patient	O
with	O
sporadic	O
RP	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Peripheral	O
blood	O
DNA	O
samples	O
were	O
obtained	O
from	O
the	O
participants	O
.	O

Targeted	O
next	O
generation	O
sequencing	O
(	O
NGS	O
)	O
was	O
applied	O
to	O
identify	O
mutations	O
in	O
these	O
patients	O
.	O

For	O
pathogenic	O
mutation	O
analyses	O
,	O
stringent	O
NGS	O
data	O
analyses	O
and	O
segregation	O
analyses	O
were	O
applied	O
.	O

Primers	O
were	O
designed	O
to	O
validate	O
the	O
identified	O
mutations	O
by	O
Sanger	O
sequencing	O
analyses	O
.	O

RESULTS	O
:	O
A	O
novel	O
heterozygous	O
insertion	O
frameshift	O
mutation	O
c.1226_1227insA	O
,	O
p	O
.	O
T410Dfs*65	O
,	O
and	O
a	O
novel	O
heterozygous	O
stopgain	O
mutation	O
c.1015C	O
>	O
T	O
,	O
p	O
.	O
Q339	O
*	O
were	O
identified	O
in	O
PRPF31	O
.	O

A	O
known	O
c.527	O
+	O
3A	O
>	O
G	O
splicing	O
mutation	O
was	O
identified	O
in	O
one	O
of	O
the	O
adRP-074	O
families	O
.	O

All	O
mutations	O
were	O
found	O
to	O
co	O
-	O
segregate	O
with	O
the	O
disease	O
,	O
and	O
none	O
of	O
these	O
mutations	O
were	O
detected	O
in	O
500	O
control	O
samples	O
.	O

CONCLUSIONS	O
:	O
Our	O
data	O
identified	O
two	O
new	O
autosomal	O
dominant	O
mutations	O
in	O
PRPF31	O
,	O
expanding	O
the	O
mutational	O
spectrum	O
of	O
this	O
gene	O
.	O

Identification	O
of	O
deletion	B-Var
-	I-Var
duplication	I-Var
in	O
HEXA	B-Gene
gene	O
in	O
five	O
children	O
with	B-Reg
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
disease	I-Disease
from	O
India	O
.	O

BACKGROUND	O
:	O
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
disease	I-Disease
(	O
TSD	O
)	O
is	O
a	O
sphingolipid	O
storage	O
disorder	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
HEXA	B-Gene
gene	O
.	O

To	O
date	O
,	O
nearly	O
170	O
mutations	O
of	O
HEXA	O
have	O
been	O
described	O
,	O
including	O
only	O
one	O
7.6	O
kb	O
large	O
deletion	O
.	O

METHODS	O
:	O
Multiplex	O
Ligation	O
-	O
dependent	O
Probe	O
Amplification	O
(	O
MLPA	O
)	O
study	O
was	O
carried	O
out	O
in	O
5	O
unrelated	O
patients	O
for	O
copy	O
number	O
changes	O
where	O
heterozygous	O
and/or	O
homozygous	O
disease	O
causing	O
mutation	O
/	O
s	O
could	O
not	O
be	O
identified	O
in	O
the	O
coding	O
region	O
by	O
sequencing	O
of	O
HEXA	O
gene	O
.	O

RESULTS	O
:	O
The	O
study	O
has	O
identified	O
the	O
presence	O
of	O
a	O
homozygous	O
deletion	O
of	O
exon-2	O
and	O
exon-3	O
in	O
two	O
patients	O
,	O
two	O
patient	O
showed	O
compound	O
heterozygosity	O
with	O
exon	O
1	O
deletion	O
combined	O
with	O
missense	O
mutation	O
p	O
.	O
E462V	O
and	O
one	O
patient	O
was	O
identified	O
with	O
duplication	O
of	O
exon-1	O
with	O
novel	O
variants	O
c.1527	O
-	O
2A	O
>	O
T	O
as	O
a	O
second	O
allele	O
.	O

CONCLUSION	O
:	O
This	O
is	O
the	O
first	O
report	O
of	O
deletion	O
/	O
duplication	O
in	O
HEXA	O
gene	O
providing	O
a	O
new	O
insight	O
into	O
the	O
molecular	O
basis	O
of	O
TSD	O
and	O
use	O
of	O
MLPA	O
assay	O
for	O
detecting	O
large	O
copy	O
number	O
changes	O
in	O
the	O
HEXA	O
gene	O
.	O

Two	O
siblings	O
with	O
11qter	O
deletion	O
syndrome	O
that	O
had	O
been	O
rescued	O
in	O
their	O
mother	O
by	O
uniparental	O
disomy	O
.	O

Jacobsen	B-Disease
syndrome	I-Disease
refers	O
to	O
a	O
congenital	O
anomaly	O
caused	B-Reg
by	I-Reg
deletion	B-Var
at	O
11q23.3-qter	B-Gene
.	O

We	O
here	O
describe	O
two	O
siblings	O
with	O
the	O
same	O
11q23.3-qter	O
deletion	O
.	O

Both	O
parents	O
were	O
healthy	O
with	O
a	O
normal	O
karyotype	O
.	O

Cytogenetic	O
microarray	O
analysis	O
revealed	O
no	O
mosaicism	O
in	O
either	O
parent	O
but	O
the	O
mother	O
showed	O
uniparental	O
disomy	O
encompassing	O
the	O
deleted	O
region	O
found	O
in	O
the	O
two	O
siblings	O
.	O

The	O
pattern	O
of	O
X	O
chromosome	O
inactivation	O
was	O
almost	O
completely	O
skewed	O
in	O
the	O
mother	O
.	O

These	O
data	O
suggested	O
that	O
the	O
mother	O
was	O
a	O
carrier	O
of	O
the	O
11q23.3-qter	O
deletion	O
but	O
that	O
this	O
had	O
been	O
rescued	O
by	O
disomy	O
formation	O
during	O
early	O
embryogenesis	O
except	O
for	O
her	O
germinal	O
cells	O
.	O

Genotyping	O
of	O
five	O
Pakistani	O
patients	O
with	O
severe	O
inherited	O
factor	O
X	O
deficiency	O
:	O
identification	O
of	O
two	O
novel	O
mutations	O
.	O

:	O
Congenital	B-Disease
factor	I-Disease
X	I-Disease
deficiency	I-Disease
is	O
a	O
rare	O
coagulation	O
defect	O
characterized	O
by	O
variable	O
bleeding	O
tendency	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
give	O
a	O
first	O
insight	O
of	B-Reg
F10	B-Gene
gene	O
mutations	B-Var
in	O
Pakistani	O
probands	O
.	O

Direct	O
sequencing	O
and/or	O
next	O
-	O
generation	O
sequencing	O
was	O
performed	O
on	O
the	O
coding	O
regions	O
,	O
boundaries	O
and	O
5	O
'	O
and	O
3	O
'	O
untranslated	O
regions	O
of	O
the	O
F10	O
gene	O
in	O
five	O
severe	O
factor	O
X	O
-	O
deficient	O
patients	O
from	O
Pakistan	O
.	O

All	O
patients	O
were	O
born	O
from	O
consanguineous	O
marriages	O
and	O
displayed	O
FX	O
:	O
C	O
levels	O
below	O
2	O
%	O
.	O

Sequencing	O
revealed	O
five	O
different	O
substitutions	O
,	O
including	O
three	O
previously	O
reported	O
p	O
.	O
Ala15Asp	O
,	O
p	O
.	O
Gly406Ser	O
,	O
and	O
p	O
.	O
Gly420Arg	O
missense	O
variants	O
,	O
and	O
also	O
two	O
novel	O
variants	O
:	O
p	O
.	O
Cys57Arg	O
and	O
p	O
.	O
Gln175	O
*	O
.	O

Though	O
one	O
genotype	O
could	O
not	O
be	O
characterized	O
,	O
we	O
were	O
able	O
to	O
confirm	O
the	O
inherited	O
nature	O
of	O
the	O
defect	O
using	O
familial	O
studies	O
.	O

As	O
the	O
copy	O
number	O
variations	O
were	O
ruled	O
out	O
,	O
we	O
hypothesized	O
the	O
presence	O
of	O
deep	O
intronic	O
mutants	O
that	O
might	O
have	O
escaped	O
detection	O
from	O
sequencing	O
or	O
abnormalities	O
in	O
epigenetic	O
regulation	O
.	O

Three	O
patients	O
presented	O
with	O
severe	O
clinical	O
symptoms	O
,	O
in	O
the	O
early	O
days	O
of	O
life	O
,	O
whereas	O
two	O
presented	O
only	O
with	O
trauma	O
-	O
provoked	O
bleeds	O
and	O
bruises	O
later	O
in	O
life	O
.	O

Those	O
patients	O
with	O
milder	O
forms	O
bore	O
the	O
p	O
.	O
Gly406Ser	O
at	O
the	O
homozygous	O
state	O
and	O
F10	O
unknown	O
alleles	O
,	O
respectively	O
.	O

F10	O
mutation	O
spectrum	O
in	O
Pakistan	O
is	O
heterogeneous	O
as	O
seen	O
in	O
other	O
populations	O
.	O

Identification	O
of	O
the	O
F10	O
mutations	O
is	O
important	O
for	O
genetic	O
counseling	O
and	O
prenatal	O
diagnosis	O
in	O
subsequent	O
pregnancies	O
.	O

Spectrum	O
of	O
MECP2	B-Gene
mutations	B-Var
in	O
Vietnamese	O
patients	O
with	B-Reg
RETT	B-Disease
syndrome	I-Disease
.	O

BACKGROUND	O
:	O
Rett	O
syndrome	O
(	O
RTT	O
)	O
is	O
a	O
severe	O
neurodevelopmental	O
disorder	O
in	O
children	O
characterized	O
by	O
a	O
normal	O
neurodevelopmental	O
process	O
in	O
the	O
first	O
6	O
-	O
18	O
months	O
followed	O
by	O
a	O
period	O
of	O
motor	O
and	O
vocal	O
deterioration	O
with	O
stereotypic	O
hand	O
movements	O
.	O

Incidence	O
of	O
RTT	B-Disease
is	O
mostly	O
due	B-Reg
to	I-Reg
de	O
novo	O
mutation	B-Var
in	O
the	O
MECP2	B-Gene
gene	O
(	O
methyl	O
-	O
CpG	O
-	O
binding	O
protein	O
2	O
)	O
.	O

METHODS	O
:	O
The	O
study	O
assessed	O
27	O
female	O
patients	O
presented	O
with	O
classical	O
RTT	O
phenotype	O
age	O
range	O
from	O
18	O
months	O
to	O
48	O
months	O
.	O

Specialist	O
carried	O
out	O
the	O
clinical	O
evaluation	O
and	O
diagnosis	O
according	O
to	O
RTT	O
diagnosis	O
criteria	O
.	O

Blood	O
samples	O
from	O
patients	O
were	O
then	O
collected	O
for	O
genomic	O
DNA	O
extraction	O
.	O

We	O
next	O
performed	O
MECP2	O
gene	O
amplification	O
and	O
sequencing	O
of	O
the	O
whole	O
coding	O
region	O
to	O
screen	O
for	O
mutations	O
.	O

RESULT	O
:	O
MECP2	O
mutation	O
was	O
found	O
in	O
20	O
patients	O
(	O
74	O
%	O
)	O
including	O
:	O
2	O
missense	O
,	O
4	O
nonsense	O
,	O
6	O
frameshift	O
and	O
2	O
deletion	O
mutation	O
.	O

The	O
study	O
identified	O
14	O
pathogenic	O
mutations	O
which	O
we	O
found	O
4	O
mutation	O
,	O
to	O
our	O
knowledge	O
and	O
extensive	O
search	O
,	O
not	O
priory	O
reported	O
in	O
any	O
mutation	O
database	O
or	O
publication	O
:	O
c.1384	O
-	O
1385DelGT	O
,	O
c.1205insT	O
,	O
c.717delC	O
and	O
c.1132_1207del77	O
.	O

High	O
percentage	O
of	O
C	O
>	O
T	O
(	O
70	O
%	O
)	O
in	O
CpG	O
sites	O
mutation	O
was	O
found	O
.	O

CONCLUSION	O
:	O
Our	O
result	O
reveals	O
a	O
high	O
percentage	O
of	O
C	O
>	O
T	O
mutation	O
in	O
CpG	O
hot	O
spot	O
,	O
which	O
is	O
more	O
prone	O
to	O
modification	O
and	O
more	O
likely	O
to	O
be	O
detected	O
in	O
RTT	O
as	O
a	O
disorder	O
is	O
strictly	O
due	O
to	O
de	O
novo	O
mutations	O
.	O

The	O
study	O
is	O
the	O
first	O
to	O
identify	O
the	O
mutation	O
spectrum	O
of	O
MECP2	O
gene	O
in	O
Vietnamese	O
patients	O
and	O
also	O
an	O
important	O
step	O
toward	O
better	O
diagnosis	O
and	O
care	O
for	O
RTT	O
patients	O
in	O
Vietnam	O
.	O

Clinical	O
presentation	O
and	O
natural	O
history	O
of	O
infantile	O
-	O
onset	O
ascending	O
spastic	O
paralysis	O
from	O
three	O
families	O
with	O
an	O
ALS2	O
founder	O
variant	O
.	O

Biallelic	B-Var
mutations	I-Var
of	O
the	O
alsin	O
Rho	O
guanine	O
nucleotide	O
exchange	O
factor	O
(	B-Gene
ALS2	I-Gene
)	I-Gene
gene	O
cause	B-Reg
a	O
group	O
of	O
overlapping	O
autosomal	O
recessive	O
neurodegenerative	O
disorders	O
including	O
infantile	B-Disease
-	I-Disease
onset	I-Disease
ascending	I-Disease
hereditary	I-Disease
spastic	I-Disease
paralysis	I-Disease
(	O
IAHSP	O
)	O
,	O
juvenile	B-Disease
primary	I-Disease
lateral	I-Disease
sclerosis	I-Disease
(	O
JPLS	O
)	O
,	O
and	O
juvenile	B-Disease
amyotrophic	I-Disease
lateral	I-Disease
sclerosis	I-Disease
(	O
JALS	O
/	O
ALS2	O
)	O
,	O
caused	B-Reg
by	I-Reg
retrograde	B-CPA
degeneration	I-CPA
of	I-CPA
the	I-CPA
upper	I-CPA
motor	I-CPA
neurons	I-CPA
of	I-CPA
the	I-CPA
pyramidal	I-CPA
tracts	I-CPA
.	O

Here	O
,	O
we	O
describe	O
11	O
individuals	O
with	O
IAHSP	O
,	O
aged	O
2	O
-	O
48	O
years	O
,	O
with	O
IAHSP	B-Disease
from	O
three	O
unrelated	O
consanguineous	O
Iranian	O
families	O
carrying	B-Reg
the	O
homozygous	O
c.1640	B-Var
+	I-Var
1G	I-Var
>	I-Var
A	I-Var
founder	O
mutation	O
in	O
ALS2	B-Gene
.	O

Three	O
affected	O
siblings	O
from	O
one	O
family	O
exhibit	O
generalized	O
dystonia	O
which	O
has	O
not	O
been	O
previously	O
described	O
in	O
families	O
with	O
IAHSP	O
and	O
has	O
only	O
been	O
reported	O
in	O
three	O
unrelated	O
consanguineous	O
families	O
with	O
JALS	O
/	O
ALS2	O
.	O

We	O
report	O
the	O
oldest	O
individuals	O
with	O
IAHSP	O
to	O
date	O
and	O
provide	O
evidence	O
that	O
these	O
patients	O
survive	O
well	O
into	O
their	O
late	O
40s	O
with	O
preserved	O
cognition	O
and	O
normal	O
eye	O
movements	O
.	O

Our	O
study	O
delineates	O
the	O
phenotypic	O
spectrum	O
of	O
IAHSP	O
and	O
ALS2-related	O
disorders	O
and	O
provides	O
valuable	O
insights	O
into	O
the	O
natural	O
disease	O
course	O
.	O

A	O
novel	O
MFSD8	B-Gene
mutation	B-Var
in	O
a	O
Russian	O
patient	O
with	B-Reg
neuronal	B-Disease
ceroid	I-Disease
lipofuscinosis	I-Disease
type	O
7	O
:	O
a	O
case	O
report	O
.	O

BACKGROUND	O
:	O
Neuronal	O
ceroid	O
lipofuscinoses	O
(	O
NCLs	O
)	O
are	O
the	O
most	O
common	O
autosomal	O
recessive	O
neurodegenerative	O
disorders	O
in	O
children	O
.	O

Clinical	O
manifestations	O
include	O
progressive	O
cognitive	O
decline	O
,	O
motor	O
impairment	O
,	O
ataxia	O
,	O
visual	O
loss	O
,	O
seizures	O
and	O
early	O
death	O
.	O

To	O
date	O
more	O
than	O
440	O
NCL	O
-	O
causing	O
mutations	O
in	O
13	O
genes	O
are	O
known	O
.	O

CASE	O
PRESENTATION	O
:	O
We	O
report	O
clinical	O
and	O
genetic	O
characteristics	O
of	O
a	O
5-year	O
-	O
old	O
girl	O
affected	O
by	O
ceroid	O
lipofuscinosis	O
type	O
7	O
(	O
NCL7	O
)	O
.	O

She	O
had	O
progressive	O
motor	O
and	O
mental	O
deterioration	O
since	O
the	O
age	O
of	O
2,5	O
years	O
.	O

Later	O
she	O
developed	O
progressive	O
vision	O
loss	O
,	O
stereotypies	O
,	O
action	O
myoclonus	O
and	O
epilepsy	O
.	O

By	O
the	O
age	O
of	O
5	O
years	O
she	O
stopped	O
walking	O
.	O

Based	O
on	O
symptoms	O
,	O
diagnosis	O
of	O
Rett	O
syndrome	O
was	O
suggested	O
,	O
but	O
no	O
abnormalities	O
were	O
detected	O
in	O
MeCP2	O
.	O

We	O
identified	O
a	O
novel	O
homozygous	O
mutation	O
in	O
MFSD8	O
gene	O
(	O
c.525	O
T	O
>	O
A	O
,	O
p	O
.	O
Cys175Ter	O
)	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
MFSD8	O
gene	O
mutation	O
in	O
a	O
Russian	O
patient	O
with	O
variant	O
late	O
-	O
infantile	O
NCL	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
enlarge	O
mutational	O
spectrum	O
of	O
ceroid	O
lipofuscinosis	O
type	O
7	O
and	O
demonstrate	O
tremendous	O
diagnosis	O
value	O
of	O
exome	O
sequencing	O
for	O
pediatric	O
NCLs	O
.	O

Also	O
we	O
confirmed	O
that	O
NCL	O
should	O
be	O
suspected	O
in	O
patients	O
with	O
Rett	O
-	O
like	O
phenotype	O
at	O
onset	O
and	O
negative	O
MECP2	O
mutation	O
.	O

Molecular	O
genetics	O
of	O
the	O
POMT1-related	O
muscular	O
dystrophy	O
-	O
dystroglycanopathies	O
.	O

Protein	O
O	O
-	O
mannosyltransferase	O
1	O
(	O
POMT1	O
)	O
is	O
a	O
critical	O
enzyme	O
participating	O
in	O
the	O
first	O
step	O
of	O
protein	O
O	O
-	O
mannosylation	O
.	O

Mutations	B-Var
in	O
the	O
coding	O
gene	O
,	O
POMT1	B-Gene
,	O
have	O
been	O
described	O
to	O
be	O
related	O
to	O
a	O
series	O
of	O
autosomal	O
recessive	O
disorders	O
associated	O
with	O
defective	B-NegReg
alpha	B-MPA
-	I-MPA
dystroglycan	I-MPA
glycosylation	I-MPA
,	O
later	O
termed	O
muscular	B-Disease
dystrophy	I-Disease
-	I-Disease
dystroglycanopathies	I-Disease
(	O
MDDGs	O
)	O
.	O

MDDGs	O
are	O
characterized	O
by	O
a	O
broad	O
phenotypic	O
spectrum	O
of	O
congenital	O
muscular	O
dystrophy	O
or	O
later	O
-	O
onset	O
limb	O
-	O
girdle	O
muscular	O
dystrophy	O
,	O
accompanied	O
by	O
variable	O
degrees	O
of	O
intellectual	O
disability	O
,	O
brain	O
defects	O
,	O
and	O
ocular	O
abnormalities	O
.	O

To	O
date	O
,	O
at	O
least	O
76	O
disease	O
-	O
associated	O
mutations	O
in	O
the	O
POMT1	O
gene	O
,	O
including	O
missense	O
,	O
nonsense	O
,	O
splicing	O
,	O
deletion	O
,	O
insertion	O
/	O
duplication	O
,	O
and	O
insertion	O
-	O
deletion	O
mutations	O
,	O
have	O
been	O
reported	O
in	O
the	O
literature	O
.	O

In	O
this	O
review	O
,	O
we	O
highlight	O
the	O
present	O
knowledge	O
of	O
the	O
identified	O
disease	O
-	O
associated	O
POMT1	O
gene	O
mutations	O
and	O
genetic	O
animal	O
models	O
related	O
to	O
the	O
POMT1	O
gene	O
.	O

This	O
review	O
may	O
help	O
further	O
normative	O
classification	O
of	O
phenotypes	O
,	O
assist	O
in	O
definite	O
clinical	O
and	O
genetic	O
diagnoses	O
,	O
and	O
genetic	O
counseling	O
,	O
and	O
may	O
comprehensively	O
improve	O
our	O
understanding	O
of	O
the	O
basis	O
of	O
complex	O
phenotypes	O
and	O
possible	O
pathogenic	O
mechanisms	O
involved	O
.	O

Segmental	O
uniparental	O
disomy	O
as	O
a	O
rare	O
cause	O
of	O
congenital	O
severe	O
factor	O
XIII	O
deficiency	O
in	O
a	O
girl	O
with	O
only	O
one	O
heterozygous	O
carrier	O
parent	O
.	O

Uniparental	B-Disease
disomy	I-Disease
(	O
UPD	O
)	O
refers	O
to	O
a	O
situation	O
when	O
a	O
person	O
inherits	O
both	O
homologs	O
of	O
a	O
region	O
or	O
complete	O
part	O
of	O
a	O
chromosome	O
from	O
only	O
one	O
parent	O
.	O

Here	O
,	O
we	O
present	O
an	O
unusual	O
case	O
of	O
UPD	O
in	O
congenital	O
severe	O
factor	O
(	O
F	O
)	O
XIII	O
deficiency	O
.	O

A	O
6-year	O
-	O
old	O
girl	O
experienced	O
cephalhematoma	O
and	O
umbilical	O
bleeding	O
after	O
birth	O
and	O
easy	O
bruising	O
,	O
and	O
postextraction	O
bleeding	O
since	O
early	O
infancy	O
.	O

FXIII	O
activity	O
was	O
0	O
%	O
[	O
mother	O
53.7	O
%	O
and	O
father	O
132.5	O
%	O
(	O
normal	O
70	O
-	O
140	O
%	O
)	O
]	O
and	O
the	O
FXIII	O
antigen	O
level	O
was	O
2.5	O
%	O
[	O
mother	O
38.9	O
%	O
and	O
father	O
151	O
%	O
(	O
normal	O
75	O
-	O
155	O
%	O
)	O
]	O
.	O

The	O
washed	O
platelet	O
FXIII	O
activity	O
was	O
0.1	O
%	O
in	O
the	O
patient	O
(	O
normal	O
64	O
-	O
144	O
%	O
)	O
,	O
suggesting	O
a	O
deficiency	O
of	O
FXIII	O
-	O
A	O
subunit	O
.	O

The	O
FXIII	O
-	O
A	O
subunit	O
genetic	O
analysis	O
detected	O
a	O
homozygous	O
p	O
.	O
Arg382Ser	O
mutation	O
.	O

A	O
similar	O
heterozygous	O
mutation	O
was	O
detected	O
in	O
the	O
mother	O
but	O
surprisingly	O
,	O
not	O
in	O
the	O
father	O
.	O

Kinship	O
was	O
confirmed	O
by	O
a	O
paternity	O
test	O
.	O

To	O
confirm	O
the	O
possibility	O
of	O
UPD	O
,	O
a	O
test	O
using	O
four	O
markers	O
in	O
the	O
vicinity	O
of	O
the	O
F13A1	B-Gene
gene	O
revealed	O
that	O
she	O
inherited	O
duplicate	B-Var
mutations	I-Var
from	O
a	O
heterozygous	O
mutation	O
in	O
her	O
mother	O
,	O
presenting	O
a	O
unique	O
case	B-Reg
of	I-Reg
unusual	O
maternal	O
segmental	O
UPD	B-Disease
in	O
otherwise	O
unexplained	O
congenital	O
(	O
homozygous	O
)	O
severe	O
FXIII	B-Disease
deficiency	I-Disease
.	O

UPD	O
as	O
a	O
rare	O
cause	O
of	O
autosomal	O
recessive	O
bleeding	O
disorder	O
when	O
only	O
one	O
parent	O
is	O
affected	O
is	O
critical	O
for	O
genetic	O
counseling	O
.	O

